european journal of
pharmacology
an international journal

MASTER

AUTHOR AND KEY WORD

INDEXES

TO

VOLUMES 159–172

1989

(EJP Molecular Pharmacology Section,
Volume 172, incorporated)

ELSEVIER

SCOPE OF THE JOURNAL

The EUROPEAN JOURNAL OF PHARMACOLOGY publishes manuscripts on the mechanisms of action of chemical substances affecting biological systems. MANUSCRIPTS SUBMITTED TO THE JOURNAL ARE ONLY ACCEPTED ON THE UNDERSTANDING THAT: (1) THEY ARE SUBJECT TO EDITORIAL REVIEW; (2) THEY HAVE NOT BEEN AND WILL NOT BE PUBLISHED IN WHOLE OR IN PART IN ANY OTHER JOURNAL; (3) THE RECOMMENDATIONS FROM THE DECLARATION OF HELSINKI AND THE INTERNATIONALLY ACCEPTED PRINCIPLES IN THE CARE AND USE OF EXPERIMENTAL ANIMALS HAVE BEEN ADHERED TO.

Editorial review

Rapid communications are evaluated by the editorial office and are either accepted or rejected. Full length manuscripts and short communications are generally submitted to 2 referees who are chosen for their ability to evaluate the work. Authors may request that certain referees should not be chosen. Members of the Editorial Board will usually be called upon for advice when there is disagreement among the referees or between referees and authors, or when the editor believes that the manuscript has not received adequate consideration from the referees. In order to reduce mailing costs, manuscripts will not be returned. Only the decision of the editorial office, together with the advice of the referees will be sent to the author(s). Referees will be requested to keep the copy of the manuscript which they have received for evaluation, and to destroy it once they have been notified of the final decision concerning the manuscript. When authors submit a revised manuscript, they should reply to the comments of the referees, indicating which comments have been incorporated and the reasons for disregarding any suggestions considered unacceptable. Revised manuscripts should be returned in duplicate to the editor. A revised manuscript should be received by the editorial office not later than 5 weeks (in case of minor revision) or 10 weeks (in case of extensive revision) after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript. Handwritten additions or corrections will not be accepted. Only complete retyping of the pages affected by revision is acceptable.

GENERAL INSTRUCTIONS

For extensive 'Notice to authors' see Vol. 175, No. 1, p. v.

The original and 2 copies, complete with 3 sets of figures and tables should be sent to:

The editorial office of the European Journal of Pharmacology, tel. 31 (030) 884685,
P.O. Box 5023, 3502 JA Utrecht, The Netherlands,
or: Vondellaan 6, 3521 GD Utrecht, The Netherlands

Manuscripts should be typewritten with double line spacing and with wide margins to the left *and* to the right (not more than 26 lines per page). The pages should be numbered consecutively, the title page being p. 1. Manuscripts should be written in English. The manuscripts will, if necessary, be corrected for English style and language. Such correction will be carried out by a qualified pharmacologist and is final.

1. Rapid communications

(a) Reports on exciting new results within the scope of the Journal can be submitted for publication in the rapid communications section.

(b) A rapid communication should not exceed 600 words and should contain no or only one simple table or figure of not more than *7.5 cm = 1 column width*. A figure of more than 1 column width will delay publication by at least 14 days.

(c) A maximum of 5 references may be used.

(d) The rapid communication should be typewritten, lines double spaced, with wide margins, without any subheadings and without an abstract. The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words), surname(s) of author(s), preceded by one name spelled out in full, name and address of the establishment where the work was done (all on one page); text; Acknowledgement(s); References; figure legend or table. Name, full postal address, telephone and telex numbers of author to whom correspondence is to be sent should be mentioned on the title page.

(e) Rapid communications have priority at the editorial office and publishers.

(f) All proofreading will be done by the editorial staff of the publishers; no proofs will be sent to the author(s).

(g) Upon acceptance of a rapid communication a reprint order form will be sent to the author(s).

2. Full length manuscripts

(a) The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words), surname(s) of author(s), preceded by one name spelled out in full, name and address of the establishment where the work was done, name, full postal address, telephone and telex numbers of author to whom proofs and other correspondence should be sent (all on one page); abstract and key words (indexing terms; normally 3–6 items); 4 sections numbered as indicated: 1. Introduction, 2. Materials and methods, 3. Results, 4. Discussion; Acknowledgements; References; figure legends; tables and figures. Subdivisions of a section should also be numbered within that section: 2.1., 2.2., 2.3. etc.

(b) Abstracts and key words: an abstract not exceeding 150 words and stating what was done, what was found, and what was concluded should be typed on a separate sheet. It will appear at the beginning of the article. Below the abstract, type 3–6 key words or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, key words should be selected from Index Medicus or Excerpta Medica Index. First category key words (e.g. Hyperphagia; G-Strophantidin; Fiber shortening) will all be listed and cross-indexed. Second category key words (e.g. Rat, Cold, Metabolites) will only be listed under the index entry for the first category key words. If the editors feel that key words should be adjusted to the standards of the journal this will be done without consultation of the author(s).

(c) Standard nomenclature should be used throughout; unfamiliar or new terms and arbitrary abbreviations should be defined when first used. Unnecessary abbreviations and symbols are to be avoided. Words at the end of a line should not be divided. Use of hyphens, capital letters, numbers written or spelled out (e.g. 8 or eight) should be consistent throughout the manuscript.

(d) Legends of illustrations and footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout the text, should be used as little as possible.

(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses the first time the name of the drug appears in the text. The form of the drug used should be indicated.

3. Short communications should be prepared as described under 2., except for the following:

(a) The average length of a short communication should be between 1500 and 2000 words, which is about 4 double-spaced typewritten pages with a maximum of 2 illustrations (figures and tables).

(b) An abstract of not more than 75 words should be provided and 3–6 key words should be listed immediately below the abstract.

(c) Papers will generally be either accepted or rejected; they may be accepted after modification.

(d) All proofreading will be done by the editorial staff of the publishers; no proofs will be sent to the author(s).

(e) Short communications should not contain more than 10 references.

(f) Upon acceptance of a short communication a reprint order form will be sent to the author(s).

4. References

References in the text to literature cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Downie and Larsson (1984) *or* (Hicks et al., 1984; 1985; Seeman et al., 1985; Stoof and Kebabian, 1987a,b,c). For three or more authors the name of the first author followed by et al. should be used. Journal names should be abbreviated according to the List of Serial Title Word Abbreviations (available from the International Organization for Standardization, 20 rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8). References should be listed alphabetically at the end of the paper. Two or more references to the same first author with the same publication year should have a, b, c, etc. suffixed to the year indicating the alphabetical order of the second or third author, etc. Citations of the literature in the list of references should include the full title of the article referred to. Personal communications and unpublished data should not appear in the list of references.

(continued on page 3 of cover)

EUROPEAN JOURNAL OF PHARMACOLOGY

INDEXES 1989

European Journal of Pharmacology

editor

D. DE WIED

Author and Key word Indexes, 1989
Volumes 159–172
(EJP Molecular Pharmacology Section, Volume 172, incorporated)

ELSEVIER SCIENCE PUBLISHERS B.V.— AMSTERDAM

© 1990 Elsevier Science Publishers B.V. (Biomedical Division)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the publisher recommends that independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extent to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

This journal is printed on acid-free paper.

Printed in The Netherlands

CONTENTS

Introduction vii

Author index 1

Key word index 47

Introduction

For the Key word index, up to six key words (or short phrases) are selected for each article; these are printed together, and each is selected in turn to form an index entry. Important factors of each investigation are selected as key words; general terms such as enzyme, rat, spectroscopy, etc. will not be found as separate entries. However, such words may be found in parentheses at the end of a group of key words. These words are sub-key words and are intended to provide useful supplementary information; they do not, however, constitute sufficiently precise indexing terms to be used as index entries.

Also in parentheses at the end of each group of key words will be found the name of the first author, the volume and the first page number of the article. The full published title and co-authors of an article can be found by consulting the relevant entry for the first author in the Author index.

The editors and publishers welcome any comments on the usefulness of this index, together with suggestions for improvements.

0014-2999/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division)

Author index
volumes 159–172
1989

Master author index to volumes 159–172

Aas, P., Tansø, R. and Fonnum, F.
Stimulation of peripheral cholinergic nerves by glutamate indicates a new peripheral glutamate receptor (164) 93
Abbamondi, A., see Di Patre, P.L. (162) 43
Abbate, R., see Modesti, P.A. (169) 85
Abe, K., Saito, H. and Matsuki, N.
Potentiation by treatment with reserpine of α_2-adrenoceptor-mediated contractions of rat tail artery (171) 59
Abe, Y., see Shoji, T. (171) 219
Abel, P.W., see Bockman, C.S. (171) 255
Abiko, Y., see Ichihara, K. (165) 19
Abiko, Y., see Nakamura, K. (160) 61
Abiko, Y., see Nakamura, K. (169) 259
Abraham, W.M., see Tomioka, K. (170) 209
Abrahamsson, T.
Characterization of the β_1-adrenoceptor stimulatory effects of the partial β_1-agonists acebutolol, xamoterol, H142/08 and H201/70 (164) 121
Abrahamsson, T., see Carlsson, L. (166) 157
Acad, B.-A., see Joselevitz-Goldman, J. (166) 283
Ackerman, M., see Kerkman, D.J. (166) 481
Acquas, E., see Carboni, E. (164) 515
Acuff, C.G., see Rockhold, R.W. (166) 571
Adachi, H., Tomoike, H., Nishijima, H., Egashira, S. and Nakamura, M.
Sustained dilatation of large coronary artery by α-human atrial natriuretic peptide in conscious dogs: a comparison with nitroglycerin (161) 189
Adamson, P., Hajimohamadreza, I., Brammer, M.J. and Campbell, I.C.
Intrasynaptosomal free calcium concentration is increased by phorbol esters via a 1,4-dihydropyridine-sensitive (L-type) Ca^{2+} channel (162) 59
Adessi, G., see Massol, J. (160) 395
Adler-Graschinsky, E., see Elgoyhen, B. (164) 467
Aghajanian, G.K., see Sprouse, J.S. (167) 375
Ågmo, A., Fernández, H. and Picker, Z.
Naloxone inhibits the facilitatory effects of 8-OH-DPAT on male rat sexual behaviour (166) 115
Agnati, L.F., see Von Euler, G. (172) 435
Agui, T., Kurihara, M. and Saavedra, J.M.
Multiple types of receptors for atrial natriuretic peptide (162) 301
Aharony, D., see Krell, R.D. (159) 73
Aharony, D., see Redkar-Brown, D.G. (165) 113
Ahmed, A., see Tomioka, K. (170) 209
Ahmed, H.N., see Gomaa, A.A. (170) 129
Aihara, K., see Sakai, Y. (162) 475
Ais, G., Novo, C., López-Farré, A., Romeo, J.M. and López-Novoa, J.M.
Effect of endothelin on systemic and regional hemodynamics in rats (170) 113
Aiso, M., see Fochtmann, L.J. (167) 305
Akahane, K., see Furukawa, Y. (161) 1
Akil, H., see Young, E.A. (167) 229
Akima, M., see Imagawa, J.-i. (167) 167
Alavijeh, M.S., see Mitchell, S.N. (167) 311
Albanese, V., see Nicoletti, F. (160) 299
Albrightson, C.R., see Brooks, D.P. (160) 159
Aldes, L.D., see Marco, L.A. (164) 171
Alesiani, M., see Moroni, F. (163) 123
Aletras, A.J., see Voukelatou, G. (162) 179
Alfredson, M.L., see Armour, C.L. (165) 215
Alheid, U., Reichwehr, I. and Förstermann , U.
Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP (164) 103
Allan, A.M., see Buck, K.J. (160) 359
Allaoua, H. and Chicheportiche, R.
Anaesthetic properties of phencyclidine (PCP) and analogues may be related to their interaction with Na^+ channels (163) 327
Allessie, M.A., see Kirchhof, C.J.H.J. (160) 369
Allgaier, C., see Huang, H.Y. (169) 115
Allgaier, C., see Nakov, R. (164) 45
Almeida, A.A., see Assreuy, J. (168) 231
Altar, A.C., see Cosi, C. (165) 209
Amann, R., see Giuliani, S. (163) 91
Ambar, I., Kloog, Y. and Sokolovsky, M.
Solubilization of endothelin/sarafotoxin receptors in an active binding form (170) 119
Amenta, F., see De Michele, M. (169) 297
Amenta, F., see Erdö, S.L. (165) 79
Amerini, S., see Mantelli, L. (170) 217
Amiranoff, B., Lorinet, A.-M., Yanaihara, N. and Laburthe, M.
Structural requirement for galanin action in the pancreatic β cell line Rin m 5F (163) 205
Amiranoff, B., see Lorinet, A.-M. (160) 405
Amoroso, S., see Di Renzo, G. (162) 371
Andersen, P.H.
The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action (166) 493
Andersen, P.H., see Nielsen, E.B. (160) 253
Ando, H., see Kuno, T. (172) 263
Andrási, F., see Tarnawa, I. (167) 193

Andres-Trelles, F., see Sánchez, M. (168) 169
Angelucci, L., see Imperato, A. (165) 337
Änggård, E., see Salvemini, D. (171) 135
Angus, J., see Cocks, T.M. (171) 17
Anireddy, D.R., see Chideckel, E.W. (166) 367
Annunziato, L., see Di Renzo, G. (162) 371
Anwyl, R., see O'Connor, J.J. (167) 21
Aoki, N., see Lento, P.H. (165) 241
Aoki, S., see Koshikawa, N. (163) 227
Aono, H., see Matsuda, T. (170) 75
Aosaki, T., see Kanai, Y. (166) 553
Appel, J.B. and Callahan, P.M.
Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline (159) 41
Argiolas, A., Melis, M.R. and Gessa, G.L.
Calcium channel inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats (166) 515
Argiolas, A., see Melis, M.R. (164) 565
Århem, P., see Elinder, F. (164) 599
Armour, C.L., Johnson, P.R.A., Alfredson, M.L. and Black, J.L.
Characterization of contractile prostanoid receptors on human airway smooth muscle (165) 215
Arnt, J. and Hyttel, J.
Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT_2 agonist DOI (161) 45
Arroyo, V., see Lòpez, C. (168) 1
Artman, L.D., see Kerkman, D.J. (166) 481
Asaad, M., see Bergey, J.L. (159) 103
Asakawa, K., see Horikawa, R. (166) 87
Asaro, D., see Bonanno, G. (172) 41
Asin, K.E., see Kerkman, D.J. (166) 481
Assreuy, J., Almeida, A.A. and Guimarães, J.A.
Pharmacological properties of a new kinin-potentiating peptide generated from human serum proteins (168) 231

Baba, A., see Matsuda, T. (170) 75
Babb, S.M., see Cohen, B.M. (170) 201
Babcock, C.M., see Bell, D.R. (171) 189
Bachy, A., see Larcher, J.-C. (161) 197
Badia, A., see Baños, J. (165) 151
Badia, A., see Cuffí, M.L. (168) 111
Badia, A., see Ferré, S. (166) 303
Baganoff, M.P., see Watson, G.B. (167) 291
Bain, G.T., see Huston-Lyons, D. (169) 153
Baldwin, H.A., Johnston, A.L. and File, S.E.
Antagonistic effects of caffeine and yohimbine in animal tests of anxiety (159) 211
Balletti, J., see Pranzatelli, M.R. (170) 127
Balotta, C., see Chiabrando, C. (159) 257
Banerjee, A.K., see Dhasmana, K.M. (168) 257
Baños, J., Bosch, F. and Badia, A.
Blocking effect of diltiazem in the isolated rat phrenic hemidiaphragm (165) 151
Barabé, J., see Rhaleb, N.-E. (162) 419
Barajas-López, C. and Huizinga, J.D.
Quinidine and quinine effects on the slow wave activity of colonic circular muscle (163) 137
Barefoot, D.S., see Pinkus, L.M. (168) 355
Barkai, A.I., see Butler, P.D. (160) 93
Barker, S., see Martinez, J.R. (164) 335
Barnard, E.A., see Gut, S.H. (172) 339
Barnes, P.J., see Chilvers, E.R. (164) 587
Barnes, P.J., see Dent, G. (169) 313
Barnes, P.J., see Engels, F. (164) 139
Barnes, P.J., see Ichinose, M. (163) 383
Barnes, P.J., see Mak, J.C.W. (164) 223
Barnes, P.J., see Rhoden, K.J. (171) 247
Baron, D.A., see Oehlenschlager, W.F. (161) 159
Barra, D., see Kreil, G. (162) 123
Barrera, G., see Ferretti, C. (166) 149
Barrett, R.W., see McKinney, M. (162) 397
Bartolini, L., see Di Patre, P.L. (162) 43
Basile, V., see Di Renzo, G. (162) 371
Bassett, A.L., see Cameron, J.S. (169) 23
Bauer, V., see Machová, J. (162) 387
Baumann, B., see Bognar, I.T. (163) 263
Beart, P.M., see Cincotta, M. (160) 167
Beck, G., see Konturek, S.J. (164) 285
Becker, R., see Wiemer, G. (166) 31
Becketts, K., see Vaupel, D.B. (162) 447
Bednarz, L., see Kerkman, D.J. (166) 481
Beersma, D.G.M., see Dijk, D.J. (171) 207
Belcourt, A., see Bricca, G. (162) 1
Belcourt, A., see Bricca, G. (163) 373
Belelli, D. and Gee, K.W.
5α-Pregnan-3α,20α-diol behaves like a partial agonist in the modulation of GABA-stimulated chloride ion uptake by synaptoneurosomes (167) 173
Belelli, D., Bolger, M.B. and Gee, K.W.
Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-one (166) 325
Bell, D.R., Babcock, C.M. and Bohr, D.F.
Individualities in post-serotonin attenuation and Na^+/K^+ pump activity in vascular smooth muscle (171) 189
Bell, J.A.
Naloxone-induced facilitation of C-fiber reflexes is reduced by chronic morphine (168) 101
Bellan, J.A., see Minkes, R.K. (165) 259
Ben Ari, Y. and Lazdunski, M.
Galanin protects hippocampal neurons from the functional effects of anoxia (165) 331
Benezra, M., see Gerst, J.E. (172) 29
Bennett, T., see Gardiner, S.M. (171) 237
Benson, D.M., Blitzer, R.D. and Landau, E.M.
Ethanol suppresses hippocampal cell firing through a calcium and cyclic AMP-sensitive mechanism (164) 591
Benuck, M., Reith, M.E.A. and Lajtha, A.
Evidence for the involvement of Na^+/Ca^{2+} exchange in the stimulation of inositol phospholipid hydrolysis by sodium channel activation and depolarization (159) 187
Berdeaux, A., see Gerard, J.-L. (165) 39
Berge, J., see Young, P. (168) 381

Bergeron, F., see Durieux, C. (168) 269
Bergey, J.L., Much, D.R., Kratunis, V. and Asaad, M.
Effects of human ANF-(99-126) on sympathetic nerve function, hemodynamic parameters and plasma cGMP levels in anesthetized, ganglion-blocked dogs (159) 103
Bergstrand, H., see Fallgren, B. (170) 61
Bernardi, L., Perlini, S., Soffiantino, F., Farilla, C., Calciati, A., Soldà, P.L., Paro, M., Merlo, L., Marchetti, G. and Finardi, G.
Acute haemodynamic effects of ibopamine and dopamine on isovolumic relaxation [1] (164) 415
Berthelot, P., see Kerr, D.I.B. (164) 361
Berthold, H., Fozard, J.R. and Engel, G.
5-HT_1 receptor agonists attenuate the naloxone-induced jumping behaviour i.. morphine-dependent mice (162) 19
Bertorelli, R., see Invernizzi, R. (164) 241
Berzsenyi, P., see Tarnawa, I. (167) 193
Bettini, E., see Canonaco, M. (170) 95
Bettini, E., see Maggi, A. (172) 357
Bhargava, H.N., Ramarao, P. and Gulati, A.
Effects of morphine in rats treated chronically with U-50,488 H, a κ opioid receptor agonist (162) 257
Bhargava, H.N., see Gulati, A. (167) 185
Bhat, M.B., Mishra, S.K. and Raviprakash, V.
Sources of calcium for ATP-induced contractions in rat urinary bladder smooth muscle (164) 163
Bidard, J.-N., see Gandolfo, G. (159) 329
Bidard, J.-N., see Gandolfo, G. (160) 173
Bidard, J.-N., see Gandolfo, G. (167) 181
Biediger, A.M., see Keeton, T.K. (164) 479
Biewenga, W.J., see Hellebrekers, L.J. (164) 55
Biffignandi, P., see Franzone, J.S. (165) 269
Biggio, G., Concas, A., Corda, M.G. and Serra, M.
Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors (161) 173
Biggio, G., see Corda, M.G. (159) 233
Biggio, G., see Corda, M.G. (169) 205
Biggio, G., see Serra, M. (164) 385
Bijak, M.
Antidepressant drugs potentiate the α_1-adrenoceptor effect in hippocampal slices (166) 183
Bilčíková, Ľ., see Machová, J. (162) 387
Binder, S.B., see Trachte, G.J. (164) 425
Bing, Z., Villanueva, L. and Le Bars, D.
Effects of systemic morphine upon Aδ- and C-fibre evoked activities of subnucleus reticularis dorsalis neurones in the rat medulla (164) 85
Birch, P.J., Grossman, C.J. and Hayes, A.G.
Antagonist profile of 6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylate at excitatory amino acid receptors in the neonatal rat spinal cord (163) 127
Birdsall, N.J.M., see Schudt, C. (165) 87
Bishop, B.E. and Laverty, R.
Dose-dependent reduction by Ro 15-4513 in mice of the effects of ethanol and some other general depressant drugs (162) 265
Bissette, G., see Levant, B. (165) 327
Biziere, K., see Schumacher, C. (166) 139
Black, C.K., see Schmidt, C.J. (167) 309
Black, J.L., see Armour, C.L. (165) 215
Blanchard, J.-C., see Castel, M.-N. (166) 353
Blay, J. and Hollenberg, M.D.
Heterologous regulation of EGF receptor function in cultured aortic smooth muscle cells (172) 1
Blayac, J.-P., see Ribes, G. (162) 207
Bleck, V., see Lewin, E. (160) 101
Blengio, M., see Ferretti, C. (166) 149
Blier, P., see Lista, A. (171) 229
Blitzer, R.D., see Benson, D.M. (164) 591
Bloom, S.R., see Power, R.F. (160) 199
Bluth, L.S., Rice, K.C., Jacobson, A.E. and Bowen, W.D.
Acylation of σ receptors by Metaphit, an isothiocyanate derivative of phencyclidine (161) 273
Bobik, A., see Wolf, W.A. (163) 43
Bobillier, P., see Broussolle, E. (159) 225
Bockaert, J., see Dumuis, A. (162) 381
Bockaert, J., see Pin, J.-P. (172) 81
Bockman, C.S., Abel, P.W., Hicks, J.W. and Conlon, J.M.
Evidence that neuromedin U may regulate gut motility in reptiles but not in mammals (171) 255
Boddeke, H., see Lambrecht, G. (168) 71
Bodmer, D.M., see Waser, P.G. (172) 231
Bodnar, R.J., see Paul, D. (168) 307
Boeckxstaens, G.E., see Pelckmans, P.A. (170) 235
Boer, R., Grassegger, A., Schudt, C. and Glossmann, H.
(+)-Niguldipine binds with very high affinity to Ca^{2+} channels and to a subtype of α_1-adrenoceptors (172) 131
Boer, R., see Eltze, M. (170) 225
Boer, R., see Galvan, M. (167) 1
Boer, R., see Graziadei, I. (172) 329
Boer, R., see Schudt, C. (165) 87
Boeynaems, J.-M., see Ramboer, I. (171) 251
Boeynaems, J.M., see Raspe, E. (163) 345
Boggan, W. and Middaugh, L.
Effect of central injection of phencyclidine on QNB accumulation and motor activity (166) 123
Bognar, I.T., Baumann, B., Dammann, F., Knöll, B., Meincke, M., Pallas, S. and Fuder, H.
M_2 muscarinic receptors on the iris sphincter muscle differ from those on iris noradrenergic nerves (163) 263
Böhm, M., Gierschik, P., Ungerer, M. and Erdmann, E.
Coupling of adenosine receptors to a pertussis toxin-sensitive G protein in the human heart (172) 407
Bohr, D.F., see Bell, D.R. (171) 189
Bolanos, F. and Fillion, G.
Minaprine antagonises the serotonergic inhibitory effect of trifluoromethylphenylpiperazine (TFMPP) on acetylcholine release (168) 87
Bolanos, F., see Gozlan, H. (172) 497
Bolanos, F., see Hoyer, D. (171) 137
Bolanowski, M.A., see Watson, G.B. (167) 291
Bolger, M.B., see Belelli, D. (166) 325
Bom, A.H., Villalón, C.M., Verdouw, P.D. and Saxena, P.R.

The 5-HT_1-like receptor mediating reduction of porcine carotid arteriovenous shunting by RU 24969 is not related to either the 5-HT_{1A} or the 5-HT_{1B} subtype (171) 87
Bommelaer-Bayet, M.-C., see Wisner, A. (162) 89
Bonanno, G., Pellegrini, G., Asaro, D., Fontana, G. and Raiteri, M.
$GABA_B$ autoreceptors in rat cortex synaptosomes: response under different depolarizing and ionic conditions (172) 41
Bonanno, G., see Raiteri, M. (172) 223
Bonaventure, N., see Jardon, B. (162) 215
Bonke, F.I.M., see Kirchhof, C.J.H.J. (160) 369
Booth, R.G., see Johnson, E.A. (166) 65
Borges, R., Von Grafenstein, H. and Knight, D.E.
Tissue selectivity of endothelin (165) 223
Bormann, J.
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels (166) 591
Bormann, J., see Kornhuber, J. (166) 589
Bosch, F., see Baños, J. (165) 151
Bosker, F.J., Van Bussel, F.J., Thielen, A.P.G.M., Soei, Y.L., Sieswerda, G.T., Dijk, J., Tepper, P.G., Horn, A.S. and Möller, W.
Affinity chromatography with the immobilized agonist N-0434 yields an active and highly purified preparation of the dopamine D-2 receptor from bovine striatum (163) 319
Bossaller, C., Förstermann, U., Hertel, R., Olbricht, C., Reschke, V. and Fleck, E.
Ciclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production (165) 165
Botanch, C., see Gairin, J.-E. (172) 381
Bourgoin, S., see Collin, E. (168) 201
Bourgoin, S., see Hamon, M. (164) 315
Bourguignon, J.J., see Schumacher, C. (166) 139
Bourson, A., Moser, P.C., Gower, A.J. and Mir, A.K.
Central and peripheral effects of the dihydropyridine calcium channel activator BAY K 8644 in the rat (160) 339
Bousquet, P., see Bricca, G. (162) 1
Bousquet, P., see Bricca, G. (163) 373
Bova, S., Padrini, R., Cargnelli, G., Piovan, D. and Ferrari, M.
The influence of acidosis on the myocardial uptake and electrocardiographic effects of disopyramide (168) 179
Bowen, W.D., Hellewell, S.B. and McGarry, K.A.
Evidence for a multi-site model of the rat brain σ receptor (163) 309
Bowen, W.D., see Bluth, L.S. (161) 273
Boyet, S., see Schroeder, H. (167) 245
Boyland, P., see Feely, M. (164) 377
Bradberry, C.W., see Sprouse, J.S. (167) 375
Brady, L.S., see Rothman, R.B. (160) 71
Braff, D.L., see Mansbach, R.S. (167) 49
Brain, S.D.
The direct observation of arteriolar constriction induced by endothelin in vivo (160) 401
Brammer, M.J., see Adamson, P. (162) 59
Brantl, V., see Liebmann, C. (166) 523
Braquet, P., see Koltai, M. (164) 293
Braquet, P., see Thierry, A. (163) 97
Brasch, H.
Activation of α_2-adrenoceptors attenuates the inotropic effect of field stimulation in atria (171) 37
Brasch, H.
Pulse duration and α_2-adrenoceptors modify noradrenaline release from field-stimulated atria (171) 49
Bravo, G., see Finet, M. (164) 555
Brazell, M.P., see Mitchell, S.N. (167) 311
Breese, G.A., see Criswell, H.E. (159) 141
Brewster, W.K., see Lovenberg, T.W. (166) 111
Briand, V., Laurent, S. and Schmitt, H.
Interaction between isoproterenol and dihydropyridines in heart cells (166) 339
Bricca, G., Dontenwill, M., Molines, A., Feldman, J., Belcourt, A. and Bousquet, P.
The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem (162) 1
Bricca, G., Dontenwill, M., Molines, A., Feldman, J., Tibirica, E., Belcourt, A. and Bousquet, P.
Rilmenidine selectivity for imidazoline receptors in human brain (163) 373
Bridges, R.J., see Diener, M. (168) 219
Briggs, G.M., Morgan, J.P. and Gwathmey, J.K.
Inhibition of aftercontractions and phasic calcium release by yohimbine in ferret papillary muscle (170) 281
Brigham, T.E., see Marco, L.A. (164) 171
Brodin, E., see Lindefors, N. (160) 417
Brodin, E., see Lindefors, N. (161) 95
Brooks, D.P., Koster, P.F., Albrightson, C.R., Huffman, W.F., Moore, M.L., Stassen, F.L., Schmidt, D.B. and Kinter, L.B.
Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements (160) 159
Brooks, R.R., Carpenter, J.F., Jones, S.M. and Gregory, C.M.
Effects of dantrolene sodium in rodent models of cardiac arrhythmia (164) 521
Brooks, S.M., see Richards, I.S. (167) 155
Broussolle, E., Darriet, D., Debilly, G., Pujol, J.-F. and Bobillier, P.
RU 24722, a new eburnamine derivative, induces selective alterations in cerebral glucose utilization in freely moving rat (159) 225
Brouwer, F., see Meurs, H. (164) 369
Brouwer, F., see Van Amsterdam, R.G.M. (172) 175
Brown, C.M., see Kilpatrick, A.T. (166) 315
Brozovich, F.V., see Perreault, C.L. (165) 305
Brunelli, G., see Omini, C. (163) 195
Brunello, N., see Perez, J. (172) 305
Brunner, F., see Gillard, M. (160) 117
Brunner, F., see Groschner, K. (159) 125
Brzozowski, T., see Konturek, S.J. (164) 285
Buck, K.J., Allan, A.M. and Harris, R.A.
Fluidization of brain membranes by A_2C does not produce anesthesia and does not augment muscimol-stimulated $^{36}Cl^-$ influx (160) 359
Buckett, W.R., see Heal, D.J. (170) 11
Buckett, W.R., see Heal, D.J. (170) 19

Buckley, T.L. and Hoult, J.R.S.
Platelet activating factor is a potent colonic secretagogue with actions independent of specific PAF receptors (163) 275
Buda, M., see Suaud-Chagny, M.-F. (164) 273
Budai, D., Vu, H.Q. and Duckles, S.P.
Endothelium removal does not affect potentiation by neuropeptide Y in rabbit ear artery (168) 97
Bueno, L., see Liberge, M. (164) 147
Buga, G.M., Gold, M.E., Wood, K.S., Chaudhuri, G. and Ignarro, L.J.
Endothelium-derived nitric oxide relaxes nonvascular smooth muscle (161) 61
Bullock, A., see Titeler, M. (167) 221
Bult, H., see Deckers, I.A. (167) 415
Bunney, B.S., see Esposito, E. (162) 109
Bunting, P.B., see Winquist, R.J. (163) 199
Burbach, J.P.H., see Kovács, G.L. (161) 27
Burch, R.M.
Diacylglycerol in the synergy of bradykinin and thrombin stimulation of prostaglandin synthesis (168) 39
Burcher, E., see Mussap, C.J. (168) 337
Burgess, H.S., see Davis, T.P. (161) 283
Burkhart, C.A., see Koe, B.K. (161) 263
Burnett Jr., J.C., see Schini, V.B. (165) 333
Burnstock, G., see Hopwood, A.M. (165) 323
Burnstock, G., see Reilly, W.M. (160) 283
Buscaglia, V., see Stockert, M. (160) 11
Bush, L., see Hanson, G.R. (160) 23
Bush, L.G., see Johnson, M. (161) 181
Butler, P.D., Edwards, E. and Barkai, A.I.
Imipramine and tetrabenazine: effects on monoamine receptor binding sites and phosphoinositide hydrolysis (160) 93
Buzzi, M.G., Sakas, D.E. and Moskowitz, M.A.
Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater (165) 251
Bykov, V., see Rothman, R.B. (160) 71
Bykov, V., see Rothman, R.B. (167) 345
Byrd, J.C., see Yang, Z.W. (164) 607

Caccia, S., see Invernizzi, R. (163) 77
Calciati, A., see Bernardi, L. (164) 415
Callahan, P.M., see Appel, J.B. (159) 41
Callebert, J., see Maldonado, R. (165) 199
Camden, J., see Martinez, J.R. (164) 335
Cameron, J.S., Katz, D., Swigart, C.R. and Bassett, A.L.
Histamine attenuates the arrhythmogenic effects of norepinephrine in hearts of spontaneously hypertensive rats (169) 23
Campbell, I.C., see Adamson, P. (162) 59
Campbell, I.C., see Koshikawa, N. (170) 101
Campbell, J.K., see Winslow, E. (166) 241
Campbell, W.B., see Pfister, S.L. (161) 85
Campoleoni, A., see Chiabrando, C. (159) 257
Canonaco, M., Valenti, A., Tavolaro, R., Bettini, E. and Maggi, A.
Differential modulation of [^{3}H]flunitrazepam binding in female rat brain by sex steroid hormones (170) 95
Canonico, P.L., see Nicoletti, F. (160) 299
Cantrill, R.C., see Kurstjens, N.P. (169) 147
Cantwell, M.E. and Foreman, J.C.
The actions of retinal and retinoic acid on histamine release from rat peritoneal mast cells (160) 43
Canzoniero, L., see Di Renzo, G. (162) 371
Carboni, E., Acquas, E., Frau, R. and Di Chiara, G.
Differential inhibitory effects of a 5-HT$_3$ antagonist on drug-induced stimulation of dopamine release (164) 515
Carey, H.V. and Cooke, H.J.
Thyrotropin-releasing hormone (TRH) evokes chloride secretion via cholinergic pathways in the guinea-pig ileum (160) 183
Cargnelli, G., see Bova, S. (168) 179
Carini, D.J., see Chiu, A.T. (170) 117
Carlsson, L. and Abrahamsson, T.
Ramiprilat attenuates the local release of noradrenaline in the ischemic myocardium (166) 157
Carnuccio, R., Di Rosa, M., Iuvone, T., Marotta, P. and Sautebin, L.
Vasocortin-like proteins induced by glucocorticoids in vascular tissue (166) 535
Carpéné, C., see Saulnier-Blache, J.-S. (171) 145
Carpenter, J.F., see Brooks, R.R. (164) 521
Carstairs, J.R., see Engels, F. (164) 139
Carter, C., Rivy, J.-P. and Scatton, B.
Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-D-aspartate (NMDA) receptor (164) 611
Caruso, A., see Clementi, G. (163) 175
Caruso, A., see Clementi, G. (166) 549
Casas, M., see Ferré, S. (166) 303
Casley, D., see Gu, X.-H. (167) 281
Casley, D.J., see Gu, X.-H. (162) 509
Casley, D.J., see Kohzuki, M. (160) 193
Casolini, P., see Imperato, A. (165) 337
Castagnoli, Jr., N., see Johnson, E.A. (166) 65
Castel, M.-N., Malgouris, C., Blanchard, J.-C. and Laduron, P.M.
Retrograde axonal transport of neurotensin in the rat brain (166) 353
Castelli, M.G., see Chiabrando, C. (159) 257
Castro, A., see Del Carmen de Felipe, M. (159) 175
Cattabeni, F., see Di Luca, M. (172) 321
Cavallotti, C., see De Michele, M. (169) 297
Cawthorne, M.A., see Young, P. (168) 381
Cerbai, E., De Bonfioli Cavalcabó, P., Masini, I., Porciatti, F. and Mugelli, A.
Antiarrhythmic properties of naloxone: an electrophysiological study on sheep cardiac Purkinje fibers (162) 491
Cervo, L., Grignaschi, G., Nowakowska, E. and Samanin, R.
1-(3-Trifluoromethylphenyl)piperazine (TFMPP) in the ventral tegmental area reduces the effect of desipramine in the forced swimming test in rats: possible role of serotonin receptors (171) 119

Ceserani, R., see Reggiani, A. (168) 123
Cesselin, F., see Collin, E. (168) 201
Cesura, A.M., Galva, M.D., Imhof, R., Kyburz, E., Picotti, G.B. and Da Prada, M.
[^{3}H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B (162) 457
Chahl, L.A.
The effects of ruthenium red on the response of guinea-pig ileum to capsaicin (169) 241
Challiss, R.A.J., see Chilvers, E.R. (164) 587
Chalmers, J., see Kapoor, V. (164) 531
Chambaut-Guérin, A.-M. and Thomopoulos, P.
Forskolin inhibition of cyclic AMP generation in J774 macrophages (172) 385
Chang, C.C., see Hong, S.J. (162) 11
Chang, J.-K., see Song, D.L. (160) 141
Chang, R.S.L., see Lotti, V.J. (162) 273
Chang, W.-H., Jaw, S.-S. and Tsay, L.
Chronic haloperidol treatment with low doses may enhance the increase of homovanillic acid in rat brain (162) 151
Chaouche-Teyara, K., see Dabiré, H. (168) 369
Chaouche-Teyara, K., see Dabiré, H. (170) 109
Chapelain, B., see Mahe, L. (167) 31
Chapman, A.G. and Meldrum, B.S.
Non-competitive N-methyl-D-aspartate antagonists protect against sound-induced seizures in DBA/2 mice (166) 201
Chapman, H., see Young, P. (168) 381
Charbon, G.A., see Van Berlo, C.L.H. (160) 17
Chase, T.N., see Engber, T.M. (168) 291
Chaudhuri, G., see Buga, G.M. (161) 61
Cheetham, S.C., see De Paermentier, F. (167) 397
Chen, C.-C. and Lin Shiau, S.-Y.
Myocardial Na^+-K^+-ATPase activity and [^{3}H]ouabain binding sites in hypertensive rats (169) 67
Chen, J.-C. and Ramirez, V.D.
Effects of prolactin on tyrosine hydroxylase activity of central dopaminergic neurons of male rats (166) 473
Chen, M.-L., see Tsai, M.-C. (160) 133
Chenard, B., see Shalaby, I. (160) 309
Cherici, G., see Moroni, F. (163) 123
Cherqui, C., see Dabiré, H. (168) 369
Cherqui, C., see Dabiré, H. (170) 109
Cherqui, C., see Laubie, M. (160) 385
Chiabrando, C., Castelli, M.G., Cozzi, E., Fanelli, R., Campoleoni, A., Balotta, C., Latini, R. and Garattini, S.
Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy (159) 257
Chiba, S., see Furukawa, Y. (161) 1
Chiba, S., see Nishida, N. (166) 453
Chicheportiche, R., see Allaoua, H. (163) 327
Chideckel, E.W., Anireddy, D.R., El-Ayoubi, N. and Singh, A.
Cyclic nucleotides augment the phasic action of tetraethylammonium on guinea-pig trachealis (166) 367
Childs, M., see Martin, P. (162) 185
Chilvers, E.R., Challiss, R.A.J., Barnes, P.J. and Nahorski, S.R.
Mass changes of inositol(1,4,5)trisphosphate in trachealis muscle following agonist stimulation (164) 587
Chiodo, L.A., see Kelland, M.D. (169) 11
Chiodo, L.A., see Pitts, D.K. (162) 167
Chiou, W.-F., see Wu, C.-C. (169) 189
Chipkin, R.E., see Yaksh, T.L. (167) 367
Chippari, S., see Herrick-Davis, K. (162) 365
Chiu, A.T., McCall, D.E., Nguyen, T.T., Carini, D.J., Duncia, J.V., Herblin, W.F., Uyeda, R.T., Wong, P.C., Wexler, R.R., Johnson, A.L. and Timmermans, P.B.M.W.M.
Discrimination of angiotensin II receptor subtypes by dithiothreitol (170) 117
Chiu, T.H., see Tietz, E.I. (167) 57
Chiueh, C.C., see Miyake, H. (166) 49
Cho, A.K., see Gazzara, R.A. (168) 209
Cho, A.K., see Hiramatsu, M. (166) 359
Chong, P.N., see Löschmann, P.-A. (166) 373
Choo, L.K. and Mitchelson, F.
Characterization of the antimuscarinic effect of heptane-1,7-bis-(dimethyl-3′-phthalimidopropyl ammonium bromide) (162) 429
Christensen, J.D., Hansen, E.W. and Fjalland, B.
Interleukin-1β stimulates the release of vasopressin from rat neurohypophysis (171) 233
Christensen, J.D., see Grell, S. (166) 41
Christophe, J., see Gillard, M. (160) 117
Christophe, J., see Lambrecht, G. (168) 71
Chronister, R.B., see Marco, L.A. (164) 171
Chuang, D.-M., see Lin, W.W. (166) 581
Cicero, T.J., see Nock, B. (162) 385
Cimino, M., see Di Luca, M. (172) 321
Cincotta, M., Beart, P.M., Summers, R.J. and Lodge, D.
Bidirectional transport of NMDA receptor and ionophore in the vagus nerve (160) 167
Cirillo, R., see Franzone, J.S. (165) 269
Cirino, G., Peers, S.H., Wallace, J.L. and Flower, R.J.
A study of phospholipase A_2-induced oedema in rat paw (166) 505
Clanachan, A.S., see Parkinson, F.E. (163) 69
Clapham, J.C. and Longman, S.D.
Haemodynamic differences between cromakalim and pinacidil: comparison with nifedipine (171) 109
Clark, M. and Post, R.M.
Carbamazepine, but not caffeine, is highly selective for adenosine A_1 binding sites (164) 399
Clarke, W.P. and Goldfarb, J.
Estrogen enhances a 5-HT_{1A} response in hippocampal slices from female rats [1] (160) 195
Clelland, C., see Dinh Xuan, A.T. (163) 401
Clementi, G., Caruso, A., Fiore, C.E., Leone, M.G. and Prato, A.
Effect of parathyroid hormone, centrally or peripherally injected, on gastric activity in male rats (166) 549
Clementi, G., Valerio, C., Prato, A., Caruso, A., Patti, F., Patanè, S. and Drago, F.
Effects of calcitonin on morphine tolerance and withdrawal syndrome in morphine physically dependent rats (163) 175
Cler, J., see Rao, T.S. (168) 129
Clower, B.R., see Rockhold, R.W. (166) 571
Clubb, Jr., F.J., see Pfister, S.L. (161) 85

Cluzel, J., see Thierry, A. (163) 97
Cocks, T.M., Faulkner, N.L., Sudhir, K. and Angus, J.
Reactivity of endothelin-1 on human and canine large veins compared with large arteries in vitro (171) 17
Coenen, A., see Gandolfo, G. (167) 181
Coffin, V.L. and Spealman, R.D.
Psychomotor-stimulant effects of 3-isobutyl-1-methylxanthine: comparison with caffeine and 7-(2-chloroethyl) theophylline (170) 35
Cognard, C., see Nasri-Sebdani, M. (171) 97
Cohen, B.M., Stramentinoli, G., Sosa, A.L., Babb, S.M. and Olgiati, V.
Effects of the novel antidepressant S-adenosyl-methionine on α_1- and β-adrenoceptors in rat brain (170) 201
Cohen, L.A., see Vonhof, S. (164) 77
Cole, E.A., see Thomas, G. (170) 123
Cole, O.F. and Lewis, G.P.
Prostanoid production by rat aortic endothelial cells by bradykinin and histamine (169) 307
Colella, A., see Modesti, P.A. (169) 85
Collin, E., Bourgoin, S., Gorce, P., Hamon, M. and Cesselin, F.
Intrathecal porcine calcitonin enhances the release of [Met^5]enkephalin-like material from the rat spinal cord (168) 201
Colpaert, F.C., Koek, W. and Lategan, A.
l-5-Hydroxytryptophan-induced flat body posture in the rat: antagonism by ritanserin and potentiation after 5,7-dihydroxytryptamine (169) 175
Compton, A.M., see Gardiner, S.M. (171) 237
Compton, R.P., see Hood, W.F. (161) 281
Concas, A., see Biggio, G. (161) 173
Conlon, J.M., see Bockman, C.S. (171) 255
Conlon, J.M., see Katsoulis, S. (161) 129
Connor, H.E., Feniuk, W. and Humphrey, P.P.A.
5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT$_2$ receptor activation (161) 91
Consolo, S., see Invernizzi, R. (164) 241
Contreras, P.C., see Rao, T.S. (168) 129
Convents, A., De Keyser, J., De Backer, J.-P. and Vauquelin, G.
[^{3}H]Rauwolscine labels α_2-adrenoceptors and 5-HT$_{1A}$ receptors in human cerebral cortex (159) 307
Convents, A., see De Keyser, J. (162) 437
Cook, J.M., see Sannerud, C.A. (167) 333
Cooke, H.J., see Carey, H.V. (160) 183
Cooper, S., see Di Monte, D. (166) 23
Corbett, R., see Dunn, R.W. (169) 1
Corda, M.G., Giorgi, O., Longoni, B. and Biggio, G.
Ro 15-4513, a partial inverse agonist for benzodiazepine recognition sites, has proconflict and proconvulsant effects in the rat (159) 233
Corda, M.G., Giorgi, O., Longoni, B., Ongini, E., Pesce, G., Cruciani, R. and Biggio, G.
Functional coupling of GABA$_A$ receptors and benzodiazepine recognition site subtypes in the spinal cord of the rat (169) 205
Corda, M.G., see Biggio, G. (161) 173
Cordeau, L.R., see Larcher, J.-C. (161) 197
Corringer, P.-J., see Durieux, C. (168) 269
Corsi, R., see Kreil, G. (162) 123
Corti, V., see Ledda, F. (162) 323
Cortijo, J., Ortiz, J.L., Sanz, C., Sarría, B., Pascual, R., Perpiñá, M., Esplugues, J. and Morcillo, E.J.
Modification by indomethacin of airway contractile responses in normal and sensitized guinea-pigs (162) 467
Cosi, C., Altar, A.C. and Wood, P.L.
Effect of cholecystokinin on acetylcholine turnover and dopamine release in the rat striatum and cortex (165) 209
Costello, A.H. and Hargreaves, K.M.
Suppression of carrageenan-induced hyperalgesia, hyperthermia and edema by a bradykinin antagonist (171) 259
Costello, A.H., see Hargreaves, K.M. (170) 275
Cote, T.E., see Frey, E.A. (172) 347
Cotman, C.W., see Palmer, E. (166) 585
Couture, R., see Laneuville, O. (159) 273
Cox, A., see Feely, M. (164) 377
Coy, D.H., see Minkes, R.K. (164) 571
Cozzi, E., see Chiabrando, C. (159) 257
Cragoe, Jr., E.J., see Nasri-Sebdani, M. (171) 97
Crema, A., see De Ponti, F. (168) 133
Cremei, G., see Rumbach, L. (164) 577
Crisp, T., Stafinsky, J.L., Hess, J.E. and Uram, M.
Spinal β-endorphin analgesia involves an interaction with local monoaminergic systems (160) 211
Criswell, H.E., Mueller, R.A. and Breese, G.A.
Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors (159) 141
Crocker, A.D., see Faunt, J.E. (162) 237
Croizat, B.P., see Larcher, J.-C. (161) 197
Crompton, M.R., see De Paermentier, F. (167) 397
Cros, J., see Gairin, J.-E. (172) 381
Crowell, S., see Davis, T.P. (161) 283
Cruciani, R., see Corda, M.G. (169) 205
Cruciani, R., see Fochtmann, L.J. (167) 305
Cuffi, L., see Ferré, S. (166) 303
Cuffi, M.L., Vila, E. and Badia, A.
Increased peripheral α_1-adrenoceptor sensitivity following chronic thioridazine treatment in the pithed rat (168) 111
Cui, H., see Tang, C.S. (159) 327
Culling-Berglund, A., see Davis, T.P. (161) 283
Cumming, P., Jakubovic, A. and Vincent, S.R.
Cerebral histamine levels are unaffected by MPTP administration in the mouse (166) 299
Currie, M.G., see Oehlenschlager, W.F. (161) 159
Curzon, G., see Haleem, D.J. (164) 435
Curzon, G., see Kennett, G.A. (164) 445
Custers, A.F.C.M., see IJzerman, A.P. (172) 273

Daan, S., see Dijk, D.J. (171) 207
Dabiré, H., Chaouche-Teyara, K., Cherqui, C., Fournier, B. and Schmitt, H.
DOI is a mixed agonist-antagonist at postjunctional 5-HT$_2$ receptors in the pithed rat (170) 109
Dabiré, H., Chaouche-Teyara, K., Cherqui, C., Fournier, B.,

Laubie, M. and Schmitt, H.
Characterization of DOI, a putative 5-HT_2 receptor agonist in the rat (168) 369
Dabiré, H., see Laubie, M. (160) 385
Dacquet, C., see Loirand, G. (167) 265
Daffonchio, L., Payne, A.N., Lees, I.W. and Whittle, B.J.R.
Airway hyperreactivity follows anaphylactic microshock in anaesthetized guinea-pigs (161) 135
Daffonchio, L., see Omini, C. (163) 195
Damase-Michel, C., see Montastruc, P. (166) 511
Dammann, F., see Bognar, I.T. (163) 263
Damsma, G., Day, J. and Fibiger, H.C.
Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens (168) 363
Dandona, P., see Jeremy, J.Y. (160) 107
D'Angelo, L., see De Ponti, F. (168) 133
D'Angio, M., see Serrano, A. (162) 157
Dannals, R.F., see Titeler, M. (167) 221
Da Prada, M., see Cesura, A.M. (162) 457
Dar, M.S.
Central nervous system effects and behavioral interactions with ethanol of centrally administered dilazep and its metabolites in mice (164) 303
Darriet, D., see Broussolle, E. (159) 225
Daugé, V., Dor, A., Féger, J. and Roques, B.P.
The behavioral effects of CCK8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat (163) 25
Daugé, V., see Maldonado, R. (165) 199
Dausse, J.P., see Yablonsky, F. (164) 167
DaVanzo, E.A., see McMillen, B.A. (160) 149
Daviaud, D., see Sénard, J.-M. (162) 225
David, F., see Wisner, A. (162) 89
Davis, T.P., Burgess, H.S., Crowell, S., Moody, T.W., Culling-Berglund, A. and Liu, R.H.
β-Endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells (161) 283
Day, J., see Damsma, G. (168) 363
De Backer, J.-P., see Convents, A. (159) 307
Debaert, M., see Kerr, D.I.B. (164) 361
Debilly, G., see Broussolle, E. (159) 225
Debler, E.A., Lipovac, M.N., Lajtha, A., Zlokovic, B.V., Jacobson, A.E., Rice, K.C. and Reith, M.E.A.
Metaphit, an isothiocyanate analog of PCP, induces audiogenic seizures in mice (165) 155
De Boer, T., see Ronken, E. (162) 189
De Boer, T., see Room, P. (171) 69
De Bonfioli Cavalcabó, P., see Cerbai, E. (162) 491
Deckers, I.A., Rampart, M., Bult, H. and Herman, A.G.
Evidence for the involvement of prostaglandins in modulation of acetylcholine release from canine bronchial tissue (167) 415
De Costa, B.R., see Rothman, R.B. (167) 345
DeFelice, A., Harris, A., Frering, R. and Horan, P.
Beneficial hemodynamic effects of milrinone and enalapril in conscious rats with healed myocardial infarction (167) 211
Deighton, N.M., Hamilton, C.A., Howie, C.A. and Reid, J.L.
Effects of short-term exposure to noradrenaline and adrenaline on adrenoceptor responses (169) 95
De Keyser, J., Walraevens, H., Convents, A., Ebinger, G. and Vauquelin, G.
[^{3}H]SCH 23390 labels a novel 5-hydroxytryptamine binding site in human blood platelet membranes (162) 437
De Keyser, J., see Convents, A. (159) 307
DeLander, G.E. and Wahl, J.J.
In vivo characterization of phencyclidine/σ agonist-mediated inhibition of nociception (159) 149
DeLanney, L.E., see Di Monte, D. (166) 23
Delay-Goyet, P., see De Vries, T.J. (170) 137
Delay-Goyet, P., see Meucci, E. (171) 167
Del Bianco, E., see Maggi, C.A. (170) 167
Del Carmen de Felipe, M., Jiménez, I., Castro, A. and Fuentes, J.A.
Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases (159) 175
Dellouve-Courillon, C., Lambolez, B., Potier, P. and Dodd, R.H.
First use of a β-carboline as photoaffinity label for the benzodiazepine receptor (166) 557
De Mendonça, A. and Ribeiro, J.A.
Diazepam enhances the inhibitory action of adenosine on transmission at the frog neuromuscular junction (164) 347
De Michele, M., Amenta, F. and Cavallotti, C.
Autoradiographic localization of muscarinic receptors within the rat kidney (169) 297
Demirel, E., Tulunay, F.C. and Türker, R.K.
Ergotamine enhances acetylcholine-induced relaxation in various vascular segments of rabbits (159) 195
Demoliou-Mason, C.D., see Gut, S.H. (172) 339
De Montigny, C., see Lista, A. (171) 229
De Montis, G.M., Devoto, P., Gessa, G.L., Meloni, D., Porcella, A., Saba, P., Serra, G. and Tagliamonte, A.
Chronic imipramine reduces [^{3}H]SCH 23390 binding and DA-sensitive adenylate cyclase in the limbic system (167) 299
Demura, H., see Tsuchiya, K. (166) 541
Den Hertog, A., Nelemans, A. and Van den Akker, J.
The inhibitory action of suramin on the P_2-purinoceptor response in smooth muscle cells of guinea-pig taenia caeci (166) 531
Den Hertog, A., see Molleman, A. (169) 167
Den Hertog, A., see Nelemans, A. (172) 283
Dent, G., Ukena, D., Sybrecht, G.W. and Barnes, P.J.
[^{3}H]WEB 2086 labels platelet activating factor receptors in guinea pig and human lung (169) 313
De Nucci, G., see D'Orleans-Juste, P. (165) 289
De Nucci, G., see Warner, T.D. (159) 325
De Paermentier, F., Cheetham, S.C., Crompton, M.R. and Horton, R.W.
β-Adrenoceptors in human brain labelled with [^{3}H]dihydroalprenolol and [^{3}H]CGP 12177 (167) 397
De Peyer, J.-E., see Haeusler, G. (166) 175

De Ponti, F., D'Angelo, L., Frigo, G.M. and Crema, A.
Inhibitory effects of calcium channel blockers on intestinal motility in the dog (168) 133
Deppeler, C.L., see Watson, G.B. (167) 291
De Robertis, E., see Stockert, M. (160) 11
Desban, M., see Krebs, M.-O. (166) 567
Devillier, P., Drapeau, G., Renoux, M. and Regoli, D.
Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides (168) 53
Devoto, P., see De Montis, G.M. (167) 299
De Vries, J.B., see Timmerman, W. (162) 143
De Vries, J.B., see Timmerman, W. (166) 1
De Vries, T.J., Schoffelmeer, A.N.M., Delay-Goyet, P., Roques, B.P. and Mulder, A.H.
Selective effects of [D-Ser^2(O-t-butyl),Leu^5]enkephalyl-Thr^6 and [D-Ser^2(O-t-butyl),Leu^5]enkephalyl-Thr^6(O-t-butyl), two new enkephalin analogues, on neurotransmitter release and adenylate cyclase in rat brain slices (170) 137
De Vry, J., Donselaar, I. and Van Ree, J.M.
Intraventricular self-administration of heroin in the rat: reward seems dissociated from analgesia and physical dependence (161) 19
Dewar, K.M., see Mathieu, J.-F. (162) 173
De Wied, D., see Kovács, G.L. (161) 27
De Wildt, D.J., see Van Heuven-Nolsen, D. (162) 135
Dhasmana, K.M., Banerjee, A.K. and Saxena, P.R.
Hypotension and bradycardia after intrathecal ketanserin and phentolamine in the rat (168) 257
Di Carlo, R., see Muccioli, G. (166) 223
Di Chiara, G., see Carboni, E. (164) 515
Di Chiara, G., see Imperato, A. (160) 155
Di Chiara, G., see Morelli, M. (162) 329
Di Clemente, A., see Invernizzi, R. (163) 77
Diebler, M.-F., see Gaudry-Talarmain, Y.M. (166) 427
Diecke, F.P.J., see Greenberg, S. (162) 67
Diener, M., Knobloch, S.F., Bridges, R.J., Keilmann, T. and Rummel, W.
Cholinergic-mediated secretion in the rat colon: neuronal and epithelial muscarinic responses (168) 219
Díez, J., see Esparza, N. (166) 349
Di Francesco, G.F., see Petty, M.A. (162) 359
Dijk, D.J., Beersma, D.G.M., Daan, S. and Van den Hoofdakker, R.H.
Effects of seganserin, a 5-HT$_2$ antagonist, and temazepam on human sleep stages and EEG power spectra (171) 207
Dijk, J., see Bosker, F.J. (163) 319
Di Luca, M., Cimino, M., Pia Abbracchio, M. and Cattabeni, F.
In vivo modulation of striatal phosphoproteins by dopaminergic agents (172) 321
Di Marzo, V., Tippins, J.R. and Morris, H.R.
The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides (162) 115
Di Monte, D., Irwin, I., Kupsch, A., Cooper, S., DeLanney, L.E. and Langston, J.W.
Diethyldithiocarbamate and disulfiram inhibit MPP$^+$ and dopamine uptake by striatal synaptosomes (166) 23
Dinh Xuan, A.T., Higenbottam, T.W., Pepke-Zaba, J., Clelland, C. and Wallwork, J.
Reduced endothelium-dependent relaxation of cystic fibrosis pulmonary arteries (163) 401
Dion, S., see Rhaleb, N.-E. (162) 419
Di Patre, P.L., Abbamondi, A., Bartolini, L. and Pepeu, G.
GM1 ganglioside counteracts cholinergic and behavioral deficits induced in the rat by intracerebral injection of vincristine (162) 43
Di Renzo, G., Amoroso, S., Taglialatela, M., Canzoniero, L., Basile, V., Fatatis, A. and Annunziato, L.
Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion (162) 371
Di Rosa, M., see Carnuccio, R. (166) 535
Dissing, S., see Undén, M. (164) 129
Dlewati, A., Watkins, H.O. and Lokhandwala, M.F.
Effects of SK&F 85174, a DA-1/DA-2 receptor agonist, on pre- and postganglionic sympathetic neurotransmission to the heart (164) 197
Dodd, R.H., see Dellouve-Courillon, C. (166) 557
Dolci, W., see Vallotton, M.B. (166) 219
Doly, M., see Thierry, A. (163) 97
Domenech, R.J., see Macho, P. (167) 67
Donoso, M.V. and Huidobro-Toro, J.P.
Involvement of postjunctional purinergic mechanisms in the facilitatory action of bradykinin in neurotransmission in the rat vas deferens (160) 263
Donselaar, I., see De Vry, J. (161) 19
Dontenwill, M., see Bricca, G. (162) 1
Dontenwill, M., see Bricca, G. (163) 373
Dor, A., see Daugé, V. (163) 25
D'Orleans-Juste, P., De Nucci, G. and Vane, J.R.
Endothelin-1 contracts isolated vessels independently of dihydropyridine-sensitive Ca^{2+} channel activation (165) 289
Douglas, B.R., Jebbink, M.C.W., Tjon A Tham, R.T.O., Jansen, J.B.M.J. and Lamers, C.B.H.W.
The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man (166) 307
Douglas, B.R., Woutersen, R.A., Jansen, J.B.M.J., Rovati, L.C. and Lamers, C.B.H.W.
Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters (161) 209
D'Oyley, H.M., Tabrizchi, R. and Pang, C.C.Y.
Effects of vasodilator drugs on venous tone in conscious rats (162) 337
Drago, F., see Clementi, G. (163) 175
Dragunow, M., see Robertson, G.S. (159) 99
Drapeau, G., see Devillier, P. (168) 53
Drapeau, G., see Maggi, C.A. (165) 51
Drapeau, G., see Rhaleb, N.-E. (162) 419
Dray, F., see Wisner, A. (162) 89
Drejer, J., see Honoré, T. (172) 239
Drenth, J.P.H., see Vos, M.A. (165) 139
Dresse, A., see Seutin, V. (164) 373

Drouillat, M., see Laubie, M. (160) 385
Drozdowicz, D., see Konturek, S.J. (164) 285
Dubner, R., see Hargreaves, K.M. (170) 275
Dubocovich, M.L., Shankar, G. and Mickel, M.
2-[^{125}I]Iodomelatonin labels sites with identical pharmacological characteristics in chicken brain and chicken retina (162) 289
Dubocovich, M.L., see Timmerman, W. (166) 1
Duckles, S.P., see Budai, D. (168) 97
Duerson, K.C., see Laird II, H.E. (171) 25
Dufy, B., see Mollard, P. (172) 71
Dumuis, A., Sebben, M. and Bockaert, J.
BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons (162) 381
Duncia, J.V., see Chiu, A.T. (170) 117
Dunn, R.W., Corbett, R. and Fielding, S.
Effects of 5-HT_{1A} receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze (169) 1
Dunwiddie, T.V., see Fredholm, B.B. (172) 249
Durcan, M.J. and Morgan, P.F.
Evidence for adenosine A_2 receptor involvement in the hypomobility effects of adenosine analogues in mice (168) 285
Durieux, C., Corringer, P.-J., Bergeron, F. and Roques, B.P.
[^{3}H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors (168) 269
Dutar, P., Lamour, Y. and Nicoll, R.A.
Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus (164) 355

Earley, K.J., see Tenner, Jr., T.E. (160) 291
Ebinger, G., see De Keyser, J. (162) 437
Edenius, C., see Tornhamre, S. (169) 225
Edvinsson, L., see Fallgren, B. (170) 61
Edwards, E., see Butler, P.D. (160) 93
Edwards, E., see Jr.eer, C.R.A. (166) 583
Egashira, S., see Adachi, H. (161) 189
Eilam, D. and Szechtman, H.
Biphasic effect of D-2 agonist quinpirole on locomotion and movements (161) 151
Eizirik, D.L., see Jansson, L. (161) 79
Ekholm, S. and Karppanen, H.
Cardiovascular effects of L-tyrosine: influence of blockade of tyrosine metabolism (163) 209
Ekholm, S.
Further studies on the mechanism of the cardiovascular effects of L-tyrosine (168) 145
Ekman, R., see Wahlestedt, C. (159) 285
El-Ayoubi, N., see Chideckel, E.W. (166) 367
El-Fakahany, E.E., see Lee, N.H. (167) 295
Elands, J., see Van Ree, J.M. (166) 441
Elgoyhen, B. and Adler-Graschinsky, E.
Diminution by benzodiazepines of the chronotropic responses to noradrenaline in rat isolated atria (164) 467
Elinder, F., Mohammed, A.K., Winblad, B. and Århem, P.
Effects of THA on ionic currents in myelinated axons of *Xenopus laevis* (164) 599
Eltze, M., Boer, R., Mutschler, E. and Lambrecht, G.
Affinity profiles of BTM-1086 and BTM-1041 at muscarinic receptor subtypes and at H_1- and α_1-receptors (170) 225
Eltze, M.
Competitive antagonism by glibenclamide of cromakalim inhibition of twitch contractions in rabbit vas deferens (161) 103
Eltze, M.
Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery (165) 231
Eltze, M., see Schudt, C. (165) 87
Elzinga, C.R.S., see Roffel, A.F. (172) 61
Emerit, M.B., see Gozlan, H. (172) 497
Emmett, M.R., see Rao, T.S. (168) 129
Emori, T., see Hirata, Y. (164) 603
Enero, M.A., see Taira, C.A. (159) 265
Engber, T.M., Susel, Z., Juncos, J.L. and Chase, T.N.
Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists (168) 291
Engel, G., see Berthold, H. (162) 19
Engels, F., Carstairs, J.R., Barnes, P.J. and Nijkamp, F.P.
Autoradiographic localization of changes in pulmonary β-adrenoceptors in an animal model of atopy (164) 139
Erdmann, E., see Böhm, M. (172) 407
Erdö, S.L., Ezer, E., Matuz, J., Wolff, J.R. and Amenta, F.
$GABA_A$ receptors in the rat stomach may mediate mucoprotective effects (165) 79
Erdö, S.L., see Michler, A. (167) 423
Erspamer, V., see Kreil, G. (162) 123
Erspamer, V., see Raiteri, M. (172) 223
Esparza, N. and Díez, J.
Rat atrial natriuretic peptide stimulates K^+ fluxes in human erythrocytes (166) 349
Esplugues, J., see Cortijo, J. (162) 467
Esposito, E. and Bunney, B.S.
The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons (162) 109
Evangelista, S., Renzi, D., Mantellini, P., Surrenti, C. and Meli, A.
Duodenal ulcers are associated with a depletion of duodenal calcitonin gene-related peptide-like immunoreactivity in rats (164) 389
Evans, H.G., Ryley, H.C., Hallett, I. and Lewis, M.J.
Human red blood cells inhibit endothelium-derived relaxing factor (EDRF) activity (163) 361
Ezer, E., see Erdö, S.L. (165) 79

Fahrenholz, F., see Gerstberger, R. (167) 105
Falconieri Erspamer, G., see Kreil, G. (162) 123
Fallgren, B., Bergstrand, H. and Edvinsson, L.
Calcium influx and protein kinase C activation involved in uterine vasoconstriction in guinea pigs (170) 61

Fanelli, R., see Chiabrando, C. (159) 257
Farack, U.M., see Loeschke, K. (170) 41
Fares, F., see Weizman, A. (169) 235
Farilla, C., see Bernardi, L. (164) 415
Farkas, S., see Tarnawa, I. (167) 193
Fatatis, A., see Di Renzo, G. (162) 371
Faulkner, N.L., see Cocks, T.M. (171) 17
Faunt, J.E. and Crocker, A.D.
Effects of adrenalectomy on responses mediated by dopamine D-1 and D-2 receptors (162) 237
Favit, A., see Nicoletti, F. (160) 299
Feddersen, M., see Vesperinas, G. (165) 309
Fedele, E., see Maura, G. (165) 173
Fedynyshyn, J.P., Kwiat, G. and Lee, N.M.
Characterization of high affinity opioid binding sites in rat periaqueductal gray P_2 membrane (159) 83
Feely, M., Boyland, P., Picardo, A., Cox, A. and Gent, J.P.
Lack of anticonvulsant tolerance with RU 32698 and Ro 17-1812 (164) 377
Féger, J., see Daugé, V. (163) 25
Feger, J., see Maldonado, R. (165) 199
Feifel, R., see Lambrecht, G. (168) 71
Feigenbaum, J.J., Richmond, S.A., Weissman, Y. and Mechoulam, R.
Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid (169) 159
Feldman, J., see Bricca, G. (162) 1
Feldman, J., see Bricca, G. (163) 373
Feltz, P., see Schumacher, C. (166) 139
Feniuk, W., see Connor, H.E. (161) 91
Fenu, S., see Morelli, M. (162) 329
Fernández, H., see Ågmo, A. (166) 115
Fernández, M., see Monti, J.M. (169) 61
Ferrari, M., see Bova, S. (168) 179
Ferrario, R.G., Foulkes, R., Salvati, P. and Patrono, C.
Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney (171) 127
Ferré, S., Guix, T., Sallés, J., Cuffí, L., Badia, A. and Casas, M.
BHT-920 and LY-171555 (quinpirole) have similar affinities for striatal D-2 dopamine receptors, and similar affinities for striatal D-1 dopamine receptors (166) 303
Ferretti, C., Ghi, P., Blengio, M., Gaietta, G., Barrera, G. and Genazzani, E.
Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity? (166) 149
Ferron, A., see Mathieu, J.-F. (162) 173
Feuerstein, G., see Vonhof, S. (164) 77
Fibiger, H.C., see Damsma, G. (168) 363
Field, J.L., see Freedman, S.B. (167) 411
Fielding, S., see Dunn, R.W. (169) 1
File, S.E., see Baldwin, H.A. (159) 211
Fillion, G., see Bolanos, F. (168) 87
Finardi, G., see Bernardi, L. (164) 415
Finet, M., Bravo, G. and Godfraind, T.
The protective action of R56865 against ouabain-induced intoxication in rat heart isolated atria and ventricles (164) 555
Fink, K., see Molderings, G.J. (164) 213
Fiore, C.E., see Clementi, G. (166) 549
Fischer, G., see Grohs, J.G. (161) 53
Fischer, J.A., see Vallotton, M.B. (166) 219
Fitzgerald, M.F., Parente, L. and Whittle, B.J.R.
Release of PAF-acether and eicosanoids from guinea-pig alveolar macrophages by FMLP: effect of cyclo-oxygenase and lipoxygenase inhibition (164) 539
Fjalland, B., see Christensen, J.D. (171) 233
Fjalland, B., see Grell, S. (166) 41
Fleck, E., see Bossaller, C. (165) 165
Flower, R.J., see Cirino, G. (166) 505
Flynn, D.D., Palermo, N. and Suarez, A.
Agonist binding to M_1 muscarinic receptors is sensitive to guanine nucleotides (172) 363
Fochtmann, L.J., Cruciani, R., Aiso, M. and Potter, W.Z.
Chronic electroconvulsive shock increases D-1 receptor binding in rat substantia nigra (167) 305
Foder, B., see Scharff, O. (159) 165
Fok, K.F., see Han, S.P. (159) 303
Fonnum, F., see Aas, P. (164) 93
Fontaine, J. and Lebrun, P.
Galanin: Ca^{2+}-dependent contractile effects on the isolated mouse distal colon (164) 583
Fontana, G., see Bonanno, G. (172) 41
Fontana, M.D., see Vital Brazil, O. (159) 47
Foreman, J.C., see Cantwell, M.E. (160) 43
Forray, C., see Lee, N.H. (167) 295
Förstermann, U., see Bossaller, C. (165) 165
Förstermann , U., see Alheid, U. (164) 103
Fortes, Z.B., Scivoletto, R. and Garcia-Leme, J.
Endothelin-1 induces potent constriction of lymphatic vessels in situ (170) 69
Foulkes, R., see Ferrario, R.G. (171) 127
Fournié-Zaluski, M.-C., see Maldonado, R. (165) 199
Fournier, B., see Dabiré, H. (168) 369
Fournier, B., see Dabiré, H. (170) 109
Fozard, J.R., see Berthold, H. (162) 19
Fracasso, C., see Invernizzi, R. (163) 77
Fraeyman, N., see Vanscheeuwijck, P. (172) 373
France, C.P., Woods, J.H. and Ornstein, P.
The competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 attenuates the rate-decreasing effects of NMDA in rhesus monkeys without producing ketamine-like discriminative stimulus effects (159) 133
France, C.P., see Rothman, R.B. (167) 345
Franzone, J.S., Cirillo, R. and Biffignandi, P.
Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF (165) 269
Frau, R., see Carboni, E. (164) 515
Fredholm, B.B., Proctor, W., Van der Ploeg, I. and Dunwiddie, T.V.
In vivo pertussis toxin treatment attenuates some, but not all, adenosine A_1 effects in slices of the rat hippocampus (172) 249
Fredholm, B.B., see Nordstedt, C. (172) 51
Fredholm, B.B., see Von Euler, G. (172) 435

Freedman, J.E. and Weight, F.F.
Quinine potently blocks single K^+ channels activated by dopamine D-2 receptors in rat corpus striatum neurons (164) 341
Freedman, S.B., Field, J.L., Gilbert, M.J. and Newberry, N.R.
Hexahydrodifenidol does not distinguish among M_1 receptors in rat cerebral cortex, hippocampus and superior cervical ganglion (167) 411
Freeman, A.S., see Kelland, M.D. (169) 11
Freeman, A.S., see Pitts, D.K. (162) 167
Frelin, C., see Vigne, P. (160) 295
Frering, R., see DeFelice, A. (167) 211
Frey, E.A., Gosse, M.E. and Cote, T.E.
Reconstitution of the solubilized μ-opioid receptor coupled to a GTP-binding protein (172) 347
Frey, J.M., see Huffman, R.D. (170) 179
Frigo, G.M., see De Ponti, F. (168) 133
Fritze, J., Koronakis, P., Konradi, C. and Riederer, P.
Isoelectric focusing of monoamine oxidase subtypes as identified by MAO inhibitors (172) 147
Frost, J.F., see Titeler, M. (167) 221
Fu, Q.-G., see Sandkühler, J. (160) 163
Fu, W.-M., see Lin-Shiau, S.-Y. (167) 137
Fuder, H., see Bognar, I.T. (163) 263
Fuentes, J.A., see Del Carmen de Felipe, M. (159) 175
Fujimoto, J.M., see Suh, H.H. (168) 61
Fujimoto, M., see Mihara, S. (160) 313
Fujimoto, M., see Mihara, S. (171) 179
Fujino, M., see Nishida, N. (166) 453
Fujioka, H., Horiike, K., Takahashi, M., Ishida, T., Kinoshita, M. and Nozaki, M.
Dithiothreitol-induced triphasic response of dog coronary arteries (166) 13
Fujioka, M., see Komori, K. (164) 111
Fujishima, K., see Nakayama, K. (169) 33
Fujishima, M., see Sadoshima, S. (169) 75
Fukagawa, Y., Katz, J.L. and Suzuki, T.
Effects of a selective κ-opioid agonist, U-50,488H, on morphine dependence in rats (170) 47
Fukuda, K., Hori, S., Kusuhara, M., Satoh, T., Kyotani, S., Handa, S., Nakamura, Y., Oono, H. and Yamaguchi, K.
Effect of endothelin as a coronary vasoconstrictor in the Langendorff-perfused rat heart (165) 301
Fukui, K., see Shoji, T. (171) 219
Fukumitsu, K., see Kinouchi, K. (164) 63
Fuller, C.A., see Miller, J.D. (161) 165
Funder, J., see Lin, W. (171) 9
Furukawa, H., see Takeya, K. (169) 137
Furukawa, T., see Katsuragi, T. (167) 147
Furukawa, T., see Morishita, H. (164) 507
Furukawa, Y., Ogiwara, Y., Saegusa, K., Akahane, K. and Chiba, S.
Differential vagal inhibition of the positive chronotropic and inotropic responses to cardiotonics in the isolated dog atrium (161) 1
Fuxe, K., see Von Euler, G. (172) 435

Gaietta, G., see Ferretti, C. (166) 149
Gairin, J.-E., Botanch, C., Cros, J. and Meunier, J.-C.
Binding of dynorphin A and related peptides to κ- and μ-opioid receptors: sensitivity to Na^+ ions and Gpp(NH)p (172) 381
Galand, N., see Raspe, E. (163) 345
Gallager, D.W., see Hernandez, T.D. (170) 145
Galli, A., see Moroni, F. (163) 123
Gallissot, M.C., see Hamon, M. (164) 315
Galva, M.D., see Cesura, A.M. (162) 457
Galvan, M., Boer, R. and Schudt, C.
Interaction of telenzepine with muscarinic receptors in mammalian sympathetic ganglia (167) 1
Gandolfo, G., Gottesmann, C., Bidard, J.-N. and Lazdunski, M.
Ca^{2+} channel blockers prevent seizures induced by a class of K^+ channel inhibitors (160) 173
Gandolfo, G., Gottesmann, C., Bidard, J.-N. and Lazdunski, M.
K^+ channels openers prevent epilepsy induced by the bee venom peptide MCD (159) 329
Gandolfo, G., Romettino, S., Gottesmann, C., Van Luijtelaar, G., Coenen, A., Bidard, J.-N. and Lazdunski, M.
K^+ channel openers decrease seizures in genetically epileptic rats (167) 181
Garattini, S., see Chiabrando, C. (159) 257
Garattini, S., see Invernizzi, R. (163) 77
Garattini, S., see Invernizzi, R. (164) 241
Garau, L., see Morelli, M. (162) 329
Garbarg, M., Tuong, M.D.T., Gros, C. and Schwartz, J.C.
Effects of histamine H_3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain (164) 1
Garcia-Leme, J., see Fortes, Z.B. (170) 69
García-Sevilla, J.A., see Giralt, M.T. (164) 455
Gardiner, S.M., Compton, A.M., Bennett, T., Palmer, R.M.J. and Moncada, S.
N^G-monomethyl-L-arginine does not inhibit the hindquarters vasodilator action of endothelin-1 in conscious rats (171) 237
Gargouil, Y.-M., see Mahe, L. (167) 31
Garlicki, J., see Konturek, S.J. (164) 285
Garrido, R., see Tomioka, K. (170) 209
Garsky, V.M., see Winquist, R.J. (163) 199
Garthwaite, G., see Garthwaite, J. (172) 413
Garthwaite, J., Garthwaite, G., Palmer, R.M.J. and Moncada, S.
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices (172) 413
Gary, Jr., R.K., see Woodward, D.F. (164) 323
Garzón, J., see Sánchez-Blázquez, P. (159) 9
Garzón, J., see Sánchez-Blázquez, P. (166) 193
Gašparík, J.
Biologically active conformation of [Met^5]- and [Leu^5]enkephalin on δ opioid receptor (172) 417
Gauchy, C., see Krebs, M.-O. (166) 567
Gaudry-Talarmain, Y.M., Diebler, M.-F., Robba, M., Lancelot, J.-C., Lesbats, B. and Israël, M.
Effect of cetiedil analogs on acetylcholine and choline fluxes in synaptosomes and vesicles (166) 427
Gaviraghi, G., see Reggiani, A. (168) 123

Gavish, M., see Weizman, A. (169) 235
Gaya, J., see Lòpez, C. (168) 1
Gazzara, R.A., Takeda, H., Cho, A.K. and Howard, S.G.
Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin (168) 209
Gee, K.W., see Belelli, D. (166) 325
Gee, K.W., see Belelli, D. (167) 173
Geiger, J.D., see Westerberg, V.S. (160) 275
Geisler, A., see Mørk, A. (168) 347
Gelband, C.H., Lodge, N.J. and Van Breemen, C.
A Ca^{2+}-activated K^+ channel from rabbit aorta: modulation by cromakalim (167) 201
Genazzani, E., see Ferretti, C. (166) 149
Gensini, G.F., see Modesti, P.A. (169) 85
Gent, J.P., see Feely, M. (164) 377
Gentil, B., Macquin-Mavier, I. and Harf, A.
Fentanyl-induced airway hyperreactivity in the guinea pig (159) 181
Geoffroy, M., Lambolez, B., Prado de Carvalho, L., Rossier, J. and Stinnakre, J.
Concanavalin A potentiates NMDA-evoked responses in the *Xenopus* oocyte expression system (166) 355
George, R., see Pechnick, R.N. (164) 257
George, R., see Pechnick, R.N. (166) 295
Geppetti, P., Patacchini, R., Meini, S. and Manzini, S.
Contractile effect of endothelin on isolated iris sphincter muscle of the pig (168) 119
Geppetti, P., see Maggi, C.A. (170) 167
Gerard, J.-L., Berdeaux, A. and Giudicelli, J.-F.
Cardiac and hemodynamic profile of the new cardiotonic agent, DPI 201-106, in the conscious dog (165) 39
Gerber-Wicht, C., see Vallotton, M.B. (166) 219
Gerhards, H., see Wiemer, G. (166) 31
Gerhards, H.J., see Hock, F.J. (171) 79
Gerrish, K.E., see Laird II, H.E. (171) 25
Gerst, J.E., Benezra, M., Schimmer, A. and Salomon, Y.
Phorbol ester impairs melanotropin receptor function and stimulates growth of cultured M2R melanoma cells (172) 29
Gerstberger, R. and Fahrenholz, F.
Autoradiographic localization of V_1 vasopressin binding sites in rat brain and kidney (167) 105
Gessa, G., see Rossetti, Z.L. (163) 393
Gessa, G.L., see Argiolas, A. (166) 515
Gessa, G.L., see De Montis, G.M. (167) 299
Gessa, G.L., see Melis, M.R. (164) 565
Geyer, M.A., see Mansbach, R.S. (167) 49
Ghataorre, A.S., see Lambert, D.G. (165) 71
Ghatei, M., see Power, R.F. (150) 199
Ghi, P., see Ferretti, C. (166) 149
Giachetti, A., see Maggi, C.A. (166) 121
Gião T. Rico, J.M., see Macara, B. (162) 51
Gibb, J.W., see Hanson, G.R. (160) 23
Gibb, J.W., see Johnson, M. (161) 181
Gibb, J.W., see Johnson, M. (165) 315
Gibb, J.W., see Merchant, K.M. (160) 409
Gierschik, P., Sidiropoulos, D., Steisslinger, M. and Jakobs, K.H.
Na^+ regulation of formyl peptide receptor-mediated signal transduction in HL 60 cells. Evidence that the cation prevents activation of the G-protein by unoccupied receptors (172) 481
Gierschik, P., see Böhm, M. (172) 407
Gierschik, P., see Reithmann, C. (172) 211
Gilbert, M.J., see Freedman, S.B. (167) 411
Gilbert, M.J., see Newberry, N.R. (162) 197
Gilbert, M.J., see Newberry, N.R. (163) 237
Gilbert, M.J., see Newberry, N.R. (163) 245
Giles, R.E., see Krell, R.D. (159) 73
Gillard, M., Brunner, F., Waelbroeck, M., Svoboda, M. and Christophe, J.
Bretylium tosylate binds preferentially to muscarinic receptors labelled with [^{3}H]oxotremorine M (SH or 'high affinity' receptors) in rat heart and brain cortex (160) 117
Gintzler, A.R., see Sander, H.W. (159) 205
Giordano, A.L., see Nock, B. (162) 385
Giordano, J. and Rogers, L.V.
Peripherally administered serotonin 5-HT_3 receptor antagonists reduce inflammatory pain in rats (170) 83
Giorgi, O., see Corda, M.G. (159) 233
Giorgi, O., see Corda, M.G. (169) 205
Giralt, M.T. and García-Sevilla, J.A.
Acute and long-term regulation of brain α_2-adrenoceptors after manipulation of noradrenergic transmission in the rat (164) 455
Gistrak, M.A., see Paul, D. (168) 307
Giudicelli, J.-F., see Gerard, J.-L. (165) 39
Giuliani, S., Amann, R., Papini, A.M., Maggi, C.A. and Meli, A.
Modulatory action of galanin on responses due to antidromic activation of peripheral terminals of capsaicin-sensitive sensory nerves (163) 91
Giuliani, S., see Maggi, C.A. (160) 179
Giuliani, S., see Maggi, C.A. (166) 121
Giuliani, S., see Maggi, C.A. (170) 167
Glavin, G.B.
Calcium channel modulators: effects on gastric function (160) 323
Gleason, J.G., see Woodward, D.F. (164) 323
Glennon, R.A., Ismaiel, A.E.-K.M., McCarthy, B.G. and Peroutka, S.J.
Binding of arylpiperazines to 5-HT_3 serotonin receptors: results of a structure-affinity study (168) 387
Glenthøj, B. and Hemmingsen, R.
Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat (164) 393
Glossman, H., see Graziadei, I. (172) 329
Glossmann, H., see Boer, R. (172) 131
Glowinski, J., see Krebs, M.-O. (166) 567
Gobert, J., see Gower, A.J. (166) 271
Godfraind, T., see Finet, M. (164) 555
Goffinet, A.M. and Nguyen, A.
Brain leukotriene C_4 binding sites are S-alkylglutathione binding sites (161) 99
Gold, M.E., see Buga, G.M. (161) 61

Goldberg, L.I., see Kohli, J.D. (164) 265
Goldfarb, J., see Clarke, W.P. (160) 195
Goldstein, D.S., see Szemeredi, K. (170) 53
Gomaa, A.A., Mohamed, L.H. and Ahmed, H.N.
Modification of morphine-induced analgesia, tolerance and dependence by bromocriptine (170) 129
Gonon, F.G., see Suaud-Chagny, M.-F. (164) 273
Gonsalves, S.F., Twitchell, B., Harbaugh, R.E., Krogsgaard-Larsen, P. and Schousboe, A.
Anticonvulsant activity of the glial GABA uptake inhibitor, THAO, in chemical seizures (168) 265
Goode, T.L., see Raffa, R.B. (169) 317
Gorce, P., see Collin, E. (168) 201
Gordon, J.C., see Pinkus, L.M. (168) 355
Gorgels, A.P.M., see Vos, M.A. (165) 139
Gosse, M.E., see Frey, E.A. (172) 347
Göthert, M., see Molderings, G.J. (164) 213
Goto, K., see Saito, A. (162) 353
Gottesmann, C., see Gandolfo, G. (159) 329
Gottesmann, C., see Gandolfo, G. (160) 173
Gottesmann, C., see Gandolfo, G. (167) 181
Gower, A.J., Rousseau, D., Jamsin, P., Gobert, J., Hanin, I. and Wülfert, E.
Behavioural and histological effects of low concentrations of intraventricular AF64A (166) 271
Gower, A.J., see Bourson, A. (160) 339
Gozlan, H., Schechter, L.E., Bolanos, F., Emerit, M.B., Miquel, M.C., Nielsen, M. and Hamon, M.
Determination of the molecular size of the 5-HT_3 receptor binding site by radiation inactivation (172) 497
Gozlan, H., see Hamon, M. (164) 315
Gozlan, H., see Hoyer, D. (171) 137
Grassegger, A., see Boer, R. (172) 131
Gray, J.A., see Mitchell, S.N. (167) 311
Graziadei, I., Zernig, G., Boer, R. and Glossman, H.
Stereoselective binding of niguldipine enantiomers to α_{1A}-adrenoceptors labeled with [^{3}H]5-methyl-urapidil (172) 329
Greenberg, S., Diecke, F.P.J., Peevy, K. and Tanaka, T.P.
The endothelium modulates adrenergic neurotransmission to canine pulmonary arteries and veins (162) 67
Greenblatt, D.J., see Lopez, F. (172) 453
Gregory, C.M., see Brooks, R.R. (164) 521
Greiner, H.E., see Seyfried, C.A. (160) 31
Grell, S., Fjalland, B. and Christensen, J.D.
Biphasic effect of a κ-opioid receptor agonist on plasma oxytocin levels in rats (166) 41
Grenhoff, J. and Svensson, T.H.
Clonidine modulates dopamine cell firing in rat ventral tegmental area (165) 11
Griesbacher, T., see Leighton, G.E. (161) 255
Griffiths, R.R., see Sannerud, C.A. (167) 333
Grignaschi, G., see Cervo, L. (171) 119
Grohs, J.G., Fischer, G. and Raberger, G.
Cardiac and hemodynamic effects of the selective bradycardic agent KC 8857 during exercise-induced myocardial ischemia (161) 53
Gros, C., see Garbarg, M. (164) 1
Gros, F., see Larcher, J.-C. (161) 197
Groschner, K., Ulle, P., Brunner, F. and Kukovetz, W.R.
Interaction of DPI 201-106 with cardiac muscarinic receptors (159) 125
Gross, G., Hanft, G. and Mehdorn, H.M.
Demonstration of α_{1A}- and α_{1B}-adrenoceptor binding sites in human brain tissue (169) 325
Gross, R., see Ribes, G. (162) 207
Grossman, C.J., see Birch, P.J. (163) 127
Grote, H., see Stasch, J.-P. (159) 101
Grove, E.A., see Halliwell, J.V. (163) 369
Grundler, G., see Schudt, C. (165) 87
Gryglewski, R.J., see Korbut, R. (165) 171
Gu, X.-H., Casley, D. and Nayler, W.
Specific high-affinity binding sites for ^{125}I-labelled porcine endothelin in rat cardiac membranes (167) 281
Gu, X.-H., Casley, D.J. and Nayler, W.G.
Sarafotoxin S6b displaces specifically bound ^{125}I-endothelin (162) 509
Guenet, C., Leppik, R.A., Pelton, J.T., Moelling, K., Lovenberg, W. and Harris, B.A.
HIV-1 protease: mutagenesis of asparagine 88 indicates a domain required for dimer formation (172) 443
Guglietta, A., Nardi, R.V. and Lazarus, L.H.
Indomethacin (i.c.v.) reverses the inhibitory action of peptides on gastric secretion (170) 87
Guimarães, J.A., see Assreuy, J. (168) 231
Guix, T., see Ferré, S. (166) 303
Gulati, A. and Bhargava, H.N.
Brain and spinal cord 5-HT_2 receptors of morphine-tolerant-dependent and -abstinent rats (167) 185
Gulati, A., see Bhargava, H.N. (162) 257
Gullikson, G.W., see Nemeth, P.R. (166) 387
Gurguis, G., see Turkka, J. (167) 87
Gut, S.H., Demoliou-Mason, C.D., Hunter, J.C., Hughes, J. and Barnard, E.A.
Solubilization and characterisation of the cholecystokinin$_B$ binding site from pig cerebral cortex (172) 339
Gwathmey, J.K., see Briggs, G.M. (170) 281

Haase, A.F., see Seyfried, C.A. (160) 31
Haaseth, R.C., see Heyman, J.S. (165) 1
Habermann, E., see Nakov, R. (164) 45
Hacksell, U., see Hjorth, S. (170) 269
Hadjiconstantinou, M., Weihmuller, F. and Neff, N.H.
Treatment with GM1 ganglioside reverses dopamine D-2 receptor supersensitivity induced by the neurotoxin MPTP (168) 261
Hadjiconstantinou, M., see Varol, F.G. (159) 97
Hadjiconstantinou, M., see Varol, F.G. (162) 37
Haeusler, G. and De Peyer, J.-E.
Rabbit aorta: electrical properties and agonist-induced depolarization (166) 175
Hajimohamadreza, I., see Adamson, P. (162) 59
Haka, M.S., see Kilbourn, M.R. (166) 331
Håkanson, R., see Petersson, G. (161) 37
Halbach, S., Schönsteiner, G. and Vierling, W.

The action of organic mercury compounds on the function of isolated mammalian heart muscle (167) 255
Haleem, D.J., Kennett, G.A., Whitton, P.S. and Curzon, G.
8-OH-DPAT increases corticosterone but not other 5-HT_{1A} receptor-dependent responses more in females (164) 435
Hallett, I., see Evans, H.G. (163) 361
Halliwell, J.V. and Grove, E.A.
9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones (163) 369
Hambleton, P.T. and Miller, P.
Investigation of leukocyte accumulation and vascular permeability changes in the rat sponge implantation model (163) 141
Hamilton, C.A., see Deighton, N.M. (169) 95
Hamon, M., Gallissot, M.C., Menard, F., Gozlan, H., Bourgoin, S. and Vergé, D.
5-HT_3 receptor binding sites are on capsaicin-sensitive fibres in the rat spinal cord (164) 315
Hamon, M., see Collin, E. (168) 201
Hamon, M., see Gozlan, H. (172) 497
Hamon, M., see Hoyer, D. (171) 137
Hamon, M., see Ruiz, G. (168) 251
Hamprecht, B., see Reiser, G. (172) 195
Han, S.P., Trapani, A.J., Fok, K.F., Westfall, T.C. and Knuepfer, M.M.
Effects of endothelin on regional hemodynamics in conscious rats (159) 303
Handa, S., see Fukuda, K. (165) 301
Haneda, T., Ichihara, K. and Onodera, S.
Effects of nicorandil and nipradilol on ischemic myocardium in perfused rat heart (162) 81
Hanft, G., see Gross, G. (169) 325
Hanin, I., see Gower, A.J. (166) 271
Hansen, E.W., see Christensen, J.D. (171) 233
Hanson, G.R., Smiley, P., Johnson, M., Letter, A., Bush, L. and Gibb, J.W.
Response by the neurotensin systems of the basal ganglia to cocaine treatment (160) 23
Hanson, G.R., see Johnson, M. (161) 181
Hanson, G.R., see Johnson, M. (165) 315
Hanson, G.R., see Merchant, K.M. (160) 409
Hara, M., see Inoue, M. (166) 101
Hara, S., see Mihara, S. (160) 313
Hara, S., see Mihara, S. (171) 179
Hara, T., see Ushijima, I. (161) 245
Harbaugh, R.E., see Gonsalves, S.F. (168) 265
Harf, A., see Gentil, B. (159) 181
Hargreaves, K.M., Dubner, R. and Costello, A.H.
Corticotropin releasing factor (CRF) has a peripheral site of action for antinociception (170) 275
Hargreaves, K.M., see Costello, A.H. (171) 259
Harkins, K.L., see Jr.eer, C.R.A. (166) 583
Harris, A., see DeFelice, A. (167) 211
Harris, B.A., see Guenet, C. (172) 443
Harris, E.W.
L-α-Aminodipate antagonizes the priming effect of quisqualate in hippocampal slices (161) 107
Harris, K.M., see Reynolds, I.J. (172) 9
Harris, R.A., see Buck, K.J. (160) 359
Harris, R.A., see Lewin, E. (160) 101
Hasegawa, Y., see Nishida, N. (166) 453
Hashiba, K., see Yamasaki, H. (168) 247
Hashiba, Y., see Sumita, T. (164) 69
Hashim, A., see Wiener, H.L. (163) 191
Hashimoto, T., see Koda, H. (162) 501
Hatake, K., Wakabayashi, I., Kakishita, E., Taniguchi, T., Ouchi, H., Sakaki, N. and Hishida, S.
Inhibitory effect of ethanol on endothelium-dependent vascular responsiveness (168) 277
Hatake, K., see Wakabayashi, I. (167) 177
Hattori, T. and Maehashi, H.
Stannous chloride-induced increase in calcium entry into motor nerve terminals of the frog (166) 527
Hawgood, B.J., see Kempsford, R.D. (163) 61
Hawley, S.B., see Woodward, D.F. (168) 23
Hay, D.W.P.
Guinea-pig tracheal epithelium and endothelin (171) 241
Hayashi, K., see Matsumura, Y. (166) 577
Hayes, A.G., see Birch, P.J. (163) 127
Heal, D.J., Prow, M.R. and Buckett, W.R.
Clonidine produces mydriasis in conscious mice by activating central α_2-adrenoceptors (170) 11
Heal, D.J., Prow, M.R. and Buckett, W.R.
Clonidine-induced hypoactivity and mydriasis in mice are respectively mediated via pre- and postsynaptic α_2-adrenoceptors in the brain (170) 19
Hee Seong, Y., see Matsuda, T. (170) 75
Heffner, T.G., see Meltzer, L.T. (170) 105
Heilig, M., see Wahlestedt, C. (159) 285
Heisler, S.
Direct binding of atrial natriuretic factor to adrenocortical mitochondria (162) 281
Hellebrekers, L.J., Biewenga, W.J. and Mol, J.A.
Effect of arginine vasopressin on urine formation and plasma atrial natriuretic peptide level in conscious dogs (164) 55
Heller, T., Köcher, M., Neumann, J., Schmitz, W., Scholz, H., Stemmildt, V. and Störtzel, K.
Effects of adenosine analogues on force and cAMP in the heart. Influence of adenosine deaminase (164) 179
Hellewell, S.B., see Bowen, W.D. (163) 309
Hemmingsen, R., see Glenthøj, B. (164) 393
Hemsen, A., see Morel, D.R. (167) 427
Henderson, A.H., see Shah, A.M. (163) 365
Hendrickson, H., see Schini, V.B. (165) 333
Heninger, C., see Hernandez, T.D. (170) 145
Heninger, G.R., see Krystal, J.H. (160) 331
Herblin, W.F., see Chiu, A.T. (170) 117
Herman, A.G., see Deckers, I.A. (167) 415
Herman, A.G., see Pelckmans, P.A. (170) 235
Hernandez, A., see Omini, C. (163) 195

Hernandez, T.D., Heninger, C., Wilson, M.A. and Gallager, D.W.
Relationship of agonist efficacy to changes in GABA sensitivity and anticonvulsant tolerance following chronic benzodiazepine ligand exposure (170) 145
Herrera, D.G., see Robertson, G.S. (159) 99
Herrick-Davis, K., Chippari, S., Luttinger, D. and Ward, S.J.
Evaluation of adenosine agonists as potential analgesics (162) 365
Hertel, R., see Bossaller, C. (165) 165
Hertting, G., see Huang, H.Y. (169) 115
Hertting, G., see Nakov, R. (164) 45
Hess, J.E., see Crisp, T. (160) 211
Heublein, D.M., see Schini, V.B. (165) 333
Heym, J., see Schmidt, A. (165) 335
Heyman, J.S., Jiang, Q., Rothman, R.B., Mosberg, H.I. and Porreca, F.
Modulation of μ-mediated antinociception by δ agonists: characterization with antagonists (169) 43
Heyman, J.S., Vaught, J.L., Mosberg, H.I., Haaseth, R.C. and Porreca, F.
Modulation of μ-mediated antinociception by δ agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen^2,D-Pen^5]enkephalin (165) 1
Hicks, J.W., see Bockman, C.S. (171) 255
Hidalgo, A., see Sánchez, M. (168) 169
Higenbottam, T.W., see Dinh Xuan, A.T. (163) 401
Higuchi, Y., Takano, Y., Shimazaki, H., Shimohigashi, Y., Kodama, H., Matsumoto, H., Sakaguchi, K., Nonaka, S., Saito, R., Waki, M. and Kamiya, H.
Dimeric substance P analogue shows a highly potent activity of the in vivo salivary secretion in the rat (160) 413
Hiley, C.R., see Jones, C.R. (163) 379
Hilf, G. and Jakobs, K.H.
Activation of cardiac G-proteins by muscarinic acetylcholine receptors: regulation by Mg^{2+} and Na^+ ions (172) 155
Hill, R.G., see Leighton, G.E. (161) 255
Hillaire-Buys, D., see Ribes, G. (162) 207
Hillegaart, V. and Hjorth, S.
Median raphe, but not dorsal raphe, application of the 5-HT_{1A} agonist 8-OH-DPAT stimulates rat motor activity (160) 303
Hinsch, K.D., see Joost, H.G. (172) 461
Hirai, M., see Kuno, T. (172) 263
Hiramatsu, M., Cho, A.K. and Nabeshima, T.
Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine (166) 359
Hirata, Y., Emori, T., Ohta, K., Shichiri, M. and Marumo, F.
Vasoconstrictor-induced heterologous down-regulation of vascular atrial natriuretic peptide receptor (164) 603
Hirth, C., see Stasch, J.-P. (159) 101
Hiruta, M., see Koshikawa, N. (163) 227
Hisaki, K., see Matsumura, Y. (166) 577
Hishida, S., see Hatake, K. (168) 277
Hizuka, N., see Horikawa, R. (166) 87
Hjorth, S., Sharp, T. and Hacksell, U.
Partial postsynaptic 5-HT_{1A} agonist properties of the novel stereoselective 8-OH-DPAT analogue (+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin, (+)ALK-3 (170) 269
Hjorth, S., see Hillegaart, V. (160) 303
Ho, I.K., see Lim, D.K. (165) 279
Hock, F., see Wiemer, G. (166) 31
Hock, F.J., Gerhards, H.J., Wiemer, G., Stechl, J., Rüger, W. and Urbach, H.
Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents (171) 79
Hogan, J.C., Smith, J.A., Richards, A.C. and Lewis, M.J.
Atrial natriuretic peptide inhibits the release of endothelium-derived relaxing factor from blood vessels of the rabbit (165) 129
Holaday, J.W., see Rothman, R.B. (160) 71
Hole, K., see Hunskaar, S. (160) 83
Hollenberg, M.D., see Blay, J. (172) 1
Hollenberg, M.D., see Siang Gan, B. (167) 407
Hollingsworth, P.J. and Smith, C.B.
Effects of muscarinic receptor agonists and antagonists on α_2-adrenoceptors in rat brain (168) 159
Hollingsworth, P.J., see Smith, C.B. (161) 111
Holzer, P., see Lippe, I.T. (159) 1
Holzer-Petsche, U., Seitz, H. and Lembeck, F.
Effect of capsaicin on gastric corpus smooth muscle of the rat in vitro (162) 29
Hönack, D., see Löscher, W. (162) 309
Honda, H., see Sakai, Y. (162) 475
Hong, S.J. and Chang, C.C.
Antagonism by tubocurarine and verapamil of the regenerative acetylcholine release from mouse motor nerve (162) 11
Honoré, T., Drejer, J., Nielsen, E., Watkins, J.C., Olverman, H.J. and Nielsen, M.
Molecular target size analyses of the NMDA-receptor complex in rat cortex (172) 239
Hood, W.F., Sun, E.T., Compton, R.P. and Monahan, J.B.
1-Aminocyclobutane-1-carboxylate (ACBC): a specific antagonist of the N-methyl-D-aspartate receptor coupled glycine receptor (161) 281
Hoos, B., see IJzerman, A.P. (172) 273
Hopff, W.H., see Waser, P.G. (172) 231
Hopwood, A.M., Lincoln, J., Kirkpatrick, K.A. and Burnstock, G.
Adenosine 5′-triphosphate, adenosine and endothelium-derived relaxing factor in hypoxic vasodilatation of the heart (165) 323
Horan, P. and Kang Ho, I.
Butorphanol precipitates abstinence in morphine dependent rats (170) 265
Horan, P., see DeFelice, A. (167) 211
Hori, M., Shimizu, K., Nakajyo, S. and Urakawa, N.
Inhibitory effect of lithium on muscle contractions caused by various stimulants in guinea-pig ileum (165) 63
Hori, R., see Iwata, T. (159) 321

Hori, S., see Fukuda, K. (165) 301
Horiike, K., see Fujioka, H. (166) 13
Horikawa, R., Asakawa, K., Hizuka, N., Takano, K. and Shizume, K.
Growth hormone and insulin-like growth factor I stimulate Leydig cell steroidogenesis (166) 87
Horn, A.S., see Bosker, F.J. (163) 319
Horn, A.S., see Löschmann, P.-A. (166) 373
Horn, A.S., see Timmerman, W. (162) 143
Horn, A.S., see Timmerman, W. (166) 1
Horton, R.W., see De Paermentier, F. (167) 397
Hosford, D., see Koltai, M. (164) 293
Hoskins, B., see Lim, D.K. (165) 279
Houghten, R.A., see Young, E.A. (167) 229
Hoult, J.R.S., see Buckley, T.L. (163) 275
Howard, S.G., see Gazzara, R.A. (168) 209
Howie, C.A., see Deighton, N.M. (169) 95
Howson, W., see Taylor, E.M. (161) 121
Hoyer, D., Gozlan, H., Bolanos, F., Schechter, L.E. and Hamon, M.
Interaction of psychotropic drugs with central 5-HT_3 recognition sites: fact or artifact? (171) 137
Hoyer, D., see Schoeffter, P. (166) 117
Hsu, M.-F., see Wang, J.-P. (161) 143
Huang, H.Y., Hertting, G., Allgaier, C. and Jackisch, R.
3,4-Diaminopyridine-induced noradrenaline release from CNS tissue as a model for action potential-evoked transmitter release: effects of phorbol ester (169) 115
Hübers, M., see Kornhuber, J. (166) 589
Huffman, R.D. and Frey, J.M.
Response of rat globus pallidus neurons to microiontophoretically applied μ and κ opioid receptor agonists (170) 179
Huffman, W.F., see Brooks, D.P. (160) 159
Hughes, J., see Gut, S.H. (172) 339
Hughes, J., see Leighton, G.E. (161) 255
Huidobro-Toro, J.P., see Donoso, M.V. (160) 263
Huidobro-Toro, J.P., see Macho, P. (167) 67
Huidobro-Toro, J.P., see Vesperinas, G. (165) 309
Huizinga, J.D., see Barajas-López, C. (163) 137
Humphrey, P.P.A., see Connor, H.E. (161) 91
Humphreys, T.M., see Sorensen, S.M. (163) 115
Hunskaar, S., Rosland, J.H. and Hole, K.
Mechanisms of orphenadrine-induced antinociception in mice: a role for serotonergic pathways (160) 83
Hunt, P.F., see Massardier, D. (170) 125
Hunter, J.C., see Gut, S.H. (172) 339
Hurd, Y.L. and Ungerstedt, U.
Ca^{2+} dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission (166) 261
Hurd, Y.L. and Ungerstedt, U.
In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen (166) 251
Hurt, S.D., see Schmidt, A.W. (171) 141
Huston-Lyons, D., Bain, G.T. and Kornetsky, C.
Opiate dependence alters central reward of nalbuphine or pentazocine plus tripelennamine (169) 153
Hyttel, J., see Arnt, J. (161) 45

Ibengwe, J.K., see Komori, K. (164) 111
Ichihara, K., Maie, S. and Abiko, Y.
Effect of flunarizine on ischemic myocardial metabolism in dogs (165) 19
Ichihara, K., Nabeshima, T. and Kameyama, T.
Differential effects of pimozide and SCH 23390 on acquisition of learning in mice (164) 189
Ichihara, K., see Haneda, T. (162) 81
Ichihara, K., see Nakamura, K. (160) 61
Ichihara, K., see Nakamura, K. (169) 259
Ichinose, M. and Barnes, P.J.
Inhibitory histamine H_3-receptors on cholinergic nerves in human airways (163) 383
Ide, M., see Mihara, S. (160) 313
Ide, M., see Mihara, S. (171) 179
Igarashi, H., see Kamei, J. (168) 153
Ignarro, L.J., see Buga, G.M. (161) 61
Iijima, T. and Taira, N.
β_2-Adrenoceptor-mediated increase in the slow inward calcium current in atrial cells (163) 357
IJzerman, A.P., Thedinga, K.H., Custers, A.F.C.M., Hoos, B. and Van Belle, H.
Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine (172) 273
IJzerman, A.P., see J.M. Van Galen, P. (172) 19
IJzerman, A.P., see Pirovano, I.M. (172) 185
Ikawa, K., see Motohashi, N. (166) 95
Ikeda, H., see Kay, C.D. (164) 381
Imagawa, J.-i., Akima, M. and Sakai, K.
In vivo experiments for the evaluation of α_1-adrenoceptor antagonistic effects of SGB-1534 on canine urethra (167) 167
Imai, K.Y.M. and Yoshida, S.
Mechanism of diuretic action of U-62,066E, a κ opioid receptor agonist (160) 229
Imaizumi, T., Osugi, T., Misaki, N., Uchida, S. and Yoshida, H.
Heterologous desensitization of bradykinin-induced phosphatidylinositol response and Ca^{2+} mobilization by neurotensin in NG108-15 cells (161) 203
Imaizumi, T., see Mizushima, A. (168) 375
Imanishi, M., see Miura, K. (170) 91
Imawaka, H., see Kondo, K. (168) 193
Imhof, R., see Cesura, A.M. (162) 457
Imperato, A. and Di Chiara, G.
CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats (160) 155
Imperato, A., Puglisi-Allegra, S., Casolini, P., Zocchi, A. and Angelucci, L.
Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone (165) 337
Imura, H., see Iwata, T. (159) 321

Inagaki, C., see Inoue, M. (166) 101
Inazu, M., see Sakai, Y. (162) 475
Inoki, R., see Kinouchi, K. (164) 63
Inomata, H., see Mimata, T. (163) 181
Inoue, M., Uriu, T., Otani, H., Hara, M., Omori, K. and Inagaki, C.
Intracerebroventricular injection of ethacrynic acid induces status epilepticus (166) 101
Inui, K.-i., see Iwata, T. (159) 321
Invernizzi, R., Bertorelli, R., Consolo, S., Garattini, S. and Samanin, R.
Effects of the l isomer of fenfluramine on dopamine mechanisms in rat brain: further studies (164) 241
Invernizzi, R., Fracasso, C., Caccia, S., Di Clemente, A., Garattini, S. and Samanin, R.
Effect of L-cysteine on the long-term depletion of brain indoles caused by p-chloroamphetamine and d-fenfluramine in rats. Relation to brain drug concentrations (163) 77
Irwin, I., see Di Monte, D. (166) 23
Ishibashi, S., see Yamashita, A. (159) 247
Ishida, T., see Fujioka, H. (166) 13
Ishikawa, N., see Sumita, T. (164) 69
Ishikawa, Y., see Uehara, A. (170) 257
Ishitsuka, T., see Sadoshima, S. (169) 75
Ismaiel, A.E.-K.M., see Glennon, R.A. (168) 387
Israël, M., see Gaudry-Talarmain, Y.M. (166) 427
Ito, A., see Kuno, T. (172) 263
Ito, H., see Kurachi, Y. (165) 319
Ito, Y., see Lim, D.K. (165) 279
Itoigawa, M., see Takeya, K. (169) 137
Iuvone, T., see Carnuccio, R. (166) 535
Iversen, S.D., see Tricklebank, M.D. (167) 127
Iwai, A., see Yamamoto, M. (166) 345
Iwao, H., see Shoji, T. (171) 219
Iwata, H., see Matsuda, T. (170) 75
Iwata, K., see Koshikawa, N. (163) 227
Iwata, T., Inui, K.-i., Nakao, K., Imura, H., Matsuo, H. and Hori, R.
Effect of brain natriuretic peptide on cyclic GMP accumulation in a kidney epithelial cell line (LLC-PK_1) (159) 321
Iyengar, S., see Rao, T.S. (168) 129

Jäckel, R., see Löscher, W. (163) 1
Jackisch, R., see Huang, H.Y. (169) 115
Jacobson, A.E., see Bluth, L.S. (161) 273
Jacobson, A.E., see Debler, E.A. (165) 155
Jacobson, A.E., see Rothman, R.B. (160) 71
Jacobson, A.E., see Rothman, R.B. (167) 345
Jakobs, K.H., see Gierschik, P. (172) 481
Jakobs, K.H., see Hilf, G. (172) 155
Jakobs, K.H., see Reithmann, C. (170) 243
Jakobs, K.H., see Reithmann, C. (172) 211
Jakubovic, A., see Cumming, P. (166) 299
James, F.W., see Molyvdas, P.-A. (164) 547
Jamsin, P., see Gower, A.J. (166) 271
Jansen, J.B.M.J., see Douglas, B.R. (161) 209
Jansen, J.B.M.J., see Douglas, B.R. (166) 307
Janssen, B.J.A., Struyker-Boudier, H.A.J. and Smits, J.F.M.
Acute arteriolar vasoconstriction following furosemide in conscious spontaneously hypertensive rats (170) 1
Janssen, P.A.J., see Janssens, W.J. (159) 89
Janssen, P.A.J., see Pauwels, P.J. (172) 471
Janssen, P.F.M., see Leysen, J.E. (163) 145
Janssens, W.J., Van de Water, A., Xhonneux, R., Reneman, R.S., Van Nueten, J.M. and Janssen, P.A.J.
Nebivolol is devoid of intrinsic sympathomimetic activity (159) 89
Jansson, L., Eizirik, D.L. and Sandler, S.
Terbutaline decreases the blood flow of the pancreatic islets but does not reduce the diabetogenic action of streptozotocin in the rat (161) 79
Jantos, H., see Monti, J.M. (169) 61
Jardon, B., Yücel, H. and Bonaventure, N.
Glutamatergic separation of ON and OFF retinal channels: possible modulation by glycine and acetylcholine (162) 215
Jarvis, M.F. and Williams, M.
Direct autoradiographic localization of adenosine A_2 receptors in the rat brain using the A_2-selective agonist, [^{3}H]CGS 21680 (168) 243
Jaw, S.-S., see Chang, W.-H. (162) 151
Jazayeri, A., Meyer III, W.J. and Kent, T.A.
5-HT_{1B} and 5-HT_2 serotonin binding sites in cultured Wistar-Kyoto rat aortic smooth muscle cells (169) 183
Jebbink, M.C.W., see Douglas, B.R. (166) 307
Jenner, P., see Löschmann, P.-A. (166) 373
Jenner, P., see Stewart, B.R. (162) 101
Jeremy, J.Y., Mikhailidis, D.P. and Dandona, P.
Muscarinic stimulation of prostanoid synthesis by the isolated rat trachea: calcium dependency and effect of cortisol and cigarette smoke (160) 107
Jiang, Q., see Heyman, J.S. (169) 43
Jiménez, I., see Del Carmen de Felipe, M. (159) 175
Jimenez, W., see Lòpez, C. (168) 1
Jin, J.-G., Neya, T. and Nakayama, S.
Contractions of the guinea-pig ileum evoked by stimulation of the submucous plexus (161) 73
J. Marley, R. and W. Gallager, D.
Chronic diazepam treatment produces regionally specific changes in GABA-stimulated chloride influx (159) 217
J.M. Van Galen, P., Leusen, F.J.J., IJzerman, A.P. and Soudijn, W.
Mapping the N^6-region of the adenosine A_1 receptor with computer graphics (172) 19
Jodelis, K.S., see Lahti, R.A. (166) 563
Johnson, A.L., see Chiu, A.T. (170) 117
Johnson, E.A., Wu, E.Y., Rollema, H., Booth, R.G., Trevor, A.J. and Castagnoli, Jr., N.
1-Methyl-4-phenylpyridinium (MPP^+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake (166) 65
Johnson, M., Hanson, G.R. and Gibb, J.W.
Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog (165) 315

Johnson, M., Stone, D.M., Bush, L.G., Hanson, G.R. and Gibb, J.W.
Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity (161) 181
Johnson, M., see Hanson, G.R. (160) 23
Johnson, M.C., see Kerkman, D.J. (166) 481
Johnson, P.R.A., see Armour, C.L. (165) 215
Johnston, A.L., see Baldwin, H.A. (159) 211
Johnston, C.I., see Kohzuki, M. (160) 193
Johnston, G.A.R., see Kerr, D.I.B. (164) 361
Johnston, P.R., see Vinegar, R. (164) 497
Jones, B.J., see Kilpatrick, G.J. (159) 157
Jones, C.R., Hiley, C.R., Pelton, J.T. and Miller, R.C.
Autoradiographic localisation of endothelin binding sites in kidney (163) 379
Jones, L.F. and Tackett, R.L.
Catecholaminergic and opioidergic mechanisms involved in the hypotensive response of pindolol (165) 123
Jones, S.M., see Brooks, R.R. (164) 521
Joost, H.G., Schmitz-Salue, C., Hinsch, K.D., Schultz, G. and Rosenthal, W.
Phosphorylation of G-protein α-subunits in intact adipose cells: evidence against a mediating role in insulin-dependent metabolic effects (172) 461
Joselevitz-Goldman, J., Acad, B.-A. and Weiss, H.R.
Effects of nitroglycerin on regional O_2 supply and O_2 consumption in reperfused dog myocardium (166) 283
Joseph, M.H., see Mitchell, S.N. (167) 311
Joshi, R.S., see Marco, L.A. (164) 171
Jr.eer, C.R.A., Edwards, E., Harkins, K.L. and Wang, R.Y.
Differential effect of typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells: a microiontophoretic study (166) 583
Jukic, D., see Rhaleb, N.-E. (162) 419
Juncos, J.L., see Engber, T.M. (168) 291

Kadowitz, P.J., see Minkes, R.K. (163) 163
Kadowitz, P.J., see Minkes, R.K. (164) 571
Kadowitz, P.J., see Minkes, R.K. (165) 161
Kadowitz, P.J., see Minkes, R.K. (165) 259
Kafiluddi, R., Kennedy, R.H. and Seifen, E.
Effects of buffer magnesium on positive inotropic agents in guinea pig cardiac muscle (165) 181
Kajimura, N., see Ushijima, I. (161) 245
Kakishita, E., see Hatake, K. (168) 277
Kakishita, E., see Wakabayashi, I. (167) 177
Kalant, H., see Le, A.D. (159) 25
Kamata, K., Miyata, N. and Kasuya, Y.
Functional changes in potassium channels in aortas from rats with streptozotocin-induced diabetes (166) 319
Kamei, J., Tanihara, H., Igarashi, H. and Kasuya, Y.
Effects of N-methyl-D-aspartate antagonists on the cough reflex (168) 153
Kameyama, T., see Ichihara, K. (164) 189
Kameyama, T., see Nabeshima, T. (169) 249
Kamiya, H., see Higuchi, Y. (160) 413
Kan, J.P., see Schumacher, C. (166) 139
Kanai, Y., Aosaki, T., Wada, O. and Manabe, S.
Suppression of GABA-induced chloride current by 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2) (166) 553
Kanda, T., see Matsuda, T. (170) 75
Kane, K.A., see Kwan, Y.W. (168) 31
Kaneyuki, H., see Ushijima, I. (161) 245
Kang Ho, I., see Horan, P. (170) 265
Kanse, S., see Power, R.F. (160) 199
Kaplan, G.B., see Lopez, F. (172) 453
Kapoor, V. and Chalmers, J.
Correlation between fall in blood pressure and in vivo amine release after α-methylDOPA (164) 531
Kariya, T., see Motohashi, N. (166) 95
Karlsson, G. and Olpe, H.-R.
Inhibitory processes in normal and epileptic-like rat hippocampal slices: the role of $GABA_B$ receptors (163) 285
Karppanen, H., see Ekholm, S. (163) 209
Kastin, A.J., see Kostrzewa, R.M. (163) 33
Kasuya, Y., see Kamata, K. (166) 319
Kasuya, Y., see Kamei, J. (168) 153
Kataoka, Y., see Yamasaki, H. (168) 247
Kato, H., see Kurihara, J. (165) 147
Kato, H., see Takata, Y. (164) 365
Katsoulis, S. and Conlon, J.M.
Calcitonin gene-related peptides relax guinea pig and rat gastric smooth muscle (161) 129
Katsuragi, T., Kuratomi, L., Tokunaga, T. and Furukawa, T.
Heterogeneity of the effects of monensin on two types of contractions evoked by inhibition of Na^+-K^+ ATPase in the guinea-pig vas deferens (167) 147
Katz, D., see Cameron, J.S. (169) 23
Katz, J.L., see Fukagawa, Y. (170) 47
Kauffman, H.F., see Meurs, H. (164) 369
Kavanaugh, M.P., Tester, B.A.C. and Weber, E.
Interaction of MK-801 with the nicotinic acetylcholine receptor-associated ion channel from electroplax (164) 397
Kawabata, S., see Yamamoto, M. (166) 345
Kawasaki, A., see Kondo, K. (163) 253
Kawasaki, A., see Kondo, K. (168) 193
Kawasaki, H., Urabe, M. and Takasaki, K.
Presynaptic α_2-adrenoceptor modulation of 5-hydroxytryptamine and noradrenaline release from vascular adrenergic nerves (164) 35
Kawashima, K., see Nabeshima, T. (169) 249
Kay, C.D. and Ikeda, H.
The quinoxalinediones antagonise the visual firing of sustained retinal ganglion cells (164) 381
Kazda, S., see Stasch, J.-P. (159) 101
Keane, P.E., see Larcher, J.-C. (161) 197
Kebabian, J.W., see Kerkman, D.J. (166) 481
Keenan, C.M., see Wallace, J.L. (167) 41
Keeton, T.K. and Biediger, A.M.
The differential effects of prazosin and hydralazine on sympathoadrenal activity in conscious rats (164) 479
Keilmann, T., see Diener, M. (168) 219
Keith, R.A., Mangano, T.J., Meiners, B.A., Stumpo, R.J., Klika,

A.B., Patel, J. and Salama, A.I.
HA-966 acts at a modulatory glycine site to inhibit N-methyl-D-aspartate-evoked neurotransmitter release (166) 393
Kelland, M.D., Freeman, A.S. and Chiodo, L.A.
(±)-3,4-Methylenedioxymethamphetamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons (169) 11
Kelland, M.D., see Pitts, D.K. (162) 167
Keller, E.A., see Molina, V.A. (160) 247
Keller, F., see Rimvall, K. (160) 1
Kelley, A.E. and Lang, C.G.
Effects of GBR 12909, a selective dopamine uptake inhibitor, on motor activity and operant behavior in the rat (167) 385
Kemel, M.L., see Krebs, M.-O. (166) 567
Kempsford, R.D. and Hawgood, B.J.
Assessment of the antiarrhythmic activity of nicorandil during myocardial ischemia and reperfusion (163) 61
Kennedy, R.H., see Kafiluddi, R. (165) 181
Kennett, G.A., Whitton, P., Shah, K. and Curzon, G.
Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT_{1C} receptor antagonists (164) 445
Kennett, G.A., see Haleem, D.J. (164) 435
Kent, T.A., see Jazayeri, A. (169) 183
Kerkman, D.J., Ackerman, M., Artman, L.D., MacKenzie, R.G., Johnson, M.C., Bednarz, L., Montana, W., Asin, K.E., Stampfli, H. and Kebabian, J.W.
A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor (166) 481
Kerr, D.I.B., Ong, J., Johnston, G.A.R., Berthelot, P., Debaert, M. and Vaccher, C.
Benzofuran analogues of baclofen: a new class of central and peripheral $GABA_B$-receptor antagonists (164) 361
Kerstein, M.D., see Minkes, R.K. (165) 259
Khanna, J.M., see Le, A.D. (159) 25
Kiang, J.G., see Wei, E.T. (168) 81
Kigoshi, S., see Omote, S. (160) 239
Kilbinger, H., see Schwörer, H. (165) 29
Kilbourn, M.R., Haka, M.S., Mulholland, G.K., Sherman, P.S. and Pisani, T.
Regional brain distribution of [^{18}F]GBR 13119, a dopamine uptake inhibitor, in CD-1 and C57BL/6 mice (166) 331
Kilpatrick, A.T., Brown, C.M., MacKinnon, A.C. and Spedding, M.
The α_2-adrenoceptor antagonist SK&F 104078 has high affinity for 5-HT_{1A} and 5-HT_2 receptors (166) 315
Kilpatrick, G.J., Jones, B.J. and Tyers, M.B.
Binding of the 5-HT_3 ligand, [^{3}H]GR65630, to rat area postrema, vagus nerve and the brains of several species (159) 157
Kimura, S., see Saito, A. (162) 353
King, R.A., see Rossitch, Jr., E. (163) 119
Kinoshita, M., see Fujioka, H. (166) 13
Kinouchi, K., Maeda, S., Saito, K., Inoki, R., Fukumitsu, K. and Yoshiya, I.
Effects of pentazocine and other opioids on the potassium-evoked release of [^{3}H]noradrenaline from guinea pig cortical slices (164) 63
Kinter, L.B., see Brooks, D.P. (160) 159
Kira, H., see Kondo, K. (163) 253
Kira, H., see Kondo, K. (168) 193
Király, I., see Van Ree, J.M. (166) 441
Kirchengast, M. and Raschack, M.
Effects of gallopamil, diltiazem and nifedipine on the loss of K^+ from ischaemic pig hearts (160) 349
Kirchhof, C.J.H.J., Bonke, F.I.M. and Allessie, M.A.
Effects of verapamil, diltiazem and disopyramide on sinus function: a comparison with bepridil (160) 369
Kirkpatrick, K.A., see Hopwood, A.M. (165) 323
Kitagawa, T., see Kondo, K. (163) 253
Kitayoshi, T., Watanabe, T. and Shimamoto, N.
Cardiovascular effects of endothelin in dogs: positive inotropic action in vivo (166) 519
Klaas, M. and Wadsworth, R.
Contraction followed by relaxation in response to hypoxia in the sheep isolated middle cerebral artery (168) 187
Klika, A.B., see Keith, R.A. (166) 393
Kloog, Y., see Ambar, I. (170) 119
Knight, D.E., see Borges, R. (165) 223
Knobloch, S.F., see Diener, M. (168) 219
Knöll, B., see Bognar, I.T. (163) 263
Knuepfer, M.M., see Han, S.P. (159) 303
Kobayashi, A., see Sugita, S. (165) 191
Kobayashi, M., see Koshikawa, N. (163) 227
Kobayashi, M., see Koshikawa, N. (170) 101
Koch, B. and Lutz-Bucher, B.
Indirect relationship between vasopressin-induced secretion of ACTH and cyclic nucleotides in cultured anterior pituitary cells (158) 53
Koch, R., see Reiser, G. (172) 199
Köcher, M., see Heller, T. (164) 179
Koda, H., Hashimoto, T. and Kuriyama, K.
Muscarinic receptor-mediated regulation of OM-853-enhanced dopamine release in striatum of rat (162) 501
Kodama, H., see Higuchi, Y. (160) 413
Koe, B.K., Burkhart, C.A. and Lebel, L.A.
(+)-[^{3}H]3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine binding to σ receptors in mouse brain in vivo (161) 263
Koe, B.K., see Schmidt, A. (165) 335
Koek, W., see Colpaert, F.C. (169) 175
Kohlhardt, M.
Insensitivity of the open state of (−)-DPI-modified cardiac Na^+ channels to the blocking effects of the (+) enantiomer (168) 115
Kohli, J.D., Metra, M., Satoh, Y. and Goldberg, L.I.
Dopamine receptors in the stellate ganglion of the dog [1] (164) 265
Kohzuki, M., Johnston, C.I., Yeen Chai, S., Casley, D.J. and Mendelsohn, F.A.O.
Localization of endothelin receptors in rat kidney (160) 193
Koltai, M., Tosaki, A., Hosford, D. and Braquet, P.
Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion (164) 293

Komori, K., Nagao, T., Zhang, G., Ibengwe, J.K., Fujioka, M. and Suzuki, H.
Bunazosin, an α_1-adrenoceptor blocker, differentially releases co-transmitters in dog mesenteric vessels (164) 111

Kondo, K., Seo, R., Naka, M., Kitagawa, T., Wakitani, K., Sakata, M., Kira, H., Okegawa, T. and Kawasaki, A.
Effects of ONO-3708, an antagonist of the thromboxane A_2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis (163) 253

Kondo, K., Seo, R., Omawari, N., Imawaka, H., Wakitani, K., Kira, H., Okegawa, T. and Kawasaki, A.
Effects of ONO-3708, an antagonist of the thromboxane A_2/prostaglandin endoperoxide receptor, on blood vessels (168) 193

Konradi, C., see Fritze, J. (172) 147

Konturek, S.J., Brzozowski, T., Drozdowicz, D., Garlicki, J. and Beck, G.
Role of leukotrienes and platelet activating factor in acute gastric mucosal lesions in rats (164) 285

Kopin, I.J., see Szemeredi, K. (170) 53

Kopp, R., Lambrecht, G., Mutschler, E., Moser, U., Tacke, R. and Pfeiffer, A.
Human HT-29 colon carcinoma cells contain muscarinic M_3 receptors coupled to phosphoinositide metabolism (172) 397

Korbut, R., Trabka-Janik, E. and Gryglewski, R.J.
Cytoprotection of human polymorphonuclear leukocytes by stimulators of adenylate and guanylate cyclases (165) 171

Korbut, R., see Salvemini, D. (171) 135

Kornetsky, C., see Huston-Lyons, D. (169) 153

Kornhuber, J., Bormann, J., Retz, W., Hübers, M. and Riederer, P.
Memantine displaces [^{3}H]MK-801 at therapeutic concentrations in postmortem human frontal cortex (166) 589

Kornhuber, J., Mack-Burkhardt, F., Kornhuber, M.E. and Riederer, P.
[^{3}H]MK-801 binding sites in post-mortem human frontal cortex (162) 483

Kornhuber, M.E., see Kornhuber, J. (162) 483

Koronakis, P., see Fritze, J. (172) 147

Korpi, E.R., see Malminiemi, O. (169) 53

Koshikawa, N., Aoki, S., Hiruta, M., Tomiyama, K., Kobayashi, M., Tsuboi, Y., Iwata, K., Sumino, R. and Stephenson, J.D.
Effects of intrastriatal injections of selective dopamine D-1 and D-2 agonists and antagonists on jaw movements of rats (163) 227

Koshikawa, N., Maruyama, Y. and Stephenson, J.D.
Production of wet-dog shakes in rats and down-regulation of spinal 5-HT_2 receptors (164) 595

Koshikawa, N., Maruyama, Y., Kobayashi, M. and Campbell, I.C.
Rapid development of brain β-adrenoceptor down-regulation induced by phenelzine: subcellular studies (170) 101

Koster, P.F., see Brooks, D.P. (160) 159

Kosterlitz, H.W., see Petrillo, P. (166) 213

Kostowski, W., Płaźnik, A. and Stefański, R.
Intra-hippocampal buspirone in animal models of anxiety (168) 393

Kostrzewa, R.M., White, T.G., Zadina, J.E. and Kastin, A.J.
MIF-1 attenuates apomorphine stereotypies in adult rats after neonatal 6-hydroxydopamine (163) 33

Koulu, M., Sjöholm, B., Lappalainen, J. and Virtanen, R.
Effects of acute GR38032F (odansetron), a 5-HT_3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons (169) 321

Kouvelas, E.D., see Voukelatou, G. (162) 179

Kovács, G.L., Liu, B., Burbach, J.P.H., Van Ree, J.M. and De Wied, D.
N^{α}-Acetyl-[Arg^8]vasopressin antagonizes the behavioral effect of [Cyt^6]vasopressin-(5-9), but not of vasopressin (161) 27

Kratunis, V., see Bergey, J.L. (159) 103

Krause, J.E., see Takeda, Y. (161) 267

Kream, R.M., see Sander, H.W. (159) 205

Krebs, M.-O., Kemel, M.L., Gauchy, C., Desban, M. and Glowinski, J.
Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum (166) 567

Kreil, G., Barra, D., Simmaco, M., Erspamer, V., Falconieri Erspamer, G., Negri, L., Severini, C., Corsi, R. and Melchiorri, P.
Deltorphin, a novel amphibian skin peptide with high selectivity and affinity for δ opioid receptors (162) 123

Krell, R.D., Kusner, E.J., Aharony, D. and Giles, R.E.
Biochemical and pharmacological characterization of ICI 198,615: a peptide leukotriene receptor antagonist (159) 73

Krogsgaard-Larsen, P., see Gonsalves, S.F. (168) 265

Krystal, J.H., Walker, M.W. and Heninger, G.R.
Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys (160) 331

Kubota, I., see Yongsiri, A. (171) 159

Kuhar, M.J., see Titeler, M. (167) 221

Kukovetz, W.R., see Groschner, K. (159) 125

Kukovetz, W.R., see Schmidt, K. (170) 157

Kulkarni, A.P., see Richards, I.S. (167) 155

Kuno, T., Shuntoh, H., Takeda, T., Ito, A., Sakaue, M., Hirai, M., Ando, H. and Tanaka, C.
Activation of type I cyclic AMP-dependent protein kinases is impaired by a point mutation in cyclic AMP binding sites (172) 263

Kupsch, A., see Di Monte, D. (166) 23

Kurachi, Y., Nakajima, T., Ito, H. and Sugimoto, T.
AN-132, a new class I anti-arrhythmic agent, depresses the acetylcholine-induced K^+ current in atrial myocytes (165) 319

Kuratomi, L., see Katsuragi, T. (167) 147

Kurihara, J., Oda, N. and Kato, H.
Effect of flunarizine on the attenuation of baroreflex by transient cerebral ischemia (165) 147

Kurihara, M., see Agui, T. (162) 301

Kuriyama, K., see Koda, H. (162) 501
Kuroiwa, A., see Muta, T. (159) 191
Kurokawa, T., see Yamashita, A. (159) 247
Kurstjens, N.P. and Cantrill, R.C.
Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine reduces the release of [^{3}H]dopamine from rat striatal slices (169) 147
Kusner, E.J., see Krell, R.D. (159) 73
Kusuhara, M., see Fukuda, K. (165) 301
Kuwahara, A., Ozaki, T. and Yanaihara, N.
Galanin suppresses neurally evoked contractions of circular muscle in the guinea-pig ileum (164) 175
Kvanta, A., see Nordstedt, C. (172) 51
Kwan, Y.W., Wadsworth, R.M. and Kane, K.A.
Responsiveness of sheep isolated coronary artery rings under simulated myocardial ischaemia (168) 31
Kwiat, G., see Fedynyshyn, J.P. (159) 83
Kyburz, E., see Cesura, A.M. (162) 457
Kyotani, S., see Fukuda, K. (165) 301

Labroo, V.M., see Vonhof, S. (164) 77
Laburthe, M., see Amiranoff, B. (163) 205
Laburthe, M., see Lorinet, A.-M. (160) 405
Lacković, Z., see Zdilar, D. (164) 159
Lacroix, J.-S. and Lundberg, J.M.
Adrenergic and neuropeptide Y supersensitivity in denervated nasal mucosa vasculature of the pig (169) 125
Lacroix, J.S., see Morel, D.R. (167) 427
Laduron, P.M., see Castel, M.-N. (166) 353
Lafontan, M., see Langin, D. (159) 199
Lafontan, M., see Langin, D. (167) 95
Lafontan, M., see Saulnier-Blache, J.-S. (171) 145
Lahti, R.A., Mickelson, M.M., Jodelis, K.S. and McCall, J.M.
Comparative neuroanatomical distribution of the κ and μ opioid receptors in guinea pig brain sections (166) 563
Laird II, H.E., Gerrish, K.E., Duerson, K.C., Putnam, C.W. and Russell, D.H.
Peripheral benzodiazepine binding sites in Nb 2 node lymphoma cells: effects on prolactin-stimulated proliferation and ornithine decarboxylase activity (171) 25
Lajtha, A., see Benuck, M. (159) 187
Lajtha, A., see Debler, E.A. (165) 155
Lajtha, A., see Lapin, E.P. (160) 53
Lajtha, A., see Wiener, H.L. (163) 191
Lajtha, A., see Zimányi, I. (167) 419
Lambert, D.G., Ghataorre, A.S. and Nahorski, S.R.
Muscarinic receptor binding characteristics of a human neuroblastoma SK-N-SH and its clones SH-SY5Y and SH-EP1 [1] (165) 71
Lambolez, B., see Dellouve-Courillon, C. (166) 557
Lambolez, B., see Geoffroy, M. (166) 355
Lambrecht, G., Feifel, R., Wagner-Röder, M., Strohmann, C., Zilch, H., Tacke, R., Waelbroeck, M., Christophe, J., Boddeke, H. and Mutschler, E.
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes (168) 71
Lambrecht, G., see Eltze, M. (170) 225
Lambrecht, G., see Kopp, R. (172) 397
Lamers, C.B.H.W., see Douglas, B.R. (161) 209
Lamers, C.B.H.W., see Douglas, B.R. (166) 307
Lamour, Y., see Dutar, P. (164) 355
Lancelot, J.-C., see Gaudry-Talarmain, Y.M. (166) 427
Landau, E.M., see Benson, D.M. (164) 591
Laneuville, O., Reader, T.A. and Couture, R.
Intrathecal bradykinin acts presynaptically on spinal noradrenergic terminals to produce antinociception in the rat (159) 273
Lang, C.G., see Kelley, A.E. (167) 385
Lang, U., Streller, I. and Walland, A.
Alinidine antagonizes the myocardial effects of adenosine (164) 13
Langin, D. and Lafontan, M.
[^{3}H]Idazoxan binding at non-α_2-adrenoceptors in rabbit adipocyte membranes (159) 199
Langin, D., Lafontan, M., Stillings, M.R. and Paris, H.
[^{3}H]RX821002: a new tool for the identification of α_{2A}-adrenoceptors (167) 95
Langin, D., see Saulnier-Blache, J.-S. (171) 145
Langston, J.W., see Di Monte, D. (166) 23
Lanthorn, T.H., see Watson, G.B. (167) 291
Lapin, E.P., Maker, H.S., Sershen, H. and Lajtha, A.
Action of nicotine on accumbens dopamine and attenuation with repeated administration (160) 53
Lappalainen, J., see Koulu, M. (169) 321
Larcher, J.-C., Vayssiere, J.-L., Le Marquer, F.J., Cordeau, L.R., Keane, P.E., Bachy, A., Gros, F. and Croizat, B.P.
Effects of peripheral benzodiazepines upon the O_2 consumption of neuroblastoma cells (161) 197
La Regina, A., see Petrillo, P. (166) 213
Lategan, A., see Colpaert, F.C. (169) 175
Lathrop, D.A., Varró, A. and Schwartz, A.
Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol (164) 487
Latini, R., see Chiabrando, C. (159) 257
Laubie, M., Drouillat, M., Dabiré, H., Cherqui, C. and Schmitt, H.
Ventrolateral medullary pressor area: site of hypotensive and sympatho-inhibitory effects of (±)8-OH-DPAT in anaesthetized dogs (160) 385
Laubie, M., see Dabiré, H. (168) 369
Laurent, S., see Briand, V. (166) 339
Laurent, S., see Martin, P. (162) 185
Laverty, R., see Bishop, B.E. (162) 265
La Villa, G., see Lòpez, C. (168) 1
Lazarus, L.H., see Guglietta, A. (170) 87
Lazdunski, M., see Ben Ari, Y. (165) 331
Lazdunski, M., see Gandolfo, G. (159) 329
Lazdunski, M., see Gandolfo, G. (160) 173
Lazdunski, M., see Gandolfo, G. (167) 181
Lazdunski, M., see Vigne, P. (160) 295
Le, A.D., Mana, M.J., Pham, T., Khanna, J.M. and Kalant, H.
Effects of Ro 15-4513 on the motor impairment and hypnotic effects of ethanol and pentobarbital (159) 25
Le Bars, D., see Bing, Z. (164) 85

Lebel, L., see Schmidt, A. (165) 335
Lebel, L.A., see Koe, B.K. (161) 263
Lebrun, P., see Fontaine, J. (164) 583
Ledda, F., Corti, V. and Mantelli, L.
Indirect evidence for a role of prostaglandins as second messengers of the prejunctional effect of opioids in guinea-pig ventricular preparations (162) 323
Ledda, F., see Mantelli, L. (170) 217
Lee, C.Y., see Lin, W.W. (166) 581
Lee, N.H., Forray, C. and El-Fakahany, E.E.
Methoctramine, a cardioselective muscarinic antagonist, stimulates phosphoinositide hydrolysis in rat cerebral cortex (167) 295
Lee, N.M., see Fedynyshyn, J.P. (159) 83
Lee, R.C., see Lovenberg, T.W. (166) 111
Lees, I.W., see Daffonchio, L. (161) 135
Lefer, A.M., see Lento, P.H. (165) 241
Lefer, A.M., see Stahl, G.L. (163) 55
Leighton, G.E., Griesbacher, T., Hill, R.G. and Hughes, J.
Antagonism of central and peripheral anorectic effects of caerulein by L-364,718 (161) 255
Le Marquer, F.J., see Larcher, J.-C. (161) 197
Lembeck, F., see Holzer-Petsche, U. (162) 29
Lemmer, B. and Witte, K.
Circadian rhythm of the in vitro stimulation of adenylate cyclase in rat heart tissue (159) 311
Lento, P.H., Saukkonen, K., Aoki, N., Lefer, A.M., Slivjak, M.J. and Smith III, E.F.
Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock [1] (165) 241
Leone, M.G., see Clementi, G. (166) 549
Leonhardt, S., see Titeler, M. (167) 221
Leppik, R.A., see Guenet, C. (172) 443
Lerer, B., see Newman, M.E. (162) 345
Le Roux, M.G.J. and Syce, J.A.
The effect of ketanserin on serotonin-induced vascular responses in the isolated perfused rat lung (169) 269
Lesbats, B., see Gaudry-Talarmain, Y.M. (166) 427
Letter, A., see Hanson, G.R. (160) 23
Leunissen, J.D.M., see Vos, M.A. (165) 139
Leusen, F.J.J., see J.M. Van Galen, P. (172) 19
Levant, B., Bissette, G. and Nemeroff, C.B.
Effects of anticholinergic drugs on regional brain neurotensin concentrations (165) 327
Lew, R., see Mussap, C.J. (168) 337
Lewin, E., Peris, J., Bleck, V., Zahniser, N.R. and Harris, R.A.
Chemical kindling decreases GABA-activated chloride channels of mouse brain (160) 101
Lewin, J., see Vesperinas, G. (165) 309
Lewis, G.P., see Cole, O.F. (169) 307
Lewis, G.P., see O'Neill, L.A.J. (166) 131
Lewis, M.H., see Lovenberg, T.W. (166) 111
Lewis, M.J., see Evans, H.G. (163) 361
Lewis, M.J., see Hogan, J.C. (165) 129
Lewis, M.J., see Shah, A.M. (163) 365
Leysen, J.E., Janssen, P.F.M. and Niemegeers, C.J.E.
Rapid desensitization and down-regulation of 5-HT_2 receptors by DOM treatment (163) 145
Leysen, J.E., see Pauwels, P.J. (172) 471
Leysen, J.E., see Schotte, A. (172) 99
Li, C.G. and Rand, M.J.
Prejunctional inhibition of non-adrenergic non-cholinergic transmission in the rat anococcygeus muscle (168) 107
Liberge, M. and Bueno, L.
Comparison of β_1- and β_2-adrenoceptor effects on gastric emptying of a fat meal in mice (164) 147
Lidbury, P.S., Thiemermann, C., Thomas, G.R. and Vane, J.R.
Endothelin-3: selectivity as an anti-aggregatory peptide in vivo (166) 335
Liebmann, C., Schrader, U. and Brantl, V.
Opioid receptor affinities of the blood-derived tetrapeptides hemorphin and cytochrophin (166) 523
Liggett, S.B.
β-Adrenoceptor-effector system of the human macrophage U937 cell line (163) 171
Lim, D.K., Ito, Y., Hoskins, B., Rockhold, R.W. and Ho, I.K.
Comparative studies of muscarinic and dopamine receptors in three strains of rat (165) 279
Lin-Shiau, S.-Y., Liu, S.-H. and Fu, W.-M.
Studies on the contracture of the mouse diaphragm induced by sodium selenite (167) 137
Lin, W., Singer, G. and Funder, J.
The action of corticosterone on schedule-induced wheelrunning (171) 9
Lin, W.W., Lee, C.Y. and Chuang, D.-M.
Cross-desensitization of endothelin- and sarafotoxin-induced phosphoinositide turnover in neurons (166) 581
Lincoln, J., see Hopwood, A.M. (165) 323
Lindefors, N., Brodin, E. and Ungerstedt, U.
Amphetamine facilitates the in vivo release of neurokinin A in the nucleus accumbens of the rat (160) 417
Lindefors, N., Brodin, E. and Ungerstedt, U.
Subchronic haloperidol treatment decreases the in vivo release of tachykinins in rat substantia nigra (161) 95
Lindgren, J.Å., see Tornhamre, S. (169) 225
Linnoila, M., see Turkka, J. (167) 87
Lin Shiau, S.-Y., see Chen, C.-C. (169) 67
Lipovac, M.N., see Debler, E.A. (165) 155
Lippe, I.T. and Holzer, P.
The diacylglycerol kinase inhibitor, R 59022, suppresses contractility of intestinal smooth muscle (159) 1
Lista, A., Blier, P. and De Montigny, C.
In vivo presynaptic modulation of serotonergic neurotransmission in the rat hippocampus by diazepam (171) 229
Lister, R.G., see Nutt, D.J. (165) 135
Liu, B., see Kovács, G.L. (161) 27
Liu, R.H., see Davis, T.P. (161) 283
Liu, S.-H., see Lin-Shiau, S.-Y. (167) 137
Livett, B.G., see Wan, D.C.-C. (172) 107
Livett, B.G., see Wan, D.C.-C. (172) 117
Lo, S.-C., see Tsai, M.-C. (160) 133
Lodge, D., see Cincotta, M. (160) 167
Lodge, N.J., see Gelband, C.H. (167) 201
Loeschke, K., Schmid, T. and Farack, U.M.
Inhibition by loperamide of mucus secretion in the rat colon in vivo (170) 41

Loirand, G., Dacquet, C., Pacaud, P., Rakotoarisoa, L., Sayet, I., Mironneau, C. and Mironneau, J.
Desmethoxyverapamil-sensitive calcium channels in rat portal vein smooth muscle (167) 265
Lokhandwala, M.F., see Dlewati, A. (164) 197
Long, J.B., see Rothman, R.B. (160) 71
Longman, S.D., see Clapham, J.C. (171) 109
Longoni, B., see Corda, M.G. (159) 233
Longoni, B., see Corda, M.G. (169) 205
Lòpez, C., Jimenez, W., Arroyo, V., La Villa, G., Martinez-ardo, A., Gaya, J. and Rivera, F.
Effects of atrial natriuretic peptide on urinary kallikrein excretion and renal function in rats (168) 1
Lopez, F., Miller, L.G., Greenblatt, D.J., Kaplan, G.B. and Shader, R.I.
Interaction of caffeine with the $GABA_A$ receptor complex: alterations in receptor function but not ligand binding (172) 453
López-Farré, A., Montañés, I., Millás, I. and López-Novoa, J.M.
Effect of endothelin on renal function in rats (163) 187
López-Farré, A., see Ais, G. (170) 113
López-Novoa, J.M., see Ais, G. (170) 113
López-Novoa, J.M., see López-Farré, A. (163) 187
Lorinet, A.-M., Tatemoto, K., Laburthe, M. and Amiranoff, B.
Pancreastatin inhibits insulin release from Rin m 5F cells: reversion by pertussis toxin (160) 405
Lorinet, A.-M., see Amiranoff, B. (163) 205
Löscher, W. and Hönack, D.
Comparison of the anticonvulsant efficacy of primidone and phenobarbital during chronic treatment of amygdala-kindled rats (162) 309
Löscher, W., Jäckel, R. and Müller, F.
Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model (163) 1
Löschmann, P.-A., Chong, P.N., Nomoto, M., Tepper, P.G., Horn, A.S., Jenner, P. and Marsden, C.D.
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437 (166) 373
Lotti, V.J. and Chang, R.S.L.
A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260 (162) 273
Loubatières-Mariani, M.-M., see Ribes, G. (162) 207
Lovenberg, T.W., Brewster, W.K., Mottola, D.M., Lee, R.C., Riggs, R.M., Nichols, D.E., Lewis, M.H. and Mailman, R.B.
Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist (166) 111
Lovenberg, W., see Guenet, C. (172) 443
Lowy, M.T., Nash Jr., J.F. and Meltzer, H.Y.
Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA) (163) 157
Lumma, P.K., see Winquist, R.J. (163) 199
Lundberg, J.M., Rudehill, A. and Sollevi, A.
Pharmacological characterization of neuropeptide Y and noradrenaline mechanisms in sympathetic control of pig spleen (163) 103
Lundberg, J.M., see Lacroix, J.-S. (169) 125
Lundberg, J.M., see Matran, R. (163) 15
Lundberg, J.M., see Morel, D.R. (167) 427
Lutfy, K., see Yoburn, B.C. (170) 193
Luttinger, D., see Herrick-Davis, K. (162) 365
Luttinger, D., see Rossitch, Jr., E. (163) 119
Lutz-Bucher, B., see Koch, B. (158) 53
Lyon, R.A., see Titeler, M. (167) 221

Macara, B. and Gião T. Rico, J.M.
The effect of strontium on the drug-receptor interaction on cholinergic drugs (162) 51
Macho, P., Pérez, R., Huidobro-Toro, J.P. and Domenech, R.J.
Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction (167) 67
Macnová, J., Bauer, V. and Bilčíková, Ľ.
Trachealis responses induced by vincamine and vinpocetine; inhibition by indomethacin and Ca^{2+} dependence (162) 387
Mack-Burkhardt, F., see Kornhuber, J. (162) 483
MacKenzie, R.G., Stachowiak, M.K. and Zigmond, M.J.
Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine (168) 43
MacKenzie, R.G., see Kerkman, D.J. (166) 481
MacKinnon, A.C., see Kilpatrick, A.T. (166) 315
MacNaughton, W.K., see Wallace, J.L. (167) 41
Macquin-Mavier, I., see Gentil, B. (159) 181
Madsen, B., see Song, D.L. (160) 141
Maeda, S., see Kinouchi, K. (164) 63
Maehashi, H., see Hattori, T. (166) 527
Maggi, A., Pellegrini, S. and Bettini, E.
Estrogen-induced proteins in rat hypothalamus (172) 357
Maggi, A., see Canonaco, M. (170) 95
Maggi, C.A., Giuliani, S., Patacchini, R., Santicioli, P., Rovero, P., Giachetti, A. and Meli, A.
The C-terminal hexapeptide, endothelin-(16-21), discriminates between different endothelin receptors (166) 121
Maggi, C.A., Patacchini, R., Giuliani, S. and Meli, A.
Potent contractile effect of endothelin in isolated guinea-pig airways (160) 179
Maggi, C.A., Patacchini, R., Renzi, D., Santicioli, P., Regoli, D., Rovero, P., Drapeau, G., Surrenti, C. and Meli, A.
Effect of thiorphan on response of the guinea-pig gallbladder to tachykinins (165) 51
Maggi, C.A., Patacchini, R., Rovero, P. and Meli, A.
The hamster isolated trachea: a new preparation for studying NK-2 receptors (166) 435
Maggi, C.A., Patacchini, R., Santicioli, P., Giuliani, S., Del Bianco, E., Geppetti, P. and Meli, A.
The 'efferent' function of capsaicin-sensitive nerves: Ruthenium Red discriminates between different mechanisms of activation (170) 167
Maggi, C.A., see Giuliani, S. (163) 91
Mahe, L., Chapelain, B., Neliat, G. and Gargouil, Y.-M.

The role of α- and β-adrenoceptors in the response to noradrenaline of lymphatic vessels isolated from the bovine mesentery (167) 31
Maie, S., see Ichihara, K. (165) 19
Mailman, R.B., see Lovenberg, T.W. (166) 111
Majewski, H., see Murphy, T.V. (169) 285
Major, T.C., Weishaar, R.E. and Taylor, D.G.
Two phases of contractile response in rat isolated vas deferens and their regulation by adenosine and α-receptors (167) 323
Mak, J.C.W. and Barnes, P.J.
Muscarinic receptor subtypes in human and guinea pig lung (164) 223
Maker, H.S., see Lapin, E.P. (160) 53
Maldonado, R., Daugé, V., Callebert, J., Villette, J.M., Fournié-Zaluski, M.-C., Feger, J. and Roques, B.P.
Comparison of selective and complete inhibitors of enkephalin- degrading enzymes on morphine withdrawal syndrome (165) 199
Malgouris, C., see Castel, M.-N. (166) 353
Malm, L., see Petersson, G. (161) 37
Malminiemi, O. and Korpi, E.R.
Diazepam-insensitive [^{3}H]Ro 15-4513 binding in intact cultured cerebellar granule cells (169) 53
Mana, M.J., see Le, A.D. (159) 25
Manabe, S., see Kanai, Y. (166) 553
Mangano, T.J., see Keith, R.A. (166) 393
Manjeet, S., see Sim, M.K. (163) 399
Mannhold, R., see Voigt, W. (169) 103
Mansbach, R.S., Braff, D.L. and Geyer, M.A.
Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat (167) 49
Manso, G., see Sánchez, M. (168) 169
Mantelli, L., Amerini, S. and Ledda, F.
Effects of opioid drugs on capsaicin-sensitive neurones in guinea-pig atria (170) 217
Mantelli, L., see Ledda, F. (162) 323
Mantellini, P., see Evangelista, S. (164) 389
Manzini, S., see Geppetti, P. (168) 119
Maraia, G., see Reggiani, A. (168) 123
Marchetti, G., see Bernardi, L. (164) 415
Marchi, M., see Raiteri, M. (172) 223
Marco, L.A., Joshi, R.S., Brigham, T.E., Aldes, L.D. and Chronister, R.B.
Effects of clozapine on ketamine-induced linguopharyngeal events in rats (164) 171
Marczynski, T.J., see Urbancic, M. (171) 1
Marescaux, C., see Rumbach, L. (164) 577
Marie, P.-Y., Zannad, F., Parisot, M. and Royer, R.-J.
Role of ancillary properties of β-adrenoceptor antagonists in protecting the heart from anoxia (163) 337
Marley, P.D., see Wan, D.C.-C. (172) 117
Marotta, P., see Carnuccio, R. (166) 535
Marsden, C.D., see Löschmann, P.-A. (166) 373
Marsden, C.D., see Stewart, B.R. (162) 101
Marshall, R.J., see Winslow, E. (166) 241
Martin, P., Laurent, S., Massol, J., Childs, M. and Puech, A.J.
Effects of dihydropyridine drugs on reversal by imipramine of helpless behavior in rats (162) 185
Martin, P., see Massol, J. (160) 395
Martinez, J.R., Barker, S. and Camden, J.
Amiloride inhibits ^{22}Na uptake and [^{3}H]QNB binding in rat submandibular cells (164) 335
Martinez-Pardo, A., see Lòpez, C. (168) 1
Martling, C.-R., see Matran, R. (163) 15
Marumo, F., see Hirata, Y. (164) 603
Maruyama, Y., see Koshikawa, N. (164) 595
Maruyama, Y., see Koshikawa, N. (170) 101
Marwah, J., see Pitts, D.K. (160) 201
Masaki, T., see Saito, A. (162) 353
Mashimoto, S., see Ushijima, I. (161) 245
Masini, I., see Cerbai, E. (162) 491
Massardier, D. and Hunt, P.F.
A direct non-opiate interaction of dynorphin-(1-13) with the N-methyl-D-aspartate (NMDA) receptor (170) 125
Massi, M., Polidori, C. and Melchiorre, C.
Methoctramine, a selective $M_{2\alpha}$ muscarinic receptor antagonist, does not inhibit carbachol-induced drinking in the rat (163) 387
Massol, J., Martin, P., Adessi, G. and Puech, A.J.
Gonadotropin-releasing hormone (GnRH) as antidepressant: a psychopharmacological animal study (160) 395
Massol, J., see Martin, P. (162) 185
Massotte, L., see Seutin, V. (164) 373
Mathiasen, J.R., see Raffa, R.B. (169) 317
Mathieu, J.-F., Ferron, A., Dewar, K.M. and Reader, T.A.
Acute and chronic effects of methylphenidate on cortical adrenoceptors in the rat (162) 173
Matran, R., Martling, C.-R. and Lundberg, J.M.
Inhibition of cholinergic and non-adrenergic, non-cholinergic bronchoconstriction in the guinea pig mediated by neuropeptide Y and α_2-adrenoceptors and opiate receptors (163) 15
Matsuda, T., Hee Seong, Y., Aono, H., Kanda, T., Baba, A., Saito, K.-I., Tobe, A. and Iwata, H.
Agonist activity of a novel compound, 1-[3-(3,4-methylenedioxyphenoxy)propyl]-4-phenyl piperazine (BP-554), at central 5-HT_{1A} receptors (170) 75
Matsuki, N., see Abe, K. (171) 59
Matsumoto, H., see Higuchi, Y. (160) 413
Matsumoto, M., see Tanonaka, K. (165) 97
Matsumura, Y., Hisaki, K., Ohyama, T., Hayashi, K. and Morimoto, S.
Effects of endothelin on renal function and renin secretion in anesthetized rats (166) 577
Matsuo, H., see Iwata, T. (159) 321
Matsuoka, I., see Nakahata, N. (162) 407
Matsuzaki, T., see Noguchi, K. (168) 315
Matthies, H., see Popov, N. (172) 205
Matuz, J., see Erdö, S.L. (165) 79
Maura, G., Fedele, E. and Raiteri, M.
Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine (165) 173

Mauriège, P., see Sénard, J.-M. (162) 225
Mayer, B., see Schmidt, K. (170) 157
McCall, D.E., see Chiu, A.T. (170) 117
McCall, J.M., see Lahti, R.A. (166) 563
McCarthy, B.G., see Glennon, R.A. (168) 387
McCarthy, B.G., see Peroutka, S.J. (163) 133
McConnaughey, M.M., see Miller, J.D. (161) 165
McGarry, K.A., see Bowen, W.D. (163) 309
McKinney, M. and Barrett, R.W.
Biochemical evidence for somatostatin receptors in murine neuroblastoma clone N1E-115 (162) 397
McKnight, G.W., see Wallace, J.L. (167) 41
McMillen, B.A., DaVanzo, E.A., Song, A.H., Scott, S.M. and Rodriguez, M.E.
Effects of classical and atypical antipsychotic drugs on isolation-induced aggression in male mice [1] (160) 149
McMillen, B.A., see Miller, J.D. (161) 165
McMurtry, I., see Yamaguchi, T. (161) 259
McMurtry, I.F., see Rodman, D.M. (165) 297
McNamara, D.B., see Minkes, R.K. (164) 571
McNamara, D.B., see Minkes, R.K. (165) 259
Mechoulam, R., see Feigenbaum, J.J. (169) 159
Mehdorn, H.M., see Gross, G. (169) 325
Meincke, M., see Bognar, I.T. (163) 263
Meiners, B.A., see Keith, R.A. (166) 393
Meini, S., see Geppetti, P. (168) 119
Melchiorre, C., see Massi, M. (163) 387
Melchiorri, P., see Kreil, G. (162) 123
Melchiorri, P., see Raiteri, M. (172) 223
Meldrum, B.S., see Chapman, A.G. (166) 201
Meli, A., see Evangelista, S. (164) 389
Meli, A., see Giuliani, S. (163) 91
Meli, A., see Maggi, C.A. (160) 179
Meli, A., see Maggi, C.A. (165) 51
Meli, A., see Maggi, C.A. (166) 121
Meli, A., see Maggi, C.A. (166) 435
Meli, A., see Maggi, C.A. (170) 167
Melis, M.R., Argiolas, A. and Gessa, G.L.
Evidence that apomorphine induces penile erection and yawning by releasing oxytocin in the central nervous system (164) 565
Melis, M.R., see Argiolas, A. (166) 515
Mellemkjær, S., Nielsen-Kudsk, J.E., Nielsen, C.B. and Siggaard, C.
A comparison of the relaxant effects of pinacidil in guinea-pig trachea, aorta and pulmonary artery (167) 275
Meloni, D., see De Montis, G.M. (167) 299
Meltzer, H.Y., see Lowy, M.T. (163) 157
Meltzer, L.T., Wiley, J.N. and Heffner, T.G.
The α_2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920 (170) 105
Menard, F., see Hamon, M. (164) 315
Mendelsohn, F.A.O., see Kohzuki, M. (160) 193
Merchant, K.M., Gibb, J.W. and Hanson, G.R.
Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens (160) 409
Merlo, L., see Bernardi, L. (164) 415
Metra, M., see Kohli, J.D. (164) 265
Meucci, E., Delay-Goyet, P., Roques, B.P. and Zajac, J.-M.
Binding in vivo of selective μ and δ opioid receptor agonists: opioid receptor occupancy by endogenous enkephalins (171) 167
Meunier, J.-C., see Gairin, J.-E. (172) 381
Meurs, H., Timmermans, A., Van Amsterdam, R.G.M., Brouwer, F., Kauffman, H.F. and Zaagsma, J.
Muscarinic receptors in human airway smooth muscle are coupled to phosphoinositide metabolism (164) 369
Meurs, H., see Roffel, A.F. (172) 61
Meurs, H., see Van Amsterdam, R.G.M. (172) 175
Meyer III, W.J., see Jazayeri, A. (169) 183
Meyniel, G., see Thierry, A. (163) 97
Miceli, M.O. and Steiner, M.
Novel localizations of central- and peripheral-type cholecystokinin binding sites in Syrian hamster brain as determined by autoradiography (169) 215
Michaud, J.C., see Schumacher, C. (166) 139
Michel, A.D., Stefanich, E. and Whiting, R.L.
Direct labeling of rat M_3-muscarinic receptors by [^{3}H]4DAMP (166) 459
Michler, A. and Erdö, S.L.
Stimulation by phaclofen of inositol 1,4,5-triphosphate production in cultured neurons from chick tectum (167) 423
Mick, S., see Rao, T.S. (168) 129
Mickel, M., see Dubocovich, M.L. (162) 289
Mickelson, M.M., see Lahti, R.A. (166) 563
Middaugh, L., see Boggan, W. (166) 123
Mihara, S., Hara, S., Ueda, M., Ide, M. and Fujimoto, M.
Antagonistic actions of S-145 on vascular and platelet thromboxane A_2 receptors (171) 179
Mihara, S., Hara, S., Ueda, M., Ide, M. and Fujimoto, M.
Comparison of vascular and platelet thromboxane A_2/prostaglandin H_2 receptors in the pig (160) 313
Mikhailidis, D.P., see Jeremy, J.Y. (160) 107
Millás, I., see López-Farré, A. (163) 187
Miller, J.D., McMillen, B.A., McConnaughey, M.M., Williams, H.L. and Fuller, C.A.
Effects of microgravity on brain neurotransmitter receptors (161) 165
Miller, L.G., see Lopez, F. (172) 453
Miller, P., see Hambleton, P.T. (163) 141
Miller, R.C., see Jones, C.R. (163) 379
Miller, R.J., see Reynolds, I.J. (172) 9
Mimata, T. and Inomata, H.
Effect of noradrenaline on current- and voltage-clamped muscle cells of the guinea-pig vas deferens in normal Krebs solution (163) 181
Minematsu, R., see Tanonaka, K. (165) 97
Minkes, R.K. and Kadowitz, P.J.
Differential effects of rat endothelin on regional blood flow in the cat (165) 161

Minkes, R.K. and Kadowitz, P.J.
Influence of endothelin on systemic arterial pressure and regional blood flow in the cat (163) 163
Minkes, R.K., Bellan, J.A., Kerstein, M.D., McNamara, D.B. and Kadowitz, P.J.
Nisoldipine inhibits adrenergic responses in the hindquarters vascular bed of the cat (165) 259
Minkes, R.K., Coy, D.H., Murphy, W.A., McNamara, D.B. and Kadowitz, P.J.
Effects of porcine and rat endothelin and an analog on blood pressure in the anesthetized cat (164) 571
Miquel, M.C., see Gozlan, H. (172) 497
Mir, A.K., see Bourson, A. (160) 339
Mironneau, C., see Loirand, G. (167) 265
Mironneau, J., see Loirand, G. (167) 265
Misaki, N., see Imaizumi, T. (161) 203
Misaki, N., see Mizushima, A. (168) 375
Mishra, S.K., see Bhat, M.B. (164) 163
Mitchell, S.N., Brazell, M.P., Joseph, M.H., Alavijeh, M.S. and Gray, J.A.
Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain (167) 311
Mitchelson, F., see Choo, L.K. (162) 429
Miura, K., Yukimura, T., Yamashita, Y., Shimmen, T., Okumura, M., Imanishi, M. and Yamamoto, K.
Endothelin stimulates the renal production of prostaglandin E_2 and I_2 in anesthetized dogs (170) 91
Miyake, H. and Chiueh, C.C.
Effects of MPP^+ on the release of serotonin and 5-hydroxyindoleacetic acid from rat striatum in vivo (166) 49
Miyake, K., see Tanonaka, K. (165) 97
Miyamoto, Y., Ozaki, M. and Yamamoto, H.
Effect of adrenalectomy on correlation of analgesia with tissue content of morphine (167) 11
Miyata, N., see Kamata, K. (166) 319
Mizuki, Y., see Ushijima, I. (161) 245
Mizushima, A., Uchida, S., Zhou, X.-M., Osugi, T., Imaizumi, T., Misaki, N., Tatebayashi, Y. and Yoshida, H.
The H-L subgroup of guinea-pig cardiac M_2 receptors ($M_{2\beta}$) regulates inositol phosphate formation (168) 375
Modesti, P.A., Colella, A., Abbate, R., Gensini, G.F. and Neri Serneri, G.G.
Competitive inhibition of platelet thromboxane A_2 receptor binding by picotamide (169) 85
Moelling, K., see Guenet, C. (172) 443
Moguilewsky, M., see Vincens, M. (168) 15
Mohamed, L.H., see Gomaa, A.A. (170) 129
Mohammed, A.K., see Elinder, F. (164) 599
Moises, H.C., see Smith, C.B. (161) 111
Mol, J.A., see Hellebrekers, L.J. (164) 55
Molderings, G.J., Göthert, M., Fink, K., Roth, E. and Schlicker, E.
Inhibition of noradrenaline release in the pig coronary artery via a novel serotonin receptor (164) 213
Molina, V.A., Keller, E.A. and Orsingher, O.A.
Gangliosides enhance behavioral and neurochemical effects induced by chronic desipramine (DMI) treatment (160) 247
Molines, A., see Bricca, G. (162) 1
Molines, A., see Bricca, G. (163) 373
Mollard, P., Vacher, P., Dufy, B., Winiger, B.P. and Schlegel, W.
Inhibitors of 1,2-diacylglycerol kinase potentiate the TRH-induced stimulation of Ca^{2+} activated K^+ current (172) 71
Molleman, A., Nelemans, A. and Den Hertog, A.
P_2-purinoceptor-mediated membrane currents in DDT_1 MF-2 smooth muscle cells (169) 167
Möller, W., see Bosker, F.J. (163) 319
Molyvdas, P.-A., James, F.W. and Sperelakis, N.
Azelastine effects on electrical and mechanical activities of guinea pig papillary muscles (164) 547
Monaghan, D.T., see Palmer, E. (166) 585
Monahan, J.B., see Hood, W.F. (161) 281
Moncada, S., see Gardiner, S.M. (171) 237
Moncada, S., see Garthwaite, J. (172) 413
Montana, W., see Kerkman, D.J. (166) 481
Montañés, I., see López-Farré, A. (163) 187
Montastruc, J.-L., see Montastruc, P. (166) 511
Montastruc, P., Damase-Michel, C. and Montastruc, J.-L.
Apomorphine potentiates vagal bradycardia (166) 511
Monti, J.M., Jantos, H. and Fernández, M.
Effects of the selective dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat (169) 61
Moody, E.J. and Skolnick, P.
Chlormethiazole: neurochemical actions at the γ-aminobutyric acid receptor complex (164) 153
Moody, T.W., see Davis, T.P. (161) 283
Moore, M.L., see Brooks, D.P. (160) 159
Morcillo, E.J., see Cortijo, J. (162) 467
Morel, D.R., Lacroix, J.S., Hemsen, A., Steinig, D.A., Pittet, J.-F. and Lundberg, J.M.
Increased plasma and pulmonary lymph levels of endothelin during endotoxin shock (167) 427
Morelli, M., Fenu, S., Garau, L. and Di Chiara, G.
Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity (162) 329
Morgan, J.P., see Briggs, G.M. (170) 281
Morgan, J.P., see Perreault, C.L. (165) 305
Morgan, P.F., see Durcan, M.J. (168) 285
Mori, F., see Moroni, F. (163) 123
Morimoto, S., see Matsumura, Y. (166) 577
Morishita, H. and Furukawa, T.
Low calcium and calcium antagonists potentiate the contraction of guinea-pig vas deferens induced by ATP: a permissive role for P_2-purinoceptors (164) 507
Mørk, A. and Geisler, A.
Effects of lithium ex vivo on the GTP-mediated inhibition of calcium-stimulated adenylate cyclase activity in rat brain (168) 347
Morón, M.A., Stevens, C.W. and Yaksh, T.L.
Diltiazem enhances and flunarizine inhibits nimodipine's antiseizure effects (163) 299

Moroni, F., Pellegrini-Giampietro, D.E., Alesiani, M., Cherici, G., Mori, F. and Galli, A.
Glycine and kynurenate modulate the glutamate receptors in the myenteric plexus and in cortical membranes (163) 123
Morris, H.R., see Di Marzo, V. (162) 115
Morris, J.L. and Murphy, R.
Analogues of vasoactive intestinal peptide (VIP) contract the guinea-pig uterine artery but do not antagonize VIP-induced relaxations (162) 375
Mosberg, H.I., see Heyman, J.S. (165) 1
Mosberg, H.I., see Heyman, J.S. (169) 43
Moser, P.C., see Bourson, A. (160) 339
Moser, U., see Kopp, R. (172) 397
Moskowitz, M.A., see Buzzi, M.G. (165) 251
Motohashi, N., Ikawa, K. and Kariya, T.
$GABA_B$ receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? (166) 95
Mottola, D.M., see Lovenberg, T.W. (166) 111
Muccioli, G. and Di Carlo, R.
S-Adenosyl-L-methionine restores prolactin receptors in the aged rabbit brain (166) 223
Much, D.R., see Bergey, J.L. (159) 103
Mueller, R.A., see Criswell, H.E. (159) 141
Mugelli, A., see Cerbai, E. (162) 491
Mulder, A.H., see De Vries, T.J. (170) 137
Muldoon, S.M., see Robinson-White, A.J. (172) 291
Mulholland, G.K., see Kilbourn, M.R. (166) 331
Müller, F., see Löscher, W. (163) 1
Muneoka, Y., see Yongsiri, A. (171) 159
Muramatsu, I., see Omote, S. (160) 239
Murphy, R., see Morris, J.L. (162) 375
Murphy, T.V. and Majewski, H.
Modulation of noradrenaline release in slices of rat kidney cortex through α_1- and α_2-adrenoceptors (169) 285
Murphy, W.A., see Minkes, R.K. (164) 571
Murray, A.M. and Waddington, J.L.
The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1 : D-2 interaction (160) 377
Mussap, C.J., Lew, R. and Burcher, E.
The autoradiographic distribution of substance P binding sites in guinea-pig vas deferens is altered by capsaicin pretreatment (168) 337
Mustafa, S.J., see Ramagopal, M.V. (159) 33
Mustafa, S.J., see Sabouni, M.H. (166) 311
Mustafa, S.J., see Sabouni, M.H. (168) 271
Muta, T., Takasugi, M. and Kuroiwa, A.
Chlorpropamide alters AVP-receptor binding of rat renal tubular membranes (159) 191
Mutschler, E., see Eltze, M. (170) 225
Mutschler, E., see Kopp, R. (172) 397
Mutschler, E., see Lambrecht, G. (168) 71

Nabeshima, T., Kawashima, K. and Kameyama, T.
Effect of minaprine on cycloheximide-induced amnesia in mice (169) 249
Nabeshima, T., see Hiramatsu. M. (166) 359
Nabeshima, T., see Ichihara, K. (164) 189
Nagamine, F., see Noguchi, K. (168) 315
Nagao, T., see Komori, K. (164) 111
Nagata, M. and Osumi, Y.
Dual effect of nicotine injected in the cerebral ventricles on rat gastric motility (163) 85
Nahorski, S.R., see Chilvers, E.R. (164) 587
Nahorski, S.R., see Lambert, D.G. (165) 71
Nahorski, S.R., see Rooney, T.A. (172) 425
Naka, M., see Kondo, K. (163) 253
Nakahata, N., Matsuoka, I., Ono, T. and Nakanishi, H.
Thromboxane A_2 activates phospholipase C in astrocytoma cells via pertussis toxin-insensitive G-protein (162) 407
Nakajima, T., see Kurachi, Y. (165) 319
Nakajyo, S., see Hori, M. (165) 63
Nakamura, K., Ichihara, K. and Abiko, Y.
Effect of lidocaine on the accumulation of non-esterified fatty acids in the ischemic perfused rat heart (169) 259
Nakamura, K., Ichihara, K. and Abiko, Y.
Effect of propranolol on accumulation of NEFA in the ischemic perfused rat heart (160) 61
Nakamura, M., see Adachi, H. (161) 189
Nakamura, Y., see Fukuda, K. (165) 301
Nakanishi, H., see Nakahata, N. (162) 407
Nakao, K., see Iwata, T. (159) 321
Nakayama, K., Tanaka, Y. and Fujishima, K.
Potentiation of stretch-induced myogenic tone of dog cerebral artery by hemolysate and the inhibitory action of calcium antagonists (169) 33
Nakayama, S., see Jin, J.-G. (161) 73
Nakazawa, K., see Sugita, S. (165) 191
Nakazawa, M., see Ramagopal, M.V. (159) 33
Nakov, R., Habermann, E., Hertting, G., Wurster, S. and Allgaier, C.
Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release (164) 45
Namiki, M., see Uehara, A. (170) 257
Nardi, R.V., see Guglietta, A. (170) 87
Naruse, K., see Tsuchiya, K. (166) 541
Naruse, M., see Tsuchiya, K. (166) 541
Nash Jr., J.F., see Lowy, M.T. (163) 157
Nasri-Sebdani, M., Cragoe, Jr., E.J., Cognard, C., Potreau, D. and Raymond, G.
The depressant effects of some amiloride analogues on the slow outward K^+ current and contraction of voltage-clamped frog muscle fibres (171) 97
Nauntofte, B., see Undén, M. (164) 129
Nayler, W., see Gu, X.-H. (167) 281
Nayler, W.G., see Gu, X.-H. (162) 509
Near, J.A., see Vincent, M.S. (172) 317
Neff, N.H., see Hadjiconstantinou, M. (168) 261
Neff, N.H., see Varol, F.G. (159) 97
Neff, N.H., see Varol, F.G. (162) 37
Negri, L., see Kreil, G. (162) 123
Nehlig, A., see Schroeder, H. (167) 245
Nelemans, A., Van den Akker, J. and Den Hertog, A.

Characterization of the UV-induced electrophysiological response in smooth muscle (172) 283
Nelemans, A., see Den Hertog, A. (166) 531
Nelemans, A., see Molleman, A. (169) 167
Neliat, G., see Mahe, L. (167) 31
Nelson, D.R., see Sanger, G.J. (159) 113
Němček, V., see Štolc, S. (164) 249
Nemeroff, C.B., see Levant, B. (165) 327
Nemeroff, C.B., see Rossitch, Jr., E. (163) 119
Nemeth, P.R. and Gullikson, G.W.
Gastrointestinal motility stimulating drugs and 5-HT receptors on myenteric neurons (166) 387
Neri Serneri, G.G., see Modesti, P.A. (169) 85
Neumann, J., see Heller, T. (164) 179
Newberry, N.R. and Gilbert, M.J.
5-Hydroxytryptamine evokes three distinct responses on the rat superior cervical ganglion in vitro (162) 197
Newberry, N.R. and Gilbert, M.J.
Biphasic dose-response curve to muscarine on the rat superior cervical ganglion (163) 237
Newberry, N.R. and Gilbert, M.J.
Pertussis toxin sensitivity of drug-induced potentials on the rat superior cervical ganglion (163) 245
Newberry, N.R., see Freedman, S.B. (167) 411
Newman, M.E. and Lerer, B.
Post-receptor-mediated increases in adenylate cyclase activity after chronic antidepressant treatment: relationship to receptor desensitization (162) 345
Neya, T., see Jin, J.-G. (161) 73
Nguyen, A., see Goffinet, A.M. (161) 99
Nguyen, T.T., see Chiu, A.T. (170) 117
Nichols, D.E., see Lovenberg, T.W. (166) 111
Nickel, B., see Vaupel, D.B. (162) 447
Nicolaou, K.C., see Stahl, G.L. (163) 55
Nicoletti, F., Canonico, P.L., Favit, A., Nicoletti, G. and Albanese, V.
Receptor-mediated stimulation of inositol phospholipid hydrolysis in human brain (160) 299
Nicoletti, G., see Nicoletti, F. (160) 299
Nicoll, R.A., see Dutar, P. (164) 355
Nielsen, C.B., see Mellemkjær, S. (167) 275
Nielsen, E., see Honoré, T. (172) 239
Nielsen, E.B., Randrup, K. and Andersen, P.H.
Amphetamine discrimination: effects of dopamine receptor agonists [1] (160) 253
Nielsen-Kudsk, J.E., see Mellemkjær, S. (167) 275
Nielsen, M., see Gozlan, H. (172) 497
Nielsen, M., see Honoré, T. (172) 239
Nielsen, M., see Wong, E.H.F. (172) 493
Niemegeers, C.J.E., see Leysen, J.E. (163) 145
Nieves, A.L., see Woodward, D.F. (164) 323
Nieves, A.L., see Woodward, D.F. (168) 23
Nijkamp, F.P., see Engels, F. (164) 139
Nijkamp, F.P., see Van Heuven-Nolsen, D. (162) 135
Nishida, N., Hasegawa, Y., Chiba, S., Wakimasu, M. and Fujino, M.
Reinforcing effects of the enkephalin analogs, EK-209 and EK-399, in rats (166) 453
Nishijima, H., see Adachi, H. (161) 189
Nistri, A., see Sivilotti, L. (164) 205
Nitta, K., see Tsuchiya, K. (166) 541
Niwa, M., see Yamasaki, H. (168) 247
Nock, B., Giordano, A.L. and Cicero, T.J.
ICI 197067 is a selective ligand for the U-69593-sensitive κ opiate binding site (162) 385
Noguchi, K., Ojiri, Y., Nagamine, F., Matsuzaki, T. and Sakanashi, M.
Alleviation of myocardial dysfunction and abnormal lactate metabolism during coronary stenosis in dogs by ICI 118,551 (168) 315
Nomoto, M., see Löschmann, P.-A. (166) 373
Nomura, Y., see Tohda, M. (166) 57
Nonaka, S., see Higuchi, Y. (160) 413
Nordstedt, C., Kvanta, A., Van der Ploeg, I. and Fredholm, B.B.
Dual effects of protein kinase-C on receptor stimulated cAMP accumulation in a human T-cell leukemia line (172) 51
Novales-Li, P., Sun, X.-P. and Takeuchi, H.
Suppression of calcium current in a snail neurone by eperisone and its analogues (168) 299
Novo, C., see Ais, G. (170) 113
Nowak, G. and Zak, J
Repeated electroconvulsive shock (ECS) enhances striatal D-1 dopamine receptor turnover in rats (167) 307
Nowakowska, E., see Cervo, L. (171) 119
Nozaki, M., see Fujioka, H. (166) 13
Nunes de Souza, R.L., see Siegfried, B. (168) 239
Nutt, D.J. and Lister, R.G.
3-(Methoxycarbonyl)-amino-β-carboline reduces both the sedative and anticonvulsant effects of diazepam (165) 135
Nwator, I.A.A. and Whalley, E.T.
Angiotensin converting enzyme inhibitors and expression of des-Arg^9-BK (kinin B_1) receptors in vivo (160) 125
Nwator, I.A.A., Parsons, A.A. and Whalley, E.T.
Prostanoid involvement in the relaxation of in vitro mesenteric artery by bradykinin and des-Arg^9-bradykinin (170) 29

O'Brien, R., see Yamaguchi, T. (161) 259
O'Brien, R.F., see Rodman, D.M. (165) 297
O'Connor, J.J., Rowan, M.J. and Anwyl, R.
Serotonergic involvement in the inhibitory effects of repeated buspirone treatment on synaptic transmission in the hippocampus (167) 21
Oda, N., see Kurihara, J. (165) 147
O'Donnell, S.R., see Wanstall, J.C. (159) 241
Oehlenschlager, W.F., Baron, D.A., Schomer, H. and Currie, M.G.
Atrial and brain natriuretic peptides share binding sites in the kidney and heart (161) 159
Ogiwara, Y., see Furukawa, Y. (161) 1
Ohno, M., see Yatsugi, S.-i. (166) 231
Ohta, K., see Hirata, Y. (164) 603
Ohyama, T., see Matsumura, Y. (166) 577
Ojiri, Y., see Noguchi, K. (168) 315

Okada, Y., see Sadoshima, S. (169) 75
Okamura, K., see Uehara, A. (170) 257
Okegawa, T., see Kondo, K. (163) 253
Okegawa, T., see Kondo, K. (168) 193
Okumura, M., see Miura, K. (170) 91
Okumura, T., see Uehara, A. (170) 257
Okyayuz-Baklouti, I.
The effects of torbafylline on blood flow, pO_2 and function of rat ischaemic skeletal muscle [1] (166) 75
Olbricht, C., see Bossaller, C. (165) 165
Oles, R.J., see Tricklebank, M.D. (167) 127
Olgiati, V., see Cohen, B.M. (170) 201
Olianas, M.C. and Onali, P.
Stimulation of synaptosomal dopamine synthesis by corticotropin-releasing factor in rat striatum: role of Ca^{2+}-dependent mechanisms (166) 165
Olpe, H.-R., see Karlsson, G. (163) 285
Olverman, H.J., see Honoré, T. (172) 239
Omawari, N., see Kondo, K. (168) 193
Omini, C., Brunelli, G., Hernandez, A. and Daffonchio, L.
Bradykinin and substance P potentiate acetylcholine-induced bronchospasm in guinea-pig (163) 195
Omori, K., see Inoue, M. (166) 101
Omote, S., Kigoshi, S. and Muramatsu, I.
Selective inhibition by nifedipine of the purinergic component of neurogenic vasoconstriction in the dog mesenteric artery (160) 239
Onali, P., see Olianas, M.C. (166) 165
O'Neill, L.A.J. and Lewis, G.P.
Interleukin-1 potentiates bradykinin- and TNFα-induced PGE_2 release (166) 131
Ong, J., see Kerr, D.I.B. (164) 361
Ongini, E., see Corda, M.G. (169) 205
Ono, T., see Nakahata, N. (162) 407
Onodera, S., see Haneda, T. (162) 81
Onodera, S., see Takashio, T. (169) 179
Ooboshi, H., see Sadoshima, S. (169) 75
Oono, H., see Fukuda, K. (165) 301
Ornstein, P., see France, C.P. (159) 133
Orsingher, O.A., see Molina, V.A. (160) 247
Ortiz, J.L., see Cortijo, J. (162) 467
Oshiro, M.E.M., Shimuta, S.I., Paiva, T.B. and Paiva, A.C.M.
Evidence for a regulatory site in the angiotensin II receptor of smooth muscle (166) 411
Osugi, T., see Imaizumi, T. (161) 203
Osugi, T., see Mizushima, A. (168) 375
Osumi, Y., see Nagata, M. (163) 85
Otani, H., see Inoue, M. (166) 101
Otero Losada, M.E. and Rubio, M.C.
Acute effects of S-adenosyl-L-methionine on catecholaminergic central function (163) 353
Ouchi, H., see Hatake, K. (168) 277
Ouwendijk, R.J.T., see Zijlstra, F.J. (159) 291
Ouyang, C., see Wang, J.-P. (161) 143
Ozaki, M., see Miyamoto, Y. (167) 11
Ozaki, M., see Yamasaki, H. (168) 247
Ozaki, S., see Takata, Y. (164) 365
Ozaki, T., see Kuwahara, A. (164) 175
Ozawa, Y., see Yamamoto, M. (166) 345

Paakkari, I., see Vonhof, S. (164) 77
Pacaud, P., see Loirand, G. (167) 265
Padrini, R., see Bova, S. (168) 179
Paiva, A.C.M., see Oshiro, M.E.M. (166) 411
Paiva, T.B., see Oshiro, M.E.M. (166) 411
Paleos, G.A., see Yang, Z.W. (164) 607
Palermo, N., see Flynn, D.D. (172) 363
Palermo-Neto, J., see Sandoval, M.R.L. (167) 117
Palfreyman, M.G., see Sorensen, S.M. (163) 115
Pallas, S., see Bognar, I.T. (163) 263
Palluk, R., Veress, A.T. and Sonnenberg, H.
Hyperresponsiveness to atrial natriuretic factor in adult Brattleboro rats (162) 245
Palmer, E., Monaghan, D.T. and Cotman, C.W.
Trans-ACPD, a selective agonist of the phosphoinositide-coupled excitatory amino acid receptor (166) 585
Palmer, R.M.J., see Gardiner, S.M. (171) 237
Palmer, R.M.J., see Garthwaite, J. (172) 413
Pang, C.C.Y., see D'Oyley, H.M. (162) 337
Pani, L., see Rossetti, Z.L. (163) 393
Papini, A.M., see Giuliani, S. (163) 91
Parente, L., see Fitzgerald, M.F. (164) 539
Paris, H., see Langin, D. (167) 95
Paris, H., see Sénard, J.-M. (162) 225
Parisot, M., see Marie, P.-Y. (163) 337
Parkinson, F.E. and Clanachan, A.S.
Subtypes of nucleoside transport inhibitory sites in heart: a quantitative autoradiographical analysis (163) 69
Paro, M., see Bernardi, L. (164) 415
Parsons, A.A., see Nwator, I.A.A. (170) 29
Parsons, M.E., see Taylor, E.M. (161) 121
Parsons, M.E., see Taylor, E.M. (164) 23
Pascual, R., see Cortijo, J. (162) 467
Pasternak, G.W., see Paul, D. (168) 307
Patacchini, R., see Geppetti, P. (168) 119
Patacchini, R., see Maggi, C.A. (160) 179
Patacchini, R., see Maggi, C.A. (165) 51
Patacchini, R., see Maggi, C.A. (166) 121
Patacchini, R., see Maggi, C.A. (166) 435
Patacchini, R., see Maggi, C.A. (170) 167
Pataki, Á., see Tarnawa, I. (167) 193
Patanè, S., see Clementi, G. (163) 175
Patel, J., see Keith, R.A. (166) 393
Patrono, C., see Ferrario, R.G. (171) 127
Patti, F., see Clementi, G. (163) 175
Paul, D., Bodnar, R.J., Gistrak, M.A. and Pasternak, G.W.
Different μ receptor subtypes mediate spinal and supraspinal analgesia in mice (168) 307
Pauwels, P.J., Leysen, J.E. and Janssen, P.A.J.
β-Adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol (172) 471
Pavani, N.J.P., see Vital Brazil, O. (159) 47
Payne, A.N., see Daffonchio, L. (161) 135
Peach, J.L., see Rodman, D.M. (165) 297

Peach, M.J., see Trachte, G.J. (164) 425
Pechnick, R.N. and George, R.
Naloxone does not produce withdrawal hypothermia in chronically phencyclidine-treated rats (166) 295
Pechnick, R.N., George, R. and Poland, R.E.
Characterization of the effects of the acute and repeated administration of MK-801 on the release of adrenocorticotropin, corticosterone and prolactin in the rat (164) 257
Peers, S.H., see Cirino, G. (166) 505
Peevy, K., see Greenberg, S. (162) 67
Pelckmans, P.A., Boeckxstaens, G.E., Van Maercke, Y.M., Herman, A.G. and Verbeuren, T.J.
Acetylcholine is an indirect inhibitory transmitter in the canine ileocolonic junction (170) 235
Pellegrini, G., see Bonanno, G. (172) 41
Pellegrini-Giampietro, D.E., see Moroni, F. (163) 123
Pellegrini, S., see Maggi, A. (172) 357
Pelton, J.T., see Guenet, C. (172) 443
Pelton, J.T., see Jones, C.R. (163) 379
Pepeu, G., see Di Patre, P.L. (162) 43
Pepke-Zaba, J., see Dinh Xuan, A.T. (163) 401
Perez, J., Tinelli, D., Brunello, N. and Racagni, G.
cAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment (172) 305
Pérez, R., see Macho, P. (167) 67
Peris, J., see Lewin, E. (160) 101
Perlini, S., see Bernardi, L. (164) 415
Perlman, A.J., see Song, D.L. (160) 141
Peroutka, S.J. and McCarthy, B.G.
Sumatriptan (GR 43175) interacts selectively with 5-HT_{1B} and 5-HT_{1D} binding sites (163) 133
Peroutka, S.J., see Glennon, R.A. (168) 387
Peroutka, S.J., see Schmidt, A.W. (163) 397
Peroutka, S.J., see Schmidt, A.W. (171) 141
Perpiñá, M., see Cortijo, J. (162) 467
Perreault, C.L., Brozovich, F.V., Ransil, B.J. and Morgan, J.P.
Effects of MCI-154 on Ca^{2+} activation of skinned human myocardium (165) 305
Pesce, G., see Corda, M.G. (169) 205
Petersen, E.N.
Pharmacological effects of diethylthiocarbamic acid methyl ester, the active metabolite of disulfiram? (166) 419
Petersson, G., Malm, L., Rosengren, E. and Håkanson, R.
Hyperosmolarity but not histamine evokes secretion of nasal fluid in the rat (161) 37
Petrillo, P., La Regina, A., Sbacchi, M., Tavani, A., Robson, L.E. and Kosterlitz, H.W.
Regional variations in binding capacities at μ-, δ- and κ-opioid sites in membrane suspensions from rabbit brain (166) 213
Petty, M.A. and Di Francesco, G.F.
The cardiovascular effects of centrally administered taurine in anaesthetised and conscious rats (162) 359
Pfeiffer, A., see Kopp, R. (172) 397
Pfister, S.L., Rosolowsky, M., Schmitz, J.M., Clubb, Jr., F.J. and Campbell, W.B.
Eicosapentaenoic acid alters vascular reactivity and platelet adhesion in Watanabe heritable hyperlipidemic rabbits (161) 85
Pham, T., see Le, A.D. (159) 25
Philibert, D., see Vincens, M. (168) 15
Pia Abbracchio, M., see Di Luca, M. (172) 321
Picardo, A., see Feely, M. (164) 377
Pick, C.G., see Weizman, A. (169) 235
Picker, Z., see Ågmo, A. (166) 115
Picotti, G.B., see Cesura, A.M. (162) 457
Pin, J.-P., Van Vliet, B.J. and Bockaert, J.
Complex interaction between quisqualate and kainate receptors as revealed by measurement of GABA release from striatal neurons in primary culture (172) 81
Pinkus, L.M., Sarbin, N.S., Barefoot, D.S. and Gordon, J.C.
Association of [^{3}H]zacopride with 5-HT_3 binding sites (168) 355
Piovan, D., see Bova, S. (168) 179
Pipkin, M.A., see Taylor, E.M. (161) 121
Pirovano, I.M., IJzerman, A.P., Van Galen, P.J.M. and Soudijn, W.
Influence of the molecular structure of N^6-(ω-aminoalkyl)adenosines on adenosine receptor affinity and intrinsic activity (172) 185
Pisani, T., see Kilbourn, M.R. (166) 331
Pittet, J.-F., see Morel, D.R. (167) 427
Pitts, D.K. and Marwah, J.
Chronic cocaine reduces α_2-adrenoceptor elicited mydriasis and inhibition of locus coeruleus neurons (160) 201
Pitts, D.K., Freeman, A.S., Kelland, M.D. and Chiodo, L.A.
Repeated amphetamine: reduced dopamine neuronal responsiveness to apomorphine but not quinpirole (162) 167
Płaźnik, A., see Kostowski, W. (168) 393
Polak, J.M., see Power, R.F. (160) 199
Poland, R.E., see Pechnick, R.N. (164) 257
Polidori, C., see Massi, M. (163) 387
Politi, D.M.T., Suzuki, S. and Rogawski, M.A.
BRL 34915 (cromakalim) enhances voltage-dependent K^+ current in cultured rat hippocampal neurons (168) 7
Popov, N. and Matthies, H.
Influence of dopamine receptor agonists and antagonists on calmodulin translocation in different brain regions (172) 205
Porcella, A., see De Montis, G.M. (167) 299
Porciatti, F., see Cerbai, E. (162) 491
Porreca, F., see Heyman, J.S. (165) 1
Porreca, F., see Heyman, J.S. (169) 43
Portas, C., see Rossetti, Z.L. (163) 393
Post, R.M., see Clark, M. (164) 399
Post, R.M., see Zimányi, I. (167) 419
Postema, J.B., see Van Amsterdam, R.G.M. (172) 175
Potier, P., see Dellouve-Courillon, C. (166) 557
Potreau, D., see Nasri-Sebdani, M. (171) 97
Potter, W.Z., see Fochtmann, L.J. (167) 305
Potter, W.Z., see Turkka, J. (167) 87
Power, R.F., Wharton, J., Salas, S.P., Kanse, S., Ghatei, M., Bloom, S.R. and Polak, J.M.

Autoradiographic localisation of endothelin binding sites in human and porcine coronary arteries (160) 199
Prado de Carvalho, L., see Geoffroy, M. (166) 355
Pranzatelli, M.R. and Balletti, J.
Identification of 5-HT_{1A} recognition sites in human ganglioneuroblastoma (170) 127
Prato, A., see Clementi, G. (163) 175
Prato, A., see Clementi, G. (166) 549
Preston, C., see Tricklebank, M.D. (167) 127
Price, D.L., see Titeler, M. (167) 221
Priola, D.V., see Smith, D.C. (161) 249
Prochniak, M., see Shalaby, I. (160) 309
Proctor, W., see Fredholm, B.B. (172) 249
Prow, M.R., see Heal, D.J. (170) 11
Prow, M.R., see Heal, D.J. (170) 19
Puech, A.J., see Martin, P. (162) 185
Puech, A.J., see Massol, J. (160) 395
Puglisi-Allegra, S., see Imperato, A. (165) 337
Pujol, J.-F., see Broussolle, E. (159) 225
Pullan, L.M., see Stumpo, R.J. (170) 121
Putnam, C.W., see Laird II, H.E. (171) 25

Raberger, G., see Grohs, J.G. (161) 53
Racagni, G., see Perez, J. (172) 305
Racké, K., see Schwörer, H. (165) 29
Raffa, R.B., Mathiasen, J.R. and Goode, T.L.
Central administration of p-octopamine to mice: assessment of antinociception (169) 317
Raiteri, M., Marchi, M., Bonanno, G., Melchiorri, P. and Erspamer, V.
Facilitation of [^{3}H]acetylcholine and [^{3}H]5-hydroxytryptamine release from rat cerebral cortex synaptosomes by a factor extracted from the skin of the Australian frog *Pseudophryne coriacea* (172) 223
Raiteri, M., see Bonanno, G. (172) 41
Raiteri, M., see Maura, G. (165) 173
Rakotoarisoa, L., see Loirand, G. (167) 265
Ramagopal, M.V., Nakazawa, M. and Mustafa, S.J.
Relaxing effects of adenosine in coronary artery in calcium-free medium (159) 33
Ramagopal, M.V., see Sabouni, M.H. (166) 311
Ramarao, P., see Bhargava, H.N. (162) 257
Ramboer, I. and Boeynaems, J.-M.
Pharmacological modulation of ^{86}Rb efflux from aortic endothelial cells (171) 251
Ramboer, I., see Raspe, E. (163) 345
Ramirez, V.D., see Chen, J.-C. (166) 473
Rampart, M., see Deckers, I.A. (167) 415
Ramphal, J.Y., see Stahl, G.L. (163) 55
Ramwell, P.W., see Thomas, G. (161) 279
Ramwell, P.W., see Thomas, G. (170) 123
Rand, M.J., see Li, C.G. (168) 107
Rand, M.J., see Reid, J.J. (168) 93
Randrup, K., see Nielsen, E.B. (160) 253
Ransil, B.J., see Perreault, C.L. (165) 305
Rao, T.S., Cler, J., Emmett, M.R., Mick, S., Iyengar, S., Contreras, P.C. and Wood, P.L.
Ifenprodil and SL 82.0715 antagonize N-methyl-D-aspartate (NMDA)-coupled glycine receptor responses in vivo (168) 129
Raschack, M., see Kirchengast, M. (160) 349
Raspe, E., Ramboer, I., Galand, N. and Boeynaems, J.M.
Enhanced release of prostacyclin from quin 2-loaded endothelial cells (163) 345
Raviprakash, V., see Bhat, M.B. (164) 163
Raybould, H.E. and Taché, Y.
Capsaicin-sensitive vagal afferent fibers and stimulation of gastric acid secretion in anesthetized rats (167) 237
Raymond, G., see Nasri-Sebdani, M. (171) 97
Reader, T.A., see Laneuville, O. (159) 273
Reader, T.A., see Mathieu, J.-F. (162) 173
Redkar-Brown, D.G. and Aharony, D.
Inhibition of antigen-induced contraction of guinea pig trachea by ICI 198,615 (165) 113
Redmond, D.J., see Von Lubitz, D.K.J.E. (164) 405
Reggiani, A., Maraia, G., Ceserani, R. and Gaviraghi, G.
Effect of 7-chloro kynurenic acid on glycine modulation of the N-methyl-D-aspartate response in guinea-pig myenteric plexus (168) 123
Regoli, D., see Devillier, P. (168) 53
Regoli, D., see Maggi, C.A. (165) 51
Regoli, D., see Rhaleb, N.-E. (162) 419
Reichwehr, I., see Alheid, U. (164) 103
Reid, J.J., Wong-Dusting, H.K. and Rand, M.J.
The effect of endothelin on noradrenergic transmission in rat and guinea-pig atria (168) 93
Reid, J.L., see Deighton, N.M. (169) 95
Reid, L.R., see Wong, D.T. (166) 107
Reilly, W.M., Saville, V.L. and Burnstock, G.
Vessel reactivity and prejunctional modulatory changes in the portal vein of mature spontaneously hypertensive rats (160) 283
Reimann, W. and Schneider, F.
Presynaptic α_2-adrenoceptors modulate the release of [^{3}H]noradrenaline from rat spinal cord dorsal horn neurones (167) 161
Reiser, G. and Hamprecht, B.
Serotonin raises the cyclic GMP level in a neuronal cell line via 5-HT_3 receptors (172) 195
Reiser, G. and Koch, R.
Memantine inhibits serotonin-induced rise of cytosolic Ca^{2+} activity and of cyclic GMP level in a neuronal cell line (172) 199
Reith, M.E.A., see Benuck, M. (159) 187
Reith, M.E.A., see Debler, E.A. (165) 155
Reith, M.E.A., see Zimányi, I. (167) 419
Reithmann, C., Gierschik, P., Sidiropoulos, D., Werdan, K. and Jakobs, K.H.
Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: increase in the level of inhibitory G-protein α-subunits (172) 211
Reithmann, C., Wieland, F., Jakobs, K.H. and Werdan, K.
Intrinsic sympathomimetic activity of β-adrenoceptor

antagonists: down-regulation of cardiac β_1- and β_2-adrenoceptors (170) 243
Renard, C.-A., see Wisner, A. (162) 89
Reneman, R.S., see Janssens, W.J. (159) 89
Renoux, M., see Devillier, P. (168) 53
Renzi, D., see Evangelista, S. (164) 389
Renzi, D., see Maggi, C.A. (165) 51
Reschke, V., see Bossaller, C. (165) 165
Retz, W., see Kornhuber, J. (166) 589
Reynolds, I.J., Harris, K.M. and Miller, R.J.
NMDA receptor antagonists that bind to the strychnine-insensitive glycine site and inhibit NMDA-induced Ca^{2+} fluxes and [^{3}H]GABA release (172) 9
Rhaleb, N.-E., Dion, S., Barabé, J., Rouissi, N., Jukic, D., Drapeau, G. and Regoli, D.
Receptors for kinins in isolated arterial vessels of dogs (162) 419
Rhoden, K.J. and Barnes, P.J.
Epithelial modulation of non-adrenergic, non-cholinergic and vasoactive intestinal peptide-induced responses: role of neutral endopeptidase (171) 247
Ribeiro, J.A., see De Mendonça, A. (164) 347
Ribes, G., Hillaire-Buys, D., Gross, R., Blayac, J.-P. and Loubatières-Mariani, M.-M.
Involvement of a central nervous pathway in yohimbine-induced insulin secretion (162) 207
Rice, K.C., see Bluth, L.S. (161) 273
Rice, K.C., see Debler, E.A. (165) 155
Rice, K.C., see Rothman, R.B. (160) 71
Rice, K.C., see Rothman, R.B. (167) 345
Richards, A.C., see Hogan, J.C. (165) 129
Richards, I.S., Kulkarni, A.P. and Brooks, S.M.
Ethanol-induced bronchodilatation in TEA-treated canine tracheal smooth muscle is mediated by a β-adrenoceptor-dependent mechanism (167) 155
Richmond, S.A., see Feigenbaum, J.J. (169) 159
Riedel, R., see Schudt, C. (165) 87
Riederer, P., see Fritze, J. (172) 147
Riederer, P., see Kornhuber, J. (162) 483
Riederer, P., see Kornhuber, J. (166) 589
Riggs, R.M., see Lovenberg, T.W. (166) 111
Rimvall, K., Keller, F. and Waser, P.G.
Muscarinic receptors on cultured cells of rat hippocampus: cholinergic regulation and presence of subtypes (160) 1
Rivera, F., see Lòpez, C. (168) 1
Rivy, J.-P., see Carter, C. (164) 611
Robba, M., see Gaudry-Talarmain, Y.M. (166) 427
Robertson, D.W., see Wong, D.T. (166) 107
Robertson, G.S., Herrera, D.G., Dragunow, M. and Robertson, H.A.
L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra (159) 99
Robertson, H.A., see Robertson, G.S. (159) 99
Robinson, F.C., see Robinson-White, A.J. (172) 291
Robinson-White, A.J., Muldoon, S.M. and Robinson, F.C.
Inhibition of inositol phospholipid hydrolysis in endothelial cells by pentobarbital (172) 291
Robson, L.E., see Petrillo, P. (166) 213
Rockhold, R.W., Acuff, C.G. and Clower, B.R.
Excitotoxin-induced myocardial necrosis (166) 571
Rockhold, R.W., see Lim, D.K. (165) 279
Rodman, D., see Yamaguchi, T. (161) 259
Rodman, D.M., McMurtry, I.F., Peach, J.L. and O'Brien, R.F.
Comparative pharmacology of rat and porcine endothelin in rat aorta and pulmonary artery (165) 297
Rodriguez, M.E., see McMillen, B.A. (160) 149
Røed, A.
Ca antagonistic and non-specific effects of diltiazem on the rat phrenic nerve diaphragm preparation (159) 61
Roffel, A.F., Elzinga, C.R.S., Meurs, H. and Zaagsma, J.
Allosteric interactions of three muscarine antagonists at bovine tracheal smooth muscle and cardiac M_2 receptors (172) 61
Rogawski, M.A., see Politi, D.M.T. (168) 7
Rogers, L.V., see Giordano, J. (170) 83
Rollema, H., see Johnson, E.A. (166) 65
Romeo, J.M., see Ais, G. (170) 113
Romettino, S., see Gandolfo, G. (167) 181
Ronken, E., Tonnaer, J.A.D.M., De Boer, T. and Wiegant, V.M.
Autoradiographic evidence for binding sites for des-enkephalin-γ-endorphin (ORG 5878) in rat forebrain (162) 189
Room, P., Tielemans, A.J.P.C., De Boer, T. and Tonnaer, J.A.D.M.
The neuropeptide, Org 5878 (desenkephalin-γ-endorphin, DEγE), affects local cerebral glucose utilization in freely moving rats (171) 69
Rooney, K.F. and Sewell, R.D.E.
Evaluation of selective actions of dopamine D-1 and D-2 receptor agonists and antagonists on opioid antinociception (168) 329
Rooney, T.A. and Nahorski, S.R.
Developmental aspects of muscarinic-induced inositol polyphosphate accumulation in rat cerebral cortex (172) 425
Roques, B.P., see Daugé, V. (163) 25
Roques, B.P., see De Vries, T.J. (170) 137
Roques, B.P., see Durieux, C. (168) 269
Roques, B.P., see Maldonado, R. (165) 199
Roques, B.P., see Meucci, E. (171) 167
Rosenberg, H.C., see Tietz, E.I. (167) 57
Rosengren, E., see Petersson, G. (161) 37
Rosenthal, W., see Joost, H.G. (172) 461
Rosland, J.H., see Hunskaar, S. (160) 83
Rosolowsky, M., see Pfister, S.L. (161) 85
Rossetti, Z.L., Pani, L., Portas, C. and Gessa, G.
Brain dialysis provides evidence for D_2-dopamine receptors modulating noradrenaline release in the rat frontal cortex (163) 393
Rossier, J., see Geoffroy, M. (166) 355
Rossitch, Jr., E., King, R.A., Luttinger, D. and Nemeroff, C.B.
Behavioral effects of neurotensin: operant responding and assessment of 'anhedonia' (163) 119
Roth, E., see Molderings, G.J. (164) 213

Roth, R.H., see Sprouse, J.S. (167) 375
Rothman, R.B., Bykov, V., Long, J.B., Brady, L.S., Jacobson, A.E., Rice, K.C. and Holaday, J.W.
Chronic administration of morphine and naltrexone up-regulate μ-opioid binding sites labeled by [^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin: further evidence for two μ-binding sites (160) 71
Rothman, R.B., France, C.P., Bykov, V., De Costa, B.R., Jacobson, A.E., Woods, J.H. and Rice, K.C.
Pharmacological activities of optically pure enantiomers of the κ opioid agonist, U50,488, and its cis diastereomer: evidence for three κ receptor subtypes (167) 345
Rothman, R.B., see Heyman, J.S. (169) 43
Rouissi, N., see Rhaleb, N.-E. (162) 419
Rousseau, D., see Gower, A.J. (166) 271
Rovati, L.C., see Douglas, B.R. (161) 209
Rovero, P., see Maggi, C.A. (165) 51
Rovero, P., see Maggi, C.A. (166) 121
Rovero, P., see Maggi, C.A. (166) 435
Rowan, M.J., see O'Connor, J.J. (167) 21
Royer, R.-J., see Marie, P.-Y. (163) 337
Rubio, M.C., see Otero Losada, M.E. (163) 353
Rudehill, A., see Lundberg, J.M. (163) 103
Rudolph, C., see Schächtele, C. (163) 151
Rüger, W., see Hock, F.J. (171) 79
Rüger, W., see Wiemer, G. (166) 31
Ruiz, G., Hamon, M. and Vergé, D.
Chronic phenytoin treatment decreases $GABA_A$ but not β-adrenoceptors in the cerebellum of young rats (168) 251
Rumbach, L., Cremel, G., Marescaux, C., Warter, J.-M. and Waksman, A.
Succinate transport inhibition by valproate in rat renal mitochondria (164) 577
Rummel, W., see Diener, M. (168) 219
Russell, D.H., see Laird II, H.E. (171) 25
Rydelek, L.T., see Titeler, M. (167) 221
Ryley, H.C., see Evans, H.G. (163) 361

Saavedra, J.M., see Agui, T. (162) 301
Saba, P., see De Montis, G.M. (167) 299
Sabouni, M.H. and Mustafa, S.J.
Effects of adenosine analogs and ouabain on rhythmicity in human coronary artery (168) 271
Sabouni, M.H., Ramagopal, M.V. and Mustafa, S.J.
Roles of calcium and the endothelium in the relaxations produced by 5′-N-ethylcarboxamidoadenosine (NECA) (166) 311
Sadoshima, S., Ooboshi, H., Okada, Y., Yao, H., Ishitsuka, T. and Fujishima, M.
Effect of thromboxane synthetase inhibitor on cerebral circulation and metabolism during experimental cerebral ischemia in spontaneously hypertensive rats (169) 75
Saegusa, K., see Furukawa, Y. (161) 1
Saito, A., Shiba, R., Kimura, S., Yanagisawa, M., Goto, K. and Masaki, T.
Vasoconstrictor response of large cerebral arteries of cats to endothelin, an endothelium-derived vasoactive peptide (162) 353
Saito, H., see Abe, K. (171) 59
Saito, K., see Kinouchi, K. (164) 63
Saito, K.-I., see Matsuda, T. (170) 75
Saito, R., see Higuchi, Y. (160) 413
Sakaguchi, K., see Higuchi, Y. (160) 413
Sakai, K., see Imagawa, J.-i. (167) 167
Sakai, Y., Aihara, K., Honda, H. and Inazu, M.
Calcium mobilization and phosphatidylinositol turnover in vas deferens smooth muscle of diabetic rats (162) 475
Sakaki, N., see Hatake, K. (168) 277
Sakanashi, M., see Noguchi, K. (168) 315
Sakas, D.E., see Buzzi, M.G. (165) 251
Sakata, M., see Kondo, K. (163) 253
Sakaue, M., see Kuno, T. (172) 263
Salama, A.I., see Keith, R.A. (166) 393
Salama, A.I., see Stumpo, R.J. (170) 121
Salas, S.P., see Power, R.F. (160) 199
Sallés, J., see Ferré, S. (166) 303
Salomon, Y., see Gerst, J.E. (172) 29
Salvati, P., see Ferrario, R.G. (171) 127
Salvemini, D., Korbut, R., Änggård, E. and Vane, J.R.
Lipopolysaccharide increases release of a nitric oxide-like factor from endothelial cells (171) 135
Samanin, R., see Cervo, L. (171) 119
Samanin, R., see Invernizzi, R. (163) 77
Samanin, R., see Invernizzi, R. (164) 241
Sanaka, T., see Tsuchiya, K. (166) 541
Sánchez-Blázquez, P. and Garzón, J.
Evaluation of δ receptor mediation of supraspinal opioid analgesia by in vivo protection against the β-funaltrexamine antagonist effect (159) 9
Sánchez-Blázquez, P., Ulibarri, I. and Garzón, J.
Intracerebroventricular N-ethylmaleimide differentially reduces supraspinal opioid analgesia in mice (166) 193
Sánchez, C.
The effects of dopamine D-1 and D-2 receptor agonists on body temperature in male mice (171) 201
Sánchez, M., Manso, G., Hidalgo, A. and Andres-Trelles, F.
Interactions between oxytocin- and calcium-modifying agents in the rat testicular capsule in vitro (168) 169
Sander, H.W., Kream, R.M. and Gintzler, A.R.
Spinal dynorphin involvement in the analgesia of pregnancy: effects of intrathecal dynorphin antisera (159) 205
Sandkühler, J., Willmann, E. and Fu, Q.-G.
Blockade of $GABA_A$ receptors in the midbrain periaqueductal gray abolishes nociceptive spinal dorsal horn neuronal activity (160) 163
Sandler, S., see Jansson, L. (161) 79
Sandoval, M.R.L. and Palermo-Neto, J.
Behavioral aspects of GABAergic–dopaminergic interactions in the central nervous system (167) 117
Sanger, G.J. and Nelson, D.R.
Selective and functional 5-hydroxytryptamine$_3$ receptor antagonism by BRL 43694 (granisetron) (159) 113

Sanna, E., see Serra, M. (164) 385
Sannerud, C.A., Cook, J.M. and Griffiths, R.R.
Behavioral differentiation of benzodiazepine ligands after repeated administration in baboons (167) 333
Sano, T., see Suzuki-Nishimura, T. (167) 75
Santicioli, P., see Maggi, C.A. (165) 51
Santicioli, P., see Maggi, C.A. (166) 121
Santicioli, P., see Maggi, C.A. (170) 167
Sanz, C., see Cortijo, J. (162) 467
Sarbin, N.S., see Pinkus, L.M. (168) 355
Sarría, B., see Cortijo, J. (162) 467
Satake, T., see Sumita, T. (164) 69
Satoh, T., see Fukuda, K. (165) 301
Satoh, Y., see Kohli, J.D. (164) 265
Saukkonen, K., see Lento, P.H. (165) 241
Saulnier-Blache, J.-S., Carpéné, C., Langin, D. and Lafontan, M.
Imidazolinic radioligands for the identification of hamster adipocyte α_2-adrenoceptors (171) 145
Sautebin, L., see Carnuccio, R. (166) 535
Saville, V.L., see Reilly, W.M. (160) 283
Saxena, P.R., see Bom, A.H. (171) 87
Saxena, P.R., see Dhasmana, K.M. (168) 257
Sayet, I., see Loirand, G. (167) 265
Sbacchi, M., see Petrillo, P. (166) 213
Scatton, B., see Carter, C. (164) 611
Scatton, B., see Serrano, A. (162) 157
Schächtele, C., Wagner, B. and Rudolph, C.
Effect of Ca^{2+} entry blockers on myosin light-chain kinase and protein kinase C (163) 151
Scharff, O. and Foder, B.
Halothane inhibits hyperpolarization and potassium channels in human red blood cells (159) 165
Schechter, L.E., see Gozlan, H. (172) 497
Schechter, L.E., see Hoyer, D. (171) 137
Schimmer, A., see Gerst, J.E. (172) 29
Schini, V.B., Hendrickson, H., Heublein, D.M., Burnett Jr., J.C. and Vanhoutte, P.M.
Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells (165) 333
Schlegel, W., see Mollard, P. (172) 71
Schlicker, E., see Molderings, G.J. (164) 213
Schmid, T., see Loeschke, K. (170) 41
Schmidt, A., Lebel, L., Koe, B.K., Seeger, T. and Heym, J.
Sertraline potently displaces (+)-[^{3}H]3-PPP binding to σ sites in rat brain (165) 335
Schmidt, A.W. and Peroutka, S.J.
Antidepressant interactions with 5-hydroxytryptamine$_3$ receptor binding sites (163) 397
Schmidt, A.W., Hurt, S.D. and Peroutka, S.J.
'[^{3}H]Quipazine' degradation products label 5-HT uptake sites (171) 141
Schmidt, C.J. and Black, C.K.
The putative 5-HT$_3$ agonist phenylbiguanide induces carrier-mediated release of [^{3}H]dopamine (167) 309
Schmidt, D.B., see Brooks, D.P. (160) 159
Schmidt, K., Mayer, B. and Kukovetz, W.R.
Effect of calcium on endothelium-derived relaxing factor formation and cGMP levels in endothelial cells (170) 157
Schmitt, H., see Briand, V. (166) 339
Schmitt, H., see Dabiré, H. (168) 369
Schmitt, H., see Dabiré, H. (170) 109
Schmitt, H., see Laubie, M. (160) 385
Schmitz, J.M., see Pfister, S.L. (161) 85
Schmitz-Salue, C., see Joost, H.G. (172) 461
Schmitz, W., see Heller, T. (164) 179
Schneider, F., see Reimann, W. (167) 161
Schoeffter, P. and Hoyer, D.
Is the sumatriptan (GR 43175)-induced endothelium-dependent relaxation of pig coronary arteries mediated by 5-HT$_{1D}$ receptors? (166) 117
Schoffelmeer, A.N.M., Yao, Y.-H. and Simon, E.J.
Cross-linking of human ^{125}I-β-endorphin to a μ-δ opioid receptor complex in rat striatum (166) 357
Schoffelmeer, A.N.M., see De Vries, T.J. (170) 137
Schofield, T.L., see Winquist, R.J. (163) 199
Scholz, H., see Heller, T. (164) 179
Schomer, H., see Oehlenschlager, W.F. (161) 159
Schönsteiner, G., see Halbach, S. (167) 255
Schotte, A. and Leysen, J.E.
Identification of 5-HT$_2$ receptors, α_1-adrenoceptors and amine release sites in rat brain by autoradiography with [^{125}I]7-amino-8-iodo-ketanserin (172) 99
Schousboe, A., see Gonsalves, S.F. (168) 265
Schoute, E., see Van Heuven-Nolsen, D. (162) 135
Schrader, U., see Liebmann, C. (166) 523
Schroeder, H., Boyet, S. and Nehlig, A.
Effects of caffeine and doxapram perfusion on local cerebral glucose utilization in conscious rats (167) 245
Schudt, C., Boer, R., Eltze, M., Riedel, R., Grundler, G. and Birdsall, N.J.M.
The affinity, selectivity and biological activity of telenzepine enantiomers (165) 87
Schudt, C., see Boer, R. (172) 131
Schudt, C., see Galvan, M. (167) 1
Schultz, G., see Joost, H.G. (172) 461
Schumacher, C., Steinberg, R., Kan, J.P., Michaud, J.C., Bourguignon, J.J., Wermuth, C.G., Feltz, P., Worms, P. and Biziere, K.
Pharmacological characterization of the aminopyridazine SR 95639A, a selective M_1 muscarinic agonist (166) 139
Schwartz, A., see Lathrop, D.A. (164) 487
Schwartz, J.C., see Garbarg, M. (164) 1
Schwörer, H., Racké, K. and Kilbinger, H.
GABA receptors are involved in the modulation of the release of 5-hydroxytryptamine from the vascularly perfused small intestine of the guinea-pig (165) 29
Scivoletto, R., see Fortes, Z.B. (170) 69
Scott, S.M., see McMillen, B.A. (160) 149
Sebben, M., see Dumuis, A. (162) 381
Seeger, T., see Schmidt, A. (165) 335
Segawa, T., see Zhang, X. (166) 401
Seifen, E., see Kafiluddi, R. (165) 181
Seitz, H., see Holzer-Petsche, U. (162) 29

Sekiya, C., see Uehara, A. (170) 257
Selph, J.L., see Vinegar, R. (164) 497
Sénard, J.-M., Mauriège, P., Daviaud, D. and Paris, H.
α_2-Adrenoceptor in HT29 human colon adenocarcinoma cell-line: study of [^{3}H](−)-adrenaline binding (162) 225
Seo, R., see Kondo, K. (163) 253
Seo, R., see Kondo, K. (168) 193
Serra, G., see De Montis, G.M. (167) 299
Serra, M., Sanna, E. and Biggio, G.
Isoniazid, an inhibitor of GABAergic transmission, enhances [^{35}S]TBPS binding in rat cerebral cortex (164) 385
Serra, M., see Biggio, G. (161) 173
Serrano, A., D'Angio, M. and Scatton, B.
NMDA antagonists block restraint-induced increase in extracellular DOPAC in rat nucleus accumbens (162) 157
Sershen, H., see Lapin, E.P. (160) 53
Sershen, H., see Wiener, H.L. (163) 191
Seutin, V., Verbanck, P., Massotte, L. and Dresse, A.
Galanin decreases the activity of locus coeruleus neurons in vitro (164) 373
Severini, C., see Kreil, G. (162) 123
Sewell, R.D.E., see Rooney, K.F. (168) 329
Seyfried, C.A., Greiner, H.E. and Haase, A.F.
Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems (160) 31
Shader, R.I., see Lopez, F. (172) 453
Shah, A.M., Lewis, M.J. and Henderson, A.H.
Inotropic effects of endothelin in ferret ventricular myocardium (163) 365
Shah, K., see Kennett, G.A. (164) 445
Shalaby, I., Chenard, B. and Prochniak, M.
Glycine reverses 7-Cl kynurenate blockade of glutamate neurotoxicity in cell culture (160) 309
Shankar, G., see Dubocovich, M.L. (162) 289
Sharp, T., see Hjorth, S. (170) 269
Sherman, P.S., see Kilbourn, M.R. (166) 331
Shiba, R., see Saito, A. (162) 353
Shichiri, M., see Hirata, Y. (164) 603
Shigematsu, K., see Yamasaki, H. (168) 247
Shimamoto, N., see Kitayoshi, T. (166) 519
Shimazaki, H., see Higuchi, Y. (160) 413
Shimizu, K., see Hori, M. (165) 63
Shimizu, M., see Yamamoto, M. (166) 345
Shimizu, M., see Yamamoto, M. (166) 545
Shimmen, T., see Miura, K. (170) 91
Shimohigashi, Y., see Higuchi, Y. (160) 413
Shimuta, S.I., see Oshiro, M.E.M. (166) 411
Shizume, K., see Horikawa, R. (166) 87
Shoji, T., Tamaki, T., Fukui, K., Iwao, H. and Abe, Y.
Renal hemodynamic responses to 5-hydroxytryptamine (5-HT): involvement of the 5-HT receptor subtypes in the canine kidney (171) 219
Shu, C., see Vincens, M. (168) 15
Shuntoh, H., see Kuno, T. (172) 263
Siang Gan, B. and Hollenberg, M.D.
Autoradiographic localization of binding sites for epidermal growth factor-urogastrone (EGF-URO) in coronary arteries (167) 407
Sidiropoulos, D., see Gierschik, P. (172) 481
Sidiropoulos, D., see Reithmann, C. (172) 211
Siegfried, B. and Nunes de Souza, R.L.
NMDA receptor blockade in the periaqueductal grey prevents stress-induced analgesia in attacked mice (168) 239
Sierra, V., see Yoburn, B.C. (170) 193
Sieswerda, G.T., see Bosker, F.J. (163) 319
Siggaard, C., see Mellemkjær, S. (167) 275
Sim, M.K. and Manjeet, S.
Endothelial muscarinic receptors in the rabbit aorta (163) 399
Simmaco, M., see Kreil, G. (162) 123
Simon, E.J., see Schoffelmeer, A.N.M. (166) 357
Singer, G., see Lin, W. (171) 9
Singh, A., see Chideckel, E.W. (166) 367
Singh, L., see Tricklebank, M.D. (167) 127
Sivilotti, L. and Nistri, A.
Pharmacology of a novel effect of γ-aminobutyric acid on the frog optic tectum in vitro (164) 205
Sjöholm, B., see Koulu, M. (169) 321
Sjöquist, B., see Tornhamre, S. (169) 225
Skolnick, P., see Moody, E.J. (164) 153
Slivjak, M.J., see Lento, P.H. (165) 241
Slivjak, M.J., see Smith III, E.F. (159) 297
Smedegård, G., see Tornhamre, S. (169) 225
Smiley, P., see Hanson, G.R. (160) 23
Smith, C.B., Moises, H.C., Spengler, R.N. and Hollingsworth, P.J.
Changes in α_2-adrenoceptor number and function in brains of morphine-dependent rats (161) 111
Smith, C.B., see Hollingsworth, P.J. (168) 159
Smith, D.C. and Priola, D.V.
Enhanced acetylcholine release from denervated atria: intrinsic neural supersensitivity (161) 249
Smith, J.A., see Hogan, J.C. (165) 129
Smith III, E.F. and Slivjak, M.J.
Evidence for high and low affinity leukotriene D_4 receptors mediating vascular responses in the conscious rat (159) 297
Smith III, E.F., see Lento, P.H. (165) 241
Smits, J.F.M., see Janssen, B.J.A. (170) 1
Soei, Y.L., see Bosker, F.J. (163) 319
Soeters, P.B., see Van Berlo, C.L.H. (160) 17
Soffiantino, F., see Bernardi, L. (164) 415
Sokolovsky, M., see Ambar, I. (170) 119
Soldá, P.L., see Bernardi, L. (164) 415
Sollevi, A., see Lundberg, J.M. (163) 103
Song, A.H., see McMillen, B.A. (160) 149
Song, D.L., Madsen, B., Chang, J.-K. and Perlman, A.J.
Development of more potent atrial natriuretic factor (ANF) analogs (160) 141
Sonnenberg, H., see Palluk, R. (162) 245
Sorensen, S.M., Humphreys, T.M. and Palfreyman, M.G.
Effect of acute and chronic MDL 73,147EF, a 5-HT_3 receptor antagonist, on A9 and A10 dopamine neurons (163) 115

Sosa, A.L., see Cohen, B.M. (170) 201
Soudijn, W., see J.M. Van Galen, P. (172) 19
Soudijn, W., see Pirovano, I.M. (172) 185
Spada, C.S., see Woodward, D.F. (168) 23
Spealman, R.D., see Coffin, V.L. (170) 35
Spedding, M., see Kilpatrick, A.T. (166) 315
Spengler, R.N., see Smith, C.B. (161) 111
Sperelakis, N., see Molyvdas, P.-A. (164) 547
Sprouse, J.S., Bradberry, C.W., Roth, R.H. and Aghajanian, G.K.
MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin (167) 375
Sripairojthikoon, W. and Wyss, J.M.
High NaCl diets increase α_2-adrenoceptors in renal cortex and medulla of NaCl-sensitive spontaneously hypertensive rats (167) 355
Stachowiak, M.K., see MacKenzie, R.G. (168) 43
Stafinsky, J.L., see Crisp, T. (160) 211
Stahl, G.L., Tsao, P., Lefer, A.M., Ramphal, J.Y. and Nicolaou, K.C.
Pharmacologic profile of lipoxins A_5 and B_5: new biologically active eicosanoids (163) 55
Stampfli, H., see Kerkman, D.J. (166) 481
Stasch, J.-P., Grote, H., Kazda, S. and Hirth, C.
Dynorphin stimulates the release of ANP from isolated rat atria (159) 101
Stassen, F.L., see Brooks, D.P. (160) 159
Stechl, J., see Hock, F.J. (171) 79
Stechl, J., see Wiemer, G. (166) 31
Stefanich, E., see Michel, A.D. (166) 459
Stefański, R., see Kostowski, W. (168) 393
Steinberg, R., see Schumacher, C. (166) 139
Steiner, M., see Miceli, M.O. (169) 215
Steinfels, G.F. and Tam, S.W.
Selective σ receptor agonist and antagonist affect dopamine neuronal activity (163) 167
Steinig, D.A., see Morel, D.R. (167) 427
Steisslinger, M., see Gierschik, P. (172) 481
Stemmildt, V., see Heller, T. (164) 179
Stephenson, J.D., see Koshikawa, N. (163) 227
Stephenson, J.D., see Koshikawa, N. (164) 595
Stevens, C.W. and Yaksh, T.L.
Magnitude of opioid dependence after continuous intrathecal infusion of μ- and δ-selective opioids in the rat (166) 467
Stevens, C.W., see Morón, M.A. (163) 299
Stevenson, J.S., see Tomioka, K. (170) 209
Stewart, B.R., Jenner, P. and Marsden, C.D.
Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs (162) 101
Stillings, M.R., see Langin, D. (167) 95
Stinnakre, J., see Geoffroy, M. (166) 355
Stockert, M., Buscaglia, V. and De Robertis, E.
In vivo action of phosphatidylserine, amitryptiline and stress on the binding of [^{3}H]imipramine to membranes of the rat cerebral cortex (160) 11
Stöcklin, K., see Waldmeier, P.C. (169) 197
Štolc, S., Nemček, V. and Szöcsová, H.
Local anesthetics: lipophilicity, charge, diffusion and site of action in isolated neuron (164) 249
Stone, D.M., see Johnson, M. (161) 181
Störtzel, K., see Heller, T. (164) 179
Stramentinoli, G., see Cohen, B.M. (170) 201
Streller, I., see Lang, U. (164) 13
Strohmann, C., see Lambrecht, G. (168) 71
Struble, R.G., see Titeler, M. (167) 221
Struyker-Boudier, H.A.J., see Janssen, B.J.A. (170) 1
Stull, R., see Szemeredi, K. (170) 53
Stumpo, R.J., Pullan, L.M. and Salama, A.I.
Glutamine mimics glycine to enhance [^{3}H]TCP binding at the NMDA receptor complex (170) 121
Stumpo, R.J., see Keith, R.A. (166) 393
Suarez, A., see Flynn, D.D. (172) 363
Suaud-Chagny, M.-F., Buda, M. and Gonon, F.G.
Pharmacology of electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry (164) 273
Sudhir, K., see Cocks, T.M. (171) 17
Sugimoto, T., see Kurachi, Y. (165) 319
Sugino, N., see Tsuchiya, K. (166) 541
Sugita, S., Kobayashi, A., Suzuki, S., Yoshida, T. and Nakazawa, K.
Correlative changes of serotonin and catecholamines with pharmacokinetic alterations of imipramine in rat brain (165) 191
Suh, H.H., Fujimoto, J.M. and Tseng, L.L.-F.
Differential mechanisms mediating β-endorphin- and morphine-induced analgesia in mice (168) 61
Sumi, T., see Umeda, Y. (163) 291
Sumino, R., see Koshikawa, N. (163) 227
Sumita, T., Ishikawa, N., Hashiba, Y., Takagi, K. and Satake, T.
5-Hydroxytryptamine receptor subtypes participating in pulmonary edema in dogs [1] (164) 69
Summers, R.J., see Cincotta, M. (160) 167
Sun, E.T., see Hood, W.F. (161) 281
Sun, X.-P., see Novales-Li, P. (168) 299
Surrenti, C., see Evangelista, S. (164) 389
Surrenti, C., see Maggi, C.A. (165) 51
Susel, Z., see Engber, T.M. (168) 291
Suzuki, H., see Komori, K. (164) 111
Suzuki-Nishimura, T., Sano, T. and Uchida, M.K.
Effects of benzodiazepines on serotonin release from rat mast cells (167) 75
Suzuki, S., see Politi, D.M.T. (168) 7
Suzuki, S., see Sugita, S. (165) 191
Suzuki, T., see Fukagawa, Y. (170) 47
Svensson, T.H., see Grenhoff, J. (165) 11
Svoboda, M., see Gillard, M. (160) 117
Swann, A.C.
Noradrenaline and thyroid function regulate (Na^+,K^+)-adenosine triphosphatase independently in vivo (169) 275
Swigart, C.R., see Cameron, J.S. (169) 23

Sybrecht, G.W., see Dent, G. (169) 313
Syce, J.A., see Le Roux, M.G.J. (169) 269
Szechtman, H., see Eilam, D. (161) 151
Szemeredi, K., Stull, R., Kopin, I.J. and Goldstein, D.S.
Effects of a peripherally acting α_2-adrenoceptor antagonist (L-659,066) on hemodynamics and plasma levels of catechols in conscious rats (170) 53
Szöcsová, H., see Štolc, S. (164) 249

Tabrizchi, R., see D'Oyley, H.M. (162) 337
Taché, Y., see Raybould, H.E. (167) 237
Tacke, R., see Kopp, R. (172) 397
Tacke, R., see Lambrecht, G. (168) 71
Tackett, R.L., see Jones, L.F. (165) 123
Taglialatela, M., see Di Renzo, G. (162) 371
Tagliamonte, A., see De Montis, G.M. (167) 299
Taira, C.A. and Enero, M.A.
Central muscarinic involvement in cardiovascular control in sinoaortic-denervated rats (159) 265
Taira, N., see Iijima, T. (163) 357
Takagi, K., see Sumita, T. (164) 69
Takahashi, M., see Fujioka, H. (166) 13
Takano, K., see Horikawa, R. (166) 87
Takano, Y., see Higuchi, Y. (160) 413
Takasaki, K., see Kawasaki, H. (164) 35
Takashio, T., Yamashita, H. and Onodera, S.
Effects of a β-agonist and antagonist on the pulmonary circulation and the pulmonary pressor response to 5-HT (169) 179
Takasu, T., see Tohda, M. (166) 57
Takasugi, M., see Muta, T. (159) 191
Takasugi, Y., see Uehara, A. (170) 257
Takata, Y., Yoshida, Y., Ozaki, S. and Kato, H.
Increases in vascular α_1-adrenoceptor affinity and PI turnover in DOCA-salt hypertensive rats (164) 365
Takeda, H., see Gazzara, R.A. (168) 209
Takeda, T., see Kuno, T. (172) 263
Takeda, Y. and Krause, J.E.
γ-Preprotachykinin-(72-92)-peptide amide potentiates substance P-induced salivation (161) 267
Takeo, S., see Tanonaka, K. (165) 97
Takeuchi, H., see Novales-Li, P. (168) 299
Takeuchi, H., see Yongsiri, A. (171) 159
Takeya, K., Itoigawa, M. and Furukawa, H.
Triphasic inotropic response of guinea-pig papillary muscle to murrayaquinone-A isolated from Rutaceae (169) 137
Tam, S.W., see Steinfels, G.F. (163) 167
Tamaki, T., see Shoji, T. (171) 219
Tanaka, C., see Kuno, T. (172) 263
Tanaka, T.P., see Greenberg, S. (162) 67
Tanaka, Y., see Nakayama, K. (169) 33
Tang, C.S., Cui, H., Yuan, Q.X. and Tang, J.
Hemodynamic responses to BNP in rats (159) 327
Tang, J., see Tang, C.S. (159) 327
Taniguchi, T., see Hatake, K. (168) 277
Tanihara, H., see Kamei, J. (168) 153
Tanonaka, K., Matsumoto, M., Miyake, K., Minematsu, R. and Takeo, S.
Protective action of YM-12617, an α_1-adrenoceptor antagonist, on the hypoxic and reoxygenated myocardium (165) 97
Tansø, R., see Aas, P. (164) 93
Tarnawa, I., Farkas, S., Berzsenyi, P., Pataki, Á. and Andrási, F.
Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466 (167) 193
Tatebayashi, Y., see Mizushima, A. (168) 375
Tatemoto, K., see Lorinet, A.-M. (160) 405
Tavani, A., see Petrillo, P. (166) 213
Tavolaro, R., see Canonaco, M. (170) 95
Taylor, D.G., see Major, T.C. (167) 323
Taylor, E.M. and Parsons, M.E.
Adrenergic and purinergic neurotransmission in arterial resistance vessels of the cat intestinal circulation (164) 23
Taylor, E.M., Parsons, M.E., Wright, P.W., Pipkin, M.A. and Howson, W.
The effects of adenosine triphosphate and related purines on arterial resistance vessels in vitro and in vivo (161) 121
Teng, C.-M., see Wang, J.-P. (161) 143
Teng, C.-M., see Wang, J.-P. (161) 9
Tenner, Jr., T.E., Earley, K.J. and Young, J.A.
Characterization of β-adrenoceptor subtypes in rabbit mononuclear leukocytes (160) 291
Tepper, P.G., see Bosker, F.J. (163) 319
Tepper, P.G., see Löschmann, P.-A. (166) 373
Tepper, P.G., see Timmerman, W. (162) 143
Tepper, P.G., see Timmerman, W. (166) 1
Terzic, A., see Vogel, S.M. (164) 231
Tessel, R.E., see Yourick, D.L. (160) 219
Tester, B.A.C., see Kavanaugh, M.P. (164) 397
Thanei-Wyss, P. and Waser, P.G.
Interaction of quaternary ammonium compounds with acetylcholinesterase: characterization of the active site (172) 165
Thedinga, K.H., see IJzerman, A.P. (172) 273
Thielen, A.P.G.M., see Bosker, F.J. (163) 319
Thiemermann, C., see Lidbury, P.S. (166) 335
Thierry, A., Doly, M., Braquet, P., Cluzel, J. and Meyniel, G.
Presence of specific platelet-activating factor binding sites in the rat retina (163) 97
Thomas, G. and Ramwell, P.W.
Streptozotocin: a nitric oxide carrying molecule and its effect on vasodilation (161) 279
Thomas, G., Cole, E.A. and Ramwell, P.W.
N^G-monomethyl L-arginine is a non-specific inhibitor of vascular relaxation (170) 123
Thomas, G.R., see Lidbury, P.S. (166) 335
Thomopoulos, P., see Chambaut-Guérin, A.-M. (172) 385
Tiberghien, C., see Wisner, A. (162) 89
Tibirica, E., see Bricca, G. (163) 373
Tielemans, A.J.P.C., see Room, P. (171) 69
Tietz, E.I., Chiu, T.H. and Rosenberg, H.C.

Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment (167) 57
Timmerman, W., Dubocovich, M.L., Westerink, B.H.C., De Vries, J.B., Tepper, P.G. and Horn, A.S.
The enantiomers of the dopamine agonist N-0437: in vivo and in vitro effects on the release of striatal dopamine (166) 1
Timmerman, W., Westerink, B.H.C., De Vries, J.B., Tepper, P.G. and Horn, A.S.
Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437 (162) 143
Timmermans, A., see Meurs, H. (164) 369
Timmermans, A., see Van Amsterdam, R.G.M. (172) 175
Timmermans, P.B.M.W.M., see Chiu, A.T. (170) 117
Tinelli, D., see Perez, J. (172) 305
Tippins, J.R., see Di Marzo, V. (162) 115
Titeler, M., Lyon, R.A., Kuhar, M.J., Frost, J.F., Dannals, R.F., Leonhardt, S., Bullock, A., Rydelek, L.T., Price, D.L. and Struble, R.G.
μ Opiate receptors are selectively labelled by [^{3}H]carfentanil in human and rat brain (167) 221
Tjon A Tham, R.T.O., see Douglas, B.R. (166) 307
Tobe, A., see Matsuda, T. (170) 75
Tohda, M., Takasu, T. and Nomura, Y.
Effects of antidepressants on serotonin-evoked current in *Xenopus* oocytes injected with rat brain mRNA (166) 57
Tokunaga, T., see Katsuragi, T. (167) 147
Tomioka, K., Garrido, R., Ahmed, A., Stevenson, J.S. and Abraham, W.M.
YM461, a PAF antagonist, blocks antigen-induced late airway responses and airway hyperresponsiveness in allergic sheep (170) 209
Tomiyama, K., see Koshikawa, N. (163) 227
Tomoike, H., see Adachi, H. (161) 189
Tonnaer, J.A.D.M., see Ronken, E. (162) 189
Tonnaer, J.A.D.M., see Room, P. (171) 69
Tornhamre, S., Edenius, C., Smedegård, G., Sjöquist, B. and Lindgren, J.Å.
Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products (169) 225
Tosaki, A., see Koltai, M. (164) 293
Trabka-Janik, E., see Korbut, R. (165) 171
Trachte, G.J., Binder, S.B. and Peach, M.J.
Indirect evidence for separate vesicular neuronal origins of norepinephrine and ATP in the rabbit vas deferens (164) 425
Trapani, A.J., see Han, S.P. (159) 303
Travers, J.B., see Varol, F.G. (159) 97
Trevor, A.J., see Johnson, E.A. (166) 65
Tricklebank, M.D., Singh, L., Oles, R.J., Preston, C. and Iversen, S.D.
The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor (167) 127
Truax, J.F., see Vinegar, R. (164) 497
Tsai, G.-C., see Tsai, M.-C. (160) 133
Tsai, M.-C., Chen, M.-L., Lo, S.-C. and Tsai, G.-C.
Effects of memantine on the twitch tension of mouse diaphragm (160) 133
Tsao, P., see Stahl, G.L. (163) 55
Tsay, L., see Chang, W.-H. (162) 151
Tseng, L.L.-F., see Suh, H.H. (168) 61
Tsuboi, Y., see Koshikawa, N. (163) 227
Tsuchiya, K., Naruse, M., Sanaka, T., Naruse, K., Nitta, K., Demura, H. and Sugino, N.
Effects of endothelin on renal regional blood flow in dogs (166) 541
Tulunay, F.C., see Demirel, E. (159) 195
Tuong, M.D.T., see Garbarg, M. (164) 1
Türker, R.K., see Demirel, E. (159) 195
Turkka, J., Gurguis, G., Potter, W.Z. and Linnoila, M.
Ten day administration of desipramine produces an increase in K_L/K_H for β-receptors in rat hippocampus (167) 87
Twitchell, B., see Gonsalves, S.F. (168) 265
Tyers, M.B., see Kilpatrick, G.J. (159) 157

Uchida, M.K., see Suzuki-Nishimura, T. (167) 75
Uchida, S., see Imaizumi, T. (161) 203
Uchida, S., see Mizushima, A. (168) 375
Ueda, M., see Mihara, S. (160) 313
Ueda, M., see Mihara, S. (171) 179
Uehara, A., Ishikawa, Y., Okumura, T., Okamura, K., Sekiya, C., Takasugi, Y. and Namiki, M.
Indomethacin blocks the anorexic action of interleukin-1 (170) 257
Ueki, S., see Yatsugi, S.-i. (166) 231
Ukena, D., see Dent, G. (169) 313
Ulibarri, I., see Sánchez-Blázquez, P. (166) 193
Ulle, P., see Groschner, K. (159) 125
Umeda, Y. and Sumi, T.
Evoked release of endogenous amino acids from rat striatal slices and its modulation (163) 291
Undén, M., Nauntofte, B. and Dissing, S.
Anticholinergic effects of cis-chlorprothixene characterized in rat parotid acini (164) 129
Une, Y., see Yamashita, A. (159) 247
Ungerer, M., see Böhm, M. (172) 407
Ungerstedt, U., see Hurd, Y.L. (166) 251
Ungerstedt, U., see Hurd, Y.L. (166) 261
Ungerstedt, U., see Lindefors, N. (160) 417
Ungerstedt, U., see Lindefors, N. (161) 95
Urabe, M., see Kawasaki, H. (164) 35
Urakawa, N., see Hori, M. (165) 63
Uram, M., see Crisp, T. (160) 211
Urbach, H., see Hock, F.J. (171) 79
Urbancic, M. and Marczynski, T.J.
Chronic exposure to Ro 15-1788: differential effect on flunitrazepam binding to cortex and hippocampus (171) 1
Uriu, T., see Inoue, M. (166) 101
Ushijima, I., Mizuki, Y., Hara, T., Kaneyuki, H., Mashimoto, S., Kajimura, N. and Yamada, M.

Effects of dilazep (Comelian) on the central purinergic system: inhibitory effects on clonidine-induced aggressive behavior (161) 245
Uyeda, R.T., see Chiu, A.T. (170) 117

Vaccher, C., see Kerr, D.I.B. (164) 361
Vacher, P., see Mollard, P. (172) 71
Valenti, A., see Canonaco, M. (170) 95
Valerio, C., see Clementi, G. (163) 175
Vallotton, M.B., Dolci, W., Gerber-Wicht, C. and Fischer, J.A.
Action of calcitonin gene-related peptide on rat aortic smooth muscle (166) 219
Van Amsterdam, R.G.M., Meurs, H., Brouwer, F., Postema, J.B., Timmermans, A. and Zaagsma, J.
Role of phosphoinositide metabolism in functional antagonism of airway smooth muscle contraction by β-adrenoceptor agonists (172) 175
Van Amsterdam, R.G.M., see Meurs, H. (164) 369
Van Belle, H., see IJzerman, A.P. (172) 273
Van Berlo, C.L.H., Soeters, P.B. and Charbon, G.A.
Influences of nifedipine on vascular conductance of portally drained viscera, liver and kidney (160) 17
Van Breemen, C., see Gelband, C.H. (167) 201
Van Bussel, F.J., see Bosker, F.J. (163) 319
Van den Akker, J., see Den Hertog, A. (166) 531
Van den Akker, J., see Nelemans, A. (172) 283
Van den Hoofdakker, R.H., see Dijk, D.J. (171) 207
Van der Ploeg, I., see Fredholm, B.B. (172) 249
Van der Ploeg, I., see Nordstedt, C. (172) 51
Van der Ploeg, I., see Von Euler, G. (172) 435
Van de Velde, E., see Vanscheeuwijck, P. (172) 373
Van de Water, A., see Janssens, W.J. (159) 89
Vane, J.R., see D'Orleans-Juste, P. (165) 289
Vane, J.R., see Lidbury, P.S. (166) 335
Vane, J.R., see Salvemini, D. (171) 135
Vane, J.R., see Warner, T.D. (159) 325
Van Galen, P.J.M., see Pirovano, I.M. (172) 185
Van Heuven-Nolsen, D., Schoute, E., Verdouw, P.D., De Wildt, D.J. and Nijkamp, F.P.
In vivo β_2-adrenoceptor hyporesponsiveness in the cardiovascular system of the pig after *Bordetella pertussis* (162) 135
Vanhoutte, P.M., see Schini, V.B. (165) 333
Van Luijtelaar, G., see Gandolfo, G. (167) 181
Van Maercke, Y.M., see Pelckmans, P.A. (170) 235
Van Nueten, J.M., see Janssens, W.J. (159) 89
Van Ree, J.M., Elands, J., Király, I. and Wolterink, G.
Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems (166) 441
Van Ree, J.M., see De Vry, J. (161) 19
Van Ree, J.M., see Kovács, G.L. (161) 27
Vanscheeuwijck, P., Van de Velde, E. and Fraeyman, N.
Effect of aging on properties and function of β-adrenoceptors in rat lung (172) 373
Van Vliet, B.J., see Pin, J.-P. (172) 81
Varol, F.G., Hadjiconstantinou, M., Travers, J.B. and Neff, N.H.
Platelet-activating factor stimulates phosphotidylinositol hydrolysis in the rat myometrium (159) 97
Varol, F.G., Hadjiconstantinou, M., Zuspan, F.P. and Neff, N.H.
Angiotensin II stimulates phosphoinositide turnover in the rat myometrium (162) 37
Varró, A., see Lathrop, D.A. (164) 487
Vassalle, M., see Yang, L. (170) 261
Vaught, J.L., see Heyman, J.S. (165) 1
Vaupel, D.B., Nickel, B. and Becketts, K.
Flupirtine antinociception in the dog is primarily mediated by nonopioid supraspinal mechanisms (162) 447
Vauquelin, G., see Convents, A. (159) 307
Vauquelin, G., see De Keyser, J. (162) 437
Vayssiere, J.-L., see Larcher, J.-C. (161) 197
Verbanck, P., see Seutin, V. (164) 373
Verbeuren, T.J., see Pelckmans, P.A. (170) 235
Verdouw, P.D., see Bom, A.H. (171) 87
Verdouw, P.D., see Van Heuven-Nolsen, D. (162) 135
Veress, A.T., see Palluk, R. (162) 245
Vergé, D., see Hamon, M. (164) 315
Vergé, D., see Ruiz, G. (168) 251
Vermeer, M.A., see Zijlstra, F.J. (159) 291
Vesperinas, G., Feddersen, M., Lewin, J. and Huidobro-Toro, J.P.
The use of ryanodine and calcium channel blockers to characterize intra- and extracellular calcium pools mobilized by noradrenaline in the rat vas deferens (165) 309
Vierling, W., see Halbach, S. (167) 255
Vigne, P., Lazdunski, M. and Frelin, C.
Guanabenz, guanochlor, guanoxan and idazoxan bind with high affinity to non-adrenergic sites in pig kidney membranes (160) 295
Vila, E., see Cuffí, M.L. (168) 111
Villalón, C.M., see Bom, A.H. (171) 87
Villanueva, L., see Bing, Z. (164) 85
Villette, J.M., see Maldonado, R. (165) 199
Vincens, M., Shu, C., Moguilewsky, M. and Philibert, D.
A progesterone metabolite enhances the activity of the $GABA_A$ receptor complex at the pituitary level (168) 15
Vincent, J.E., see Zijlstra, F.J. (159) 291
Vincent, M.S. and Near, J.A.
Interaction of dihydrotetrabenazine binding activity with immobilized lectins (172) 317
Vincent, S.R., see Cumming, P. (166) 299
Vinegar, R., Truax, J.F., Selph, J.L. and Johnston, P.R.
Pharmacological characterization of the algesic response to the subplantar injection of serotonin in the rat (164) 497
Virtanen, R., see Koulu, M. (169) 321
Vital Brazil, O., Fontana, M.D. and Pavani, N.J.P.
Effect of 4-aminopyridine on the postsynaptic action of polymyxin B (159) 47
Vogel, S.M. and Terzic, A.
α-Adrenergic regulation of action potentials in isolated rat cardiomyocytes (164) 231
Voigt, W. and Mannhold, R.
Characterization, localization and pharmacological profile of a high-affinity [^{3}H]lidocaine binding site (169) 103

Von Euler, G., Fuxe, K., Van der Ploeg, I., Fredholm, B.B. and Agnati, L.F.
Pertussis toxin treatment counteracts intramembrane interactions between neuropeptide Y receptors and α_2-adrenoceptors (172) 435
Von Grafenstein, H., see Borges, R. (165) 223
Vonhof, S., Paakkari, I., Feuerstein, G., Cohen, L.A. and Labroo, V.M.
Receptor binding of fluorinated histidine analogs of thyrotropin-releasing hormone in various regions of the rat brain (164) 77
Von Lubitz, D.K.J.E. and Redmond, D.J.
Cerebral ischemia in gerbils: improvement of survival after postischemic treatment with oligo-prostaglandin B (164) 405
Vos, M.A., Gorgels, A.P.M., Drenth, J.P.H., Leunissen, J.D.M. and Wellens, H.J.J.
Termination of ouabain-induced ventricular tachycardia by flunarizine in conscious dogs (165) 139
Voukelatou, G., Aletras, A.J. and Kouvelas, E.D.
Identification of L-glutamate binding sites in chick brain by photoaffinity labeling (162) 179
Vu, H.Q., see Budai, D. (168) 97

Wada, O., see Kanai, Y. (166) 553
Waddington, J.L., see Murray, A.M. (160) 377
Wadsworth, R., see Klaas, M. (168) 187
Wadsworth, R.M., see Kwan, Y.W. (168) 31
Waelbroeck, M., see Gillard, M. (160) 117
Waelbroeck, M., see Lambrecht, G. (168) 71
Wagner, B., see Schächtele, C. (163) 151
Wagner-Röder, M., see Lambrecht, G. (168) 71
Wahl, J.J., see DeLander, G.E. (159) 149
Wahlestedt, C., Ekman, R., Heilig, M. and Widerlöv, E.
Effects of psychoactive drugs on delta sleep-inducing peptide concentrations in rat brain (159) 285
Wakabayashi, I., Hatake, K. and Kakishita, E.
Effect of aclarubicin on contractile response of rat aorta (167) 177
Wakabayashi, I., see Hatake, K. (168) 277
Waki, M., see Higuchi, Y. (160) 413
Wakimasu, M., see Nishida, N. (166) 453
Wakitani, K., see Kondo, K. (163) 253
Wakitani, K., see Kondo, K. (168) 193
Waksman, A., see Rumbach, L. (164) 577
Waldmann, R. and Walter, U.
Cyclic nucleotide elevating vasodilators inhibit platelet aggregation at an early step of the activation cascade (159) 317
Waldmeier, P.C. and Stöcklin, K.
The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo (169) 197
Walker, M.W., see Krystal, J.H. (160) 331
Wallace, J.L., Keenan, C.M., MacNaughton, W.K. and McKnight, G.W.
Comparison of the effects of endothelin-1 and endothelin-3 on the rat stomach (167) 41
Wallace, J.L., see Cirino, G. (166) 505
Walland, A., see Lang, U. (164) 13
Wallwork, J., see Dinh Xuan, A.T. (163) 401
Walraevens, H., see De Keyser, J. (162) 437
Walter, U., see Waldmann, R. (159) 317
Wan, D.C.-C. and Livett, B.G.
Induction of phenylethanolamine N-methyltransferase mRNA expression by glucocorticoids in cultured bovine adrenal chromaffin cells (172) 107
Wan, D.C.-C., Marley, P.D. and Livett, B.G.
Histamine activates proenkephalin A mRNA but not phenylethanolamine N-methyltransferase mRNA expression in cultured bovine adrenal chromaffin cells (172) 117
Wang, J.-P. and Teng, C.-M.
Roles of mast cells and PMN leukocytes in cardiotoxin-induced rat paw edema (161) 9
Wang, J.-P., Hsu, M.-F., Ouyang, C. and Teng, C.-M.
Edematous response caused by [Thi^{5,8},D-Phe^{7}]bradykinin, a B_2 receptor antagonist, is due to mast cell degranulation (161) 143
Wang, R.Y., see Jr.eer, C.R.A. (166) 583
Wann, K.T., see Wardley-Smith, B. (165) 107
Wanstall, J.C. and O'Donnell, S.R.
Influence of age on calcium entry blocking drugs in rat aorta is spasmogen-dependent (159) 241
Ward, S.J., see Herrick-Davis, K. (162) 365
Wardley-Smith, B. and Wann, K.T.
The effects of non-competitive NMDA receptor antagonists on rats exposed to hyperbaric pressure (165) 107
Warner, T.D., De Nucci, G. and Vane, J.R.
Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat (159) 325
Warter, J.-M., see Rumbach, L. (164) 577
Waser, P.G., Bodmer, D.M. and Hopff, W.H.
Isolation and purification of acetylcholine receptor proteins by affinity chromatography (172) 231
Waser, P.G., see Rimvall, K. (160) 1
Waser, P.G., see Thanei-Wyss, P. (172) 165
Wasserman, M.A., see Woodward, D.F. (164) 323
Watanabe, T., see Kitayoshi, T. (166) 519
Watkins, H.O., see Dlewati, A. (164) 197
Watkins, J.C., see Honoré, T. (172) 239
Watson, G.B., Bolanowski, M.A., Baganoff, M.P., Deppeler, C.L. and Lanthorn, T.H.
Glycine antagonist action of 1-aminocyclobutane-1-carboxylate (ACBC) in *Xenopus* oocytes injected with rat brain mRNA (167) 291
Weber, E., see Kavanaugh, M.P. (164) 397
Wei, E.T. and Kiang, J.G.
Peptides of the corticoliberin superfamily attenuate thermal and neurogenic inflammation in rat pawskin (168) 81
Weight, F.F., see Freedman, J.E. (164) 341
Weihmuller, F., see Hadjiconstantinou, M. (168) 261
Weishaar, R.E., see Major, T.C. (167) 323
Weiss, H.R., see Joselevitz-Goldman, J. (166) 283
Weiss, S.R.B., see Zimányi, I. (167) 419
Weissman, Y., see Feigenbaum, J.J. (169) 159

Weizman, A., Fares, F., Pick, C.G., Yanai, J. and Gavish, M.
Chronic phenobarbital administration affects GABA and benzodiazepine receptors in the brain and periphery (169) 235
Wellens, H.J.J., see Vos, M.A. (165) 139
Werdan, K., see Reithmann, C. (170) 243
Werdan, K., see Reithmann, C. (172) 211
Wermuth, C.G., see Schumacher, C. (166) 139
Westerberg, V.S. and Geiger, J.D.
Adenosine analogs inhibit gastric acid secretion (160) 275
Westerink, B.H.C., see Timmerman, W. (162) 143
Westerink, B.H.C., see Timmerman, W. (166) 1
Westfall, T.C., see Han, S.P. (159) 303
Wettstein, J.G.
Behavioral studies with the β-carboline FG 7142 combined with related drugs in monkeys (163) 219
Wexler, R.R., see Chiu, A.T. (170) 117
W. Gallager, D., see J. Marley, R. (159) 217
Whalley, E.T., see Nwator, I.A.A. (160) 125
Whalley, E.T., see Nwator, I.A.A. (170) 29
Wharton, J., see Power, R.F. (160) 199
White, T.G., see Kostrzewa, R.M. (163) 33
Whiting, R.L., see Michel, A.D. (166) 459
Whittle, B.J.R., see Daffonchio, L. (161) 135
Whittle, B.J.R., see Fitzgerald, M.F. (164) 539
Whitton, P., see Kennett, G.A. (164) 445
Whitton, P.S., see Haleem, D.J. (164) 435
Widerlöv, E., see Wahlestedt, C. (159) 285
Wiegant, V.M., see Ronken, E. (162) 189
Wieland, F., see Reithmann, C. (170) 243
Wiemer, G., Becker, R., Gerhards, H., Hock, F., Stechl, J. and Rüger, W.
Effects of Hoe 065, a compound structurally related to inhibitors of angiotensin converting enzyme, on acetylcholine metabolism in rat brain [1] (166) 31
Wiemer, G., see Hock, F.J. (171) 79
Wiener, H.L., Hashim, A., Lajtha, A. and Sershen, H.
Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier (163) 191
Wiley, J.N., see Meltzer, L.T. (170) 105
Williams, H.L., see Miller, J.D. (161) 165
Williams, L.S., see Woodward, D.F. (164) 323
Williams, L.S., see Woodward, D.F. (168) 23
Williams, M., see Jarvis, M.F. (168) 243
Willmann, E., see Sandkühler, J. (160) 163
Wilson, J.H.P., see Zijlstra, F.J. (159) 291
Wilson, M.A., see Hernandez, T.D. (170) 145
Winblad, B., see Elinder, F. (164) 599
Winiger, B.P., see Mollard, P. (172) 71
Winquist, R.J., Bunting, P.B., Garsky, V.M., Lumma, P.K. and Schofield, T.L.
Prominent depressor response to endothelin in spontaneously hypertensive rats (163) 199
Winslow, E., Wright, P., Campbell, J.K. and Marshall, R.J.
Comparative effects of the isomers of bepridil on isolated coronary and aortic arteries (166) 241
Wisner, A., Bommelaer-Bayet, M.-C., Tiberghien, C., Renard, C.-A., David, F. and Dray, F.
Hypothalamic prostaglandin E_2 receptors coupled to an adenylyl cyclase (162) 89
Witte, K., see Lemmer, B. (159) 311
Wolf, W.A. and Bobik, A.
α-Methyldopa metabolism in central serotonergic nerve terminals: effects on serotonin levels, synthesis and release (163) 43
Wolff, J.R., see Erdö, S.L. (165) 79
Wolterink, G., see Van Ree, J.M. (166) 441
Wong, D.T., Robertson, D.W. and Reid, L.R.
Specific [^{3}H]LY278584 binding to 5-HT_3 recognition sites in rat cerebral cortex (166) 107
Wong-Dusting, H.K., see Reid, J.J. (168) 93
Wong, E.H.F. and Nielsen, M.
The N-methyl-D-aspartate receptor channel complex and the σ site have different target sizes (172) 493
Wong, P.C., see Chiu, A.T. (170) 117
Wood, K.S., see Buga, G.M. (161) 61
Wood, P.L., see Cosi, C. (165) 209
Wood, P.L., see Rao, T.S. (168) 129
Woods, J.H., see France, C.P. (159) 133
Woods, J.H., see Rothman, R.B. (167) 345
Woodward, D.F., Nieves, A.L., Williams, L.S., Gary, Jr., R.K., Wasserman, M.A. and Gleason, J.G.
Interactive effects of peptidoleukotrienes and histamine on microvascular permeability and their involvement in experimental cutaneous and conjunctival immediate hypersensitivity (164) 323
Woodward, D.F., Spada, C.S., Nieves, A.L., Hawley, S.B. and Williams, L.S.
Platelet-activating factor causes goblet cell depletion in the conjunctiva (168) 23
Worms, P., see Schumacher, C. (166) 139
Woutersen, R.A., see Douglas, B.R. (161) 209
Wright, P., see Winslow, E. (166) 241
Wright, P.W., see Taylor, E.M. (161) 121
Wu, C.-C., Chiou, W.-F. and Yen, M.-H.
A possible mechanism of action of tetramethylpyrazine on vascular smooth muscle in rat aorta (169) 189
Wu, E.Y., see Johnson, E.A. (166) 65
Wülfert, E., see Gower, A.J. (166) 271
Wurster, S., see Nakov, R. (164) 45
Wyss, J.M., see Sripairojthikoon, W. (167) 355

Xhonneux, R., see Janssens, W.J. (159) 89

Yablonsky, F. and Dausse, J.P.
Amiloride interacts with [^{3}H]idazoxan and [^{3}H]rauwolscine binding sites in rabbit urethra (164) 167
Yaksh, T.L. and Chipkin, R.E.
Studies on the effect of SCH-34826 and thiorphan on [Met^5]enkephalin levels and release in rat spinal cord (167) 367
Yaksh, T.L., see Morón, M.A. (163) 299

Yaksh, T.L., see Stevens, C.W. (166) 467
Yamada, M., see Ushijima, I. (161) 245
Yamaguchi, K., see Fukuda, K. (165) 301
Yamaguchi, T., Rodman, D., O'Brien, R. and McMurtry, I.
Modulation of pulmonary artery contraction by endothelium-derived relaxing factor (161) 259
Yamamoto, H., see Miyamoto, Y. (167) 11
Yamamoto, K., see Miura, K. (170) 91
Yamamoto, M. and Shimizu, M.
Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice (166) 545
Yamamoto, M., Iwai, A., Kawabata, S., Ozawa, Y. and Shimizu, M.
Effects of indeloxazine hydrochloride on passive avoidance behavior of senescence-accelerated mice (166) 345
Yamamoto, T., see Yatsugi, S.-i. (166) 231
Yamasaki, H., Niwa, M., Yamashita, K., Kataoka, Y., Shigematsu, K., Hashiba, K. and Ozaki, M.
Specific ^{125}I-endothelin-1 binding sites in the atrioventricular node of the porcine heart (168) 247
Yamashita, A., Kurokawa, T., Une, Y. and Ishibashi, S.
Reduction in the stability of the G_s-catalytic unit complex of adenylate cyclase in isoproterenol-induced heterologous desensitization (159) 247
Yamashita, H., see Takashio, T. (169) 179
Yamashita, K., see Yamasaki, H. (168) 247
Yamashita, Y., see Miura, K. (170) 91
Yanagisawa, M., see Saito, A. (162) 353
Yanai, J., see Weizman, A. (169) 235
Yanaihara, N., see Amiranoff, B. (163) 205
Yanaihara, N., see Kuwahara, A. (164) 175
Yang, L. and Vassalle, M.
Quinacrine decreases the slow inward current and force in guinea pig ventricular tissue (170) 261
Yang, Z.W., Paleos, G.A. and Byrd, J.C.
Expression of (+)-3-PPP binding sites in the PC12 pheochromocytoma cell line (164) 607
Yao, H., see Sadoshima, S. (169) 75
Yao, Y.-H., see Schoffelmeer, A.N.M. (166) 357
Yatsugi, S.-i., Yamamoto, T., Ohno, M. and Ueki, S.
Effect of S-adenosyl-L-methionine on impairment of working memory induced in rats by cerebral ischemia and scopolamine (166) 231
Yeen Chai, S., see Kohzuki, M. (160) 193
Yen, M.-H., see Wu, C.-C. (169) 189
Yoburn, B.C., Sierra, V. and Lutfy, K.
Chronic opioid antagonist treatment: assessment of receptor upregulation (170) 193
Yongsiri, A., Takeuchi, H., Kubota, I. and Muneoka, Y.
Effects of *Mytilus* inhibitory peptides on a giant neurone of *Achatina fulica* Férussac (171) 159
Yoshida, H., see Imaizumi, T. (161) 203
Yoshida, H., see Mizushima, A. (168) 375
Yoshida, S., see Imai, K.Y.M. (160) 229
Yoshida, T., see Sugita, S. (165) 191
Yoshida, Y., see Takata, Y. (164) 365
Yoshiya, I., see Kinouchi, K. (164) 63
Young, E.A., Houghten, R.A. and Akil, H.
Degradation of [^{3}H]β-endorphin in rat plasma is increased with chronic stress (167) 229
Young, J.A., see Tenner, Jr., T.E. (160) 291
Young, P., Berge, J., Chapman, H. and Cawthorne, M.A.
Novel α_2-adrenoceptor antagonists show selectivity for α_{2A}- and α_{2B}-adrenoceptor subtypes (168) 381
Yourick, D.L. and Tessel, R.E.
Mechanisms of phenylalanine-induced pressor effects in conscious rats (160) 219
Yuan, Q.X., see Tang, C.S. (159) 327
Yücel, H., see Jardon, B. (162) 215
Yukimura, T., see Miura, K. (170) 91

Zaagsma, J., see Meurs, H. (164) 369
Zaagsma, J., see Roffel, A.F. (172) 61
Zaagsma, J., see Van Amsterdam, R.G.M. (172) 175
Zadina, J.E., see Kostrzewa, R.M. (163) 33
Zahniser, N.R., see Lewin, E. (160) 101
Zajac, J.-M., see Meucci, E. (171) 167
Zak, J., see Nowak, G. (167) 307
Zannad, F., see Marie, P.-Y. (163) 337
Zavecz, J.H.
Theophylline affects the inotropic status of guinea-pig left atria by actions on the sarcolemma and sarcoplasmic reticulum (160) 187
Zdilar, D. and Lacković, Z.
[^{3}H]SCH 23390 labels dopamine D-1 receptor sites in the rat kidney (164) 159
Zernig, G., see Graziadei, I. (172) 329
Zhang, G., see Komori, K. (164) 111
Zhang, X. and Segawa, T.
Investigation of rat striatal dopamine D-1 receptors solubilized by digitonin with a precipitation method (166) 401
Zhou, X.-M., see Mizushima, A. (168) 375
Zigmond, M.J., see MacKenzie, R.G. (168) 43
Zijlstra, F.J., Wilson, J.H.P., Vermeer, M.A., Ouwendijk, R.J.T. and Vincent, J.E.
Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells (159) 291
Zilch, H., see Lambrecht, G. (168) 71
Zimányi, I., Weiss, S.R.B., Lajtha, A., Post, R.M. and Reith, M.E.A.
Evidence for a common site of action of lidocaine and carbamazepine in voltage-dependent sodium channels (167) 419
Zlokovic, B.V., see Debler, E.A. (165) 155
Zocchi, A., see Imperato, A. (165) 337
Zuspan, F.P., see Varol, F.G. (162) 37

Key word index
volumes 159–172
1989

Master key word index to volumes 159–172

A-69024
Dopamine D-1 receptor antagonists; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Abstinence
Morphine; Tolerance-dependence; 5-HT_2 receptors; Brain regions; Spinal cord (Gulati, A. (167) 185)

Acebutolol
Xamoterol; H142/08; H201/70; β-Adrenoceptor agonists (partial); Atrium (right, isolated); (Rat) (Abrahamsson, T. (164) 121)

Acetylcholine
Ergotamine; Vascular segments; Endothelium; Endothelium-derived relaxing factor (EDRF) (Demirel, E. (159) 195)

Dopamine receptors (presynaptic, postsynaptic); Indolylbutylamines; Turning behaviour; Serotonin; 5-HT_{1A} receptors (Seyfried, C.A. (160) 31)

Cardiac nerves (intrinsic); Cardiac muscle (isolated); Cardiac contractility; Nicotine; (Denervation, Supersensitivity) (Smith, D.C. (161) 249)

2-Amino-4-phosphonobutyrate (APB); Cis-2,3-piperidine dicarboxylic acid (PDA); Glutamate; Retina; Glycine; (ON channel, OFF channel, Receptive field, Frog) (Jardon, B. (162) 215)

L-Glutamate; L-Aspartate; Bronchi; Chinese restaurant syndrome; (Modulation) (Aas, P. (164) 93)

Aorta; Endothelium; Glyceryl trinitrate; 6-keto-Prostaglandin $F_{1\alpha}$; Prostaglandin $F_{1\alpha}$; (Radioimmunoassay, Rat) (Bossaller, C. (165) 165)

Cholecystokinin (CCK); CR 1409; Fronto-parietal cortex; Striatum; Dopamine; 3-Methoxytyramine (Cosi, C. (165) 209)

AN-132; Anticholinergic effect; Muscarinic K^+ channels; Atrial myocyte (Kurachi, Y. (165) 319)

Myocardial ischaemia (simulated); Coronary artery; Adenosine; 5-Hydroxytryptamine; U-46,619; Iloprost; (Sheep) (Kwan, Y.W. (168) 31)

Dopamine; Striatum; (Recovery of function, Release, Slices) (MacKenzie, R.G. (168) 43)

Acetylcholine-5-HT interaction
Chewing behaviour; 5-HT agonists; 5-HT antagonists (Stewart, B.R. (162) 101)

Acetylcholine metabolism
Hoe 065; cGMP content; Brain; (Rat) (Wiemer, G. (166) 31)

Acetylcholine receptors
Acetylcholine release; Ca^{2+} channel blockers; Tubocurarine; Verapamil (Hong, S.J. (162) 11)

Strontium; Smooth muscle (Macara, B. (162) 51)

Acetylcholine release
Acetylcholine receptors; Ca^{2+} channel blockers; Tubocurarine; Verapamil (Hong, S.J. (162) 11)

Galanin; Hippocampus (ventral); (Intracellular recording, Slice, Rat) (Dutar, P. (164) 355)

5-HT_1 receptor subtypes; Hippocampus; (Electrically stimulated slices, Rat) (Maura, G. (165) 173)

Acetylcholine vesicular uptake; Choline uptake; Electric organ of *Torpedo marmorata*; Cetiedil (Gaudry-Talarmain, Y.M. (166) 427)

Bronchial tissue; Atropine; Indomethacin; Prostaglandin E_2; Prostaglandin D_2 (Deckers, I.A. (167) 415)

5-HT_1 receptors; Minaprine; Hippocampus (Bolanos, F. (168) 87)

Skin (*Pseudophryne coriacea*); Cerebral cortex (rat); 5-HT release; (Superfused synaptosomes) (Raiteri, M. (172) 223)

Acetylcholine release in vivo
l-Fenfluramine; l-Norfenfluramine; Dopamine metabolism; Striatum; Nucleus accumbens (Invernizzi, R. (164) 241)

Acetylcholinesterase
AF64A; Cognitive deficits; Habituation; Learning (maze); (Histology) (Gower, A.J. (166) 271)

Acetylcholinesterase (EC 3.1.1.7)
Quaternary ammonium compounds; Esteratic subsite; (Active site) (Thanei-Wyss, P. (172) 165)

Acetylcholine vesicular uptake
Acetylcholine release; Choline uptake; Electric organ of *Torpedo marmorata*; Cetiedil (Gaudry-Talarmain, Y.M. (166) 427)

Acetyl vasopressin
[Cyt^6]vasopressin-(5-9); Vasopressin; Passive avoidance behavior; Exploratory behavior; Body temperature (Kovács, G.L. (161) 27)

Acidosis
Disopyramide; ECG effects; Myocardial uptake (Bova, S. (168) 179)

Aclarubicin
Anthracycline antibiotics; Vasoconstriction (Wakabayashi, I. (167) 177)

A_2C (2-[2-methoxyethoxy]-ethyl 8-[cis-2-n-octylcyclopropyl]-octanoate)
Membrane fluidity; Anaesthetics; TBPS (t-butylbicyclophosphorothionate); Temperature; GABA-activated chloride channels (Buck, K.J. (160) 359)

Aconitine
Dantrolene sodium; Antiarrhythmia agents; Cardiac arrhythmia models; Coronary artery ligation; Ventricular fibrillation threshold; Ouabain (Brooks, R.R. (164) 521)

ACTH
Vasopressin; cAMP; cGMP; Pituitary cells; AtT-20 corticotrophs; Corticotropin-releasing factor (CRF) (Koch, B. (158) 53)

MK-801; Pituitary; Adrenal; Corticosterone; Prolactin; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Action potential
Vas deferens (guinea-pig); Noradrenaline; Ca^{2+} currents; K^+ currents (Mimata, T. (163) 181)

Action potential (augmented, slow)
Murrayaquinone-A; Papillary muscle (guinea-pig); Mitochondrial oxidative phosphorylation; Inotropic response (triphasic) (Takeya, K. (169) 137)

Action potential duration
Sotalol; OPC-8212; Antiarrhythmics (class III); (Rate-dependent effects) (Lathrop, D.A. (164) 487)

Action potentials (slow)
Cardiac muscle; Azelastine; Cardiac electrophysiology (Molyvdas, P.-A. (164) 547)

Adamantane derivative
5-HT_3 receptors; Ion channels; cGMP; Neuroblastoma× glioma hybrid cells (Reiser, G. (172) 199)

Adenosine
Antinociception; Anti-writhing activity (Herrick-Davis, K. (162) 365)

Nitrobenzylthioinosine; Nucleoside transport; Autoradiography (quantitative); Heart; (Guinea-pig) (Parkinson, F.E. (163) 69)

9-Amino-1,2,3,4-tetrahydroacridine (THA); K^+ conductance (inwardly rectifying); Hippocampus; Baclofen; 5-HT; (Alzheimer's disease) (Halliwell, J.V. (163) 369)

Myocardium; Contractility; Alinidine; Heart rate; (Action potential) (Lang, U. (164) 13)

5′-N-Ethylcarboxamideadenosine (NECA); Negative inotropic effect; Heart; Adenylate cyclase; cAMP content; (−)-N^6-Phenylisopropyladenosine (PIA); (Guinea-pig) (Heller, T. (164) 179)

Diazepam; Neuromuscular junction; Sartorius muscle; Nucleoside uptake; Dipyridamole; (Frog) (De Mendonça, A. (164) 347)

Hypoxia; Heart; ATP; Endothelium-derived relaxing factor (EDRF) (Hopwood, A.M. (165) 323)

Myocardial ischaemia (simulated); Coronary artery; 5-Hydroxytryptamine; Acetylcholine; U-46,619; Iloprost; (Sheep) (Kwan, Y.W. (168) 31)

Adenosine A_2 receptors; Striatum; Autoradiography (Jarvis, M.F. (168) 243)

Prostaglandins; Lymphocytes; Cholera toxin; Phorbol esters; (Receptors) (Nordstedt, C. (172) 51)

A_1 adenosine receptors; Pertussis toxin; Heart (human); G proteins; Heart failure (Böhm, M. (172) 407)

Adenosine agonists
Vas deferens (rat); Contractions (electrically evoked); Smooth muscle (non-vascular); (Presynaptic) (Major, T.C. (167) 323)

Locomotor activity; Behaviour (exploratory); (Mouse) (Durcan, M.J. (168) 285)

Adenosine A_1 receptors
N^6 region; Computer graphics (J.M. Van Galen, P. (172) 19)

A_2 adenosine receptors; Adenylate cyclase; N^6-(ω-Aminoalkyl)adenosines; (Affinity and intrinsic activity, Species differences, Radioligand binding) (Pirovano, I.M. (172) 185)

Adenosine; Pertussis toxin; Heart (human); G proteins; Heart failure (Böhm, M. (172) 407)

Adenosine A_2 receptors
Adenosine; Striatum; Autoradiography (Jarvis, M.F. (168) 243)

A_1 adenosine receptors; Adenylate cyclase; N^6-(ω-Aminoalkyl)adenosines; (Affinity and intrinsic activity, Species differences, Radioligand binding) (Pirovano, I.M. (172) 185)

Adenosine receptor agonists
Adenosine receptors; Gastric acid secretion; (Rat) (Westerberg, V.S. (160) 275)

Adenosine receptors
Ca^{2+}; Coronary circulation; Smooth muscle (vascular); Prostaglandin $F_{2\alpha}$ (Ramagopal, M.V. (159) 33)

Adenosine receptor agonists; Gastric acid secretion; (Rat) (Westerberg, V.S. (160) 275)

Endothelium; Coronary artery; Ca^{2+} (Sabouni, M.H. (166) 311)

Rhythmicity; Coronary artery (human); Prostaglandin $F_{2\alpha}$; Ouabain (Sabouni, M.H. (168) 271)

S-Adenosyl-L-methionine
Catecholamines; Brain areas (Otero Losada, M.E. (163) 353)

Brain; Aging; Prolactin receptors (Muccioli, G. (166) 223)

Cerebral ischemia; Scopolamine; Runway task (3-panel); Memory (working); Amnesia (Yatsugi, S.-i. (166) 231)

α_1-Adrenoceptors; Antidepressants; β-Adrenoceptors; Imipramine; (Chronic treatment) (Cohen, B.M. (170) 201)

Adenylate cyclase
Heterologous desensitization; G_s proteins; β-Adrenoceptor agonists; Reticulocytes; (Rat) (Yamashita, A. (159) 247)

Antidepressants; Electroconvulsive shock; Brain; (Rat) (Newman, M.E. (162) 345)

β-Adrenoceptors; Macrophages (human) (Liggett, S.B. (163) 171)

Adenosine; 5′-N-Ethylcarboxamideadenosine (NECA); Negative inotropic effect; Heart; cAMP content; (−)-N^6-Phenylisopropyladenosine (PIA); (Guinea-pig) (Heller, T. (164) 179)

Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Imipramine; Dopamine D-1 receptors; α-Methyltyrosine (De Montis, G.M. (167) 299)

Hippocampus; Striatum; Ca^{2+}; Lithium (Mørk, A. (168) 347)

δ Opioid receptors; Enkephalin analogues; Neurotransmitter release; Brain slices; (Rat) (De Vries, T.J. (170) 137)

MSH receptors; Phorbol ester; Melanoma; Cell proliferation (Gerst, J.E. (172) 29)

A_1 adenosine receptors; A_2 adenosine receptors; N^6-(ω-Aminoalkyl)adenosines; (Affinity and intrinsic activity, Species differences, Radioligand binding) (Pirovano, I.M. (172) 185)

Guanine nucleotide-binding protein; Noradrenaline; Heart cells; (Desensitization) (Reithmann, C. (172) 211)

Aging; β-Adrenoceptors; Lung; (Rat) (Vanscheeuwijck, P. (172) 373)

cAMP; Forskolin; Forskolin analogues; Guanine nucleotide regulatory proteins; Macrophages; Manganese; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

Adenylate cyclase (cardiac)
Forskolin; Gpp(NH)p (5′-guanylyl amidophosphate); (Circadian rhythm, In vitro stimulation) (Lemmer, B. (159) 311)

Adenylyl cyclase
Prostaglandin E_2; Luteinizing hormone-releasing hormone (LHRH); Hypothalamus; Guanyl-5′-yl-imidophosphate (Wisner, A. (162) 89)

μ-Opioid receptors; GTP-binding protein; Pertussis toxin (Frey, E.A. (172) 347)

Adipocytes
[^{3}H]Idazoxan; Imidazoline; Amiloride; α_2-Adrenoceptors; (Rabbit) (Langin, D. (159) 199)

α_2-Adrenoceptors; Lipolysis; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]Idazoxan; [^{3}H]RX 821002; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Adrenal
MK-801; Pituitary; ACTH; Corticosterone; Prolactin; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Adrenal chromaffin cells
Histamine; Proenkephalin A; PNMT (phenylethanolamine N-methyltransferase); Gene regulation (Wan, D.C.-C. (172) 117)

Adrenal cortex
ANF binding; Mitochondria (Heisler, S. (162) 281)

Adrenalectomy
Delta sleep-inducing peptide; Antidepressants; Haloperidol; Pentobarbital; Brain regions; (Rat) (Wahlestedt, C. (159) 285)

Corticosterone; 3,4-Methylenedioxymethamphetamine (MDMA); Serotonin (5-HT); Tryptophan hydroxylase; (Neurotoxicity) (Johnson, M. (161) 181)

Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Raclopride; Stereotypy; Hypothermia; Adrenocortical hormones; (Rat) (Faunt, J.E. (162) 237)

Morphine analgesia; (Tissue content-effect correlation, Sensitivity to morphine, Subcutaneous, Intracerebroventricular, Rat) (Miyamoto, Y. (167) 11)

Schedule-induced wheelrunning; Corticosterone; Dexamethasone; (Rat) (Lin, W. (171) 9)

Adrenaline
Noradrenaline; Adrenoceptors; (Desensitisation) (Deighton, N.M. (169) 95)

Adrenal medulla
σ Receptors; PCP receptors; PC12 cells; Chromaffin cells (Yang, Z.W. (164) 607)

Adrenergic nerve stimulation
Neuropeptide Y; Endothelium; Ear artery; (Rabbit) (Budai, D. (168) 97)

Adrenergic nerves (vascular)
5-Hydroxytryptamine; Noradrenaline; α_2-Adrenoceptors (presynaptic) (Kawasaki, H. (164) 35)

Adrenergic neurotransmission
Smooth muscle (vascular); Pulmonary arteries; Pulmonary veins; Endothelium; Endothelium-derived relaxing factor (EDRF) (Greenberg, S. (162) 67)

Purinergic neurotransmission; PGE_2; Guanabenz; Guanethidine; (Neuromodulators) (Trachte, G.J. (164) 425)

Adrenergic/purinergic neurotransmission
α-Adrenoceptor antagonists; α,β-Methylene ATP; Resistance vessels (pre-capillary); (In vivo) (Taylor, E.M. (164) 23)

β-Adrenergic relaxation
Functional antagonism; Smooth muscle (airway); Muscarinic receptor agonists; Histamine; Phosphoinositide metabolism (Van Amsterdam, R.G.M. (172) 175)

Adrenergic responses
Nisoldipine; α_1-Adrenoceptors; α_2-Adrenoceptors; Vascular bed (hindquarters) (Minkes, R.K. (165) 259)

Adrenergic transmission
Nifedipine; Purinergic transmission (sympathetic); Artery (Omote, S. (160) 239)

β-Adrenoceptor agonists
Heterologous desensitization; Adenylate cyclase; G_s proteins; Reticulocytes; (Rat) (Yamashita, A. (159) 247)

Adrenoceptors; Clenbuterol; Gastric emptying; (Mouse) (Liberge, M. (164) 147)

β-Adrenoceptor agonists (partial)
Acebutolol; Xamoterol; H142/08; H201/70; Atrium (right, isolated); (Rat) (Abrahamsson, T. (164) 121)

α-Adrenoceptor antagonists
Adrenergic/purinergic neurotransmission; α,β-Methylene ATP; Resistance vessels (pre-capillary); (In vivo) (Taylor, E.M. (164) 23)

Cell membrane permeability; Creatine kinase; High-energy phosphates; Hypoxia; Reoxygenation; YM-12617 (Tanonaka, K. (165) 97)

α_1-Adrenoceptor antagonists
SGB-1534; Canine urethra; Hypogastric nerve stimulation (Imagawa, J.-i. (167) 167)

α_2-Adrenoceptor antagonists
Atipamezole; Idazoxan; Ethanol; Ro 15-4513; Hypothermia; (Mouse) (Löschmann, P.-A. (166) 381)

β-Adrenoceptor antagonists
Cardioprotection; Anoxia; Heart (isolated, working); (Guinea-pig) (Marie, P.-Y. (163) 337)

Pindolol; Opioids; α_2-Adrenoceptors (Jones, L.F. (165) 123)

Sympathomimetic activity (intrinsic); β_1 Selectivity; Noradrenaline; Heart cells (Reithmann, C. (170) 243)

β-Adrenoceptor-mediated cAMP accumulation; Cardiac cells; Nebivolol; (Rat) (Pauwels, P.J. (172) 471)

β-Adrenoceptor binding sites
β_1-Adrenoceptors; β_2-Adrenoceptors; [^{3}H]Dihydroalprenolol; [^{3}H]CGP 12177; CGP 20712A; ICI 118,551; (Post-mortem human brain) (De Paermentier, F. (167) 397)

β-Adrenoceptor blockade
α_1-Adrenoceptors; Cardiac action potential; Epinephrine; Prazosin; Myocytes (ventricular); (Adult rat) (Vogel, S.M. (164) 231)

β_1-Adrenoceptor blockade
Nebivolol; Pindolol; Practolol; Reserpinized animals; Atria (isolated); Blood vessels (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

β-Adrenoceptor-mediated cAMP accumulation
Cardiac cells; Nebivolol; β-Adrenoceptor antagonist; (Rat) (Pauwels, P.J. (172) 471)

Adrenoceptors
Noradrenaline; Neuropeptide Y; Spleen; Vasoconstriction; (Transmitter release) (Lundberg, J.M. (163) 103)

β-Adrenoceptor agonists; Clenbuterol; Gastric emptying; (Mouse) (Liberge, M. (164) 147)

Lymphatic vessel; (Spontaneous contractions) (Mahe, L. (167) 31)

Autoradiography; Kidney; Noradrenaline; Renal nerve; Sympathetic nervous system (Sripairojthikoon, W. (167) 355)

Blood pressure; 5-HT receptors; Ketanserin; Phentolamine (Dhasmana, K.M. (168) 257)

Noradrenaline; Adrenaline; (Desensitisation) (Deighton, N.M. (169) 95)

α-Adrenoceptors
Imidazoline receptors; Blood pressure; Brainstem; Clonidine; (Binding) (Bricca, G. (162) 1)

Bronchi; Neuropeptide Y; UK 14,304; Cholinergic contraction; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Noradrenaline; Morphine; (Guinea-pig) (Matran, R. (163) 15)

Bunazosin; Mesenteric vessels; Noradrenaline; Excitatory junction potential (Komori, K. (164) 111)

Aorta; Electrophysiological properties; Electromechanical coupling; Noradrenaline; Angiotensin II; (Rabbit) (Haeusler, G. (166) 175)

Noradrenaline; Neuropeptide Y (NPY); ATP; Nasal vasculature; (Denervation) (Lacroix, J.-S. (169) 125)

α_1-Adrenoceptor subtypes; [^{3}H]Prazosin binding; Brain (human); Cerebral cortex (Gross, G. (169) 325)

Mydriasis; Central nervous system (CNS); Clonidine; (Functional model, Mouse) (Heal, D.J. (170) 11)

α_1-Adrenoceptors
Tetrabenazine; Imipramine; β-Adrenoceptors; 5-HT_2 receptors; Phosphoinositide hydrolysis (Butler, P.D. (160) 93)

Diabetic rats; Ca^{2+} channels; Phosphatidylinositol turnover; (Hyper-reactivity) (Sakai, Y. (162) 475)

Cardiac action potential; Epinephrine; Prazosin; β-Adrenoceptor blockade; Myocytes (ventricular); (Adult rat) (Vogel, S.M. (164) 231)

Nisoldipine; Adrenergic responses; α_2-Adrenoceptors; Vascular bed (hindquarters) (Minkes, R.K. (165) 259)

Antidepressants; Phenylephrine; Hippocampal slice (Bijak, M. (166) 183)

Smooth muscle; P_2-purinoceptors; Suramin (Den Hertog, A. (166) 531)

Thioridazine; α_2-Adrenoceptors; Pithed rat (Cuffi, M.L. (168) 111)

Antidepressants; β-Adrenoceptors; Imipramine; S-Adenosyl-L-methionine; (Chronic treatment) (Cohen, B.M. (170) 201)

BTM-1086; BTM-1041; Muscarinic receptor subtypes; Histamine H_1 receptors; (Stereoselectivity) (Eltze, M. (170) 225)

[^{125}I]7-Amino-8-iodo-ketanserin ([^{125}I]AMIK); 5-HT_2 receptors; Release sites; (Quantitative autoradiography) (Schotte, A. (172) 99)

1,4-Dihydropyridine; Niguldipine; (Subtype, bivalent ligands) (Boer, R. (172) 131)

α_2-Adrenoceptors
[^{3}H]Idazoxan; Imidazoline; Amiloride; Adipocytes; (Rabbit) (Langin, D. (159) 199)

[^{3}H]Rauwolscine; 5-HT_{1A} receptors; Cerebral cortex membranes (human) (Convents, A. (159) 307)

Locus coeruleus; Mydriasis; Clonidine; Cocaine (Pitts, D.K. (160) 201)

Morphine dependence; Morphine withdrawal; Hippocampal slices; [^{3}H]Clonidine binding; Brain; (Field stimulation, Rat) (Smith, C.B. (161) 111)

[^{3}H](−)-Adrenaline; HT29 cell-line; [^{3}H]Yohimbine; [^{3}H]Clonidine; Colon adenocarcinoma (Sénard, J.-M. (162) 225)

Urethra (rabbit); [^{3}H]Idazoxan; [^{3}H]Rauwolscine; Amiloride (Yablonsky, F. (164) 167)

Pindolol; β-Adrenoceptor antagonists; Opioids (Jones, L.F. (165) 123)

Nisoldipine; Adrenergic responses; α_1-Adrenoceptors; Vascular bed (hindquarters) (Minkes, R.K. (165) 259)

SK&F 104078; 5-HT_{1A} receptors; 5HT_2 receptors (Kilpatrick, A.T. (166) 315)

Noradrenaline release; Spinal cord; DSP-4; (Slices, Rat) (Reimann, W. (167) 161)

Thioridazine; α_1-Adrenoceptors; Pithed rat (Cuffi, M.L. (168) 111)

Muscarinic receptor agonists; Muscarinic receptor antagonists; [^{3}H]Clonidine binding; Brain (rat) (Hollingsworth, P.J. (168) 159)

[^{3}H]Rauwolscine binding; (Heterogeneity) (Young, P. (168) 381)

Hypoactivity; Sedation; Mydriasis; MHPG (3-methoxy-4-hydroxyphenylglycol); Clonidine; Brain; Behaviour; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

Epinephrine; Norepinephrine; Sympathetic nervous system (Szemeredi, K. (170) 53)

Atrium (guinea-pig); Field stimulation; Inotropic effect; Presynaptic autoinhibition (Brasch, H. (171) 37)

Atrium (guinea-pig); Field stimulation; Noradrenaline release; Inotropic effect; Presynaptic autoinhibition (Brasch, H. (171) 49)

Adipocytes; Lipolysis; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]Idazoxan; [^{3}H]RX 821002; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Neuropeptide Y (NPY); G-protein; Pertussis toxin; Medulla oblongata; (Rat) (Von Euler, G. (172) 435)

α_{2A}-Adrenoceptors
[^{3}H]RX821002; [^{3}H]Yohimbine; [^{3}H]Idazoxan; [^{3}H]-UK14,304; HT29 cell-line (Langin, D. (167) 95)

β-Adrenoceptors
Tetrabenazine; Imipramine; α_1-Adrenoceptors; 5-HT$_2$ receptors; Phosphoinositide hydrolysis (Butler, P.D. (160) 93)

Gangliosides; Desipramine; Forced swimming test; (Down-regulation) (Molina, V.A. (160) 247)

Cardiovascular system; *Bordetella pertussis*; (Pig) (Van Heuven-Nolsen, D. (162) 135)

Macrophages (human); Adenylate cyclase (Liggett, S.B. (163) 171)

Desipramine; Down-regulation; Coupling (Turkka, J. (167) 87)

Phenytoin; Cerebellum; GABA$_A$ binding sites; Benzodiazepine binding sites; (Development) (Ruiz, G. (168) 251)

Down-regulation; Phenelzine; Internalization; Cerebral cortex; (Rat) (Koshikawa, N. (170) 101)

α_1-Adrenoceptors; Antidepressants; Imipramine; S-Adenosyl-L-methionine; (Chronic treatment) (Cohen, B.M. (170) 201)

Aging; Lung; Adenylate cyclase; (Rat) (Vanscheeuwijck, P. (172) 373)

β_1-Adrenoceptors
β-Adrenoceptor binding sites; β_2-Adrenoceptors; [^{3}H]Dihydroalprenolol; [^{3}H]CGP 12177; CGP 20712A; ICI 118,551; (Post-mortem human brain) (De Paermentier, F. (167) 397)

β_2-Adrenoceptors
Atrial cells; Ventricular cells; Slow inward calcium current; Procaterol; ICI-118551 (Iijima, T. (163) 357)

β-Adrenoceptor binding sites; β_1-Adrenoceptors; [^{3}H]Dihydroalprenolol; [^{3}H]CGP 12177; CGP 20712A; ICI 118,551; (Post-mortem human brain) (De Paermentier, F. (167) 397)

ICI 118,551; Atenolol; Myocardial ischemia; Coronary stenosis; (Regional myocardial function) (Noguchi, K. (168) 315)

α_2-Adrenoceptors (brain)
[^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Clorgyline; Tranylcypromine; Cocaine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

α-Adrenoceptors (prejunctional)
Noradrenaline release; Renal nerves (Murphy, T.V. (169) 285)

α_2-Adrenoceptors (presynaptic)
5-Hydroxytryptamine; Noradrenaline; Adrenergic nerves (vascular) (Kawasaki, H. (164) 35)

Botulinum A toxin; Phorbol ester; Protein kinase C; Noradrenaline release; 5-HT release (Nakov, R. (164) 45)

α_1-Adrenoceptor subtypes
α-Adrenoceptors; [^{3}H]Prazosin binding; Brain (human); Cerebral cortex (Gross, G. (169) 325)

5-HT$_{1A}$ receptors; Niguldipine; [^{3}H]5-Methyl-urapidil (Graziadei, I. (172) 329)

β-Adrenoceptor subtypes
Cardiac muscle; Mononuclear leukocytes (Tenner, Jr., T.E. (160) 291)

α-Adrenoceptor subtypes (postsynaptic)
Reserpine; Tail artery (rat); Ca^{2+} influx (Abe, K. (171) 59)

Adrenocortical hormones
Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Raclopride; Stereotypy; Hypothermia; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

AF64A
Cognitive deficits; Habituation; Learning (maze); Acetylcholinesterase; (Histology) (Gower, A.J. (166) 271)

AF-DX 116
Muscarinic M_3 receptor subtypes; HT-29 colon carcinoma cells; Phosphatidylinositol metabolism; Sila-hexocyclium; Hexhydro-sila-difenidol; Methoctramine (Kopp, R. (172) 397)

Affinity chromatography
Dopamine D-2 receptors; N-0434; (Purification) (Bosker, F.J. (163) 319)

Affinity labelling
σ Receptors; Phencyclidine receptors; Metaphit; Isothiocyanates (Bluth, L.S. (161) 273)

Monoamine oxidase-B (MAO-B); Ro 19-6327; Ro 16-6491; (Mechanism-based reversible inhibition, High-affinity binding) (Cesura, A.M. (162) 457)

After-depolarizations (delayed)
Flunarizine; Ouabain-induced ventricular tachycardia; (Conscious dog, Triggered activity) (Vos, M.A. (165) 139)

After-hyperpolarization
Ethanol; Hippocampus; cAMP; Ca^{2+}; (Neuronal firing) (Benson, D.M. (164) 591)

Aggression (intraspecies)
Dopamine receptors; SCH 23390; Clozapine; Haloperidol (McMillen, B.A. (160) 149)

Aggressive behaviour
Dilazep; Clonidine; Purinergic action (central) (Ushijima, I. (161) 245)

Aging
Ca^{2+} entry blocking drugs; Aorta (rat); Felodipine; Diltiazem (Wanstall, J.C. (159) 241)

S-Adenosyl-L-methionine; Brain; Prolactin receptors (Muccioli, G. (166) 223)

β-Adrenoceptors; Lung; Adenylate cyclase; (Rat) (Vanscheeuwijck, P. (172) 373)

Airway epithelium
Endothelin; Trachea; Bronchi (main); (Guinea-pig) (Maggi, C.A. (160) 179)

Endothelin; Trachea (guinea-pig); Peptidase inhibitors; Indomethacin; Captopril (Hay, D.W.P. (171) 241)

Airway hyperreactivity
Anaphylaxis; Inflammation; Histamine (Daffonchio, L. (161) 135)

Bradykinin; Substance P; Cholinergic system (Omini, C. (163) 195)

Airway hyperresponsiveness
PAF antagonists; YM-461; (*Ascaris suum*, Late response, Allergic sheep) (Tomioka, K. (170) 209)

Algesia
5-Hydroxytryptamine (serotonin, 5-HT); Arachidonate cyclooxygenase (inhibitors); Prostaglandins; Methysergide (Vinegar, R. (164) 497)

Alinidine
Myocardium; Contractility; Adenosine; Heart rate; (Action potential) (Lang, U. (164) 13)

Alveolar macrophages
Platelet activating factor (PAF-acether, PAF); Leukotriene B_4 (LTB_4); Thromboxane B_2; BW 137C; BW 755C; 5-Lipoxygenase inhibitors; Indomethacin (Fitzgerald, M.F. (164) 539)

Amiloride
[^{3}H]Idazoxan; Imidazoline; α_2-Adrenoceptors; Adipocytes; (Rabbit) (Langin, D. (159) 199)

Imidazolidines; Idazoxan (Vigne, P. (160) 295)

Urethra (rabbit); [^{3}H]Idazoxan; [^{3}H]Rauwolscine; α_2-Adrenoceptors (Yablonsky, F. (164) 167)

Submandibular acini; ^{22}Na; [^{3}H]QNB binding; Furosemide (Martinez, J.R. (164) 335)

Voltage clamp; Skeletal muscle; Ca^{2+}-dependent K^+ currents; (Frog) (Nasri-Sebdani, M. (171) 97)

N^6-(ω-Aminoalkyl)adenosines
A_1 adenosine receptors; A_2 adenosine receptors; Adenylate cyclase; (Affinity and intrinsic activity, Species differences, Radioligand binding) (Pirovano, I.M. (172) 185)

Amino-γ-carboline
γ-Aminobutyric acid; Sensory neuron; (Whole cell clamp, Mouse) (Kanai, Y. (166) 553)

1-Aminocyclobutane-1-carboxylate (ACBC)
N-Methyl-D-aspartate (NMDA); Glycine; HA-966 (1-hydroxy-3-aminopyrrolidone-2); D-AP-7 (D-2-Amino-7-phosphonoheptanoate); Oocytes (*Xenopus*) (Watson, G.B. (167) 291)

[^{125}I]7-Amino-8-iodo-ketanserin ([^{125}I]AMIK)
5-HT_2 receptors; α_1-Adrenoceptors; Release sites; (Quantitative autoradiography) (Schotte, A. (172) 99)

2-Amino-4-phosphonobutyrate (APB)
Cis-2,3-piperidine dicarboxylic acid (PDA); Glutamate; Retina; Acetylcholine; Glycine; (ON channel, OFF channel, Receptive field, Frog) (Jardon, B. (162) 215)

4-Aminopyridine
Polymyxin B; Neuromuscular junction; (End-plate receptor desensitization) (Vital Brazil, O. (159) 47)

9-Amino-1,2,3,4-tetrahydroacridine (THA)
K^+ conductance (inwardly rectifying); Hippocampus; Adenosine; Baclofen; 5-HT; (Alzheimer's disease) (Halliwell, J.V. (163) 369)

Amnesia
S-Adenosyl-L-methionine; Cerebral ischemia; Scopolamine; Runway task (3-panel); Memory (working) (Yatsugi, S.-i. (166) 231)

Minaprine; Cycloheximide; Serotonergic system; Cholinergic system; 5-HT_2 receptors; (Mouse) (Nabeshima, T. (169) 249)

cAMP
Vasopressin; ACTH; cGMP; Pituitary cells; AtT-20 corticotrophs; Corticotropin-releasing factor (CRF) (Koch, B. (158) 53)

Vasodilators; Protein phosphorylation; cGMP; Platelets; Phosphatidylinositols (Waldmann, R. (159) 317)

Sympathetic-parasympathetic interaction; Sinus node pacemaker activity; Atrial contractility; Ca^{2+} channels; Atrium (isolated, canine) (Furukawa, Y. (161) 1)

Vasoactive intestinal peptide (VIP); Leukotriene; Platelet activating factor (PAF-acether, PAF); Lungs; Neuropeptides (Di Marzo, V. (162) 115)

Somatostatin receptors; Neuroblastoma cells (McKinney, M. (162) 397)

Galanin; Insulin release; Rin m 5F cells (Amiranoff, B. (163) 205)

Endothelium-derived relaxing factor (EDRF); Prostacyclin; Platelet aggregation; cGMP (Alheid, U. (164) 103)

Ethanol; Hippocampus; Ca^{2+}; After-hyperpolarization; (Neuronal firing) (Benson, D.M. (164) 591)

Prostacyclin; Pertussis toxin; Angiotensin II; Vasopressin (Vallotton, M.B. (166) 219)

cGMP; Cyclic nucleotides; Tetraethylammonium; Trachealis (Chideckel, E.W. (166) 367)

G-proteins; Transmitter release; K^+ conductance; Pyramidal cells (Fredholm, B.B. (172) 249)

Adenylate cyclase; Forskolin; Forskolin analogues; Guanine nucleotide regulatory proteins; Macrophages; Manganese; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

cAMP content
Adenosine; 5′-N-Ethylcarboxamideadenosine (NECA); Negative inotropic effect; Heart; Adenylate cyclase; (−)-N^6-Phenylisopropyladenosine (PIA); (Guinea-pig) (Heller, T. (164) 179)

cAMP-dependent phosphorylation
Antidepressants; Microtubule-associated protein (Perez, J. (172) 305)

cAMP-dependent protein kinase
Regulatory subunit; Catalytic subunit; Recombinant DNA; Expression vector; (*E. coli*) (Kuno, T. (172) 263)

cAMP formation
5-Hydroxytryptamine (5-HT); Benzamides (substituted); 5-HT receptors (non-classical) (Dumuis, A. (162) 381)

Amphetamine
Neurokinin A; Tachykinin; Nucleus accumbens; Caudate-putamen; Microdialysis (Lindefors, N. (160) 417)

Dopamine; Microdialysis; 5-HT_3 receptors; ICS 205-930; Morphine (Carboni, E. (164) 515)

Dopamine uptake inhibitors; Dopamine metabolism; Microdialysis (in vivo); Methylphenidate; Nomifensine (Hurd, Y.L. (166) 251)

Dopamine uptake carrier; Microdialysis (in vivo); Ca^{2+}-dependent dopamine release; Dopamine metabolism (Hurd, Y.L. (166) 261)

Dopamine; 5-Hydroxytryptamine (5-HT, serotonin); Voltammetry (in vivo); d,l-p-Chloroamphetamine; (±)-3,4-Methylenedioxymethamphetamine (MDMA) (Gazzara, R.A. (168) 209)

Haloperidol; Dopamine; Striatum; Hippocampus; Calmodulin translocation (Popov, N. (172) 205)

d-Amphetamine
Dopamine neurons; Apomorphine; Quinpirole; SCH 23390; Nigrostriatal dopamine neurons (Pitts, D.K. (162) 167)

Amphetamine discrimination
Dopamine D-1 receptors; Dopamine D-2 receptors; [^{3}H]SCH 23390; [^{3}H]Raclopride; Dopamine (Nielsen, E.B. (160) 253)

Amygdala kindling
Tardive dyskinesia; Oral dyskinesia; Haloperidol (intermittent); Neuroleptic sensitization; (Drug holidays, Rat) (Glenthøj, B. (164) 393)

AN-132
Anticholinergic effect; Acetylcholine; Muscarinic K^+ channels; Atrial myocyte (Kurachi, Y. (165) 319)

Anaesthetics
Membrane fluidity; A_2C (2-[2-methoxyethoxy]-ethyl 8-[cis-2-n-octylcyclopropyl]-octanoate); TBPS (t-butylbicyclophosphorothionate); Temperature; GABA-activated chloride channels (Buck, K.J. (160) 359)

Na^+ channels (voltage-sensitive); $^{22}Na^+$ uptake (synaptosomal); Veratridine; [^{3}H]Batrachotoxin binding; [^{3}H]TCP binding; PCP-like drugs; PCP receptors (Allaoua, H. (163) 327)

Barbiturates; Endothelium; Pentobarbital; Phosphatidylinositol hydrolysis; Phosphatidylinositol (Robinson-White, A.J. (172) 291)

Anaesthetics (local)
Ileum and colon (terminal); Nicotinic receptors; Non-adrenergic, non-cholinergic (NANC) system; Vasoactive intestinal polypeptide (VIP); (Electrical stimulation) (Pelckmans, P.A. (170) 235)

Analgesia
Periaqueductal gray; Opioid binding sites (Fedynyshyn, J.P. (159) 83)

Pregnancy; Spinal cord; κ Opioid receptors; Dynorphin A (Sander, H.W. (159) 205)

Formalin test; Hot plate test; Nociception; Orphenadrine citrate; Serotonin (Hunskaar, S. (160) 83)

Pain; Bicuculline; (Descending inhibition, Rat) (Sandkühler, J. (160) 163)

U-50,488H; Morphine; κ Opioid receptors; Tolerance; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Calcitonin; Morphine; Withdrawal syndrome; Ca^{2+} (Clementi, G. (163) 175)

β-Endorphin; Morphine; Pain control systems (descending) (Suh, H.H. (168) 61)

Opioid receptors; Tail flick; Naloxonazine; ICI 154,129; β-Funaltrexamine; Opioid peptides; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

5-Hydroxytryptamine (5-HT, serotonin); 5-HT_3 receptors; ICS 205-930; MDL 72222; Inflammation (Giordano, J. (170) 83)

Opioids; Naltrexone; Upregulation; Supersensitivity; Morphine; (Dose dependence) (Yoburn, B.C. (170) 193)

Corticotropin releasing factor (CRF); Inflammation; Hyperalgesia; Pain (Hargreaves, K.M. (170) 275)

Analgesia (intrathecal)
β-Endorphin; Serotonin; Norepinephrine (Crisp, T. (160) 211)

Analgesia (non-opioid)
p-Octopamine; Spinal; Supraspinal; (Mouse) (Raffa, R.B. (169) 317)

Anaphylaxis
Airway hyperreactivity; Inflammation; Histamine (Daffonchio, L. (161) 135)

ANF binding
Mitochondria; Adrenal cortex (Heisler, S. (162) 281)

ANF-(99-126) (human)
cGMP (plasma); Cardiac accelerator nerve; Blood pressure; Cardiac output; Heart rate; (Neurotransmission, Anesthetized dog) (Bergey, J.L. (159) 103)

Angiotensin-converting enzyme
Endothelin-1; BAY k 8644; Veins; Methylene blue (D'Orleans-Juste, P. (165) 289)

Kinin; Kinin potentiation; Kininases; Endopeptidase (neutral); (Peptide) (Assreuy, J. (168) 231)

Angiotensin converting enzyme inhibitors
Kinin receptors; Inflammation; Bradykinin; Des-Arg^9-bradykinin (Nwator, I.A.A. (160) 125)

Angiotensin II
Uterus; Pregnancy; Phospholipase C; (Receptors, Rat) (Varol, F.G. (162) 37)

Aorta; Electrophysiological properties; Electromechanical coupling; Noradrenaline; α-Adrenoceptors; (Rabbit) (Haeusler, G. (166) 175)

cAMP; Prostacyclin; Pertussis toxin; Vasopressin (Vallotton, M.B. (166) 219)

Receptors; Smooth muscle; Ileum; (Guinea-pig, Desensitization) (Oshiro, M.E.M. (166) 411)

'Anhedonia'
Neurotensin; Neuroleptics; Operant responding; Central nervous system (CNS); (Dose-response curve) (Rossitch, Jr., E. (163) 119)

Anococcygeus (rat)
Clonidine; McN-A-343; Methoxamine; Non-adrenergic, non-cholinergic (NANC) transmission; Rilmenidine; (Prejunctional receptors) (Li, C.G. (168) 107)

Anorexia
L-364,718; Cholecystokinin antagonists; Caerulein (Leighton, G.E. (161) 255)

Anoxia
β-Adrenoreceptor antagonists; Cardioprotection; Heart (isolated, working); (Guinea-pig) (Marie, P.-Y. (163) 337)

Anthracycline antibiotics
Aclarubicin; Vasoconstriction (Wakabayashi, I. (167) 177)

Antiarrhythmia agents
Dantrolene sodium; Cardiac arrhythmia models; Coronary artery ligation; Ventricular fibrillation threshold; Aconitine; Ouabain (Brooks, R.R. (164) 521)

Antiarrhythmic activity
Naloxone; Purkinje fibers; Oscillatory afterpotentials; (Triggered activity) (Cerbai, E. (162) 491)

Antiarrhythmics
Lidocaine binding site; Na^+ channels; Heart; Liver (Voigt, W. (169) 103)

Antiarrhythmics (class III)
Sotalol; OPC-8212; Action potential duration; (Rate-dependent effects) (Lathrop, D.A. (164) 487)

Anticholinergic action
DPI 201-106; Cardiac muscarinic receptors; (Mode of interaction) (Groschner, K. (159) 125)

Anticholinergic effect
AN-132; Acetylcholine; Muscarinic K^+ channels; Atrial myocyte (Kurachi, Y. (165) 319)

Anticonvulsants
Audiogenic seizure; Non-competitive NMDA antagonists; Phencyclidine; MK-801; Dextromethorphan (Chapman, A.G. (166) 201)

Seizures; Steroids; Progesterone metabolite; GABA receptors; Cl^- ionophore (Belelli, D. (166) 325)

MK-801; Phencyclidine (PCP); NMDA receptor antagonists; Drug discrimination; (Behaviour) (Tricklebank, M.D. (167) 127)

Anticonvulsant tolerance
Diazepam; Ro 17-1812; RU 32698; (Partial agonists) (Feely, M. (164) 377)

Antidepressants
Thiorphan; Bestatin; Iprindole; Imipramine; Forced swimming test; Motor activity; Opioids (Del Carmen de Felipe, M. (159) 175)

Delta sleep-inducing peptide; Haloperidol; Pentobarbital; Brain regions; Adrenalectomy; (Rat) (Wahlestedt, C. (159) 285)

Gonadotropin-releasing hormone (GnRH); Learned helplessness; (Rats) (Massol, J. (160) 395)

Nimodipine; BAY k 8644; Learned helplessness (Martin, P. (162) 185)

Adenylate cyclase; Electroconvulsive shock; Brain; (Rat) (Newman, M.E. (162) 345)

Imipramine; 5-Hydroxytryptamine (5-HT, serotonin); Brain mRNA; (*Xenopus* oocytes, Current) (Tohda, M. (166) 57)

α_1-Adrenoceptors; Phenylephrine; Hippocampal slice (Bijak, M. (166) 183)

α_1-Adrenoceptors; β-Adrenoceptors; Imipramine; S-Adenosyl-L-methionine; (Chronic treatment) (Cohen, B.M. (170) 201)

cAMP-dependent phosphorylation; Microtubule-associated protein (Perez, J. (172) 305)

Antidiuresis
Vasopressin antagonists; (Rhesus monkey, Human) (Brooks, D.P. (160) 159)

Antidromic activation
MDMA (3,4-methylenedioxymethamphetamine); Apomorphine; Quinpirole; Midbrain dopamine neurons; (Electrophysiology) (Kelland, M.D. (169) 11)

Antiemetic drugs
Autonomic ganglia; Enteric neurons; Gastrointestinal motility; 5-Hydroxytryptamine (5-HT, serotonin) (Nemeth, P.R. (166) 387)

Antiestrogens
Catecholestrogens; Estrogens; Tamoxifen; Dopamine receptor supersensitivity; Striatum (Ferretti, C. (166) 149)

Antigen
Leukotrienes; ICI 198,615; Trachea (Redkar-Brown, D.G. (165) 113)

Anti-inflammatory drugs
Dura mater; Trigeminal ganglion; Neurogenic inflammation (Buzzi, M.G. (165) 251)

Phospholipase A_2; Oedema; Mast cell amines (Cirino, G. (166) 505)

Anti-inflammatory drugs (non-steroidal)
Aspirin; Salicylic acid; Prostaglandins; Inflammation; Carrageenin (Chiabrando, C. (159) 257)

Anti-inflammatory response
Corticotropin-releasing factor (CRF); Sauvagine; Urotensin I; CRF-(9-41) antagonist (α-helical); Thermal injury; Vascular permeability (Wei, E.T. (168) 81)

Antimuscarinic agents
Methoctramine; Phosphoinositide hydrolysis; Muscarinic receptors; Brain; Muscarinic receptor subtypes (Lee, N.H. (167) 295)

Antinociception
Substance P; Excitatory amino acids; Phencyclidine receptors (DeLander, G.E. (159) 149)

Adenosine; Anti-writhing activity (Herrick-Davis, K. (162) 365)

Flupirtine; Pentazocine; Flexor reflex; Skin twitch reflex (Vaupel, D.B. (162) 447)

Dopamine receptor agonists; Dopamine receptor antagonists; Opioid receptor agonists (Rooney, K.F. (168) 329)

Antipsychotic agents
Dopamine; 5-HT_3 receptor antagonists; Substantia nigra; (Electrophysiology) (Sorensen, S.M. (163) 115)

Antipsychotics
[^{14}C]2-Deoxyglucose; Cholinergic pathways; Desenkephalin-γ-endorphin; Glucose uptake; Local cerebral glucose utilization; Org 5878; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Antipsychotic substances
Dopamine; Haloperidol; Sulpiride; Desenkephalin-γ-endorphin (DEγE); Brain regions (Van Ree, J.M. (166) 441)

Anti-writhing activity
Adenosine; Antinociception (Herrick-Davis, K. (162) 365)

Anxiety
Caffeine; Yohimbine; (Rat) (Baldwin, H.A. (159) 211)

Ro 15-4513; β-Carbolines; Benzodiazepine recognition sites; Proconflict effect; Convulsions; [^{3}H]GABA binding (Corda, M.G. (159) 233)

mCPP (1-(3-chlorophenyl)piperazine); TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); 5-HT_{1C} receptors (Kennett, G.A. (164) 445)

Anxiolytic effect
5-HT_{1A} receptor agonists; NMDA receptor antagonists; Social interaction; (Elevated plus maze) (Dunn, R.W. (169) 1)

Aorta
Endothelium-derived relaxing factor (EDRF); Atrial natriuretic peptide (ANP); Central ear artery; (Rabbit) (Hogan, J.C. (165) 129)

Acetylcholine; Endothelium; Glyceryl trinitrate; 6-keto-Prostaglandin $F_{1\alpha}$; Prostaglandin $F_{1\alpha}$; (Radioimmunoassay, Rat) (Bossaller, C. (165) 165)

Endothelin; Endothelium; Pulmonary artery; (Rat) (Rodman, D.M. (165) 297)

Electrophysiological properties; Electromechanical coupling; Noradrenaline; α-Adrenoceptors; Angiotensin II; (Rabbit) (Haeusler, G. (166) 175)

Diabetes; K^+ channels; Cromakalim (Kamata, K. (166) 319)

Planar lipid bilayer; Ca^{2+}-activated K^+ channels; $[Ca^{2+}]_i$ sensitivity; Cromakalim; (Rabbit) (Gelband, C.H. (167) 201)

Ethanol; Clonidine; Endothelium; Smooth muscle (vascular); Vasorelaxation; (Rat) (Hatake, K. (168) 277)

Tetramethylpyrazine; Phenylephrine; Endothelium; (High potassium, Rat) (Wu, C.-C. (169) 189)

Aorta (rat)
Ca^{2+} entry blocking drugs; Aging; Felodipine; Diltiazem (Wanstall, J.C. (159) 241)

Aortic endothelial cells
Bradykinin; Histamine; (Rat) (Cole, O.F. (169) 307)

AP-7
Social conflict analgesia; Periaqueductal grey; NMDA receptors; MK-801; Naloxone; (Mouse) (Siegfried, B. (168) 239)

D-AP-7 (D-2-amino-7-phosphonoheptanoate)
N-Methyl-D-aspartate (NMDA); Glycine; 1-Aminocyclobutane-1-carboxylate (ACBC); HA-966 (1-hydroxy-3-aminopyrrolidone-2); Oocytes (*Xenopus*) (Watson, G.B. (167) 291)

Apomorphine
Dopamine neurons; d-Amphetamine; Quinpirole; SCH 23390; Nigrostriatal dopamine neurons (Pitts, D.K. (162) 167)

MIF-1; Prolyl-leucyl-glycinamide; Dopamine; 6-Hydroxydopamine (6-OHDA, neonatal); (Behaviour, Development) (Kostrzewa, R.M. (163) 33)

Quinpirole; SCH 23390; Sulpiride; SK&F 38393; Jaw movements (Koshikawa, N. (163) 227)

γ-Aminobutyric acid (GABA); Aspartate; Glutamate; Striatal slices; Haloperidol; (K^+-evoked endogenous release) (Umeda, Y. (163) 291)

Oxytocin; Oxytocin antagonists; Penile erection; Yawning; (Rat) (Melis, M.R. (164) 565)

Dopamine; Dopamine DA2 receptors; Heart rate; Domperidone; SCH 23390; Vagus nerve (Montastruc, P. (166) 511)

Ca^{2+} channel inhibitors; Penile erection; Yawning; Oxytocin; (Rat) (Argiolas, A. (166) 515)

Levodopa; Behaviour (rotational); SKF 38393; Quinpirole; (Chronic treatment) (Engber, T.M. (168) 291)

MDMA (3,4-methylenedioxymethamphetamine); Quinpirole; Midbrain dopamine neurons; Antidromic activation; (Electrophysiology) (Kelland, M.D. (169) 11)

Appetitive behaviour
Immunoneuroendocrinology; Immunopharmacology; Prostaglandin; Interleukin-1; Indomethacin (Uehara, A. (170) 257)

Arachidonate cyclooxygenase (inhibitors)
5-Hydroxytryptamine (serotonin, 5-HT); Algesia; Prostaglandins; Methysergide (Vinegar, R. (164) 497)

Area postrema
5-HT_3 receptors; [^{3}H]GR65630; Vagus nerve; Brain (human); (Binding) (Kilpatrick, G.J. (159) 157)

Arginine
NMDA receptors; Nitric oxide; cGMP (Garthwaite, J. (172) 413)

[^{3}H][Arg^8]vasopressin
Chlorpropamide; [Arg^8]vasopressin receptor; Renal tubular basolateral membrane; (Rat) (Muta, T. (159) 191)

[Arg^8]vasopressin (AVP)
κ Opioid receptor agonists; U-62,066E; κ Opioid receptor antagonists; MR-2266; Diuresis; Collecting duct; Water permeability (Imai, K.Y.M. (160) 229)

Atrial natriuretic factor; Brattleboro rats; Diuresis; Lithium clearance; Natriuresis (Palluk, R. (162) 245)

Atrial natriuretic peptide (ANP); Urine formation; (Dog) (Hellebrekers, L.J. (164) 55)

[Arg^8]vasopressin receptor
Chlorpropamide; Renal tubular basolateral membrane; [^{3}H][Arg^8]vasopressin; (Rat) (Muta, T. (159) 191)

Arrhythmias
Nicorandil; Ischemia; Reperfusion; Heart; (Rat) (Kempsford, R.D. (163) 61)

Platelet activating factor (PAF-acether, PAF); BN 52021; Heart functions; Ischemia and reperfusion; (Rat) (Koltai, M. (164) 293)

Arterial pressure
Blood flow (gastric, hepatic, intestinal, kidney); Heart rate; Nifedipine (Van Berlo, C.L.H. (160) 17)

Endothelin; Vascular resistance (regional) (Minkes, R.K. (163) 163)

Endothelin (porcine); Endothelin (rat); Monocyclic porcine analog (Minkes, R.K. (164) 571)

Arterial pressure (mean)
Phenylalanine; Tyrosine; Heart rate; Phenethylamine; (Rat) (Yourick, D.L. (160) 219)

Arterial pressure regulation
Endothelin; Hemodynamics (regional); Vasoconstriction (Han, S.P. (159) 303)

Arteriolar vasoconstrictors
Endothelin; Cheek pouch (hamster) (Brain, S.D. (160) 401)

Arteriole
Endothelin; Vasopressin; Lymphatic vessels; Venule (Fortes, Z.B. (170) 69)

Arteriovenous anastomoses
Carotid blood flow; 5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptors; 5-HT_1-like receptors; Migraine; RU 24969 (Bom, A.H. (171) 87)

Artery
Nifedipine; Purinergic transmission (sympathetic); Adrenergic transmission (Omote, S. (160) 239)

Endothelin-1; Vein; Vasoconstriction; (Dog, Human) (Cocks, T.M. (171) 17)

Arylpiperazines
5-Hydroxytryptamine (5-HT, serotonin); 5-HT_3 (sites); Quipazine; (Radioligand binding) (Glennon, R.A. (168) 387)

Aspartate
γ-Aminobutyric acid (GABA); Glutamate; Striatal slices; Apomorphine; Haloperidol; (K^+-evoked endogenous release) (Umeda, Y. (163) 291)

L-Aspartate
L-Glutamate; Acetylcholine; Bronchi; Chinese restaurant syndrome; (Modulation) (Aas, P. (164) 93)

Aspirin
Salicylic acid; Anti-inflammatory drugs (non-steroidal); Prostaglandins; Inflammation; Carrageenin (Chiabrando, C. (159) 257)

Asthma (experimental)
Trachealis; Lung parenchyma; Sensitized guinea-pig; Indomethacin; (Non-specific hyperresponsiveness, Guinea-pig) (Cortijo, J. (162) 467)

Ataxia
Dopamine turnover; MK-801; Phencyclidine (PCP); 5-HT uptake; Stereotyped behavior; (Rat) (Hiramatsu, M. (166) 359)

YM-14673; Thyrotropin releasing hormone (TRH); Cytosine arabinoside (Yamamoto, M. (166) 545)

Atenolol
ICI 118,551; Myocardial ischemia; Coronary stenosis; β_2-Adrenoceptors; (Regional myocardial function) (Noguchi, K. (168) 315)

Atipamezole
α_2-Adrenoceptor antagonists; Idazoxan; Ethanol; Ro 15-4513; Hypothermia; (Mouse) (Löschmann, P.-A. (166) 381)

Atopic guinea-pig
Haemophilus influenzae; Pulmonary β-adrenoceptors; (Autoradiography) (Engels, F. (164) 139)

ATP
Verapamil; Diltiazem; ^{45}Ca uptake; Tyrode solution (Ca^{2+}-free) (Bhat, M.B. (164) 163)

Ca^{2+} antagonists; P_2 purinoceptors; Vas deferens; (Guinea-pig) (Morishita, H. (164) 507)

Hypoxia; Heart; Adenosine; Endothelium-derived relaxing factor (EDRF) (Hopwood, A.M. (165) 323)

Noradrenaline; Neuropeptide Y (NPY); Nasal vasculature; α-Adrenoceptors; (Denervation) (Lacroix, J.-S. (169) 125)

DDT_1 MF-2 cells; G protein; Sulfonylureas; (Patch clamp) (Molleman, A. (169) 167)

ATP receptors
Bradykinin; Vas deferens; P_2 purinoceptors; Bradykinin B_2 receptors; Bradykinin antagonists (Donoso, M.V. (160) 263)

Atrial cells
Ventricular cells; Slow inward calcium current; β_2-Adrenoceptors; Procaterol; ICI-118551 (Iijima, T. (163) 357)

Atrial contractility
Sympathetic-parasympathetic interaction; Sinus node pacemaker activity; cAMP; Ca^{2+} channels; Atrium (isolated, canine) (Furukawa, Y. (161) 1)

Atrial myocyte
AN-132; Anticholinergic effect; Acetylcholine; Muscarinic K^+ channels (Kurachi, Y. (165) 319)

Atrial natriuretic factor (ANF)
Blood pressure; Urine; (Analogs, Receptors) (Song, D.L. (160) 141)

[Arg^8]vasopressin; Brattleboro rats; Diuresis; Lithium clearance; Natriuresis (Palluk, R. (162) 245)

Atrial natriuretic peptide (ANP)
Brain natriuretic peptide (BNP); cGMP; Kidney epithelial cell line ($LLC\text{-}PK_1$) (Iwata, T. (159) 321)

Brain natriuretic peptide (BNP); Kidney; Heart; Endothelium; (Receptor) (Oehlenschlager, W.F. (161) 159)

Pituitary gland; Thymus gland; (Receptor, classification, Olfactory bulb) (Agui, T. (162) 301)

[Arg^8]vasopressin (AVP); Urine formation; (Dog) (Helebrekers, L.J. (164) 55)

Smooth muscle cells (vascular); (Vasoconstrictor, Receptor down-regulation) (Hirata, Y. (164) 603)

Endothelium-derived relaxing factor (EDRF); Aorta; Central ear artery; (Rabbit) (Hogan, J.C. (165) 129)

Urinary kallikrein excretion; Renal function (López, C. (168) 1)

Atrial natriuretic peptide (rat)
Erythrocytes; Ca^{2+} flux; K^+ flux (Esparza, N. (166) 349)

Atrial responses
Benzodiazepines; Sympathetic neurotransmission; Norepinephrine; (Peripheral effects) (Elgoyhen, B. (164) 467)

Atrioventricular node
Endothelin receptors; ^{125}I-Endothelin-1; Heart (porcine); Autoradiography (quantitative receptor) (Yamasaki, H. (168) 247)

Atrium
Ileal longitudinal muscle; Muscarine receptors; C_7/3′-phthalimidopropyl; (Guinea-pig) (Choo, L.K. (162) 429)

Capsaicin; Sensory nerves ('efferent' function of); Galanin; Bronchi; (Guinea-pig) (Giuliani, S. (163) 91)

Capsaicin sensitive sensory nerves ('efferent' function of); Ruthenium Red; Bronchi; (Guinea-pig) (Maggi, C.A. (170) 167)

Atrium (guinea-pig)
Field stimulation; Inotropic effect; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 37)

Field stimulation; Noradrenaline release; Inotropic effect; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 49)

Atrium (isolated)
β_1-Adrenoceptor blockade; Nebivolol; Pindolol; Practolol; Reserpinized animals; Blood vessels (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

Endothelin; Noradrenergic transmission; (Rat, Guinea-pig) (Reid, J.J. (168) 93)

Atrium (isolated, canine)
Sympathetic-parasympathetic interaction; Sinus node pacemaker activity; Atrial contractility; cAMP; Ca^{2+} channels (Furukawa, Y. (161) 1)

Atrium (right, isolated)
Acebutolol; Xamoterol; H142/08; H201/70; β-Adrenoceptor agonists (partial); (Rat) (Abrahamsson, T. (164) 121)

Atropine
Neurotensin; Haloperidol; Scopolamine; Nucleus accumbens; Caudate nucleus (Levant, B. (165) 327)

Acetylcholine release; Bronchial tissue; Indomethacin; Prostaglandin E_2; Prostaglandin D_2 (Deckers, I.A. (167) 415)

AtT-20 corticotrophs
Vasopressin; ACTH; cAMP; cGMP; Pituitary cells; Corticotropin-releasing factor (CRF) (Koch, B. (158) 53)

Atypical neuroleptics
Dopamine D-1 receptor antagonists; Dopamine D-2 receptor antagonists; Clozapine; SKF-38393; LY-171555; (Behavior) (Criswell, H.E. (159) 141)

Audiogenic seizures
Metaphit; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA) (Debler, E.A. (165) 155)

Anticonvulsants; Non-competitive NMDA antagonists; Phencyclidine; MK-801; Dextromethorphan (Chapman, A.G. (166) 201)

Autonomic ganglia
Antiemetic drugs; Enteric neurons; Gastrointestinal motility; 5-Hydroxytryptamine (5-HT, serotonin) (Nemeth, P.R. (166) 387)

Autonomic nervous system
L-Tyrosine; Blood pressure; Heart rate; Histamine receptors; Prostaglandin synthesis (Ekholm, S. (168) 145)

Autoradiography
Kidney; Noradrenaline; Adrenoceptors; Renal nerve; Sympathetic nervous system (Sripairojthikoon, W. (167) 355)

Epidermal growth factor-urogastrone; Smooth muscle (vascular) (Siang Gan, B. (167) 407)

Adenosine; Adenosine A_2 receptors; Striatum (Jarvis, M.F. (168) 243)

Muscarinic receptors; Hypertension; Kidney; (Rat) (De Michele, M. (169) 297)

Autoradiography (quantitative)
Adenosine; Nitrobenzylthioinosine; Nucleoside transport; Heart; (Guinea-pig) (Parkinson, F.E. (163) 69)

Steroids; Flunitrazepam; Forebrain (Canonaco, M. (170) 95)

Autoradiography (quantitative receptor)
Endothelin receptors; ^{125}I-Endothelin-1; Heart (porcine); Atrioventricular node (Yamasaki, H. (168) 247)

Avoidance (inhibitory, passive)
Hoe 065; Learning; Memory; (Up-hill avoidance, Eight-arm radial maze) (Hock, F.J. (171) 79)

Axonal transport
NMDA receptors; Ionophore complex; (Autoradiography) (Cincotta, M. (160) 167)

Azelastine
Cardiac muscle; Action potentials (slow); Cardiac electrophysiology (Molyvdas, P.-A. (164) 547)

Baclofen
9-Amino-1,2,3,4-tetrahydroacridine (THA); K^+ conductance (inwardly rectifying); Hippocampus; Adenosine; 5-HT; (Alzheimer's disease) (Halliwell, J.V. (163) 369)

$GABA_B$ receptor antagonists; Benzofuran-baclofen analogues; Ileum (guinea-pig); Neocortex (rat) (Kerr, D.I.B. (164) 361)

5-Hydroxytryptamine (5-HT, serotonin); Intestine (small); Enterochromaffin cells; GABA receptors; Muscimol (Schwörer, H. (165) 29)

(−)-Baclofen
$GABA_B$ autoreceptors; [^{3}H]GABA release; Phaclofen; Muscimol; (Superfused synaptosomes) (Bonanno, G. (172) 41)

[^{3}H](−)-Baclofen
Lithium; Carbamazepine; [^{3}H]Muscimol; $GABA_B$ receptors; Hippocampus (Motohashi, N. (166) 95)

Barbiturates
Anaesthetics; Endothelium; Pentobarbital; Phosphatidylinositol hydrolysis; Phosphatidylinositol (Robinson-White, A.J. (172) 291)

Barbiturate site
Progesterone metabolites; $GABA_A$ receptor complex; Prolactin; Pituitary (Vincens, M. (168) 15)

Baroreceptor deafferentation
Cholinergic system; Blood pressure control (Taira, C.A. (159) 265)

Baroreflex
Cerebral ischemia; Flunarizine; Papaverine; (Cerebral protection) (Kurihara, J. (165) 147)

Basal ganglia
Cocaine; Dopamine; GBR 12909; Neurotensin; Substantia nigra; Striatum (Hanson, G.R. (160) 23)

[^{3}H]Batrachotoxin binding
Na^+ channels (voltage-sensitive); $^{22}Na^+$ uptake (synaptosomal); Veratridine; [^{3}H]TCP binding; PCP-like drugs; PCP receptors; Anaesthetics (Allaoua, H. (163) 327)

Lidocaine; Carbamazepine; Phenytoin; Seizures (lidocaine-kindled); Hippocampus (Zimányi, I. (167) 419)

BAY k 8644
Dihydropyridine-sensitive Ca^{2+} channels; Tail flick; (Neurotransmitter metabolites, Intracerebroventricular administration) (Bourson, A. (160) 339)

Nimodipine; Antidepressants; Learned helplessness (Martin, P. (162) 185)

Cardiac glycosides; Norepinephrine; Ca^{2+} (extracellular); Mg^{2+} (extracellular); Cardiac muscle; (Guinea-pig) (Kafiluddi, R. (165) 181)

Endothelin-1; Veins; Methylene blue; Angiotensin converting enzyme (D'Orleans-Juste, P. (165) 289)

Mast cells; Benzodiazepine binding sites; 5-HT release; Ca^{2+} influx; Calmodulin (Suzuki-Nishimura, T. (167) 75)

Endothelin; Sarafotoxin S6b; Ca^{2+} antagonists; ω-Conotoxin; Na^+/H^+ exchanger (Gu, X.-H. (167) 281)

Behaviour
α_2-Adrenoceptors; Hypoactivity; Sedation; Mydriasis; MHPG (3-methoxy-4-hydroxyphenylglycol); Clonidine; Brain; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

8-OH-DPAT; 5-HT_{1A} receptors; Stereoselectivity; Partial agonists; (+)ALK-3 ((+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin); (Rat) (Hjorth, S. (170) 269)

Behavioural effects
IBMX (3-Isobutyl-1-methylxanthine); 7-CET (7-(2-Chloroethyl)-theophylline); Caffeine; Fixed-interval schedules; (Squirrel monkey) (Coffin, V.L. (170) 35)

Behaviour (exploratory)
Adenosine agonists; Locomotor activity; (Mouse) (Durcan, M.J. (168) 285)

Behaviour (rotational)
Levodopa; SKF 38393; Quinpirole; Apomorphine; (Chronic treatment) (Engber, T.M. (168) 291)

Benzamides (substituted)
5-Hydroxytryptamine (5-HT); cAMP formation; 5-HT receptors (non-classical) (Dumuis, A. (162) 381)

Benzodiazepine binding
Ro 15-1788; GABA; (Chronic treatment) (Urbancic, M. (171) 1)

Benzodiazepine binding sites
Mast cells; 5-HT release; Ca^{2+} influx; Calmodulin; BAY k 8644 (Suzuki-Nishimura, T. (167) 75)

Phenytoin; Cerebellum; $GABA_A$ binding sites; β-Adrenoceptors; (Development) (Ruiz, G. (168) 251)

Benzodiazepine inverse agonists
Ro 15-4513; Ethanol; Pentobarbital; Motor impairment; Hypnotics (Le, A.D. (159) 25)

Benzodiazepine receptors
Sedation; Seizures; Bicuculline; β-CMC (3-(methoxycarbonyl)-amino-β-carboline (Nutt, D.J. (165) 135)

β-Carboline; Photoaffinity labelling; Diazepam (Dellouve-Courillon, C. (166) 557)

Benzodiazepine receptors (central and peripheral types)
Phenobarbital; [^{3}H]PK 11195; [^{3}H]Flunitrazepam (Weizman, A. (169) 235)

Benzodiazepine receptors (peripheral type)
Prolactin-stimulated mitogenesis; Cell cycle regulation (Laird II, H.E. (171) 25)

Benzodiazepine receptors (type I, type II)
[^{3}H]GABA binding; [^{35}S]TBPS binding; GABA-dependent $^{36}Cl^-$ flux; Zolpidem (Biggio, G. (161) 173)

Benzodiazepine receptor subtypes
Spinal cord; 2-Oxo-quazepam; GABA receptors (Corda, M.G. (169) 205)

Benzodiazepine recognition sites
Ro 15-4513; β-Carbolines; Proconflict effect; Anxiety; Convulsions; [^{3}H]GABA binding (Corda, M.G. (159) 233)

Benzodiazepines
GABA (γ-aminobutyric acid); Diazepam (chronic); Chloride influx; Tolerance (J. Marley, R. (159) 217)

Kindling seizures; FG 7142; GABA (γ-aminobutyric acid); Cl^- channels; [^{35}S]t-Butylbicyclophosphorothionate ([^{35}S]TBPS); (Autoradiography) (Lewin, E. (160) 101)

FG 7142; β-Carbolines; Schedule-controlled behavior; CGS 8216; (Primates) (Wettstein, J.G. (163) 219)

Chlormethiazole; t-Butylbicyclophosphorothionate; Cl^- uptake; Synaptoneurosomes; γ-Aminobutyric acid (GABA) (Moody, E.J. (164) 153)

γ-Aminobutyric acid (GABA); Picrotoxin; Bicuculline; Pentobarbitone; Optic tectum (Sivilotti, L. (164) 205)

Sympathetic neurotransmission; Atrial responses; Norepinephrine; (Peripheral effects) (Elgoyhen, B. (164) 467)

γ-Aminobutyric acid (GABA); Chloride; Flurazepam; Bicuculline; (Tolerance) (Tietz, E.I. (167) 57)

Chloride ionophore; GABA receptors; Steroids; Progesterone metabolites; Clonazepam; (Partial agonists) (Belelli, D. (167) 173)

Muscle relaxants (central); Spinal cord; GABA; Cerebellar Purkinje cells; (Unit activity) (Tarnawa, I. (167) 193)

5-Hydroxytryptamine (5-HT), serotonin; Hippocampus; GABA (Lista, A. (171) 229)

Caffeine; GABA (γ-aminobutyric acid); Cl^- uptake (Lopez, F. (172) 453)

Benzodiazepines (chronic)
GABA; Tolerance; (Agonist efficacy) (Hernandez, T.D. (170) 145)

Benzofuran-baclofen analogues
$GABA_B$ receptor antagonists; Baclofen; Ileum (guinea-pig); Neocortex (rat) (Kerr, D.I.B. (164) 361)

Benzomorphans
Globus pallidus; Opioid receptors; μ-Opioid receptor agonists; κ-Opioid receptor agonists; Dynorphin A-(1-13); (Microiontophoresis) (Huffman, R.D. (170) 179)

Bepridil
Sinoatrial conduction; Sinus automaticity; Verapamil; Diltiazem; Disopyramide (Kirchhof, C.J.H.J. (160) 369)

Bepridil isomers
Smooth muscle (vascular); Ca^{2+} antagonists; Calmodulin antagonists (Winslow, E. (166) 241)

Bestatin
Antidepressants; Thiorphan; Iprindole; Imipramine; Forced swimming test; Motor activity; Opioids (Del Carmen de Felipe, M. (159) 175)

BHT-920
Quinpirole; Dopamine D-1 receptors; Dopamine D-2 receptors; Striatum; (Rat) (Ferré, S. (166) 303)

Yohimbine; Idazoxan; Stereotypy; Dopamine receptor agonists (Meltzer, L.T. (170) 105)

Bicuculline
Pain; Analgesia; (Descending inhibition, Rat) (Sandkühler, J. (160) 163)

γ-Aminobutyric acid (GABA); Picrotoxin; Pentobarbitone; Benzodiazepines; Optic tectum (Sivilotti, L. (164) 205)

Benzodiazepine receptors; Sedation; Seizures; β-CMC (3-(methoxycarbonyl)-amino-β-carboline (Nutt, D.J. (165) 135)

Benzodiazepines; γ-Aminobutyric acid (GABA); Chloride; Flurazepam; (Tolerance) (Tietz, E.I. (167) 57)

Blood flow
Cardiac output; Endothelin; Hemodynamics; Vascular resistance (Ais, G. (170) 113)

Blood flow (gastric, hepatic, intestinal, kidney)
Arterial pressure; Heart rate; Nifedipine (Van Berlo, C.L.H. (160) 17)

Blood flow (regional)
Endothelin; Vasodilation; Vasoconstriction; (Rat) (Minkes, R.K. (165) 161)

Blood platelets
5-HT receptors; Brain; [^{3}H]SCH 23390; Dopamine D-1 receptors; (Human) (De Keyser, J. (162) 437)

Blood pressure
ANF-(99-126) (human); cGMP (plasma); Cardiac accelerator nerve; Cardiac output; Heart rate; (Neurotransmission, Anesthetized dog) (Bergey, J.L. (159) 103)

Leukotriene D_4 (LTD_4); SK&F 104353; ICI 198615; Leukotriene receptors; (Conscious rat) (Smith III, E.F. (159) 297)

Atrial natriuretic factor (ANF); Urine; (Analogs, Receptors) (Song, D.L. (160) 141)

α-Adrenoceptors; Imidazoline receptors; Brainstem; Clonidine; (Binding) (Bricca, G. (162) 1)

Taurine; Heart rate; Ventilation; Pentobarbitone anaesthesia (Petty, M.A. (162) 359)

L-Tyrosine; Heart rate; Tyrosine metabolism (Ekholm, S. (163) 209)

Dopamine receptors; Sympathetic ganglionic transmission; (Presynaptic receptors) (Dlewati, A. (164) 197)

Disulfiram; Diethylthiocarbamic acid methyl ester (Me-DTC); Ethanol; Hypothermia; (Rat, Toxicity) (Petersen, E.N. (166) 419)

L-Tyrosine; Heart rate; Autonomic nervous system; Histamine receptors; Prostaglandin synthesis (Ekholm, S. (168) 145)

Adrenoceptors; 5-HT receptors; Ketanserin; Phentolamine (Dhasmana, K.M. (168) 257)

Blood pressure control
Baroreceptor deafferentation; Cholinergic system (Taira, C.A. (159) 265)

Blood vessels
Endothelin binding sites; Kidney; (Autoradiography) (Jones, C.R. (163) 379)

Endothelin; Heart; Uterus; Trachea; Vas deferens; Platelets; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Blood vessels (isolated)
β_1-Adrenoceptor blockade; Nebivolol; Pindolol; Practolol; Reserpinized animals; Atria (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

BMY 14802
σ Receptors; (+)-3-PPP; Dopamine neurons (Steinfels, G.F. (163) 167)

BN 52021
Platelet activating factor (PAF-acether, PAF); Arrhythmias; Heart functions; Ischemia and reperfusion; (Rat) (Koltai, M. (164) 293)

Body temperature
Acetyl-vasopressin; [Cyt^6]vasopressin-(5-9); Vasopressin; Passive avoidance behavior; Exploratory behavior (Kovács, G.L. (161) 27)

Dopamine D-1 receptors; Dopamine D-2 receptors; Dopamine receptor agonists; Dopamine receptor antagonists; (Mouse) (Sánchez, C. (171) 201)

Bombesin
Cholecystokinin; Pancreatic growth; (Receptor antagonist, Rat, Hamster) (Douglas, B.R. (161) 209)

Cholecystokinin (CCK); CCK-receptor antagonists; Gallbladder; Loxiglumide (Douglas, B.R. (166) 307)

Bordetella pertussis
Cardiovascular system; β-Adrenoceptors; (Pig) (Van Heuven-Nolsen, D. (162) 135)

Botulinum A toxin
α_2-Adrenoceptors (presynaptic); Phorbol ester; Protein kinase C; Noradrenaline release; 5-HT release (Nakov, R. (164) 45)

BP-554
5-HT$_{1A}$ receptor agonists; 5-HT receptors; 8-OH-DPAT (Matsuda, T. (170) 75)

Bradycardiac agents (selective)
KC 8857; Hemodynamics; Myocardial dysfunction (regional); (Exercise) (Grohs, J.G. (161) 53)

Bradykinin
Angiotensin converting enzyme inhibitors; Kinin receptors; Inflammation; Des-Arg^9-bradykinin (Nwator, I.A.A. (160) 125)

Vas deferens; P_2 purinoceptors; ATP receptors; Bradykinin B_2 receptors; Bradykinin antagonists (Donoso, M.V. (160) 263)

Carotid artery; Renal artery; Endothelium; Kinins; Bradykinin B_1 receptors; Bradykinin B_2 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

Airway hyperreactivity; Substance P; Cholinergic system (Omini, C. (163) 195)

Platelet activating factor (PAF-acether, PAF); Colonic epithelium; Cl^- channels; Prostaglandins (Buckley, T.L. (163) 275)

Interleukin-1; Tumour necrosis factor; Synovial cells; Prostaglandin E_2 (O'Neill, L.A.J. (166) 131)

Thrombin; Fibroblast; Diacylglycerol; (Homologous desensitization) (Burch, R.M. (168) 39)

Aortic endothelial cells; Histamine; (Rat) (Cole, O.F. (169) 307)

Inflammation; NPC567; Carrageenan (Costello, A.H. (171) 259)

Bradykinin receptor antagonists
Bradykinin; Vas deferens; P_2 purinoceptors; ATP receptors; Bradykinin B_2 receptors (Donoso, M.V. (160) 263)

Bradykinin B_1 receptors
Carotid artery; Renal artery; Endothelium; Kinins; Bradykinin; Bradykinin B_2 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

Bradykinin B_2 receptors
Bradykinin; Vas deferens; P_2 purinoceptors; ATP receptors; Bradykinin antagonists (Donoso, M.V. (160) 263)

Carotid artery; Renal artery; Endothelium; Kinins; Bradykinin; Bradykinin B_1 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

Bradykinin receptors
Des-Arg^9-bradykinin; Vasorelaxation; Prostaglandins (Nwator, I.A.A. (170) 29)

Brain
α_2-Adrenoceptors; Morphine dependence; Morphine withdrawal; Hippocampal slices; [^{3}H]Clonidine binding; (Field stimulation, Rat) (Smith, C.B. (161) 111)

U-50,488H; Morphine; κ Opioid receptors; Tolerance; Analgesia; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Spinal cord (Bhargava, H.N. (162) 257)

Melatonin binding site (ML-1); Retina; 2-[^{125}I]Iodomelatonin; Luzindole; (Chicken) (Dubocovich, M.L. (162) 289)

Adenylate cyclase; Antidepressants; Electroconvulsive shock; (Rat) (Newman, M.E. (162) 345)

5-HT receptors; Blood platelets; [^{3}H]SCH 23390; Dopamine D-1 receptors; (Human) (De Keyser, J. (162) 437)

Pentazocine; Noradrenaline release; Opioid receptor subtypes; Dynorphin A-(1-13); (Guinea-pig) (Kinouchi, K. (164) 63)

Hoe 065; Acetylcholine metabolism; cGMP content; (Rat) (Wiemer, G. (166) 31)

5-HT$_3$ receptor antagonists; 5-HT$_3$ binding sites; Cortex; (Rat) (Wong, D.T. (166) 107)

S-Adenosyl-L-methionine; Aging; Prolactin receptors (Muccioli, G. (166) 223)

Histamine; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Neurotoxins; (Mouse) (Cumming, P. (166) 299)

Opiate receptors; κ Opioid receptors; (Autoradiography, Guinea-pig) (Lahti, R.A. (166) 563)

Methoctramine; Phosphoinositide hydrolysis; Muscarinic receptors; Muscarinic receptor subtypes; Antimuscarinic agents (Lee, N.H. (167) 295)

α_2-Adrenoceptors; Hypoactivity; Sedation; Mydriasis; MHPG (3-methoxy-4-hydroxyphenylglycol); Clonidine; Behaviour; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

Brain areas
S-Adenosyl-L-methionine; Catecholamines (Otero Losada, M.E. (163) 353)

Brain CCK-B ligand
Gastrin antagonists; Gastric acid secretion; CCK-A receptors; (Radioligand binding, Non-peptide) (Lotti, V.J. (162) 273)

Brain (human)
5-HT$_3$ receptors; [^{3}H]GR65630; Area postrema; Vagus nerve; (Binding) (Kilpatrick, G.J. (159) 157)

Norepinephrine; Carbachol; Quisqualate; Inositol phospholipids (Nicoletti, F. (160) 299)

[^{3}H]Clonidine; Rilmenidine; Imidazoline preferring receptors (Bricca, G. (163) 373)

α-Adrenoceptors; α_1-Adrenoceptor subtypes; [^{3}H]Prazosin binding; Cerebral cortex (Gross, G. (169) 325)

Brain metabolism
2-[^{14}C]Deoxyglucose; Caffeine; Doxapram; (Rat) (Schroeder, H. (167) 245)

Brain mRNA
Imipramine; Antidepressants; 5-Hydroxytryptamine (5-HT, serotonin); (*Xenopus* oocytes, Current) (Tohda, M. (166) 57)

Brain natriuretic peptide (BNP)
Atrial natriuretic peptide (ANP); cGMP; Kidney epithelial cell line (LLC-PK$_1$) (Iwata, T. (159) 321)

Atrial natriuretic peptide (ANP); Kidney; Heart; Endothelium; (Receptor) (Oehlenschlager, W.F. (161) 159)

Brain (rat)
Vasopressin V$_1$ receptor antagonists (radioiodinated); [^{3}H]Vasopressin; Kidney (rat); (Receptor autoradiography) (Gerstberger, R. (167) 105)

α_2-Adrenoceptors; Muscarinic receptor agonists; Muscarinic receptor antagonists; [^{3}H]Clonidine binding (Hollingsworth, P.J. (168) 159)

Brain regions
Delta sleep-inducing peptide; Antidepressants; Pentobarbital; Adrenalectomy; (Rat) (Wahlestedt, C. (159) 285)

μ, δ, κ Opioid binding sites; (Binding capacities, Binding affinities, Rabbit) (Petrillo, P. (166) 213)

Antipsychotic substances; Dopamine; Haloperidol; Sulpiride; Desenkephalin-γ-endorphin (DEγE) (Van Ree, J.M. (166) 441)

Morphine; Tolerance-dependence; Abstinence; 5-HT$_2$ receptors; Spinal cord (Gulati, A. (167) 185)

Brain slices
Galanin; Locus coeruleus; (Electrophysiology, Extracellular recording) (Seutin, V. (164) 373)

δ Opioid receptors; Enkephalin analogues; Neurotransmitter release; Adenylate cyclase; (Rat) (De Vries, T.J. (170) 137)

Brainstem
α-Adrenoceptors; Imidazoline receptors; Blood pressure; Clonidine; (Binding) (Bricca, G. (162) 1)

Brain stimulation reward
Reward threshold; Tripelennamine; Pentazocine; Nalbuphine; Physical dependence (Huston-Lyons, D. (169) 153)

Brattleboro rats
[Arg^8]vasopressin; Atrial natriuretic factor; Diuresis; Lithium clearance; Natriuresis (Palluk, R. (162) 245)

Bremazocine
Naloxone; Opiates; Oxytocin; (In vitro, In vivo) (Grell, S. (166) 41)

[^{3}H]Bremazocine
5-HT_3 receptors; Opiate receptors; [^{3}H]Zacopride; [^{3}H]Naloxone; Spinal cord; Capsaicin; (Rat) (Hamon, M. (164) 315)

Bretylium tosylate
Heart; Cerebral cortex (rat); Muscarinic receptors (Gillard, M. (160) 117)

BRL 43694 (endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride)
5-Hydroxytryptamine (5-HT, serotonin); 5-HT_3 receptors (Sanger, G.J. (159) 113)

Brofaromine
5-HT uptake; [^{3}H]Cyanoimipramine binding; Moclobemide; Ifoxetine; 5-HT uptake inhibitors (Waldmeier, P.C. (169) 197)

Bromocriptine
Morphine; (Mouse) (Gomaa, A.A. (170) 129)

Bromomercurihydroxypropane
Myocardium (isolated); Contractility; Transmembrane potential; Ca^{2+} action potential; Na^+,K^+-ATPase; Methylmercury; Chlormerodrin; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Bronchi
Neuropeptide Y; UK 14,304; α-Adrenoceptors; Cholinergic contraction; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Noradrenaline; Morphine; (Guinea-pig) (Matran, R. (163) 15)

Capsaicin; Sensory nerves ('efferent' function of); Galanin; Atrium; (Guinea-pig) (Giuliani, S. (163) 91)

Histamine H_3-receptor agonists; (R)-α-Methylhistamine; Electrical field stimulation; (Human) (Ichinose, M. (163) 383)

L-Glutamate; L-Aspartate; Acetylcholine; Chinese restaurant syndrome; (Modulation) (Aas, P. (164) 93)

Capsaicin sensitive sensory nerves ('efferent' function of); Ruthenium Red; Atrium; (Guinea-pig) (Maggi, C.A. (170) 167)

Bronchial tissue
Acetylcholine release; Atropine; Indomethacin; Prostaglandin E_2; Prostaglandin D_2 (Deckers, I.A. (167) 415)

Bronchi (main)
Endothelin; Trachea; Airway epithelium; (Guinea-pig) (Maggi, C.A. (160) 179)

Bronchoconstriction
Doxofylline; Platelet-activating factor (PAF-acether, PAF) (Franzone, J.S. (165) 269)

Bronchomotor tone
Electromechanical activity; Membrane potentials; Catecholamines; (Action potentials, Cellular electrophysiology) (Richards, I.S. (167) 155)

Bronchus (in vitro, human)
Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2 receptors; Thromboxane A_2 antagonists (Armour, C.L. (165) 215)

BTM-1041
BTM-1086; Muscarinic receptor subtypes; Histamine H_1 receptors; α_1-Adrenoceptors; (Stereoselectivity) (Eltze, M. (170) 225)

BTM-1086
BTM-1041; Muscarinic receptor subtypes; Histamine H_1 receptors; α_1-Adrenoceptors; (Stereoselectivity) (Eltze, M. (170) 225)

Bunazosin
Mesenteric vessels; Noradrenaline; Excitatory junction potential; α-Adrenoceptors (Komori, K. (164) 111)

Buspirone
Hippocampus; 5-Hydroxytryptamine (5-HT, serotonin); Excitatory synaptic transmission (O'Connor, J.J. (167) 21)

Hippocampus; Elevated plus maze; Open field; (Microinjections) (Kostowski, W. (168) 393)

Butorphanol
Withdrawal; Naloxone; Morphine dependence (Horan, P. (170) 265)

BW 137C
Platelet activating factor (PAF-acether, PAF); Alveolar macrophages; Leukotriene B_4 (LTB_4); Thromboxane B_2; BW 755C; 5-Lipoxygenase inhibitors; Indomethacin (Fitzgerald, M.F. (164) 539)

BW 755C
Platelet activating factor (PAF-acether, PAF); Alveolar macrophages; Leukotriene B_4 (LTB_4); Thromboxane B_2; BW 137C; 5-Lipoxygenase inhibitors; Indomethacin (Fitzgerald, M.F. (164) 539)

Hypoxia; Cerebral artery (middle); Endothelium; Haemolysate; 5-Hydroxytryptamine (5-HT, serotonin); (Sheep) (Klaas, M. (168) 187)

Ca^{2+}
Adenosine receptors; Coronary circulation; Smooth muscle (vascular); Prostaglandin $F_{2\alpha}$ (Ramagopal, M.V. (159) 33)

Halothane; K^+ channels; Hyperpolarization (Scharff, O. (159) 165)

Histamine release; Retinoic acid; Retinal; Phorbol esters; Mast cells (Cantwell, M.E. (160) 43)

Trachea; Cigarette smoke; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2; Cortisol; Muscarinic stimulation (Jeremy, J.Y. (160) 107)

Theophylline; Positive staircase; Positive inotropism; (Post-rest potentiation) (Zavecz, J.H. (160) 187)

Endothelin; Cerebral artery; Vasoconstriction; (Cat) (Saito, A. (162) 353)

Vincamine; Vinpocetine; Trachealis; Indomethacin; (Guinea pig) (Machová, J. (162) 387)

Calcitonin; Morphine; Analgesia; Withdrawal syndrome (Clementi, G. (163) 175)

Quin-2; Prostacyclin; Endothelium; P_2 purinoceptors (Raspe, E. (163) 345)

Ethanol; Hippocampus; cAMP; After-hyperpolarization; (Neuronal firing) (Benson, D.M. (164) 591)

Corticotropin-releasing factor; Dopamine synthesis; Synaptosomes; Protein kinase C; Striatum; (Rat) (Olianas, M.C. (166) 165)

Adenosine receptors; Endothelium; Coronary artery (Sabouni, M.H. (166) 311)

Adenylate cyclase; Hippocampus; Striatum; Lithium (Mørk, A. (168) 347)

Endothelium-derived relaxing factor (EDRF); cGMP; Endothelial cell (Schmidt, K. (170) 157)

Smooth muscle; UV light; Lipid peroxidation; Nitrite; cGMP (Nelemans, A. (172) 283)

Ca^{2+} action potential
Myocardium (isolated); Contractility; Transmembrane potential; Na^+,K^+-ATPase; Methylmercury; Chlormerodrin; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Ca^{2+}-activated K^+ channels
Aorta; Planar lipid bilayer; $[Ca^{2+}]_i$ sensitivity; Cromakalim; (Rabbit) (Gelband, C.H. (167) 201)

Ca^{2+} antagonists
Diltiazem; KCl contracture; Caffeine contracture; Diaphragm (rat); (Use-dependent inhibition) (Røed, A. (159) 61)

Myocardial ischaemia; Coronary occlusion; K^+ loss; Haemodynamics; Gallopamil; Diltiazem; Nifedipine (Kirchengast, M. (160) 349)

ATP; P_2 purinoceptors; Vas deferens; (Guinea-pig) (Morishita, H. (164) 507)

Bepridil isomers; Smooth muscle (vascular); Calmodulin antagonists (Winslow, E. (166) 241)

Endothelin; Sarafotoxin S6b; BAY k 8644; ω-Conotoxin; Na^+/H^+ exchanger (Gu, X.-H. (167) 281)

Hemolysate; Myogenic tone; Cerebral artery; Vasospasm; Endothelium (Nakayama, K. (169) 33)

Ca^{2+} channel antagonists
Mast cell degranulating peptide; Dendrotoxin; K^+ channel blockers; Seizures; NMDA antagonists (Gandolfo, G. (160) 173)

Nimodipine; Flunarizine; Diltiazem; Seizures; Dihydropyridines (Morón, M.A. (163) 299)

Ca^{2+} channel blockers
Stress ulcer; Gastric secretion; Verapamil; Nitrendipine; Diltiazem; Ethanol ulcer; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Acetylcholine receptors; Acetylcholine release; Tubocurarine; Verapamil (Hong, S.J. (162) 11)

Heart cells; Isoproterenol (Briand, V. (166) 339)

Electrical spike activity; Intestinal motility; Migrating myoelectric complex; (Computer analysis) (De Ponti, F. (168) 133)

Oxytocin; Testicular capsule; Calmodulin antagonists; (Intracellular calcium antagonists) (Sánchez, M. (168) 169)

Propiophenones; Ion channels; (Neurons, Snail) (Novales-Li, P. (168) 299)

Ca^{2+} channel inhibitors
Penile erection; Yawning; Apomorphine; Oxytocin; (Rat) (Argiolas, A. (166) 515)

Ca^{2+} channels
Sympathetic-parasympathetic interaction; Sinus node pacemaker activity; Atrial contractility; cAMP; Atrium (isolated, canine) (Furukawa, Y. (161) 1)

Calcitonin gene-related peptide (CGRP); Prostaglandins; Stomach; (Rat, Guinea pig) (Katsoulis, S. (161) 129)

Phorbol esters; Dihydropyridines; ω-Conotoxin (Adamson, P. (162) 59)

Diabetic rats; α_1-Adrenoceptors; Phosphatidylinositol turnover; (Hyper-reactivity) (Sakai, Y. (162) 475)

Stannous chloride; Ca^{2+} entry; Motor nerve terminal; Transmitter release; (Frog) (Hattori, T. (166) 527)

Phenylalkylamine; Smooth muscle (vascular); Portal vein; (Binding study, Patch-clamp) (Loirand, G. (167) 265)

Ca^{2+} channels (L-type and T-type)
Ca^{2+} (extra-and intra-cellular); Noradrenaline; Phorbol ester; K^+; Protein kinase C; Uterine vasoconstriction (Fallgren, B. (170) 61)

Ca^{2+} currents
Vas deferens (guinea-pig); Noradrenaline; K^+ currents; Action potential (Mimata, T. (163) 181)

Ca^{2+}-dependent dopamine release
Dopamine uptake carrier; Amphetamine; Microdialysis (in vivo); Dopamine metabolism (Hurd, Y.L. (166) 261)

Ca^{2+}-dependent K^+ currents
Amiloride; Voltage clamp; Skeletal muscle; (Frog) (Nasri-Sebdani, M. (171) 97)

Ca^{2+} entry
Stannous chloride; Ca^{2+} channel; Motor nerve terminal; Transmitter release; (Frog) (Hattori, T. (166) 527)

Ca^{2+} entry blockers
Myosin light-chain kinase; Protein kinase C; Smooth muscle contraction (vascular) (Schächtele, C. (163) 151)

Ca^{2+} entry blocking drugs
Aging; Aorta (rat); Felodipine; Diltiazem (Wanstall, J.C. (159) 241)

Caerulein
L-364,718; Cholecystokinin antagonists; Anorexia (Leighton, G.E. (161) 255)

Ca^{2+}-evoked contraction
Monensin; Ouabain; K^+-free medium; Noradrenaline release; Na^+/Ca^{2+} exchange transport; Vas deferens; (Guinea pig) (Katsuragi, T. (167) 147)

Ca^{2+} (extra- and intra-cellular)
Ca^{2+} channels (L-type and T-type); Noradrenaline; Phorbol ester; K^+; Protein kinase C; Uterine vasoconstriction (Fallgren, B. (170) 61)

Ca^{2+} (extracellular)
Cardiac glycosides; Norepinephrine; BAY k 8644; Mg^{2+} (extracellular); Cardiac muscle; (Guinea-pig) (Kafiluddi, R. (165) 181)

Caffeine
Yohimbine; Anxiety; (Rat) (Baldwin, H.A. (159) 211)

2-[^{14}C]Deoxyglucose; Brain metabolism; Doxapram; (Rat) (Schroeder, H. (167) 245)

IBMX (3-Isobutyl-1-methylxanthine); 7-CET (7-(2-Chloroethyl)-theophylline); Behavioural effects; Fixed-interval schedules; (Squirrel monkey) (Coffin, V.L. (170) 35)

Benzodiazepine; GABA (γ-aminobutyric acid); Cl^- uptake (Lopez, F. (172) 453)

Caffeine contracture
Diltiazem; Ca^{2+} antagonists; KCl contracture; Diaphragm (rat); (Use-dependent inhibition) (Røed, A. (159) 61)

Ca^{2+} flux
Erythrocytes; K^+ flux; Atrial natriuretic peptide (rat) (Esparza, N. (166) 349)

Ca^{2+} influx
Mast cells; Benzodiazepine binding sites; 5-HT release; Calmodulin; BAY k 8644 (Suzuki-Nishimura, T. (167) 75)

α-Adrenoceptor subtypes (postsynaptic); Reserpine; Tail artery (rat) (Abe, K. (171) 59)

Ca^{2+} (intracellular)
Na^+/Ca^{2+} exchange; Na^+ channels (Briggs, G.M. (170) 281)

NMDA receptors; MK801; HA-966; Kynurenic acid; GABA release (Reynolds, I.J. (172) 9)

Ca^{2+} ion
Dithiothreitol; Sulfhydryl compounds; Coronary artery; Smooth muscle (vascular); (Dog) (Fujioka, H. (166) 13)

Calcitonin
Morphine; Analgesia; Withdrawal syndrome; Ca^{2+} (Clementi, G. (163) 175)

Calcitonin gene-related peptide (CGRP)
Ca^{2+} channels; Prostaglandins; Stomach; (Rat, Guinea pig) (Katsoulis, S. (161) 129)

Stomach; Smooth muscle; Capsaicin (8-methyl-N-vanillyl-6-nonenamide); Tachykinins (Holzer-Petsche, U. (162) 29)

Gastric acid secretion; Neuropeptides; Indomethacin; Dermorphin; Corticotropin-releasing factor (CRF) (Guglietta, A. (170) 87)

Calcitonin gene-related peptide-like immunoreactivity (CGRP-li)
Duodenal ulcers; Dulcerozine; Cysteamine; Mepirizole (Evangelista, S. (164) 389)

Calcitonin (porcine)
[Met^5]enkephalin-like material; Spinal cord; (Intrathecal perfusion, In vivo release) (Collin, E. (168) 201)

Ca^{2+} level (cytosolic)
Li^+; Ileum (guinea-pig); Fura-2; (Skinned fiber, Relaxation) (Hori, M. (165) 63)

Calmodulin
Mast cells; Benzodiazepine binding sites; 5-HT release; Ca^{2+} influx; BAY k 8644 (Suzuki-Nishimura, T. (167) 75)

Calmodulin antagonists
Bepridil isomers; Smooth muscle (vascular); Ca^{2+} antagonists (Winslow, E. (166) 241)

Oxytocin; Testicular capsule; Ca^{2+} channel blockers; (Intracellular calcium antagonists) (Sánchez, M. (168) 169)

Calmodulin translocation
Amphetamine; Haloperidol; Dopamine; Striatum; Hippocampus (Popov, N. (172) 205)

Ca^{2+} mobilization
Neurotensin; Fura 2; Inositol trisphosphate; Heterologous desensitization; NG108-15 cells (Imaizumi, T. (161) 203)

Noradrenaline contractions; Ryanodine; Nifedipine; Vas deferens; Methoxyverapamil; (Rat) (Vesperinas, G. (165) 309)

Pituitary; Diacylglycerol; Thyrotropin releasing hormone (TRH); 1-Oleyl-2-acetyl glycerol (OAG); R59022 (Mollard, P. (172) 71)

Canine urethra
SGB-1534; α_1-Adrenoceptor antagonists; Hypogastric nerve stimulation (Imagawa, J.-i. (167) 167)

Cannabinoid
Cisplatin; Emesis; Δ^1-Tetrahydrocannabinol; 7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl; Cupric chloride; HU-211; (Pigeon) (Feigenbaum, J.J. (169) 159)

Capillary pressure
5-HT receptor subtypes; Pulmonary edema; Filtration coefficient; Ketanserin; Methysergide (Sumita, T. (164) 69)

Capsaicin (8-methyl-N-vanillyl-6-nonenamide)
Stomach; Smooth muscle; Tachykinins; Calcitonin gene-related peptide (CGRP) (Holzer-Petsche, U. (162) 29)

Sensory nerves ('efferent' function of); Galanin; Bronchi; Atrium; (Guinea-pig) (Giuliani, S. (163) 91)

5-HT_3 receptors; Opiate receptors; [^{3}H]Zacopride; [^{3}H]-Bremazocine; [^{3}H]Naloxone; Spinal cord; (Rat) (Hamon, M. (164) 315)

Gallbladder; Tachykinins; Substance P; Neurokinin A; Tachykinin receptors; Thiorphan; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Gastric distension; Gastric acid secretion; Vagus nerve; Histamine; Pentagastrin; (Cholinergic stimulation) (Raybould, H.E. (167) 237)

Substance P binding sites; Vas deferens (guinea-pig) (Mussap, C.J. (168) 337)

Ruthenium red; Primary afferent neurones; Substance P; Ileum (guinea-pig) (Chahl, L.A. (169) 241)

Heart; Sensory nerves; [D-Ala^2,D-Leu^5]enkephalin (DADLE); [D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin (DAGO) (Mantelli, L. (170) 217)

Capsaicin sensitive sensory nerves ('efferent' function of)
Ruthenium Red; Bronchi; Atrium; (Guinea-pig) (Maggi, C.A. (170) 167)

Captopril
Gallbladder; Tachykinins; Capsaicin; Substance P; Neurokinin A; Tachykinin receptors; Thiorphan; (Guinea-pig) (Maggi, C.A. (165) 51)

Endothelin; Trachea (guinea-pig); Airway epithelium; Peptidase inhibitors; Indomethacin (Hay, D.W.P. (171) 241)

Carbachol
Norepinephrine; Quisqualate; Inositol phospholipids; Brain (human) (Nicoletti, F. (160) 299)

Cromakalim; Glibenclamide; Vas deferens; (Rabbit) (Eltze, M. (161) 103)

Carbamazepine
Lithium; [^{3}H]Muscimol; [^{3}H](−)-Baclofen; $GABA_B$ receptors; Hippocampus (Motohashi, N. (166) 95)

Lidocaine; Phenytoin; Seizures (lidocaine-kindled); [^{3}H]Batrachotoxin binding; Hippocampus (Zimányi, I. (167) 419)

β-Carbolines
Ro 15-4513; Benzodiazepine recognition sites; Proconflict effect; Anxiety; Convulsions; [^{3}H]GABA binding (Corda, M.G. (159) 233)

FG 7142; Benzodiazepines; Schedule-controlled behavior; CGS 8216; (Primates) (Wettstein, J.G. (163) 219)

Benzodiazepine receptors; Photoaffinity labelling; Diazepam (Dellouve-Courillon, C. (166) 557)

Cardiac accelerator nerve
ANF-(99-126) (human); cGMP (plasma); Blood pressure; Cardiac output; Heart rate; (Neurotransmission, Anesthetized dog) (Bergey, J.L. (159) 103)

Cardiac action potential
α_1-Adrenoceptors; Epinephrine; Prazosin; β-Adrenoceptor blockade; Myocytes (ventricular); (Adult rat) (Vogel, S.M. (164) 231)

Cardiac arrhythmia models
Dantrolene sodium; Antiarrhythmia agents; Coronary artery ligation; Ventricular fibrillation threshold; Aconitine; Ouabain (Brooks, R.R. (164) 521)

Cardiac arrhythmias
Histamine; Hypertension; Myocardial hypertrophy; Spontaneously hypertensive rat (SHR) (Cameron, J.S. (169) 23)

Cardiac cells
β-Adrenoceptor-mediated cAMP accumulation; Nebivolol; β-Adrenoceptor antagonist; (Rat) (Pauwels, P.J. (172) 471)

Cardiac contractility
Cardiac nerves (intrinsic); Cardiac muscle (isolated); Acetylcholine; Nicotine; (Denervation, Supersensitivity) (Smith, D.C. (161) 249)

Cardiac electrophysiology
Cardiac muscle; Action potentials (slow); Azelastine (Molyvdas, P.-A. (164) 547)

Cardiac glycosides
Norepinephrine; BAY k 8644; Ca^{2+} (extracellular); Mg^{2+} (extracellular); Cardiac muscle; (Guinea-pig) (Kafiluddi, R. (165) 181)

Cardiac M_2 receptors
Muscarinic acetylcholine receptor subtypes; Phosphoinositide hydrolysis (Mizushima, A. (168) 375)

Cardiac muscarinic receptors
DPI 201-106; Anticholinergic action; (Mode of interaction) (Groschner, K. (159) 125)

Cardiac muscle
β-Adrenoceptor subtypes; Mononuclear leukocytes (Tenner, Jr., T.E. (160) 291)

Action potentials (slow); Azelastine; Cardiac electrophysiology (Molyvdas, P.-A. (164) 547)

Cardiac glycosides; Norepinephrine; BAY k 8644; Ca^{2+} (extracellular); Mg^{2+} (extracellular); (Guinea-pig) (Kafiluddi, R. (165) 181)

Cardiac muscle (isolated)
Cardiac nerves (intrinsic); Cardiac contractility; Acetylcholine; Nicotine; (Denervation, Supersensitivity) (Smith, D.C. (161) 249)

Cardiac Na^+ channels (non-inactivating)
Na^+ channel modifiers; (±)-DPI 201-106 (Kohlhardt, M. (168) 115)

Cardiac nerves (intrinsic)
Cardiac muscle (isolated); Cardiac contractility; Acetylcholine; Nicotine; (Denervation, Supersensitivity) (Smith, D.C. (161) 249)

Cardiac output
ANF-(99-126) (human); cGMP (plasma); Cardiac accelerator nerve; Blood pressure; Heart rate; (Neurotransmission, Anesthetized dog) (Bergey, J.L. (159) 103)

Blood flow; Endothelin; Hemodynamics; Vascular resistance (Ais, G. (170) 113)

Cardiac tissue
Muscarinic acetylcholine receptors; G-proteins; Mg^{2+}; Na^+ (Hilf, G. (172) 155)

Cardiomegaly (compensated)
Hemodynamics; Myocardially infarcted rat; Milrinone; Enalapril (DeFelice, A. (167) 211)

Cardioprotection
β-Adrenoreceptor antagonists; Anoxia; Heart (isolated, working); (Guinea-pig) (Marie, P.-Y. (163) 337)

Cardiotoxin
Hind-paw edema (rat); Mast cells; PMN (polymorphonuclear) leukocytes; Kinin formation (Wang, J.-P. (161) 9)

Cardiovascular system
Bordetella pertussis; β-Adrenoceptors; (Pig) (Van Heuven-Nolsen, D. (162) 135)

Ca^{2+} release
Diaphragm; Selenite-induced contracture (Lin-Shiau, S.-Y. (167) 137)

[^{3}H]Carfentanil
μ Opioid receptors; PET (positron emission tomography) scanning (Titeler, M. (167) 221)

Carotid artery
Renal artery; Endothelium; Kinins; Bradykinin; Bradykinin B_1 receptors; Bradykinin B_2 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

Carotid blood flow
Arteriovenous anastomoses; 5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptors; 5-HT_1-like receptors; Migraine; RU 24969 (Bom, A.H. (171) 87)

Carrageenan
Inflammation; Bradykinin; NPC567 (Costello, A.H. (171) 259)

Carrageenin
Aspirin; Salicylic acid; Anti-inflammatory drugs (non-steroidal); Prostaglandins; Inflammation (Chiabrando, C. (159) 257)

$[Ca^{2+}]_i$ sensitivity
Aorta; Planar lipid bilayer; Ca^{2+}-activated K^+ channels; Cromakalim; (Rabbit) (Gelband, C.H. (167) 201)

β-Casomorphins
Opioid receptors; Hemorphin-4; Cytochrophin-4; κ Sites (Liebmann, C. (166) 523)

Catalepsy
Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; DOPA accumulation; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Catalytic subunit
cAMP-dependent protein kinase; Regulatory subunit; Recombinant DNA; Expression vector; (*E. coli*) (Kuno, T. (172) 263)

Catecholamine overflow (endogenous and methylated)
Microdialysis (in vivo); Hypotension; MethylDOPA (Kapoor, V. (164) 531)

Catecholaminergic system
RU 24722; Eburnamine derivatives; 2-Deoxy-D-[^{14}C]-glucose; Limbic system; (Rat) (Broussolle, E. (159) 225)

Catecholamines
S-Adenosyl-L-methionine; Brain areas (Otero Losada, M.E. (163) 353)

Electromechanical activity; Membrane potentials; Bronchomotor tone; (Action potentials, Cellular electrophysiology) (Richards, I.S. (167) 155)

Corpus striatum; Glycoconjugates; Lectins; Tetrabenazine; (Chromatography, Affinity) (Vincent, M.S. (172) 317)

Catecholamines (potentiation of)
Coronary regulation; Coronary vasoconstriction; Coronary arteries (isolated); Neuropeptide Y (NPY) (Macho, P. (167) 67)

Catecholamine synthesis
Nicotine; 5-HT synthesis; Nucleus accumbens; Hypothalamus; Hippocampus (Mitchell, S.N. (167) 311)

Catecholamine uptake
MPP^+ (1-methyl-4-phenylpyridinium ion); Dopamine; Diethyldithiocarbamate; Disulfiram (Di Monte, D. (166) 23)

Catecholestrogens
Estrogens; Antiestrogens; Tamoxifen; Dopamine receptor supersensitivity; Striatum (Ferretti, C. (166) 149)

Cathepsin D
Peptidoleukotriene; Splanchnic artery occlusion; SK&F 104353; Myocardial depressant factor; Hematocrit (Lento, P.H. (165) 241)

Cation effects
Cholecystokinin$_B$ (CCK_B) receptor solubilization; Guanine nucleotide effect; (Pig) (Gut, S.H. (172) 339)

Caudate nucleus
Dopamine; Dopamine metabolism; Nicotine (acute, repeated); Nucleus accumbens; Olfactory tubercle (Lapin, E.P. (160) 53)

Quinine; K^+ channels; Dopamine D-2 receptors; Neuroleptics; (Patch-clamp) (Freedman, J.E. (164) 341)

Neurotensin; Haloperidol; Atropine; Scopolamine; Nucleus accumbens (Levant, B. (165) 327)

Caudate-putamen
Amphetamine; Neurokinin A; Tachykinin; Nucleus accumbens; Microdialysis (Lindefors, N. (160) 417)

^{45}Ca uptake
ATP; Verapamil; Diltiazem; Tyrode solution (Ca^{2+}-free) (Bhat, M.B. (164) 163)

β-CCE (3-carboethoxy-β-carboline hydrochloride)
Midazolam; Flumazenil; Tolerance; (Sensitization, Baboon) (Sannerud, C.A. (167) 333)

CCK8
Nucleus accumbens; Locomotion; Exploration; (Rat) (Daugé, V. (163) 25)

CCK-A receptors
Gastrin antagonists; Brain CCK-B ligand; Gastric acid secretion; (Radioligand binding, Non-peptide) (Lotti, V.J. (162) 273)

CCK_B receptor solubilization
Cation effects; Guanine nucleotide effect; (Pig) (Gut, S.H. (172) 339)

CCK receptor antagonists
L-364,718; Caerulein; Anorexia (Leighton, G.E. (161) 255)

Cholecystokinin (CCK); Bombesin; Gallbladder; Loxiglumide (Douglas, B.R. (166) 307)

CCK receptors
Hypothalamus; (Species differences) (Miceli, M.O. (169) 215)

β-CCM (methyl-β-carboline-3-carboxylate)
NMDA receptor antagonists; Nucleus accumbens; Dopamine metabolism; Immobilization stress; (In vivo voltammetry) (Serrano, A. (162) 157)

Cell cycle regulation
Benzodiazepine receptors (peripheral type); Prolactin-stimulated mitogenesis (Laird II, H.E. (171) 25)

Cell membrane permeability
α-Adrenoceptor antagonists; Creatine kinase; High-energy phosphates; Hypoxia; Reoxygenation; YM-12617 (Tanonaka, K. (165) 97)

Cell proliferation
MSH receptors; Phorbol ester; Adenylate cyclase; Melanoma (Gerst, J.E. (172) 29)

Central ear artery
Endothelium-derived relaxing factor (EDRF); Atrial natriuretic peptide (ANP); Aorta; (Rabbit) (Hogan, J.C. (165) 129)

Central nervous system (CNS)
5-HT receptors; Dopamine receptors; Na^+,K^+-ATPase; Hippocampus; Striatum; Spaceflight (Miller, J.D. (161) 165)

Neurotensin; Neuroleptics; Operant responding; 'Anhedonia'; (Dose-response curve) (Rossitch, Jr., E. (163) 119)

Parathyroid hormone (PTH); Gastric acid secretion; Gastric ulcers (Clementi, G. (166) 549)

α-Adrenoceptors; Mydriasis; Clonidine; (Functional model, Mouse) (Heal, D.J. (170) 11)

Central nervous system (CNS) proteins
Estrogen-inducible proteins; (Hormone action); (Two-dimensional gel electrophoresis) (Maggi, A. (172) 357)

Cerebellar Purkinje cells
Benzodiazepine; Muscle relaxants (central); Spinal cord; GABA; (Unit activity) (Tarnawa, I. (167) 193)

Cerebellum
Phenytoin; $GABA_A$ binding sites; Benzodiazepine binding sites; β-Adrenoceptors; (Development) (Ruiz, G. (168) 251)

Ro 15-4513 binding; Granule cells; GABA (γ-aminobutyric acid); Diazepam; Ethanol (Malminiemi, O. (169) 53)

Cerebral artery
Endothelin; Vasoconstriction; Ca^{2+}; (Cat) (Saito, A. (162) 353)

Hemolysate; Myogenic tone; Vasospasm; Ca^{2+} antagonists; Endothelium (Nakayama, K. (169) 33)

Cerebral artery (middle)
Hypoxia; Endothelium; BW755C; Haemolysate; 5-Hydroxytryptamine (5-HT, serotonin); (Sheep) (Klaas, M. (168) 187)

Cerebral cortex
Methylphenidate; [^{3}H]Prazosin; [^{3}H]Idazoxan; [^{3}H]Dihydroalprenolol; (Down-regulation) (Mathieu, J.-F. (162) 173)

α-Adrenoceptors; α_1-Adrenoceptor subtypes; [^{3}H]Prazosin binding; Brain (human) (Gross, G. (169) 325)

β-Adrenoceptors; Down-regulation; Phenelzine; Internalization; (Rat) (Koshikawa, N. (170) 101)

Cerebral cortex membranes (human)
[^{3}H]Rauwolscine; α_2-Adrenoceptors; 5-HT_{1A} receptors (Convents, A. (159) 307)

Cerebral cortex (rat)
Heart; Muscarinic receptors; Bretylium tosylate (Gillard, M. (160) 117)

Skin (*Pseudophryne coriacea*); Acetylcholine release; 5-HT release; (Superfused synaptosomes) (Raiteri, M. (172) 223)

Radiation inactivation; 5-HT_3 receptors; Molecular weight; [^{3}H]Zacopride (Gozlan, H. (172) 497)

Cerebral ischemia
Baroreflex; Flunarizine; Papaverine; (Cerebral protection) (Kurihara, J. (165) 147)

S-Adenosyl-L-methionine; Scopolamine; Runway task (3-panel); Memory (working); Amnesia (Yatsugi, S.-i. (166) 231)

Thromboxane synthetase inhibitor; Cerebral metabolism; Spontaneously hypertensive rat (SHR) (Sadoshima, S. (169) 75)

Cerebral metabolism
Thromboxane synthetase inhibitor; Cerebral ischemia; Spontaneously hypertensive rat (SHR) (Sadoshima, S. (169) 75)

Cerebral vasospasm
Thromboxane A_2/prostaglandin endoperoxide receptor; Thromboxane A_2/prostaglandin endoperoxide receptor antagonists (Kondo, K. (168) 193)

7-CET (7-(2-chloroethyl)-theophylline)
IBMX (3-Isobutyl-1-methylxanthine); Caffeine; Behavioural effects; Fixed-interval schedules; (Squirrel monkey) (Coffin, V.L. (170) 35)

Cetiedil
Acetylcholine release; Acetylcholine vesicular uptake; Choline uptake; Electric organ of *Torpedo marmorata* (Gaudry-Talarmain, Y.M. (166) 427)

[^{3}H]CGP 12177
β-Adrenoceptor binding sites; β_1-Adrenoceptors; β_2-Adrenoceptors; [^{3}H]Dihydroalprenolol; CGP 20712A; ICI 118,551; (Post-mortem human brain) (De Paermentier, F. (167) 397)

CGP 20712A
β-Adrenoceptor binding sites; β_1-Adrenoceptors; β_2-Adrenoceptors; [^{3}H]Dihydroalprenolol; [^{3}H]CGP 12177; ICI 118,551; (Post-mortem human brain) (De Paermentier, F. (167) 397)

CGS 8216
FG 7142; β-Carbolines; Benzodiazepines; Schedule-controlled behavior; (Primates) (Wettstein, J.G. (163) 219)

CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-1-phosphonic acid)
NMDA (N-methyl-D-aspartate); MK-801; Schedule-controlled responding; Drug discrimination; (Rhesus monkey) (France, C.P. (159) 133)

Cheek pouch (hamster)
Endothelin; Arteriolar vasoconstrictors (Brain, S.D. (160) 401)

Chewing behaviour
5-HT agonists; 5-HT antagonists; Acetylcholine-5-HT interaction (Stewart, B.R. (162) 101)

Chinese restaurant syndrome
L-Glutamate; L-Aspartate; Acetylcholine; Bronchi; (Modulation) (Aas, P. (164) 93)

Chlormerodrin
Myocardium (isolated); Contractility; Transmembrane potential; Ca^{2+} action potential; Na^+,K^+-ATPase; Methylmercury; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Chlormethiazole
t-Butylbicyclophosphorothionate; Cl^- uptake; Synaptoneurosomes; Benzodiazepines; γ-Aminobutyric acid (GABA) (Moody, E.J. (164) 153)

d,l-p-Chloroamphetamine
Dopamine; 5-Hydroxytryptamine (5-HT, serotonin); Voltammetry (in vivo); Amphetamine; (±)-3,4-Methylenedioxymethamphetamine (MDMA) (Gazzara, R.A. (168) 209)

p-Chloroamphetamine
d-Fenfluramine; d-Norfenfluramine; L-Cysteine; Serotonin; Neurotoxicity (Invernizzi, R. (163) 77)

7-Chlorokynurenic acid
Myenteric plexus; Glycine; NMDA (N-methyl-D-aspartate) (Reggiani, A. (168) 123)

p-Chloromercuribenzoic acid
Myocardium (isolated); Contractility; Transmembrane potential; Ca^{2+} action potential; Na^+,K^+-ATPase; Methylmercury; Chlormerodrin; Bromomercurihydroxypropane (Halbach, S. (167) 255)

Chlorpropamide
[Arg^8]vasopressin receptor; Renal tubular basolateral membrane; [^{3}H][Arg^8]vasopressin; (Rat) (Muta, T. (159) 191)

cis-Chlorprothixene
Xerostomia; Cytosolic free Ca^{2+}; Cl^- loss; O_2 consumption (Undén, M. (164) 129)

Cholecystokinin (CCK)
Bombesin; Pancreatic growth; (Receptor antagonist, Rat, Hamster) (Douglas, B.R. (161) 209)

CR 1409; Fronto-parietal cortex; Striatum; Acetylcholine; Dopamine; 3-Methoxytyramine (Cosi, C. (165) 209)

CCK-receptor antagonists; Bombesin; Gallbladder; Loxiglumide (Douglas, B.R. (166) 307)

Cholera toxin
Adenosine; Prostaglandins; Lymphocytes; Phorbol esters; (Receptors) (Nordstedt, C. (172) 51)

Choline acetyltransferase
GM1 ganglioside; Vincristine; Choline uptake (high-affinity); Hippocampus (Di Patre, P.L. (162) 43)

Cholinergic contraction
Bronchi; Neuropeptide Y; UK 14,304; α-Adrenoceptors; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Noradrenaline; Morphine; (Guinea-pig) (Matran, R. (163) 15)

Cholinergic pathways
[^{14}C]2-Deoxyglucose; Antipsychotics; Desenkephalin-γ-endorphin; Glucose uptake; Local cerebral glucose utilization; Org 5878; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Cholinergic reinnervation
Cultured explants; Hippocampus; Septum; Muscarinic receptor subtypes; (Up-regulation, Down-regulation) (Rimvall, K. (160) 1)

Cholinergic system
Baroreceptor deafferentation; Blood pressure control (Taira, C.A. (159) 265)

Airway hyperreactivity; Bradykinin; Substance P (Omini, C. (163) 195)

Minaprine; Cycloheximide; Serotonergic system; 5-HT_2 receptors; Amnesia; (Mouse) (Nabeshima, T. (169) 249)

Cholinesterase
Sprague-Dawley rat (SD); Wistar-Kyoto rat (WKY); Spontaneously hypertensive rat (SHR); Muscarinic receptors; Dopamine receptors (Lim, D.K. (165) 279)

Choline uptake
Acetylcholine release; Acetylcholine vesicular uptake; Electric organ of *Torpedo marmorata*; Cetiedil (Gaudry-Talarmain, Y.M. (166) 427)

Choline uptake (high-affinity)
GM1 ganglioside; Vincristine; Choline acetyltransferase; Hippocampus (Di Patre, P.L. (162) 43)

Chromaffin cells
σ Receptors; PCP receptors; PC12 cells; Adrenal medulla (Yang, Z.W. (164) 607)

Endothelin; Heart; Blood vessels; Uterus; Trachea; Vas deferens; Platelets; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Proenkephalin; PNMT (phenylethanolamine N-methyltransferase); mRNA; Glucocorticoids; Dexamethasone; Gene expression (Wan, D.C.-C. (172) 107)

Cigarette smoke
Trachea; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2; Cortisol; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Cisplatin
Emesis; Cannabinoid; Δ^1-Tetrahydrocannabinol; 7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl; Cupric chloride; HU-211; (Pigeon) (Feigenbaum, J.J. (169) 159)

Cl^- channels
Kindling seizures; FG 7142; GABA (γ-aminobutyric acid); Benzodiazepines; [^{35}S]t-Butylbicyclophosphorothionate ([^{35}S]TBPS); (Autoradiography) (Lewin, E. (160) 101)

Platelet activating factor (PAF-acether, PAF); Bradykinin; Colonic epithelium; Prostaglandins (Buckley, T.L. (163) 275)

$GABA_A$ receptors; [^{35}S]TBPS binding; Isoniazid; (Modulators of GABAergic synapses) (Serra, M. (164) 385)

Clenbuterol
Adrenoceptors; β-Adrenoceptor agonists; Gastric emptying; (Mouse) (Liberge, M. (164) 147)

Cl^-
Benzodiazepines; γ-Aminobutyric acid (GABA); Flurazepam; Bicuculline; (Tolerance) (Tietz, E.I. (167) 57)

Cl^- influx
GABA (γ-aminobutyric acid); Benzodiazepines; Diazepam (chronic); Tolerance (J. Marley, R. (159) 217)

Cl^- ionophore
Anticonvulsants; Seizures; Steroids; Progesterone metabolite; GABA receptors (Belelli, D. (166) 325)

Benzodiazepines; GABA receptors; Steroids; Progesterone metabolites; Clonazepam; (Partial agonists) (Belelli, D. (167) 173)

Cl^- loss
Cis-chlorprothixene; Xerostomia; Cytosolic free Ca^{2+}; O_2 consumption (Undén, M. (164) 129)

Clonazepam
Chloride ionophore; Benzodiazepines; GABA receptors; Steroids; Progesterone metabolites; (Partial agonists) (Belelli, D. (167) 173)

Clonidine
Locus coeruleus; α_2-Adrenoceptors; Mydriasis; Cocaine (Pitts, D.K. (160) 201)

Dilazep; Aggressive behaviour; Purinergic action (central) (Ushijima, I. (161) 245)

α-Adrenoceptors; Imidazoline receptors; Blood pressure; Brainstem; (Binding) (Bricca, G. (162) 1)

α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Clorgyline; Tranylcypromine; Cocaine; Protriptyline; Yohimbine (Giralt, M.T. (164) 455)

Dopamine; Idazoxan; Mesolimbic dopamine system; Ventral tegmental area; (Firing pattern) (Grenhoff, J. (165) 11)

Anococcygeus (rat); McN-A-343; Methoxamine; Non-adrenergic, non-cholinergic (NANC) transmission; Rilmenidine; (Prejunctional receptors) (Li, C.G. (168) 107)

Ethanol; Aorta; Endothelium; Smooth muscle (vascular); Vasorelaxation; (Rat) (Hatake, K. (168) 277)

α-Adrenoceptors; Mydriasis; Central nervous system (CNS); (Functional model, Mouse) (Heal, D.J. (170) 11)

α_2-Adrenoceptors; Hypoactivity; Sedation; Mydriasis; MHPG (3-methoxy-4-hydroxyphenylglycol); Brain; Behaviour; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

[^{3}H]Clonidine
α_2-Adrenoceptors; [^{3}H](−)-Adrenaline; HT29 cell-line; [^{3}H]Yohimbine; Colon adenocarcinoma (Sénard, J.-M. (162) 225)

Rilmenidine; Imidazoline preferring receptors; Brain (human) (Bricca, G. (163) 373)

α_2-Adrenoceptors (brain); α-Methyl-p-tyrosine; Reserpine; Clorgyline; Tranylcypromine; Cocaine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

[^{3}H]Clonidine binding
α_2-Adrenoceptors; Morphine dependence; Morphine withdrawal; Hippocampal slices; Brain; (Field stimulation, Rat) (Smith, C.B. (161) 111)

α_2-Adrenoceptors; Muscarinic receptor agonists; Muscarinic receptor antagonists; Brain (rat) (Hollingsworth, P.J. (168) 159)

Clorgyline
α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Tranylcypromine; Cocaine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

Clozapine
Atypical neuroleptics; Dopamine D-1 receptor antagonists; Dopamine D-2 receptor antagonists; SKF-38393; LY-171555; (Behavior) (Criswell, H.E. (159) 141)

Dopamine receptors; Aggression (intraspecies); SCH 23390; Haloperidol (McMillen, B.A. (160) 149)

Ketamine; Dyskinesia; Tongue protrusion; Tongue retrusion; Swallow (Marco, L.A. (164) 171)

Cl^- transport
Ethacrynic acid; Epilepsy; Excitatory amino acid (Inoue, M. (166) 101)

Cl^- uptake
Chlormethiazole; t-Butylbicyclophosphorothionate; Synaptoneurosomes; Benzodiazepines; γ-Aminobutyric acid (GABA) (Moody, E.J. (164) 153)

Caffeine; Benzodiazepine; GABA (γ-aminobutyric acid) (Lopez, F. (172) 453)

β-CMC (3-(methoxycarbonyl)-amino-β-carboline
Benzodiazepine receptors; Sedation; Seizures; Bicuculline (Nutt, D.J. (165) 135)

CNQX (6-cyano-7-nitroquinoxaline-2,3-dione)
DNQX (dinitroquinoxaline-2,3-dione); CPP (3-(±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); Excitatory amino acids; Retinal ganglion cell (Kay, C.D. (164) 381)

Cocaine
Basal ganglia; Dopamine; GBR 12909; Neurotensin; Substantia nigra; Striatum (Hanson, G.R. (160) 23)

Locus coeruleus; α_2-Adrenoceptors; Mydriasis; Clonidine (Pitts, D.K. (160) 201)

α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Clorgyline; Tranylcypromine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

Cognitive deficits
AF64A; Habituation; Learning (maze); Acetylcholinesterase; (Histology) (Gower, A.J. (166) 271)

Collecting duct
κ Opioid receptor agonists; U-62,066E; κ Opioid receptor antagonists; MR-2266; [Arg^8]vasopressin; Diuresis; Water permeability (Imai, K.Y.M. (160) 229)

Colon
Loperamide; Mucus secretion; (Rat) (Loeschke, K. (170) 41)

Colon adenocarcinoma
α_2-Adrenoceptors; [^{3}H](−)-Adrenaline; HT29 cell-line; [^{3}H]Yohimbine; [^{3}H]Clonidine (Sénard, J.-M. (162) 225)

Colon (distal)
Galanin; Nifedipine; (Contraction, Mouse) (Fontaine, J. (164) 583)

Colon electrophysiology
Quinidine; Quinine; Interstitial cells of Cajal; Slow waves; Pacemaker activity (Barajas-López, C. (163) 137)

Colonic epithelium
Platelet activating factor (PAF-acether, PAF); Bradykinin; Cl^- channels; Prostaglandins (Buckley, T.L. (163) 275)

Complement depletion
Leukocyte accumulation; Vascular permeability; Prostaglandins (Hambleton, P.T. (163) 141)

Computer graphics
Adenosine A_1 receptors; N^6 region (J.M. Van Galen, P. (172) 19)

Conjunctiva
Platelet-activating factor (PAF-acether, PAF); Inflammation; Mucus; Goblet cells (Woodward, D.F. (168) 23)

ω-Conotoxin
Phorbol esters; Ca^{2+} channels; Dihydropyridines (Adamson, P. (162) 59)

Endothelin; Sarafotoxin S6b; Ca^{2+} antagonists; BAY k 8644; Na^+/H^+ exchanger (Gu, X.-H. (167) 281)

Contractility
Myocardium; Adenosine; Alinidine; Heart rate; (Action potential) (Lang, U. (164) 13)

DPI 201-106; Hemodynamic effects; Positive inotropic effects; Heart rate; (Conscious dog) (Gerard, J.-L. (165) 39)

Myocardium (isolated); Transmembrane potential; Ca^{2+} action potential; Na^+,K^+-ATPase; Methylmercury; Chlormerodrin; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Contractions (electrically evoked)
Adenosine agonists; Vas deferens (rat); Smooth muscle (non-vascular); (Presynaptic) (Major, T.C. (167) 323)

Converting enzyme inhibitors
Myocardial ischemia; Noradrenaline; (Rat) (Carlsson, L. (166) 157)

Convulsions
Ro 15-4513; β-Carbolines; Benzodiazepine recognition sites; Proconflict effect; Anxiety; [^{3}H]GABA binding (Corda, M.G. (159) 233)

γ-Aminobutyric acid (GABA); Dopamine; Haloperidol treatment; Stereotypy (Sandoval, M.R.L. (167) 117)

Coronary artery
Dithiothreitol; Sulfhydryl compounds; Smooth muscle (vascular); Ca^{2+} ion; (Dog) (Fujioka, H. (166) 13)

Adenosine receptors; Endothelium; Ca^{2+} (Sabouni, M.H. (166) 311)

Myocardial ischaemia (simulated); Adenosine; 5-Hydroxytryptamine; Acetylcholine; U-46,619; Iloprost; (Sheep) (Kwan, Y.W. (168) 31)

Coronary artery (contraction)
Thromboxane A_2/prostaglandin H_2 receptors (pig); Vascular system; Platelets; Platelet aggregation; (Ligand binding) (Mihara, S. (160) 313)

Coronary artery (human)
5-Hydroxytryptamine; 5-HT_2 receptors; Ketanserin; 5-HT_1-like receptors; GR43175 (Connor, H.E. (161) 91)

Rhythmicity; Prostaglandin $F_{2\alpha}$; Adenosine receptors; Ouabain (Sabouni, M.H. (168) 271)

Coronary artery (isolated)
Coronary regulation; Catecholamines (potentiation of); Coronary vasoconstriction; Neuropeptide Y (NPY) (Macho, P. (167) 67)

Coronary artery ligation
Dantrolene sodium; Antiarrhythmia agents; Cardiac arrhythmia models; Ventricular fibrillation threshold; Aconitine; Ouabain (Brooks, R.R. (164) 521)

Coronary artery (pig)
5-HT receptors; Noradrenaline release; (Presynaptic receptors) (Molderings, G.J. (164) 213)

Coronary circulation
Adenosine receptors; Ca^{2+}; Smooth muscle (vascular); Prostaglandin $F_{2\alpha}$ (Ramagopal, M.V. (159) 33)

Endothelin; Nifedipine; Langendorff preparation; Vasoconstriction (Fukuda, K. (165) 301)

Coronary occlusion
Myocardial ischaemia; K^+ loss; Haemodynamics; Ca^{2+} antagonists; Gallopamil; Diltiazem; Nifedipine (Kirchengast, M. (160) 349)

Coronary regulation
Catecholamines (potentiation of); Coronary vasoconstriction; Coronary arteries (isolated); Neuropeptide Y (NPY) (Macho, P. (167) 67)

Coronary stenosis
ICI 118,551; Atenolol; Myocardial ischemia; β_2-Adrenoceptors; (Regional myocardial function) (Noguchi, K. (168) 315)

Coronary thrombosis
Thromboxane A_2/prostaglandin endoperoxide receptor; Platelet aggregation; Thromboxane A_2/prostaglandin endoperoxide antagonists (Kondo, K. (163) 253)

Coronary vasoconstriction
Coronary regulation; Catecholamines (potentiation of); Coronary arteries (isolated); Neuropeptide Y (NPY) (Macho, P. (167) 67)

Coronary vasodilatation
α-Human atrial natriuretic peptide (α-hANP); Nitroglycerin; (Conscious dog, Intracoronary administration) (Adachi, H. (161) 189)

Corpus striatum
Catecholamines; Glycoconjugates; Lectins; Tetrabenazine; (Chromatography, Affinity) (Vincent, M.S. (172) 317)

Cortex
5-HT_3 receptor antagonists; 5-HT_3 binding sites; Brain; (Rat) (Wong, D.T. (166) 107)

4-DAMP (4-diphenylacetoxy-N-methyl-piperidine methiodide); Muscarinic receptors; Submaxillary gland; Heart (Michel, A.D. (166) 459)

Corticosterone
Adrenalectomy; 3,4-Methylenedioxymethamphetamine (MDMA); Serotonin (5-HT); Tryptophan hydroxylase; (Neurotoxicity) (Johnson, M. (161) 181)

3,4-Methylenedioxymethamphetamine (MDMA); Glucocorticoid receptors; 5-Hydroxytryptamine; Striatum; Neurotoxicity (Lowy, M.T. (163) 157)

MK-801; Pituitary; Adrenal; ACTH; Prolactin; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Hypothalamus; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); 5-Hydroxytryptamine (5-HT, serotonin); Paraventricular nucleus; (Sex differences) (Haleem, D.J. (164) 435)

Schedule-induced wheelrunning; Adrenalectomy; Dexamethasone; (Rat) (Lin, W. (171) 9)

Corticotropin-releasing factor (CRF)
Vasopressin; ACTH; cAMP; cGMP; Pituitary cells; AtT-20 corticotrophs (Koch, B. (158) 53)

Dopamine synthesis; Synaptosomes; Ca^{2+}; Protein kinase C; Striatum; (Rat) (Olianas, M.C. (166) 165)

Sauvagine; Urotensin I; CRF-(9-41) antagonist (α-helical); Anti-inflammatory response; Thermal injury; Vascular permeability (Wei, E.T. (168) 81)

Gastric acid secretion; Neuropeptides; Indomethacin; Dermorphin; Calcitonin gene-related peptide (CGKP) (Guglietta, A. (170) 87)

Analgesia; Inflammation; Hyperalgesia; Pain (Hargreaves, K.M. (170) 275)

Cortisol
Trachea; Cigarette smoke; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Cough reflex
N-Methyl-D-aspartate (NMDA); MK-801 (Kamei, J. (168) 153)

Coupling
Desipramine; β-Adrenoceptors; Down-regulation (Turkka, J. (167) 87)

C_7/3′-phthalimidopropyl
Atrium; Ileal longitudinal muscle; Muscarine receptors; (Guinea-pig) (Choo, L.K. (162) 429)

CPP (3-(±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid)
CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); DNQX (dinitroquinoxaline-2,3-dione); Excitatory amino acids; Retinal ganglion cell (Kay, C.D. (164) 381)

N-Methyl-D-aspartate (NMDA); NMDA-receptor complex; TCP (N-1[2-thienyl]cyclohexyl)3,4-piperidine; Glycine; (Molecular target size, Receptors) (Honoré, T. (172) 239)

mCPP (1-(3-chlorophenyl)piperazine)
Anxiety; TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine); 5-HT_{1C} receptors (Kennett, G.A. (164) 445)

CR 1409
Cholecystokinin (CCK); Fronto-parietal cortex; Striatum; Acetylcholine; Dopamine; 3-Methoxytyramine (Cosi, C. (165) 209)

Creatine kinase
α-Adrenoceptor antagonists; Cell membrane permeability; High-energy phosphates; Hypoxia; Reoxygenation; YM-12617 (Tanonaka, K. (165) 97)

CRF-(9-41) antagonist (α-helical)
Corticotropin-releasing factor (CRF); Sauvagine; Urotensin I; Anti-inflammatory response; Thermal injury; Vascular permeability (Wei, E.T. (168) 81)

Cromakalim (BRL 34915)
Carbachol; Glibenclamide; Vas deferens; (Rabbit) (Eltze, M. (161) 103)

Diabetes; Aorta; K^+ channels (Kamata, K. (166) 319)

Aorta; Planar lipid bilayer; Ca^{2+}-activated K^+ channels; $[Ca^{2+}]_i$ sensitivity; (Rabbit) (Gelband, C.H. (167) 201)

Hippocampus; K^+ channels; Tetraethylammonium; (Whole cell patch clamp) (Politi, D.M.T. (168) 7)

Pinacidil; Nifedipine; Renal blood flow; Renin activity (plasma); (Cat) (Clapham, J.C. (171) 109)

Cultured explants
Hippocampus; Septum; Cholinergic reinnervation; Muscarinic receptor subtypes; (Up-regulation, Down-regulation) (Rimvall, K. (160) 1)

Cupric chloride
Cisplatin; Emesis; Cannabinoid; Δ^1-Tetrahydrocannabinol; 7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl; HU-211; (Pigeon) (Feigenbaum, J.J. (169) 159)

CY 208-243
Dopamine; Microdialysis; (Release) (Imperato, A. (160) 155)

[^{3}H]Cyanoimipramine binding
5-HT uptake; Brofaromine; Moclobemide; Ifoxetine; 5-HT uptake inhibitors (Waldmeier, P.C. (169) 197)

Cyclic nucleotides
cAMP; cGMP; Tetraethylammonium; Trachealis (Chideckel, E.W. (166) 367)

Cycloheximide
Minaprine; Serotonergic system; Cholinergic system; 5-HT_2 receptors; Amnesia; (Mouse) (Nabeshima, T. (169) 249)

Cyclooxygenase
Gastroprotection; Lipoxygenase; Gastric lesions (Konturek, S.J. (164) 285)

Endothelin; Platelet aggregation; Haemodynamics; Piroxicam; (Rabbit) (Lidbury, P.S. (166) 335)

Sulfasalazine; Sulfasalazine analogues; Leukotrienes; Lipoxygenase; Thromboxane synthase (Tornhamre, S. (169) 225)

Cysteamine
Calcitonin gene-related peptide-like immunoreactivity (CGRP-li); Duodenal ulcers; Dulcerozine; Mepirizole (Evangelista, S. (164) 389)

L-Cysteine
d-Fenfluramine; d-Norfenfluramine; p-Chloroamphetamine; Serotonin; Neurotoxicity (Invernizzi, R. (163) 77)

Cytochrophin-4
Opioid receptors; Hemorphin-4; κ Sites; β-Casomorphins (Liebmann, C. (166) 523)

Cytosine arabinoside
YM-14673; Thyrotropin releasing hormone (TRH); Ataxia (Yamamoto, M. (166) 545)

Cytosolic free Ca^{2+}
Cis-chlorprothixene; Xerostomia; Cl^- loss; O_2 consumption (Undén, M. (164) 129)

[Cyt^6]vasopressin-(5-9)
Acetyl-vasopressin; Vasopressin; Passive avoidance behavior; Exploratory behavior; Body temperature (Kovács, G.L. (161) 27)

DADLE ([D-Ala^2,D-Leu^5]enkephalin)
Morphine; Sufentanil; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Opioid dependence; Intrathecal infusion (Stevens, C.W. (166) 467)

Heart; Sensory nerves; [D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin (DAGO); Capsaicin (Mantelli, L. (170) 217)

DAGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin)
Morphine; DADLE ([D-Ala^2,D-Leu^5]enkephalin); Sufentanil; Opioid dependence; Intrathecal infusion (Stevens, C.W. (166) 467)

Heart; Sensory nerves; [D-Ala^2,D-Leu^5]enkephalin (DADLE); Capsaicin (Mantelli, L. (170) 217)

Opioid receptors; μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; RB38A; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); (Receptor binding in vivo) (Meucci, E. (171) 167)

[^{3}H]DAGO
μ Opioid receptors; Morphine; Naltrexone; β-Funaltrexamine; κ Opioid receptors; (Receptor upregulation) (Rothman, R.B. (160) 71)

4-DAMP (4-diphenylacetoxy-N-methyl-piperidine methiodide)
Muscarinic receptors; Submaxillary gland; Cortex; Heart (Michel, A.D. (166) 459)

Dantrolene sodium
Antiarrhythmia agents; Cardiac arrhythmia models; Coronary artery ligation; Ventricular fibrillation threshold; Aconitine; Ouabain (Brooks, R.R. (164) 521)

DARPP-32
Protein phosphorylation; Striatum; Dopamine D-1 receptor; (Pharmacological modulation) (Di Luca, M. (172) 321)

DDT_1 MF-2 cells
ATP; G protein; Sulfonylureas; (Patch clamp) (Molleman, A. (169) 167)

DEγE (desenkephalin-γ-endorphin)
Antipsychotic substances; Dopamine; Haloperidol; Sulpiride; Brain regions (Van Ree, J.M. (166) 441)

[^{14}C]2-Deoxyglucose; Antipsychotics; Cholinergic pathways; Glucose uptake; Local cerebral glucose utilization; Org 5878; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Delta sleep-inducing peptide
Antidepressants; Haloperidol; Pentobarbital; Brain regions; Adrenalectomy; (Rat) (Wahlestedt, C. (159) 285)

Deltorphin
δ Opioid receptor agonists; (Isolation, Sequencing) (Kreil, G. (162) 123)

Dendrotoxin
Mast cell degranulating peptide; K^+ channel blockers; Ca^{2+} channel antagonists; Seizures; NMDA antagonists (Gandolfo, G. (160) 173)

Deoxycorticosterone acetate-salt hypertensive rats
Norepinephrine; Phosphatidylinositol turnover; Mesenteric vasculature; (Contraction) (Takata, Y. (164) 365)

2-Deoxy-D-[^{14}C]-glucose
RU 24722; Eburnamine derivatives; Catecholaminergic system; Limbic system; (Rat) (Broussolle, E. (159) 225)

2-[^{14}C]Deoxyglucose
Brain metabolism; Caffeine; Doxapram; (Rat) (Schroeder, H. (167) 245)

Antipsychotics; Cholinergic pathways; Desenkephalin-γ-endorphin; Glucose uptake; Local cerebral glucose utilization; Org 5878; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Dependence
Phencyclidine (PCP); Opiates; Naloxone; Temperature; Hypothermia (Pechnick, R.N. (166) 295)

Morphine; U-50,488H; κ-Opioid agonists (Fukagawa, Y. (170) 47)

Depolarization
Inositol phospholipids; Na^+ channels; Na^+/Ca^{2+} exchange (Benuck, M. (159) 187)

Depolarization block
SCH 23390; Haloperidol; Dopamine; (Electrophysiology, Rat) (Esposito, E. (162) 109)

L-Deprenyl
Monoamine oxidase-B activity; Dopamine uptake carrier; [^{3}H]Mazindol binding; Dopamine metabolism (Wiener, H.L. (163) 191)

Dermorphin
Gastric acid secretion; Neuropeptides; Indomethacin; Corticotropin-releasing factor (CRF); Calcitonin gene-related peptide (CGKP) (Guglietta, A. (170) 87)

Des-Arg^9-bradykinin
Angiotensin converting enzyme inhibitors; Kinin receptors; Inflammation; Bradykinin (Nwator, I.A.A. (160) 125)

Bradykinin receptors; Vasorelaxation; Prostaglandins (Nwator, I.A.A. (170) 29)

Desipramine
Gangliosides; β-Adrenoceptors; Forced swimming test; (Down-regulation) (Molina, V.A. (160) 247)

β-Adrenoceptors; Down-regulation; Coupling (Turkka, J. (167) 87)

TFMPP (1-(3-trifluoromethylphenyl)piperazine); 5-HT_{1B} receptor subtypes; Ventral tegmental area; Forced swimming test; (Rat) (Cervo, L. (171) 119)

Dexamethasone
Glucocorticoids; Vascular tissue; Vasocortin; Dextran oedema (Carnuccio, R. (166) 535)

Schedule-induced wheelrunning; Adrenalectomy; Corticosterone; (Rat) (Lin, W. (171) 9)

Chromaffin cells; Proenkephalin; PNMT (phenylethanolamine N-methyltransferase); mRNA; Glucocorticoids; Gene expression (Wan, D.C.-C. (172) 107)

Dextran oedema
Glucocorticoids; Dexamethasone; Vascular tissue; Vasocortin (Carnuccio, R. (166) 535)

Dextromethorphan
Audiogenic seizure; Anticonvulsants; Non-competitive NMDA antagonists; Phencyclidine; MK-801 (Chapman, A.G. (166) 201)

5,7-DHT (5,7-dihydroxytryptamine)
l-5-Hydroxytryptophan (l-5-HTP); Ritanserin; 5-HT syndrome; 5-HT_{1C} receptors (Colpaert, F.C. (169) 175)

Diabetes
Aorta; K^+ channels; Cromakalim (Kamata, K. (166) 319)

Diabetic rats
Pancreatic islets; Islet blood flow; Pancreatic blood flow; Streptozotocin (Jansson, L. (161) 79)

Ca^{2+} channels; α_1-Adrenoceptors; Phosphatidylinositol turnover; (Hyper-reactivity) (Sakai, Y. (162) 475)

Diacylglycerol
Smooth muscle (intestinal); Signal-contraction coupling; Histamine; Substance P; K^+ depolarization; (Guinea-pig) (Lippe, I.T. (159) 1)

Bradykinin; Thrombin; Fibroblast; (Homologous desensitization) (Burch, R.M. (168) 39)

Pituitary; Ca^{2+} mobilization; Thyrotropin releasing hormone (TRH); 1-Oleyl-2-acetyl glycerol (OAG); R59022 (Mollard, P. (172) 71)

3,4-Diaminopyridine
Noradrenaline release; Hippocampus; Phorbol ester; Protein kinase C (Huang, H.Y. (169) 115)

Diaphragm
Selenite-induced contracture; Ca^{2+} release (Lin-Shiau, S.-Y. (167) 137)

Diaphragm (rat)
Diltiazem; Ca^{2+} antagonists; KCl contracture; Caffeine contracture; (Use-dependent inhibition) (Røed, A. (159) 61)

Diazepam
Adenosine; Neuromuscular junction; Sartorius muscle; Nucleoside uptake; Dipyridamole; (Frog) (De Mendonça, A. (164) 347)

Anticonvulsant tolerance; Ro 17-1812; RU 32698; (Partial agonists) (Feely, M. (164) 377)

Benzodiazepine receptors; β-Carboline; Photoaffinity labelling (Dellouve-Courillon, C. (166) 557)

Ro 15-4513 binding; Granule cells; Cerebellum; GABA (γ-aminobutyric acid); Ethanol (Malminiemi, O. (169) 53)

Diazepam (chronic)
GABA (γ-aminobutyric acid); Benzodiazepines; Chloride influx; Tolerance (J. Marley, R. (159) 217)

6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylate
Excitatory amino acid receptor pharmacology (Birch, P.J. (163) 127)

Diethyldithiocarbamate
Catecholamine uptake; MPP^+ (1-methyl-4-phenylpyridinium ion); Dopamine; Disulfiram (Di Monte, D. (166) 23)

Diethylthiocarbamic acid methyl ester (Me-DTC)
Disulfiram; Ethanol; Hypothermia; Blood pressure; (Rat, Toxicity) (Petersen, E.N. (166) 419)

Digitalis toxicity
R56865; Ouabain; Na^+ pump; Myocardium (isolated); (Rat) (Finet, M. (164) 555)

[^{3}H]Dihydroalprenolol
Methylphenidate; Cerebral cortex; [^{3}H]Prazosin; [^{3}H]Idazoxan; (Down-regulation) (Mathieu, J.-F. (162) 173)

β-Adrenoceptor binding sites; β_1-Adrenoceptors; β_2-Adrenoceptors; [^{3}H]CGP 12177; CGP 20712A; ICI 118,551; (Post-mortem human brain) (De Paermentier, F. (167) 397)

1,4-Dihydropyridine
α_1-Adrenoceptors; Niguldipine; (Subtype, bivalent ligands) (Boer, R. (172) 131)

Dihydropyridines
Phorbol esters; Ca^{2+} channels; ω-Conotoxin (Adamson, P. (162) 59)

Nimodipine; Flunarizine; Diltiazem; Ca^{2+} channel antagonists; Seizures (Morón, M.A. (163) 299)

Dihydropyridine-sensitive Ca^{2+} channels
BAY k 8644; Tail flick; (Neurotransmitter metabolites, Intracerebroventricular administration) (Bourson, A. (160) 339)

Dilazep
Clonidine; Aggressive behaviour; Purinergic action (central) (Ushijima, I. (161) 245)

Dilazep metabolites; Ethanol; Motor incoordination; (Intracerebroventricularly) (Dar, M.S. (164) 303)

Dilazep metabolites
Dilazep; Ethanol; Motor incoordination; (Intracerebroventricularly) (Dar, M.S. (164) 303)

Diltiazem
Ca^{2+} antagonists; KCl contracture; Caffeine contracture; Diaphragm (rat); (Use-dependent inhibition) (Røed, A. (159) 61)

Ca^{2+} entry blocking drugs; Aging; Aorta (rat); Felodipine (Wanstall, J.C. (159) 241)

Ca^{2+} channel blockers; Stress ulcer; Gastric secretion; Verapamil; Nitrendipine; Ethanol ulcer; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Myocardial ischaemia; Coronary occlusion; K^+ loss; Haemodynamics; Ca^{2+} antagonists; Gallopamil; Nifedipine (Kirchengast, M. (160) 349)

Sinoatrial conduction; Sinus automaticity; Bepridil; Verapamil; Disopyramide (Kirchhof, C.J.H.J. (160) 369)

Nimodipine; Flunarizine; Ca^{2+} channel antagonists; Seizures; Dihydropyridines (Morón, M.A. (163) 299)

ATP; Verapamil; ^{45}Ca uptake; Tyrode solution (Ca^{2+}-free) (Bhat, M.B. (164) 163)

Flunarizine; Energy charge potential; Glycolysis (Ichihara, K. (165) 19)

Neuromuscular junction; Nicotinic receptor-ion channel complex; Muscle twitch (Baños, J. (165) 151)

1,3-Di-o-tolylguanidine
σ Receptors; Haloperidol; Psychotomimetic (+)-benzomorphans; (+)-3-(3-Hydroxyphenyl)-N-(1-propyl)piperidine; (Allosteric interaction) (Bowen, W.D. (163) 309)

Dipyridamole
Adenosine; Diazepam; Neuromuscular junction; Sartorius muscle; Nucleoside uptake; (Frog) (De Mendonça, A. (164) 347)

Disopyramide
Sinoatrial conduction; Sinus automaticity; Bepridil; Verapamil; Diltiazem (Kirchhof, C.J.H.J. (160) 369)

Acidosis; ECG effects; Myocardial uptake (Bova, S. (168) 179)

Dissociability
Local anesthetics (tertiary and quaternary amine); Lipophilicity; Neuronal membrane (site of action); Ion pairs (Štolc, S. (164) 249)

Disulfiram
Catecholamine uptake; MPP^+ (1-methyl-4-phenylpyridinium ion); Dopamine; Diethyldithiocarbamate (Di Monte, D. (166) 23)

Diethylthiocarbamic acid methyl ester (Me-DTC); Ethanol; Hypothermia; Blood pressure; (Rat, Toxicity) (Petersen, E.N. (166) 419)

Dithiothreitol
Sulfhydryl compounds; Coronary artery; Smooth muscle (vascular); Ca^{2+} ion; (Dog) (Fujioka, H. (166) 13)

Diuresis
κ Opioid receptor agonists; U-62,066E; κ Opioid receptor antagonists; MR-2266; [Arg^8]vasopressin; Collecting duct; Water permeability (Imai, K.Y.M. (160) 229)

[Arg^8]vasopressin; Atrial natriuretic factor; Brattleboro rats; Lithium clearance; Natriuresis (Palluk, R. (162) 245)

DNQX (dinitroquinoxaline-2,3-dione)
CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); CPP (3-(±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); Excitatory amino acids; Retinal ganglion cell (Kay, C.D. (164) 381)

DOCA/NaCl hypertension
Na^+,K^+-ATPase; [^{3}H]Ouabain binding; Ventricles; Renal hypertension (Chen, C.-C. (169) 67)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
5-HT_2 receptors; 5-Hydroxytryptamine (5-HT, serotonin); Pithed rat (Dabiré, H. (168) 369)

5-HT_2 receptors; (Partial agonism) (Dabiré, H. (170) 109)

DOM (1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane)
5-HT_2 receptor down-regulation; 5-HT_2 receptor agonists (Leysen, J.E. (163) 145)

Domperidone
Apomorphine; Dopamine; Dopamine DA2 receptors; Heart rate; SCH 23390; Vagus nerve (Montastruc, P. (166) 511)

DOPA (2,4-dihydroxyphenylalanine)
Prolactin; Tyrosine hydroxylase; DOPAC (3,4-dihydroxyphenylacetic acid); Striatum; Nucleus accumbens (Chen, J.-C. (166) 473)

DOPA accumulation
Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

DOPAC (3,4-dihydroxyphenylacetic acid)
Prolactin; Tyrosine hydroxylase; DOPA (2,4-dihydroxyphenylalanine); Nucleus accumbens; Striatum (Chen, J.-C. (166) 473)

Dopamine
Basal ganglia; Cocaine; GBR 12909; Neurotensin; Substantia nigra; Striatum (Hanson, G.R. (160) 23)

Dopamine metabolism; Nicotine (acute, repeated); Nucleus accumbens; Caudate nucleus; Olfactory tubercle (Lapin, E.P. (160) 53)

CY 208-243; Microdialysis; (Release) (Imperato, A. (160) 155)

Amphetamine discrimination; Dopamine D-1 receptors; Dopamine D-2 receptors; [^{3}H]SCH 23390; [^{3}H]Raclopride (Nielsen, E.B. (160) 253)

Dopamine D-1 receptor agonists; Grooming; Vacuous chewing (Murray, A.M. (160) 377)

Hyperactivity; Hypoactivity; (Forward progression, Movement, Rat) (Eilam, D. (161) 151)

SCH 23390; Haloperidol; Depolarization block; (Electrophysiology, Rat) (Esposito, E. (162) 109)

Dopamine D-1 receptors; Dopamine D-2 receptors; Turning; (Receptor supersensitivity) (Morelli, M. (162) 329)

MIF-1; Prolyl-leucyl-glycinamide; Apomorphine; 6-Hydroxydopamine (6-OHDA, neonatal); (Behaviour, Development) (Kostrzewa, R.M. (163) 33)

Antipsychotic agents; 5-HT_3 receptor antagonists; Substantia nigra; (Electrophysiology) (Sorensen, S.M. (163) 115)

Olfactory tubercle; Electrochemistry; (Electrical stimulation, Drug effects) (Suaud-Chagny, M.-F. (164) 273)

Ibopamine; Haemodynamics; Isovolumic relaxation; (Mathematical models) (Bernardi, L. (164) 415)

Microdialysis; 5-HT_3 receptors; ICS 205-930; Morphine; Amphetamine (Carboni, E. (164) 515)

Clonidine; Idazoxan; Mesolimbic dopamine system; Ventral tegmental area; (Firing pattern) (Grenhoff, J. (165) 11)

Cholecystokinin (CCK); CR 1409; Fronto-parietal cortex; Striatum; Acetylcholine; 3-Methoxytyramine (Cosi, C. (165) 209)

Catecholamine uptake; MPP^+ (1-methyl-4-phenylpyridinium ion); Diethyldithiocarbamate; Disulfiram (Di Monte, D. (166) 23)

MPP^+ (1-methyl-4-phenylpyridinium); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Serotonin; Serotonin syndrome; Microdialysis (Miyake, H. (166) 49)

Dopamine uptake inhibitors; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); (Mouse) (Kilbourn, M.R. (166) 331)

Antipsychotic substances; Haloperidol; Sulpiride; Desenkephalin-γ-endorphin (DEγE); Brain regions (Van Ree, J.M. (166) 441)

Apomorphine; Dopamine DA2 receptors; Heart rate; Domperidone; SCH 23390; Vagus nerve (Montastruc, P. (166) 511)

γ-Aminobutyric acid (GABA); Haloperidol treatment; Convulsions; Stereotypy (Sandoval, M.R.L. (167) 117)

GBR 12909; Motor activity; Reinforcement (conditioned); (Sensitization, Fixed-interval) (Kelley, A.E. (167) 385)

Acetylcholine; Striatum; (Recovery of function, Release, Slices) (MacKenzie, R.G. (168) 43)

5-Hydroxytryptamine (5-HT, serotonin); Voltammetry (in vivo); d,l-p-Chloroamphetamine; Amphetamine; (±)-3,4-Methylenedioxymethamphetamine (MDMA) (Gazzara, R.A. (168) 209)

Microdialysis; Nucleus accumbens; Nicotine; Tolerance; (Rat) (Damsma, G. (168) 363)

Amphetamine; Haloperidol; Striatum; Hippocampus; Calmodulin translocation (Popov, N. (172) 205)

Dopamine DA_1 receptor agonists
Ganglionic inhibition; Dopamine DA_1 receptors; Dopamine DA_2 receptors; Dopamine DA_1 receptor antagonists; Dopamine DA_2 receptor agonists; Dopamine DA_2 receptor antagonists (Kohli, J.D. (164) 265)

Dopamine DA_2 receptor agonists
Ganglionic inhibition; Dopamine DA_1 receptors; Dopamine DA_2 receptors; Dopamine DA_1 receptor agonists; Dopamine DA_1 receptor antagonists; Dopamine DA_2 receptor antagonists (Kohli, J.D. (164) 265)

Dopamine DA_1 receptor antagonists
Ganglionic inhibition; Dopamine DA_1 receptors; Dopamine DA_2 receptors; Dopamine DA_1 receptor agonists; Dopamine DA_2 receptor agonists; Dopamine DA_2 receptor antagonists (Kohli, J.D. (164) 265)

Dopamine DA_2 receptor antagonists
Ganglionic inhibition; Dopamine DA_1 receptors; Dopamine DA_2 receptors; Dopamine DA_1 receptor agonists; Dopamine DA_1 receptor antagonists; Dopamine DA_2 receptor agonists (Kohli, J.D. (164) 265)

Dopamine DA_1 receptors
Ganglionic inhibition; Dopamine DA_2 receptors; Dopamine DA_1 receptor agonists; Dopamine DA_1 receptor antagonists; Dopamine DA_2 receptor agonists; Dopamine DA_2 receptor antagonists (Kohli, J.D. (164) 265)

Dopamine DA_2 receptors
Ganglionic inhibition; Dopamine DA_1 receptors; Dopamine DA_1 receptor agonists; Dopamine DA_1 receptor antagonists; Dopamine DA_2 receptor agonists; Dopamine DA_2 receptor antagonists (Kohli, J.D. (164) 265)

Apomorphine; Dopamine; Heart rate; Domperidone; SCH 23390; Vagus nerve (Montastruc, P. (166) 511)

Dopamine D-1 receptor agonists
Dopamine; Grooming; Vacuous chewing (Murray, A.M. (160) 377)

Dopamine D-2 receptor agonists
MPTP; Parkinsonism; N-0437; (Transdermal administration, Common marmoset) (Löschmann, P.-A. (166) 373)

Dopamine D-1 receptor antagonists
Atypical neuroleptics; Dopamine D-2 receptor antagonists; Clozapine; SKF-38393; LY-171555; (Behavior) (Criswell, H.E. (159) 141)

A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; $5\text{-}HT_{1C}$; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Dopamine D-2 receptor antagonists
Atypical neuroleptics; Dopamine D-1 receptor antagonists; Clozapine; SKF-38393; LY-171555; (Behavior) (Criswell, H.E. (159) 141)

Dopamine D-1 receptors
Amphetamine discrimination; Dopamine D-2 receptors; [^{3}H]SCH 23390; [^{3}H]Raclopride; Dopamine (Nielsen, E.B. (160) 253)

Dopamine; Dopamine D-2 receptors; Turning; (Receptor supersensitivity) (Morelli, M. (162) 329)

5-HT receptors; Blood platelets; Brain; [^{3}H]SCH 23390; (Human) (De Keyser, J. (162) 437)

[^{3}H]SCH 23390; Kidney (Zdilar, D. (164) 159)

BHT-920; Quinpirole; Dopamine D-2 receptors; Striatum; (Rat) (Ferré, S. (166) 303)

Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-2 receptors; $5\text{-}HT_{1C}$; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Imipramine; Adenylate cyclase; α-Methyltyrosine (De Montis, G.M. (167) 299)

Dopamine D-2 receptors; Body temperature; Dopamine receptor agonists; Dopamine receptor antagonists; (Mouse) (Sánchez, C. (171) 201)

Protein phosphorylation; Striatum; DARPP-32; (Pharmacological modulation) (Di Luca, M. (172) 321)

Dopamine D-2 receptors
Amphetamine discrimination; Dopamine D-1 receptors; [^{3}H]SCH 23390; [^{3}H]Raclopride; Dopamine (Nielsen, E.B. (160) 253)

Dopamine; Dopamine D-1 receptors; Turning; (Receptor supersensitivity) (Morelli, M. (162) 329)

N-0434; Affinity chromatography; (Purification) (Bosker, F.J. (163) 319)

Quinine; K^+ channels; Neuroleptics; Caudate nucleus; (Patch-clamp) (Freedman, J.E. (164) 341)

BHT-920; Quinpirole; Dopamine D-1 receptors; Striatum; (Rat) (Ferré, S. (166) 303)

Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; 5-HT_{1C}; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Sleep; Wakefulness; REM (rapid eye movement) sleep; Quinpirole; YM-09151-2 (Monti, J.M. (169) 61)

Dopamine D-1 receptors; Body temperature; Dopamine receptor agonists; Dopamine receptor antagonists; (Mouse) (Sánchez, C. (171) 201)

Dopamine D-1 receptors (solubilized)
Polyethylene glycol; [^{3}H]SCH 23390; Guanine nucleotide (GTP); Striatum; (Rat) (Zhang, X. (166) 401)

Dopamine D-1 receptor subtypes
Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Raclopride; Stereotypy; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

Dopamine D-2 receptor subtypes
Dopamine D-1 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Raclopride; Stereotypy; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

[^{3}H]Dopamine release
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatum; [^{3}H]Acetylcholine release; [^{3}H]Spiroperidol binding; (Rat) (Kurstjens, N.P. (169) 147)

Dopamine metabolism
Dopamine; Nicotine (acute, repeated); Nucleus accumbens; Caudate nucleus; Olfactory tubercle (Lapin, E.P. (160) 53)

NMDA receptor antagonists; Nucleus accumbens; Immobilization stress; Methyl-β-carboline-3-carboxylate (β-CCM); (In vivo voltammetry) (Serrano, A. (162) 157)

L-Deprenyl; Monoamine oxidase-B activity; Dopamine uptake carrier; [^{3}H]Mazindol binding (Wiener, H.L. (163) 191)

l-Fenfluramine; l-Norfenfluramine; Acetylcholine release in vivo; Striatum; Nucleus accumbens (Invernizzi, R. (164) 241)

Dopamine uptake inhibitors; Microdialysis (in vivo); Amphetamine; Methylphenidate; Nomifensine (Hurd, Y.L. (166) 251)

Dopamine uptake carrier; Amphetamine; Microdialysis (in vivo); Ca^{2+}-dependent dopamine release (Hurd, Y.L. (166) 261)

Odansetron (GR 38032F); 5-HT_3 receptors; 5-HT metabolism (Koulu, M. (169) 321)

Dopamine neurons
d-Amphetamine; Apomorphine; Quinpirole; SCH 23390; Nigrostriatal dopamine neurons (Pitts, D.K. (162) 167)

σ Receptors; (+)-3-PPP; BMY 14802 (Steinfels, G.F. (163) 167)

Dopamine receptor agonists
Microdialysis; Dopamine release; Stereoisomers; Transdermal application; Oral administration (Timmerman, W. (162) 143)

Microdialysis; Dopamine release; N-0437; (Stereoisomers, Slices) (Timmerman, W. (166) 1)

Dopamine receptor antagonists; Opioid receptor agonists; Antinociception (Rooney, K.F. (168) 329)

B-HT 920; Yohimbine; Idazoxan; Stereotypy (Meltzer, L.T. (170) 105)

Dopamine D-1 receptors; Dopamine D-2 receptors; Body temperature; Dopamine receptor antagonists; (Mouse) (Sánchez, C. (171) 201)

Dopamine receptor antagonists
Dopamine receptor agonists; Opioid receptor agonists; Antinociception (Rooney, K.F. (168) 329)

Dopamine D-1 receptors; Dopamine D-2 receptors; Body temperature; Dopamine receptor agonists; (Mouse) (Sánchez, C. (171) 201)

Dopamine receptors
Aggression (intraspecies); SCH 23390; Clozapine; Haloperidol (McMillen, B.A. (160) 149)

Neurotensin; Striatum; Nucleus accumbens (Merchant, K.M. (160) 409)

5-HT receptors; Na^+,K^+-ATPase; Hippocampus; Striatum; Central nervous system (CNS); Spaceflight (Miller, J.D. (161) 165)

Blood pressure; Sympathetic ganglionic transmission; (Presynaptic receptors) (Dlewati, A. (164) 197)

Sprague-Dawley rat (SD); Wistar-Kyoto rat (WKY); Spontaneously hypertensive rat (SHR); Cholinesterase; Muscarinic receptors (Lim, D.K. (165) 279)

MPTP; Nigrostriatal dopaminergic neurons; GM1 ganglioside (Hadjiconstantinou, M. (168) 261)

Dopamine receptors (presynaptic, postsynaptic)
Indolylbutylamines; Acetylcholine; Turning behaviour; Serotonin; 5-HT_{1A} receptors (Seyfried, C.A. (160) 31)

Dopamine receptor supersensitivity
Catecholestrogens; Estrogens; Antiestrogens; Tamoxifen; Striatum (Ferretti, C. (166) 149)

Dopamine release
Microdialysis; Stereoisomers; Dopamine receptor agonists; Transdermal application; Oral administration (Timmerman, W. (162) 143)

OM-853; Muscarinic receptors; Striatum (Koda, H. (162) 501)

Microdialysis; Dopamine receptor agonists; N-0437; (Stereoisomers, Slices) (Timmerman, W. (166) 1)

Striatum; N-Methyl-D-aspartate (NMDA); Glycine; Kynurenic acid; (Rat) (Krebs, M.-O. (166) 567)

Dopamine synthesis
Corticotropin-releasing factor; Synaptosomes; Ca^{2+}; Protein kinase C; Striatum; (Rat) (Olianas, M.C. (166) 165)

Dopamine turnover
Ataxia; MK-801; Phencyclidine (PCP); 5-HT uptake; Stereotyped behavior; (Rat) (Hiramatsu, M. (166) 359)

Dopamine uptake
MPP^+ (1-methyl-4-phenylpyridinium); Striatal synaptosomes; (Neurotoxicity) (Johnson, E.A. (166) 65)

GBR 12909 (1-(2-(bis(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenylpropyl)piperazine); Na^+ channels; Piperazine site; (Neurochemical properties, Voltage-dependent) (Andersen, P.H. (166) 493)

Dopamine uptake carrier
L-Deprenyl; Monoamine oxidase-B activity; [^{3}H]Mazindol binding; Dopamine metabolism (Wiener, H.L. (163) 191)

Amphetamine; Microdialysis (in vivo); Ca^{2+}-dependent dopamine release; Dopamine metabolism (Hurd, Y.L. (166) 261)

Dopamine uptake inhibitors
Dopamine metabolism; Microdialysis (in vivo); Amphetamine; Methylphenidate; Nomifensine (Hurd, Y.L. (166) 251)

Dopamine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); (Mouse) (Kilbourn, M.R. (166) 331)

Dorsal raphe nucleus
MDMA (3,4-methylenedioxymethamphetamine); Single unit recording; Microdialysis; Neurotransmitter release (Sprouse, J.S. (167) 375)

Down-regulation
Desipramine; β-Adrenoceptors; Coupling (Turkka, J. (167) 87)

β-Adrenoceptors; Phenelzine; Internalization; Cerebral cortex; (Rat) (Koshikawa, N. (170) 101)

Doxapram
2-[^{14}C]Deoxyglucose; Brain metabolism; Caffeine; (Rat) (Schroeder, H. (167) 245)

Doxofylline
Bronchoconstriction; Platelet-activating factor (PAF-acether, PAF) (Franzone, J.S. (165) 269)

DPI 201-106
Anticholinergic action; Cardiac muscarinic receptors; (Mode of interaction) (Groschner, K. (159) 125)

Hemodynamic effects; Positive inotropic effects; Contractility; Heart rate; (Conscious dog) (Gerard, J.-L. (165) 39)

(±)-DPI 201-106
Cardiac Na^+ channels (non-inactivating); Na^+ channel modifiers (Kohlhardt, M. (168) 115)

Drinking
Methoctramine; Muscarinic M_1/M_2 receptors; Muscarinic receptor subtypes (Massi, M. (163) 387)

Drug discrimination
Hallucinogens; Mescaline; 5-HT receptors; 5-HT_1 receptors; 5-HT_2 receptors (Appel, J.B. (159) 41)

NMDA (N-methyl-D-aspartate); MK-801; CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-1-phosphonic acid); Schedule-controlled responding; (Rhesus monkey) (France, C.P. (159) 133)

MK-801; Phencyclidine (PCP); NMDA receptor antagonists; Anticonvulsants; (Behaviour) (Tricklebank, M.D. (167) 127)

DSP-4
Noradrenaline release; α_2-Adrenoceptors; Spinal cord; (Slices, Rat) (Reimann, W. (167) 161)

DTLET ([D-Thr^2,Leu^5]enkephalyl-Thr)
Opioid receptors; μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; RB38A; Enkephalin metabolism; [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Dulcerozine
Calcitonin gene-related peptide-like immunoreactivity (CGRP-li); Duodenal ulcers; Cysteamine; Mepirizole (Evangelista, S. (164) 389)

Duodenal ulcers
Calcitonin gene-related peptide-like immunoreactivity (CGRP-li); Dulcerozine; Cysteamine; Mepirizole (Evangelista, S. (164) 389)

Dura mater
Antiinflammatory drugs; Trigeminal ganglion; Neurogenic inflammation (Buzzi, M.G. (165) 251)

Dynorphin
Opioid receptors; Prostaglandins; Heart (Ledda, F. (162) 323)

Dynorphin A
Analgesia; Pregnancy; Spinal cord; κ Opioid receptors (Sander, H.W. (159) 205)

Dynorphin A-(1-13)
Pentazocine; Noradrenaline release; Brain; Opioid receptor subtypes; (Guinea-pig) (Kinouchi, K. (164) 63)

Globus pallidus; Opioid receptors; μ-Opioid receptor agonists; κ-Opioid receptor agonists; Benzomorphans; (Microiontophoresis) (Huffman, R.D. (170) 179)

μ-Opioid receptors; κ-Opioid receptors; Na^+ ions; 5′-Guanylyl amidodiphosphate (Gpp(NH)p) sensitivity; (Agonist peptides); (Antagonist peptides) (Gairin, J.-E. (172) 381)

Dyskinesia
Clozapine; Ketamine; Tongue protrusion; Tongue retrusion; Swallow (Marco, L.A. (164) 171)

Ear artery
Neuropeptide Y; Endothelium; Adrenergic nerve stimulation; (Rabbit) (Budai, D. (168) 97)

Eburnamine derivatives
RU 24722; 2-Deoxy-D-[^{14}C]-glucose; Catecholaminergic system; Limbic system; (Rat) (Broussolle, E. (159) 225)

ECG effects
Acidosis; Disopyramide; Myocardial uptake (Bova, S. (168) 179)

EEG (human)
Seganserin; 5-HT_2 receptor antagonists; Sleep; Spectral analysis (Dijk, D.J. (171) 207)

Eicosapentaenoic acid
Serotonin; Norepinephrine; Platelet adhesion; Vascular reactivity (Pfister, S.L. (161) 85)

Electrical field stimulation
Histamine H_3-receptor agonists; (R)-α-Methylhistamine; Bronchi; (Human) (Ichinose, M. (163) 383)

Electrical spike activity
Ca^{2+} channel blockers; Intestinal motility; Migrating myoelectric complex; (Computer analysis) (De Ponti, F. (168) 133)

Electric organ of *Torpedo marmorata*
Acetylcholine release; Acetylcholine vesicular uptake; Choline uptake; Cetiedil (Gaudry-Talarmain, Y.M. (166) 427)

Electrochemistry
Dopamine; Olfactory tubercle; (Electrical stimulation, Drug effects) (Suaud-Chagny, M.-F. (164) 273)

Electroconvulsive shock
Adenylate cyclase; Antidepressants; Brain; (Rat) (Newman, M.E. (162) 345)

Electromechanical activity
Membrane potentials; Bronchomotor tone; Catecholamines; (Action potentials, Cellular electrophysiology) (Richards, I.S. (167) 155)

Electromechanical coupling
Aorta; Electrophysiological properties; Noradrenaline; α-Adrenoceptors; Angiotensin II; (Rabbit) (Haeusler, G. (166) 175)

Electrophysiological properties
Aorta; Electromechanical coupling; Noradrenaline; α-Adrenoceptors; Angiotensin II; (Rabbit) (Haeusler, G. (166) 175)

Elevated plus maze
Buspirone; Hippocampus; Open field; (Microinjections) (Kostowski, W. (168) 393)

Emesis
Cisplatin; Cannabinoid; Δ^1-Tetrahydrocannabinol; 7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl; Cupric chloride; HU-211; (Pigeon) (Feigenbaum, J.J. (169) 159)

Enalapril
Hemodynamics; Myocardially infarcted rat; Milrinone; Cardiomegaly (compensated) (DeFelice, A. (167) 211)

Endopeptidase (neutral)
Kinin; Kinin potentiation; Kininases; Angiotensin-converting enzyme (ACE); (Peptide) (Assreuy, J. (168) 231)

Non-adrenergic, non-cholinergic (NANC); Vasoactive intestinal peptide (VIP); Trachea; Epithelium (Rhoden, K.J. (171) 247)

β-Endorphin
Analgesia (intrathecal); Serotonin; Norepinephrine (Crisp, T. (160) 211)

γ-Endorphin; Stress (chronic); Opioid peptides (Young, E.A. (167) 229)

Morphine; Analgesia; Pain control systems (descending) (Suh, H.H. (168) 61)

γ-Endorphin
β-Endorphin; Stress (chronic); Opioid peptides (Young, E.A. (167) 229)

Endothelial cell
Endothelium-derived relaxing factor (EDRF); cGMP; Ca^{2+} (Schmidt, K. (170) 157)

Endothelin
Hemodynamics (regional); Vasoconstriction; Arterial pressure regulation (Han, S.P. (159) 303)

Trachea; Bronchi (main); Airway epithelium; (Guinea-pig) (Maggi, C.A. (160) 179)

Cheek pouch (hamster); Arteriolar vasoconstrictors (Brain, S.D. (160) 401)

Cerebral artery; Vasoconstriction; Ca^{2+}; (Cat) (Saito, A. (162) 353)

Arterial pressure; Vascular resistance (regional) (Minkes, R.K. (163) 163)

Endothelium; Glomerulus; Glomerular filtration rate; Mesangial cells; Renal plasma flow; (Contraction) (López-Farré, A. (163) 187)

Papillary muscle; (Contraction, Ferret) (Shah, A.M. (163) 365)

Blood flow (regional); Vasodilation; Vasoconstriction; (Rat) (Minkes, R.K. (165) 161)

Heart; Blood vessels; Uterus; Trachea; Vas deferens; Platelets; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Endothelin-1
BAY k 8644; Veins; Methylene blue; Angiotensin converting enzyme (D'Orleans-Juste, P. (165) 289)

Aorta; Endothelium; Pulmonary artery; (Rat) (Rodman, D.M. (165) 297)

Coronary circulation; Nifedipine; Langendorff preparation; Vasoconstriction (Fukuda, K. (165) 301)

Platelet aggregation; Haemodynamics; Piroxicam; Cyclooxygenase; (Rabbit) (Lidbury, P.S. (166) 335)

Positive inotropic effect; Vasoconstriction; (Anesthetized dogs) (Kitayoshi, T. (166) 519)

Renal blood flow; Renal cortex; Renal medulla (Tsuchiya, K. (166) 541)

Renal function; Urine formation; Renin secretion; (Anesthetized rat) (Matsumura, Y. (166) 577)

Ulcer; Gastric mucosa; Vasoconstrictors; Endothelium (Wallace, J.L. (167) 41)

Sarafotoxin S6b; Ca^{2+} antagonists; BAY k 8644; ω-Conotoxin; Na^+/H^+ exchanger (Gu, X.-H. (167) 281)

Noradrenergic transmission; Atrium (isolated); (Rat, Guinea-pig) (Reid, J.J. (168) 93)

Iris sphincter muscle; (Pig) (Geppetti, P. (168) 119)

Vasopressin; Lymphatic vessels; Arteriole; Venule (Fortes, Z.B. (170) 69)

Prostaglandin E_2; Prostaglandin I_2; Renal blood flow (Miura, K. (170) 91)

Blood flow; Cardiac output; Hemodynamics; Vascular resistance (Ais, G. (170) 113)

Artery; Vein; Vasoconstriction; (Dog, Human) (Cocks, T.M. (171) 17)

Thromboxane analogs; Thromboxane antagonists; Kidney (isolated, rat); Glomerular hemodynamics; Tubular function (Ferrario, R.G. (171) 127)

Vasodilatation; Nitric oxide; N^G-Monomethyl-L-arginine (Gardiner, S.M. (171) 237)

Trachea (guinea-pig); Airway epithelium; Peptidase inhibitors; Indomethacin; Captopril (Hay, D.W.P. (171) 241)

^{125}I-Endothelin-1
Endothelin receptors; Heart (porcine); Atrioventricular node; Autoradiography (quantitative receptor) (Yamasaki, H. (168) 247)

Endothelin binding sites
Kidney; Blood vessels; (Autoradiography) (Jones, C.R. (163) 379)

Endothelin (porcine)
Endothelin (rat); Monocyclic porcine analog; Arterial pressure (Minkes, R.K. (164) 571)

Endothelin (rat)
Endothelin (porcine); Monocyclic porcine analog; Arterial pressure (Minkes, R.K. (164) 571)

Endothelin receptors
^{125}I-Endothelin-1; Heart (porcine); Atrioventricular node; Autoradiography (quantitative receptor) (Yamasaki, H. (168) 247)

Endothelium
Ergotamine; Vascular segments; Acetylcholine; Endothelium-derived relaxing factor (EDRF) (Demirel, E. (159) 195)

Smooth muscle (relaxation); Vasodilation; cGMP; Nitric oxide; Nitrates (Buga, G.M. (161) 61)

Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Kidney; Heart; (Receptor) (Oehlenschlager, W.F. (161) 159)

Pulmonary arteries; Endothelium-derived relaxing factor (EDRF); Hemoglobin; (Modulation of contraction) (Yamaguchi, T. (161) 259)

Smooth muscle (vascular); Pulmonary arteries; Pulmonary veins; Endothelium-derived relaxing factor (EDRF); Adrenergic neurotransmission (Greenberg, S. (162) 67)

Carotid artery; Renal artery; Kinins; Bradykinin; Bradykinin B_1 receptors; Bradykinin B_2 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

Endothelin; Glomerulus; Glomerular filtration rate; Mesangial cells; Renal plasma flow; (Contraction) (López-Farré, A. (163) 187)

Quin-2; Ca^{2+}; Prostacyclin; P_2 purinoceptors (Raspe, E. (163) 345)

Aorta; Acetylcholine; Glyceryl trinitrate; 6-keto-Prostaglandin F_{1a}; Prostaglandin F_{1a}; (Radioimmunoassay, Rat) (Bossaller, C. (165) 165)

Aorta; Endothelin; Pulmonary artery; (Rat) (Rodman, D.M. (165) 297)

Adenosine receptors; Coronary artery; Ca^{2+} (Sabouni, M.H. (166) 311)

Ulcer; Gastric mucosa; Vasoconstrictors; Endothelin (Wallace, J.L. (167) 41)

Neuropeptide Y; Adrenergic nerve stimulation; Ear artery; (Rabbit) (Budai, D. (168) 97)

Hypoxia; Cerebral artery (middle); BW755C; Haemolysate; 5-Hydroxytryptamine (5-HT, serotonin); (Sheep) (Klaas, M. (168) 187)

Ethanol; Clonidine; Aorta; Smooth muscle (vascular); Vasorelaxation; (Rat) (Hatake, K. (168) 277)

Hemolysate; Myogenic tone; Cerebral artery; Vasospasm; Ca^{2+} antagonists (Nakayama, K. (169) 33)

Tetramethylpyrazine; Phenylephrine; Aorta; (High potassium, Rat) (Wu, C.-C. (169) 189)

K^+ channels; Quinine; Sulfonylureas; Pinacidil (Ramboer, I. (171) 251)

Anesthetics; Barbiturates; Pentobarbital; Phosphatidylinositol hydrolysis; Phosphatidylinositol (Robinson-White, A.J. (172) 291)

Endothelium-derived relaxing factor (EDRF)
Ergotamine; Vascular segments; Acetylcholine; Endothelium (Demirel, E. (159) 195)

Pulmonary arteries; Endothelium; Hemoglobin; (Modulation of contraction) (Yamaguchi, T. (161) 259)

Smooth muscle (vascular); Pulmonary arteries; Pulmonary veins; Endothelium; Adrenergic neurotransmission (Greenberg, S. (162) 67)

Red blood cells; Haemoglobin (Evans, H.G. (163) 361)

Prostacyclin; Platelet aggregation; cAMP; cGMP (Alheid, U. (164) 103)

Atrial natriuretic peptide (ANP); Aorta; Central ear artery; (Rabbit) (Hogan, J.C. (165) 129)

Hypoxia; Heart; ATP; Adenosine (Hopwood, A.M. (165) 323)

cGMP; Ca^{2+}; Endothelial cell (Schmidt, K. (170) 157)

Energy charge potential
Flunarizine; Diltiazem; Glycolysis (Ichihara, K. (165) 19)

Enkephalin analogues
Reinforcing effects; Self-administration; Morphine (Nishida, N. (166) 453)

δ Opioid receptors; Neurotransmitter release; Adenylate cyclase; Brain slices; (Rat) (De Vries, T.J. (170) 137)

Enkephalinase
Thiorphan; Spinal cord; [Met^5]enkephalin; SCH 34826 (Yaksh, T.L. (167) 367)

Enkephalinase inhibitors
Morphine withdrawal; Naloxone; Kelatorphan; Thiorphan (Maldonado, R. (165) 199)

Enkephalin metabolism
Opioid receptors; μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; RB38A; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Enkephalins (endogenous)
Opioid receptors; μ Opioid ligands; δ Opioid ligands; Peptidase inhibitors; Thiorphan; RB38A; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Enteric nervous system
Intestinal secretion (Diener, M. (168) 219)

Enteric neurons
Antiemetic drugs; Autonomic ganglia; Gastrointestinal motility; 5-Hydroxytryptamine (5-HT, serotonin) (Nemeth, P.R. (166) 387)

Enterochromaffin cells
5-Hydroxytryptamine (5-HT, serotonin); Intestine (small); GABA receptors; Muscimol; Baclofen (Schwörer, H. (165) 29)

Epidermal growth factor receptors
Vascular smooth muscle; Epidermal growth factor-urogastrone; Vasopressins; Serotonin (Blay, J. (172) 1)

Epidermal growth factor-urogastrone
Smooth muscle (vascular); Autoradiography (Siang Gan, B. (167) 407)

Vascular smooth muscle; Epidermal growth factor receptors; Vasopressins; Serotonin (Blay, J. (172) 1)

Epilepsy
Primidone; Phenobarbital; Kindling (Löscher, W. (162) 309)

Kindling; GABA aminotransferase; γ-Vinyl GABA (Löscher, W. (163) 1)

Cl^- transport; Ethacrynic acid; Excitatory amino acid (Inoue, M. (166) 101)

Epinephrine
α_1-Adrenoceptors; Cardiac action potential; Prazosin; β-Adrenoceptor blockade; Myocytes (ventricular); (Adult rat) (Vogel, S.M. (164) 231)

Norepinephrine; Sympathetic nervous system; α_2-Adrenoceptors (Szemeredi, K. (170) 53)

Epithelium
Non-adrenergic, non-cholinergic (NANC); Vasoactive intestinal peptide (VIP); Trachea; Endopeptidase (neutral) (Rhoden, K.J. (171) 247)

EPSP (excitatory postsynaptic potential, slow)
Telenzepine; Muscarinic receptors; Sympathetic ganglion; (Ligand binding) (Galvan, M. (167) 1)

Ergotamine
Vascular segments; Acetylcholine; Endothelium; Endothelium-derived relaxing factor (EDRF) (Demirel, E. (159) 195)

Erythrocytes
Ca^{2+} flux; K^+ flux; Atrial natriuretic peptide (rat) (Esparza, N. (166) 349)

Esteratic subsite
Quaternary ammonium compounds; Acetylcholinesterase (EC 3.1.1.7); (Active site) (Thanei-Wyss, P. (172) 165)

Estrogen-inducible proteins
Central nervous system (CNS) proteins; (Hormone action); (Two-dimensional gel electrophoresis) (Maggi, A. (172) 357)

Estrogens
Catecholestrogens; Antiestrogens; Tamoxifen; Dopamine receptor supersensitivity; Striatum (Ferretti, C. (166) 149)

Ethacrynic acid
Cl^- transport; Epilepsy; Excitatory amino acid (Inoue, M. (166) 101)

Ethanol
Ro 15-4513; Benzodiazepine inverse agonists; Pentobarbital; Motor impairment; Hypnotics (Le, A.D. (159) 25)

Ro 15-4513; General depressants; Ethanol reduction (Bishop, B.E. (162) 265)

Dilazep; Dilazep metabolites; Motor incoordination; (Intracerebroventricularly) (Dar, M.S. (164) 303)

Hippocampus; cAMP; Ca^{2+}; After-hyperpolarization; (Neuronal firing) (Benson, D.M. (164) 591)

α_2-Adrenoceptor antagonists; Atipamezole; Idazoxan; Ro 15-4513; Hypothermia; (Mouse) (Löschmann, P.-A. (166) 381)

Disulfiram; Diethylthiocarbamic acid methyl ester (Me-DTC); Hypothermia; Blood pressure; (Rat, Toxicity) (Petersen, E.N. (166) 419)

Clonidine; Aorta; Endothelium; Smooth muscle (vascular); Vasorelaxation; (Rat) (Hatake, K. (168) 277)

Ro 15-4513 binding; Granule cells; Cerebellum; GABA (γ-aminobutyric acid); Diazepam (Malminiemi, O. (169) 53)

Ethanol reduction
Ethanol; Ro 15-4513; General depressants (Bishop, B.E. (162) 265)

Ethanol ulcer
Ca^{2+} channel blockers; Stress ulcer; Gastric secretion; Verapamil; Nitrendipine; Diltiazem; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

[^{3}H]Ethylketocyclazocine
U-50,488H; Morphine; κ Opioid receptors; Tolerance; Analgesia; Hypothermia; Hyperthermia; Brain; Spinal cord (Bhargava, H.N. (162) 257)

N-Ethylmaleimide (NEM)
Ca^{2+} channel blockers; Stress ulcer; Gastric secretion; Verapamil; Nitrendipine; Diltiazem; Ethanol ulcer; Indomethacin (Glavin, G.B. (160) 323)

Opioids; Supraspinal analgesia; Opioid receptors; (Agonist efficacy) (Sánchez-Blázquez, P. (166) 193)

Muscarinic receptor subtypes; [^{3}H]Pirenzepine; Hippocampus; Receptor-G protein coupling; (Agonists) (Flynn, D.D. (172) 363)

Excitatory amino acid receptor pharmacology
6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylate (Birch, P.J. (163) 127)

Excitatory amino acids
Antinociception; Substance P; Phencyclidine receptors (DeLander, G.E. (159) 149)

CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); DNQX (dinitroquinoxaline-2,3-dione); CPP (3-(±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); Retinal ganglion cell (Kay, C.D. (164) 381)

Cl^- transport; Ethacrynic acid; Epilepsy (Inoue, M. (166) 101)

HA-966 (1-hydroxy-3-aminopyrrolidone-2); N-Methyl-D-aspartate (NMDA); Hippocampus; Norepinephrine release (Keith, R.A. (166) 393)

Excitatory junction potential
Bunazosin; Mesenteric vessels; Noradrenaline; α-Adrenoceptors (Komori, K. (164) 111)

Excitatory synaptic transmission
Buspirone; Hippocampus; 5-Hydroxytryptamine (5-HT, serotonin) (O'Connor, J.J. (167) 21)

Exploration
CCK8; Nucleus accumbens; Locomotion; (Rat) (Daugé, V. (163) 25)

Exploratory behavior
Acetyl-vasopressin; [Cyt^6]vasopressin-(5-9); Vasopressin; Passive avoidance behavior; Body temperature (Kovács, G.L. (161) 27)

Expression vector
cAMP-dependent protein kinase; Regulatory subunit; Catalytic subunit; Recombinant DNA; (*E. coli*) (Kuno, T. (172) 263)

Fat cells
α_2-Adrenoceptors; Adipocytes; Lipolysis; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]Idazoxan; [^{3}H]RX 821002; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Fatty acids (non-esterified)
Lidocaine; Ischemia; Myocardium; Heart (perfused working); (Rat) (Nakamura, K. (169) 259)

Felodipine
Ca^{2+} entry blocking drugs; Aging; Aorta (rat); Diltiazem (Wanstall, J.C. (159) 241)

d-Fenfluramine
d-Norfenfluramine; p-Chloroamphetamine; L-Cysteine; Serotonin; Neurotoxicity (Invernizzi, R. (163) 77)

l-Fenfluramine
l-Norfenfluramine; Dopamine metabolism; Acetylcholine release in vivo; Striatum; Nucleus accumbens (Invernizzi, R. (164) 241)

Fentanyl
5-Hydroxytryptamine; Histamine; Respiratory conductance; (Guinea-pig) (Gentil, B. (159) 181)

FG 7142
Kindling seizures; GABA (γ-aminobutyric acid); Benzodiazepines; Cl^- channels; [^{35}S]t-Butylbicyclophosphorothionate ([^{35}S]TBPS); (Autoradiography) (Lewin, E. (160) 101)

β-Carbolines; Benzodiazepines; Schedule-controlled behavior; CGS 8216; (Primates) (Wettstein, J.G. (163) 219)

Fibroblast
Bradykinin; Thrombin; Diacylglycerol; (Homologous desensitization) (Burch, R.M. (168) 39)

Field stimulation
Atrium (guinea-pig); Inotropic effect; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 37)

Atrium (guinea-pig); Noradrenaline release; Inotropic effect; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 49)

Filtration coefficient
5-HT receptor subtypes; Pulmonary edema; Capillary pressure; Ketanserin; Methysergide (Sumita, T. (164) 69)

Fixed-interval schedules
IBMX (3-isobutyl-1-methylxanthine); 7-CET (7-(2-chloroethyl)-theophylline); Caffeine; Behavioural effects; (Squirrel monkey) (Coffin, V.L. (170) 35)

Flexor reflex
Flupirtine; Pentazocine; Antinociception; Skin twitch reflex (Vaupel, D.B. (162) 447)

Flumazenil
Midazolam; βCCE (3-carboethoxy-β-carboline hydrochloride); Tolerance; (Sensitization, Baboon) (Sannerud, C.A. (167) 333)

Flunarizine
Nimodipine; Diltiazem; Ca^{2+} channel antagonists; Seizures; Dihydropyridines (Morón, M.A. (163) 299)

Diltiazem; Energy charge potential; Glycolysis (Ichihara, K. (165) 19)

Ouabain-induced ventricular tachycardia; After-depolarizations (delayed); (Conscious dog, Triggered activity) (Vos, M.A. (165) 139)

Cerebral ischemia; Baroreflex; Papaverine; (Cerebral protection) (Kurihara, J. (165) 147)

Flunitrazepam
Steroids; Forebrain; Autoradiography (quantitative) (Canonaco, M. (170) 95)

[^{3}H]Flunitrazepam
Benzodiazepine receptors (central and peripheral types); Phenobarbital; [^{3}H]PK 11195 (Weizman, A. (169) 235)

p-Fluoro-hexahydro-sila-difenidol
Muscarinic receptor subtypes; Muscarinic M_3-selective antagonists; Hexahydro-sila-difenidol analogues; Pirenzepine; Methoctramine; Vas deferens (rabbit); Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

Flupirtine
Pentazocine; Antinociception; Flexor reflex; Skin twitch reflex (Vaupel, D.B. (162) 447)

Flurazepam
Benzodiazepines; γ-Aminobutyric acid (GABA); Chloride; Bicuculline; (Tolerance) (Tietz, E.I. (167) 57)

FMLP (N-formylmethionine-leucyl-phenylalanine)
Guanine nucleotide-binding protein (G-protein); Na^+; Pertussis toxin; HL 60 cells (Gierschik, P. (172) 481)

Force
Quinacrine; Slow inward current; Na^+/Ca^{2+} exchange (Yang, L. (170) 261)

Forced swimming test
Antidepressants; Thiorphan; Bestatin; Iprindole; Imipramine; Motor activity; Opioids (Del Carmen de Felipe, M. (159) 175)

Gangliosides; Desipramine; β-Adrenoceptors; (Down-regulation) (Molina, V.A. (160) 247)

TFMPP (1-(3-trifluoromethylphenyl)piperazine); 5-HT_{1B} receptor subtypes; Ventral tegmental area; Desipramine; (Rat) (Cervo, L. (171) 119)

Forebrain
Steroids; Flunitrazepam; Autoradiography (quantitative) (Canonaco, M. (170) 95)

Forepaw treading
5-HT_{1A} receptor agonists; 5-HT_{1B} receptor agonists; 5-HT_2 receptor agonists; Head twitches (Arnt, J. (161) 45)

Formalin test
Analgesia; Hot plate test; Nociception; Orphenadrine citrate; Serotonin (Hunskaar, S. (160) 83)

Forskolin
Adenylate cyclase (cardiac); Gpp(NH)p (5′-guanylyl amidophosphate); (Circadian rhythm, In vitro stimulation) (Lemmer, B. (159) 311)

Adenylate cyclase; cAMP; Forskolin analogues; Guanine nucleotide regulatory proteins; Macrophages; Manganese; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

Forskolin analogues
Adenylate cyclase; cAMP; Forskolin; Guanine nucleotide regulatory proteins; Macrophages; Manganese; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

Fronto-parietal cortex
Cholecystokinin (CCK); CR 1409; Striatum; Acetylcholine; Dopamine; 3-Methoxytyramine (Cosi, C. (165) 209)

β-Funaltrexamine (β-FNA)
Opioids; Supraspinal analgesia; Periaqueductal gray; δ Receptors; μ Receptors; (Binding) (Sánchez-Blázquez, P. (159) 9)

μ Opioid receptors; [^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Morphine; Naltrexone; κ Opioid receptors; (Receptor upregulation) (Rothman, R.B. (160) 71)

Analgesia; Opioid receptors; Tail flick; Naloxonazine; ICI 154,129; Opioid peptides; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

Opioid antinociception; μ Opioid receptors; δ Opioid receptors; Naloxonazine; (Intracerebroventricular, Mouse) (Heyman, J.S. (169) 43)

Functional antagonism
Smooth muscle (airway); Muscarinic receptor agonists; Histamine; Phosphoinositide metabolism; β-Adrenergic relaxation (Van Amsterdam, R.G.M. (172) 175)

Fura 2
Neurotensin; Ca^{2+} mobilization; Inositol trisphosphate; Heterologous desensitization; NG108-15 cells (Imaizumi, T. (161) 203)

Li^+; Ileum (guinea-pig); Ca^{2+} level (cytosolic); (Skinned fiber, Relaxation) (Hori, M. (165) 63)

Furosemide
Submandibular acini; ^{22}Na; [^{3}H]QNB binding; Amiloride (Martinez, J.R. (164) 335)

Loop diuretics; Hemodynamic response (acute); Spontaneously hypertensive rats (SHR); Sinoaortic baroreceptors (Janssen, B.J.A. (170) 1)

GABA-activated chloride channels
Membrane fluidity; A_2C (2-[2-methoxyethoxy]-ethyl 8-[cis-2-n-octylcyclopropyl]-octanoate); Anesthetics; TBPS (t-butylbicyclophosphorothionate); Temperature (Buck, K.J. (160) 359)

GABA (γ-aminobutyric acid)
Benzodiazepines; Diazepam (chronic); Chloride influx; Tolerance (J. Marley, R. (159) 217)

Kindling seizures; FG 7142; Benzodiazepines; Cl^- channels; [^{35}S]t-Butylbicyclophosphorothionate ([^{35}S]TBPS); (Autoradiography) (Lewin, E. (160) 101)

Aspartate; Glutamate; Striatal slices; Apomorphine; Haloperidol; (K^+-evoked endogenous release) (Umeda, Y. (163) 291)

Chlormethiazole; t-Butylbicyclophosphorothionate; Cl^- uptake; Synaptoneurosomes; Benzodiazepines (Moody, E.J. (164) 153)

Picrotoxin; Bicuculline; Pentobarbitone; Benzodiazepines; Optic tectum (Sivilotti, L. (164) 205)

Amino-γ-carboline; Sensory neuron; (Whole cell clamp, Mouse) (Kanai, Y. (166) 553)

Benzodiazepines; Chloride; Flurazepam; Bicuculline; (Tolerance) (Tietz, E.I. (167) 57)

Dopamine; Haloperidol treatment; Convulsions; Stereotypy (Sandoval, M.R.L. (167) 117)

Benzodiazepine; Muscle relaxants (central); Spinal cord; Cerebellar Purkinje cells; (Unit activity) (Tarnawa, I. (167) 193)

Benzodiazepines (chronic); Tolerance; (Agonist efficacy) (Hernandez, T.D. (170) 145)

Benzodiazepine binding; Ro 15-1788; (Chronic treatment) (Urbancic, M. (171) 1)

Benzodiazepines; 5-Hydroxytryptamine (5-HT), serotonin; Hippocampus (Lista, A. (171) 229)

Ro 15-4513 binding; Granule cells; Cerebellum; Diazepam; Ethanol (Malminiemi, O. (169) 53)

Caffeine; Benzodiazepine; Cl^- uptake (Lopez, F. (172) 453)

GABA aminotransferase
Kindling; Epilepsy; γ-Vinyl GABA (Löscher, W. (163) 1)

$GABA_B$ autoreceptors
[^{3}H]GABA release; (−)-Baclofen; Phaclofen; Muscimol; (Superfused synaptosomes) (Bonanno, G. (172) 41)

[^{3}H]GABA binding
Ro 15-4513; β-Carbolines; Benzodiazepine recognition sites; Proconflict effect; Anxiety; Convulsions (Corda, M.G. (159) 233)

[^{35}S]TBPS binding; GABA-dependent $^{36}Cl^-$ flux; Zolpidem; Benzodiazepine receptors (type I, type II) (Biggio, G. (161) 173)

$GABA_A$ receptors; Gastric ulcer; Gastric mucoprotection; Stomach; [^{3}H]Muscimol binding; (Rat) (Erdö, S.L. (165) 79)

$GABA_A$ binding sites
Phenytoin; Cerebellum; Benzodiazepine binding sites; β-Adrenoceptors; (Development) (Ruiz, G. (168) 251)

GABA-dependent $^{36}Cl^-$ flux
[^{3}H]GABA binding; [^{35}S]TBPS binding; Zolpidem; Benzodiazepine receptors (type I, type II) (Biggio, G. (161) 173)

$GABA_B$ receptor antagonists
Benzofuran-baclofen analogues; Baclofen; Ileum (guinea-pig); Neocortex (rat) (Kerr, D.I.B. (164) 361)

$GABA_A$ receptor complex
Progesterone metabolites; Barbiturate site; Prolactin; Pituitary (Vincens, M. (168) 15)

GABA receptors
Pertussis toxins; Sympathetic ganglion; (Rat) (Newberry, N.R. (163) 245)

5-Hydroxytryptamine (5-HT, serotonin); Intestine (small); Enterochromaffin cells; Muscimol; Baclofen (Schwörer, H. (165) 29)

Anticonvulsants; Seizures; Steroids; Progesterone metabolite; Cl^- ionophore (Belelli, D. (166) 325)

Chloride ionophore; Benzodiazepines; Steroids; Progesterone metabolites; Clonazepam; (Partial agonists) (Belelli, D. (167) 173)

Phaclofen; Inositol 1,4,5-triphosphate; Neuronal cultures (Michler, A. (167) 423)

Benzodiazepine receptor subtypes; Spinal cord; 2-Oxo-quazepam (Corda, M.G. (169) 205)

$GABA_A$ receptors
Cl^- channels; [^{35}S]TBPS binding; Isoniazid; (Modulators of GABAergic synapses) (Serra, M. (164) 385)

Gastric ulcer; Gastric mucoprotection; Stomach; [^{3}H]GABA binding; [^{3}H]Muscimol binding; (Rat) (Erdö, S.L. (165) 79)

$GABA_B$ receptors
Lithium; Carbamazepine; [^{3}H]Muscimol; [^{3}H](−)-Baclofen; Hippocampus (Motohashi, N. (166) 95)

Phaclofen; Hippocampus; Pyramidal cells (Karlsson, G. (163) 285)

GABA release
NMDA receptors; MK801; HA-966; Kynurenic acid; Ca^{2+} (intracellular) (Reynolds, I.J. (172) 9)

Quisqualate receptors; Kainate receptors; Glutamate; Striatal neurons; (Primary culture) (Pin, J.-P. (172) 81)

[^{3}H]GABA release
$GABA_B$ autoreceptors; (−)-Baclofen; Phaclofen; Muscimol; (Superfused synaptosomes) (Bonanno, G. (172) 41)

GABA uptake
THAO (5,6,7,8-tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol); Glia; Seizures; Pentylenetetrazol (PTZ); Isonicotinic acid hydrazide (Gonsalves, S.F. (168) 265)

Galanin
Capsaicin; Sensory nerves ('efferent' function of); Bronchi; Atrium; (Guinea-pig) (Giuliani, S. (163) 91)

Insulin release; cAMP; Rin m 5F cells (Amiranoff, B. (163) 205)

Myenteric plexus; Small intestine; (Circular muscle contraction, Guinea-pig) (Kuwahara, A. (164) 175)

Acetylcholine release; Hippocampus (ventral); (Intracellular recording, Slice, Rat) (Dutar, P. (164) 355)

Locus coeruleus; Brain slices; (Electrophysiology, Extracellular recording) (Seutin, V. (164) 373)

Colon (distal); Nifedipine; (Contraction, Mouse) (Fontaine, J. (164) 583)

Gallbladder
Tachykinins; Capsaicin; Substance P; Neurokinin A; Tachykinin receptors; Thiorphan; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Cholecystokinin (CCK); CCK-receptor antagonists; Bombesin; Loxiglumide (Douglas, B.R. (166) 307)

Gallopamil
Myocardial ischaemia; Coronary occlusion; K^+ loss; Haemodynamics; Ca^{2+} antagonists; Diltiazem; Nifedipine (Kirchengast, M. (160) 349)

Ganglia
5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptors; (Rat) (Newberry, N.R. (162) 197)

Ganglia (rat)
Muscarinic receptor subtypes; Muscarinic M_3-selective antagonists; Hexahydro-sila-difenidol analogues; p-Fluorohexahydro-sila-difenidol; Pirenzepine; Methoctramine; Vas deferens (rabbit); (Structure-activity relationships) (Lambrecht, G. (168) 71)

Ganglionic blocking agents
Vasodilators; Venous tone; Venodilators; Hexamethonium (D'Oyley, H.M. (162) 337)

Ganglionic inhibition
Dopamine DA_1 receptors; Dopamine DA_2 receptors; Dopamine DA_1 receptor agonists; Dopamine DA_1 receptor antagonists; Dopamine DA_2 receptor agonists; Dopamine DA_2 receptor antagonists (Kohli, J.D. (164) 265)

Gangliosides
Desipramine; β-Adrenoceptors; Forced swimming test; (Down-regulation) (Molina, V.A. (160) 247)

Gastric acid secretion
Adenosine receptors; Adenosine receptor agonists; (Rat) (Westerberg, V.S. (160) 275)

Gastrin antagonists; Brain CCK-B ligand; CCK-A receptors; (Radioligand binding, Non-peptide) (Lotti, V.J. (162) 273)

Parathyroid hormone (PTH); Gastric ulcers; CNS (Clementi, G. (166) 549)

Capsaicin; Gastric distension; Vagus nerve; Histamine; Pentagastrin; (Cholinergic stimulation) (Raybould, H.E. (167) 237)

Neuropeptides; Indomethacin; Dermorphin; Corticotropin-releasing factor (CRF); Calcitonin gene-related peptide (CGKP) (Guglietta, A. (170) 87)

Gastric distension
Capsaicin; Gastric acid secretion; Vagus nerve; Histamine; Pentagastrin; (Cholinergic stimulation) (Raybould, H.E. (167) 237)

Gastric emptying
Adrenoceptors; β-Adrenoceptor agonists; Clenbuterol; (Mouse) (Liberge, M. (164) 147)

Gastric lesions
Gastroprotection; Lipoxygenase; Cyclooxygenase (Konturek, S.J. (164) 285)

Gastric motility
Nicotine; Vagus nerve; Nicotinic receptors (central) (Nagata, M. (163) 85)

Gastric mucoprotection
$GABA_A$ receptors; Gastric ulcer; Stomach; [^{3}H]GABA binding; [^{3}H]Muscimol binding; (Rat) (Erdö, S.L. (165) 79)

Gastric mucosa
Ulcer; Vasoconstrictors; Endothelium; Endothelin (Wallace, J.L. (167) 41)

Gastric secretion
Ca^{2+} channel blockers; Stress ulcer; Verapamil; Nitrendipine; Diltiazem; Ethanol ulcer; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Gastric ulcers
$GABA_A$ receptors; Gastric mucoprotection; Stomach; [^{3}H]GABA binding; [^{3}H]Muscimol binding; (Rat) (Erdö, S.L. (165) 79)

Parathyroid hormone (PTH); Gastric acid secretion; CNS (Clementi, G. (166) 549)

Gastrin antagonists
Brain CCK-B ligand; Gastric acid secretion; CCK-A receptors; (Radioligand binding, Non-peptide) (Lotti, V.J. (162) 273)

Gastrointestinal motility
Antiemetic drugs; Autonomic ganglia; Enteric neurons; 5-Hydroxytryptamine (5-HT, serotonin) (Nemeth, P.R. (166) 387)

Gastroprotection
Lipoxygenase; Cyclooxygenase; Gastric lesions (Konturek, S.J. (164) 285)

GBR 12909 (1-(2-(bis(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenylpropyl)piperazine)
Basal ganglia; Cocaine; Dopamine; Neurotensin; Substantia nigra; Striatum (Hanson, G.R. (160) 23)

Dopamine uptake; Na^+ channels; Piperazine site; (Neurochemical properties, Voltage-dependent) (Andersen, P.H. (166) 493)

Motor activity; Dopamine; Reinforcement (conditioned); (Sensitization, Fixed-interval) (Kelley, A.E. (167) 385)

Gene expression
Chromaffin cells; Proenkephalin; PNMT (phenylethanolamine N-methyltransferase); mRNA; Glucocorticoids; Dexamethasone (Wan, D.C.-C. (172) 107)

General depressants
Ethanol; Ro 15-4513; Ethanol reduction (Bishop, B.E. (162) 265)

Gene regulation
Histamine; Proenkephalin A; PNMT (phenylethanolamine N-methyltransferase); Adrenal chromaffin cells (Wan, D.C.-C. (172) 117)

Glia
THAO (5,6,7,8-tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol); GABA uptake; Seizures; Pentylenetetrazol (PTZ); Isonicotinic acid hydrazide (Gonsalves, S.F. (168) 265)

Glibenclamide
Carbachol; Cromakalim; Vas deferens; (Rabbit) (Eltze, M. (161) 103)

K^+ channel activators; Pulmonary artery; (Guinea-pig) (Eltze, M. (165) 231)

Globus pallidus
μ-Opioid receptor agonists; κ-Opioid receptor agonists; Benzomorphans; Opioid receptors; Dynorphin A-(1-13); (Microiontophoresis) (Huffman, R.D. (170) 179)

Glomerular filtration rate
Endothelium; Endothelin; Glomerulus; Mesangial cells; Renal plasma flow; (Contraction) (López-Farré, A. (163) 187)

Glomerular hemodynamics
Endothelin; Thromboxane analogs; Thromboxane antagonists; Kidney (isolated, rat); Tubular function (Ferrario, R.G. (171) 127)

Glomerulus
Endothelium; Endothelin; Glomerular filtration rate; Mesangial cells; Renal plasma flow; (Contraction) (López-Farré, A. (163) 187)

Glucagon
Insulin; Somatostatin; Yohimbine; Propranolol; Vagotomy; (Secretion) (Ribes, G. (162) 207)

Glucocorticoid receptors
3,4-Methylenedioxymethamphetamine (MDMA); 5-Hydroxytryptamine; Striatum; Corticosterone; Neurotoxicity (Lowy, M.T. (163) 157)

Glucocorticoids
Dexamethasone; Vascular tissue; Vasocortin; Dextran oedema (Carnuccio, R. (166) 535)

Chromaffin cells; Proenkephalin; PNMT (phenylethanolamine N-methyltransferase); mRNA; Dexamethasone; Gene expression (Wan, D.C.-C. (172) 107)

Glucose uptake
[^{14}C]2-Deoxyglucose; Antipsychotics; Cholinergic pathways; Desenkephalin-γ-endorphin; Local cerebral glucose utilization; Org 5878; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Glutamate
2-Amino-4-phosphonobutyrate (APB); Cis-2,3-piperidine dicarboxylic acid (PDA); Retina; Acetylcholine; Glycine; (ON channel, OFF channel, Receptive field, Frog) (Jardon, B. (162) 215)

MK-801; Ketamine; Phencyclidine; N-Methyl-D-aspartate (NMDA); Glycine; Magnesium; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

NMDA receptors; Glycine; Kynurenate; Myenteric plexus (Moroni, F. (163) 123)

γ-Aminobutyric acid (GABA); Aspartate; Striatal slices; Apomorphine; Haloperidol; (K^+-evoked endogenous release) (Umeda, Y. (163) 291)

Quisqualate receptors; Kainate receptors; GABA release; Striatal neurons; (Primary culture) (Pin, J.-P. (172) 81)

L-Glutamate
Photoaffinity labeling; (Binding sites) (Voukelatou, G. (162) 179)

L-Aspartate; Acetylcholine; Bronchi; Chinese restaurant syndrome; (Modulation) (Aas, P. (164) 93)

Glutathione
Leukotriene C_4 (LTC_4); Glutathione transferase; (Receptors) (Goffinet, A.M. (161) 99)

Glutathione transferase
Leukotriene C_4 (LTC_4); Glutathione; (Receptors) (Goffinet, A.M. (161) 99)

Glyceryl trinitrate
Aorta; Acetylcholine; Endothelium; 6-keto-Prostaglandin $F_{1\alpha}$; Prostaglandin $F_{1\alpha}$; (Radioimmunoassay, Rat) (Bossaller, C. (165) 165)

Glycine
2-Amino-4-phosphonobutyrate (APB); Cis-2,3-piperidine dicarboxylic acid (PDA); Glutamate; Retina; Acetylcholine; (ON channel, OFF channel, Receptive field, Frog) (Jardon, B. (162) 215)

MK-801; Ketamine; Phencyclidine; N-Methyl-D-aspartate (NMDA); Glutamate; Magnesium; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

NMDA receptors; Kynurenate; Glutamate; Myenteric plexus (Moroni, F. (163) 123)

Dopamine release; Striatum; N-Methyl-D-aspartate (NMDA); Kynurenic acid; (Rat) (Krebs, M.-O. (166) 567)

N-Methyl-D-aspartate (NMDA); 1-Aminocyclobutane-1-carboxylate (ACBC); HA-966 (1-hydroxy-3-aminopyrrolidone-2); D-AP-7 (D-2-Amino-7-phosphonoheptanoate); Oocytes (*Xenopus*) (Watson, G.B. (167) 291)

Myenteric plexus; NMDA (N-methyl-D-aspartate); 7-Chlorokynurenic acid (Reggiani, A. (168) 123)

N-Methyl-D-aspartate (NMDA); NMDA-receptor complex; 3-(±)-2-(Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP); TCP (N-1[2-thienyl]cyclohexyl)3,4-piperidine; (Molecular target size, Receptors) (Honoré, T. (172) 239)

Glycoconjugates
Catecholamines; Corpus striatum; Lectins; Tetrabenazine; (Chromatography, Affinity) (Vincent, M.S. (172) 317)

Glycolysis
Flunarizine; Diltiazem; Energy charge potential (Ichihara, K. (165) 19)

GM1 ganglioside
Vincristine; Choline acetyltransferase; Choline uptake (high-affinity); Hippocampus (Di Patre, P.L. (162) 43)

MPTP; Nigrostriatal dopaminergic neurons; Dopamine receptors (Hadjiconstantinou, M. (168) 261)

cGMP
Vasopressin; ACTH; cAMP; Pituitary cells; AtT-20 corticotrophs; Corticotropin-releasing factor (CRF) (Koch, B. (158) 53)

Vasodilators; Protein phosphorylation; cAMP; Platelets; Phosphatidylinositols (Waldmann, R. (159) 317)

Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Kidney epithelial cell line (LLC-PK_1) (Iwata, T. (159) 321)

Smooth muscle (relaxation); Vasodilation; Endothelium; Nitric oxide; Nitrates (Buga, G.M. (161) 61)

Endothelium-derived relaxing factor (EDRF); Prostacyclin; Platelet aggregation; cAMP (Alheid, U. (164) 103)

cAMP; Cyclic nucleotides; Tetraethylammonium; Trachealis (Chideckel, E.W. (166) 367)

Endothelium-derived relaxing factor (EDRF); Ca^{2+}; Endothelial cell (Schmidt, K. (170) 157)

5-HT_3 receptors; Neuroblastoma × glioma hybrid cells (Reiser, G. (172) 195)

5-HT_3 receptors; Ion channels; Adamantane derivative; Neuroblastoma × glioma hybrid cells (Reiser, G. (172) 199)

Smooth muscle; UV light; Lipid peroxidation; Nitrite; Ca^{2+} (Nelemans, A. (172) 283)

NMDA receptors; Nitric oxide; Arginine (Garthwaite, J. (172) 413)

cGMP content
Hoe 065; Acetylcholine metabolism; Brain; (Rat) (Wiemer, G. (166) 31)

cGMP (plasma)
ANF-(99-126) (human); Cardiac accelerator nerve; Blood pressure; Cardiac output; Heart rate; (Neurotransmission, Anesthetized dog) (Bergey, J.L. (159) 103)

Goblet cells
Platelet-activating factor (PAF-acether, PAF); Inflammation; Mucus; Conjunctiva (Woodward, D.F. (168) 23)

Gonadotropin-releasing hormone (GnRH)
Antidepressants; Learned helplessness; (Rats) (Massol, J. (160) 395)

Gpp(NH)p (5′-guanylyl amidodiphosphate)
Adenylate cyclase (cardiac); Forskolin; (Circadian rhythm, In vitro stimulation) (Lemmer, B. (159) 311)

Gpp(NH)p sensitivity
Dynorphin A; μ-Opioid receptors; κ-Opioid receptors; Na^+ ions; (Agonist peptides); (Antagonist peptides) (Gairin, J.-E. (172) 381)

G-proteins (guanine nucleotide-binding proteins)
DDT_1 MF-2 cells; ATP; Sulfonylureas; (Patch clamp) (Molleman, A. (169) 167)

Muscarinic acetylcholine receptors; Cardiac tissue; Mg^{2+}; Na^+ (Hilf, G. (172) 155)

Adenylate cyclase; Noradrenaline; Heart cells; (Desensitization) (Reithmann, C. (172) 211)

Transmitter release; K^+ conductance; Pyramidal cells; cAMP (Fredholm, B.B. (172) 249)

Adenosine; A_1 adenosine receptors; Pertussis toxin; Heart (human); Heart failure (Böhm, M. (172) 407)

Neuropeptide Y (NPY); α_2-Adrenoceptors; Pertussis toxin; Medulla oblongata; (Rat) (Von Euler, G. (172) 435)

Insulin; Pharmacodynamics; Protein phosphorylation (Joost, H.G. (172) 461)

N-Formylmethionine-leucyl-phenylalanine (FMLP); Na^+; Pertussis toxin; HL 60 cells (Gierschik, P. (172) 481)

G_s-proteins
Heterologous desensitization; Adenylate cyclase; β-Adrenoceptor agonists; Reticulocytes; (Rat) (Yamashita, A. (159) 247)

GR43175
5-Hydroxytryptamine; 5-HT_2 receptors; Ketanserin; Coronary artery (human); 5-HT_1-like receptors (Connor, H.E. (161) 91)

[^{3}H]GR65630
5-HT_3 receptors; Area postrema; Vagus nerve; Brain (human); (Binding) (Kilpatrick, G.J. (159) 157)

Granule cells
Ro 15-4513 binding; Cerebellum; GABA (γ-aminobutyric acid); Diazepam; Ethanol (Malminiemi, O. (169) 53)

Grooming
Dopamine; Dopamine D-1 receptor agonists; Vacuous chewing (Murray, A.M. (160) 377)

Growth hormone
Leydig cells; Testosterone; Insulin-like growth factor I (IGF-I) (Horikawa, R. (166) 87)

GTP binding protein
Thromboxane A_2 receptors; Phosphoinositide hydrolysis; Pertussis toxin (IAP) (Nakahata, N. (162) 407)

GTP-binding protein
μ-Opioid receptors; Pertussis toxin; Adenylyl cyclase (Frey, E.A. (172) 347)

Guanabenz
Adrenergic neurotransmission; Purinergic neurotransmission; PGE_2; Guanethidine; (Neuromodulators) (Trachte, G.J. (164) 425)

Guanethidine
Adrenergic neurotransmission; Purinergic neurotransmission; PGE_2; Guanabenz; (Neuromodulators) (Trachte, G.J. (164) 425)

Guanine nucleotide effect
Cholecystokinin$_B$ (CCK_B) receptor solubilization; Cation effects; (Pig) (Gut, S.H. (172) 339)

Guanine nucleotide (GTP)
Dopamine D-1 receptors (solubilized); Polyethylene glycol; [^{3}H]SCH 23390; Striatum; (Rat) (Zhang, X. (166) 401)

Guanine nucleotide regulatory proteins
Adenylate cyclase; cAMP; Forskolin; Forskolin analogues; Macrophages; Manganese; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

Guanyl-5′-yl-imidophosphate
Prostaglandin E_2; Luteinizing hormone-releasing hormone (LHRH); Hypothalamus; Adenylyl cyclase (Wisner, A. (162) 89)

Gut motility
Neuromedin U; (Turtle) (Bockman, C.S. (171) 255)

H142/08
Acebutolol; Xamoterol; H201/70; β-Adrenoceptor agonists (partial); Atrium (right, isolated); (Rat) (Abrahamsson, T. (164) 121)

H201/70
Acebutolol; Xamoterol; H142/08; β-Adrenoceptor agonists (partial); Atrium (right, isolated); (Rat) (Abrahamsson, T. (164) 121)

Habituation
AF64A; Cognitive deficits; Learning (maze); Acetylcholinesterase; (Histology) (Gower, A.J. (166) 271)

[^{3}H]Acetylcholine release
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatum; [^{3}H]Dopamine release; [^{3}H]Spiroperidol binding; (Rat) (Kurstjens, N.P. (169) 147)

[^{3}H](−)-Adrenaline
α_2-Adrenoceptors; HT29 cell-line; [^{3}H]Yohimbine; [^{3}H]Clonidine; Colon adenocarcinoma (Sénard, J.-M. (162) 225)

Haemodynamics
Myocardial ischaemia; Coronary occlusion; K^+ loss; Ca^{2+} antagonists; Gallopamil; Diltiazem; Nifedipine (Kirchengast, M. (160) 349)

Dopamine; Ibopamine; Isovolumic relaxation; (Mathematical models) (Bernardi, L. (164) 415)

Endothelin; Platelet aggregation; Piroxicam; Cyclo-oxygenase; (Rabbit) (Lidbury, P.S. (166) 335)

Haemoglobin
Endothelium-derived relaxing factor (EDRF); Red blood cells (Evans, H.G. (163) 361)

Haemolysate
Hypoxia; Cerebral artery (middle); Endothelium; BW755C; 5-Hydroxytryptamine (5-HT, serotonin); (Sheep) (Klaas, M. (168) 187)

Haemophilus influenzae
Pulmonary β-adrenoceptors; Atopic guinea-pig; (Autoradiography) (Engels, F. (164) 139)

HA-966 (1-hydroxy-3-aminopyrrolidone-2)
Excitatory amino acids; N-Methyl-D-aspartate (NMDA); Hippocampus; Norepinephrine release (Keith, R.A. (166) 393)

N-Methyl-D-aspartate (NMDA); Glycine; 1-Aminocyclobutane-1-carboxylate (ACBC); D-AP-7 (D-2-Amino-7-phosphonoheptanoate); Oocytes (*Xenopus*) (Watson, G.B. (167) 291)

NMDA receptors; MK801; Kynurenic acid; GABA release; Ca^{2+} (intracellular) (Reynolds, I.J. (172) 9)

Hallucinogens
Drug discrimination; Mescaline; 5-HT receptors; 5-HT_1 receptors; 5-HT_2 receptors (Appel, J.B. (159) 41)

Haloperidol
Delta sleep-inducing peptide; Antidepressants; Pentobarbital; Brain regions; Adrenalectomy; (Rat) (Wahlestedt, C. (159) 285)

Dopamine receptors; Aggression (intraspecies); SCH 23390; Clozapine (McMillen, B.A. (160) 149)

Neurokinin A; Substance P; Tachykinin; Substantia nigra; Microdialysis (Lindefors, N. (161) 95)

SCH 23390; Dopamine; Depolarization block; (Electrophysiology, Rat) (Esposito, E. (162) 109)

Homovanillic acid; Striatum; Prefrontal cortex; (Tolerance) (Chang, W.-H. (162) 151)

γ-Aminobutyric acid (GABA); Aspartate; Glutamate; Striatal slices; Apomorphine; (K^+-evoked endogenous release) (Umeda, Y. (163) 291)

σ Receptors; Psychotomimetic (+)-benzomorphans; 1,3-Di-o-tolylguanidine; (+)-3-(3-Hydroxyphenyl)-N-(1-propyl)piperidine; (Allosteric interaction) (Bowen, W.D. (163) 309)

Neurotensin; Atropine; Scopolamine; Nucleus accumbens; Caudate nucleus (Levant, B. (165) 327)

Antipsychotic substances; Dopamine; Sulpiride; Desenkephalin-γ-endorphin (DEγE); Brain regions (Van Ree, J.M. (166) 441)

Amphetamine; Dopamine; Striatum; Hippocampus; Calmodulin translocation (Popov, N. (172) 205)

Haloperidol (intermittent)
Tardive dyskinesia; Oral dyskinesia; Neuroleptic sensitization; Amygdala kindling; (Drug holidays, Rat) (Glenthøj, B. (164) 393)

Haloperidol treatment
γ-Aminobutyric acid (GABA); Dopamine; Convulsions; Stereotypy (Sandoval, M.R.L. (167) 117)

Halothane
K^+ channels; Hyperpolarization; Ca^{2+} (Scharff, O. (159) 165)

Head twitches
5-HT_{1A} receptor agonists; 5-HT_{1B} receptor agonists; 5-HT_2 receptor agonists; Forepaw treading (Arnt, J. (161) 45)

Heart
Cerebral cortex (rat); Muscarinic receptors; Bretylium tosylate (Gillard, M. (160) 117)

Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Kidney; Endothelium; (Receptor) (Oehlenschlager, W.F. (161) 159)

Opioid receptors; Prostaglandins; Dynorphin (Ledda, F. (162) 323)

Nicorandil; Ischemia; Reperfusion; Arrhythmias; (Rat) (Kempsford, R.D. (163) 61)

Adenosine; Nitrobenzylthioinosine; Nucleoside transport; Autoradiography (quantitative); (Guinea-pig) (Parkinson, F.E. (163) 69)

Adenosine; 5′-N-Ethylcarboxamideadenosine (NECA); Negative inotropic effect; Adenylate cyclase; cAMP content; (−)-N^6-Phenylisopropyladenosine (PIA); (Guinea-pig) (Heller, T. (164) 179)

Endothelin; Blood vessels; Uterus; Trachea; Vas deferens; Platelets; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Hypoxia; ATP; Adenosine; Endothelium-derived relaxing factor (EDRF) (Hopwood, A.M. (165) 323)

4-DAMP (4-diphenylacetoxy-N-methyl-piperidine methiodide); Muscarinic receptors; Submaxillary gland; Cortex (Michel, A.D. (166) 459)

Antiarrhythmics; Lidocaine binding site; Na^+ channels; Liver (Voigt, W. (169) 103)

Sensory nerves; [D-Ala^2,D-Leu^5]enkephalin (DADLE); [D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin (DAGO); Capsaicin (Mantelli, L. (170) 217)

Heart cells
Isoproterenol; Ca^{2+} channel blockers (Briand, V. (166) 339)

β-Adrenoceptor antagonists; Sympathomimetic activity (intrinsic); β_1 Selectivity; Noradrenaline (Reithmann, C. (170) 243)

Adenylate cyclase; Guanine nucleotide-binding protein; Noradrenaline; (Desensitization) (Reithmann, C. (172) 211)

Heart failure
Adenosine; A_1 adenosine receptors; Pertussis toxin; Heart (human); G proteins (Böhm, M. (172) 407)

Heart functions
Platelet activating factor (PAF-acether, PAF); BN 52021; Arrhythmias; Ischemia and reperfusion; (Rat) (Koltai, M. (164) 293)

Heart (human)
Adenosine; A_1 adenosine receptors; Pertussis toxin; G proteins; Heart failure (Böhm, M. (172) 407)

Heart (isolated, working)
β-Adrenoreceptor antagonists; Cardioprotection; Anoxia; (Guinea-pig) (Marie, P.-Y. (163) 337)

Heart (perfused, working)
Propranolol; Ischemia; Myocardium; Non-esterified fatty acids; (Rat) (Nakamura, K. (160) 61)

Ischemia; Nicorandil; Nipradilol; (Rat) (Haneda, T. (162) 81)

Lidocaine; Ischemia; Myocardium; Fatty acids (non-esterified); (Rat) (Nakamura, K. (169) 259)

Heart (porcine)
Endothelin receptors; ^{125}I-Endothelin-1; Atrioventricular node; Autoradiography (quantitative receptor) (Yamasaki, H. (168) 247)

Heart rate
ANF-(99-126) (human); cGMP (plasma); Cardiac accelerator nerve; Blood pressure; Cardiac output; (Neurotransmission, Anesthetized dog) (Bergey, J.L. (159) 103)

Blood flow (gastric, hepatic, intestinal, kidney); Arterial pressure; Nifedipine (Van Berlo, C.L.H. (160) 17)

Phenylalanine; Tyrosine; Arterial pressure (mean); Phenethylamine; (Rat) (Yourick, D.L. (160) 219)

Taurine; Blood pressure; Ventilation; Pentobarbitone anaesthesia (Petty, M.A. (162) 359)

L-Tyrosine; Blood pressure; Tyrosine metabolism (Ekholm, S. (163) 209)

Myocardium; Contractility; Adenosine; Alinidine; (Action potential) (Lang, U. (164) 13)

DPI 201-106; Hemodynamic effects; Positive inotropic effects; Contractility; (Conscious dog) (Gerard, J.-L. (165) 39)

Apomorphine; Dopamine; Dopamine DA2 receptors; Domperidone; SCH 23390; Vagus nerve (Montastruc, P. (166) 511)

L-Tyrosine; Blood pressure; Autonomic nervous system; Histamine receptors; Prostaglandin synthesis (Ekholm, S. (168) 145)

Hematocrit
Peptidoleukotriene; Splanchnic artery occlusion; SK&F 104353; Myocardial depressant factor; Cathepsin D (Lento, P.H. (165) 241)

Hemodynamic effects
DPI 201-106; Positive inotropic effects; Contractility; Heart rate; (Conscious dog) (Gerard, J.-L. (165) 39)

Hemodynamic response (acute)
Furosemide; Loop diuretics; Spontaneously hypertensive rats (SHR); Sinoaortic baroreceptors (Janssen, B.J.A. (170) 1)

Hemodynamics
KC 8857; Bradycardiac agents (selective); Myocardial dysfunction (regional); (Exercise) (Grohs, J.G. (161) 53)

Myocardially infarcted rat; Milrinone; Enalapril; Cardiomegaly (compensated) (DeFelice, A. (167) 211)

Blood flow; Cardiac output; Endothelin; Vascular resistance (Ais, G. (170) 113)

Hemodynamics (regional)
Endothelin; Vasoconstriction; Arterial pressure regulation (Han, S.P. (159) 303)

Hemoglobin
Pulmonary arteries; Endothelium; Endothelium-derived relaxing factor (EDRF); (Modulation of contraction) (Yamaguchi, T. (161) 259)

Hemolysate
Myogenic tone; Cerebral artery; Vasospasm; Ca^{2+} antagonists; Endothelium (Nakayama, K. (169) 33)

Hemorphin-4
Opioid receptors; Cytochrophin-4; κ Sites; β-Casomorphins (Liebmann, C. (166) 523)

Heroin
Self-administration; Narcotic analgesia; Physical dependence; (Unit dose, Intraventricular, Rat) (De Vry, J. (161) 19)

Heterologous desensitization
Adenylate cyclase; G_s proteins; β-Adrenoceptor agonists; Reticulocytes; (Rat) (Yamashita, A. (159) 247)

Neurotensin; Fura 2; Ca^{2+} mobilization; Inositol trisphosphate; NG108-15 cells (Imaizumi, T. (161) 203)

Hexahydrodifenidol
Muscarinic M_1 receptors (Freedman, S.B. (167) 411)

Hexahydro-sila-difenidol
Muscarinic M_3 receptor subtypes; HT-29 colon carcinoma cells; Phosphatidylinositol metabolism; AF-DX 116; Silahexocyclium; Methoctramine (Kopp, R. (172) 397)

Hexahydro-sila-difenidol analogues
Muscarinic receptor subtypes; Muscarinic M_3-selective antagonists; p-Fluoro-hexahydro-sila-difenidol; Pirenzepine; Methoctramine; Vas deferens (rabbit); Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

Hexamethonium
Vasodilators; Venous tone; Venodilators; Ganglionic blocking agents (D'Oyley, H.M. (162) 337)

High-energy phosphates
α-Adrenoceptor antagonists; Cell membrane permeability; Creatine kinase; Hypoxia; Reoxygenation; YM-12617 (Tanonaka, K. (165) 97)

High pressure neurological syndrome
NMDA receptor antagonists (non-competitive); NMDA receptor channel complex (Wardley-Smith, B. (165) 107)

Hind-paw edema (rat)
Cardiotoxin; Mast cells; PMN (polymorphonuclear) leukocytes; Kinin formation (Wang, J.-P. (161) 9)

Hippocampal slices
α_2-Adrenoceptors; Morphine dependence; Morphine withdrawal; [^{3}H]Clonidine binding; Brain; (Field stimulation, Rat) (Smith, C.B. (161) 111)

Antidepressants; α_1-Adrenoceptors; Phenylephrine (Bijak, M. (166) 183)

Hippocampus
Cultured explants; Septum; Cholinergic reinnervation; Muscarinic receptor subtypes; (Up-regulation, Down-regulation) (Rimvall, K. (160) 1)

5-HT receptors; Dopamine receptors; Na^+,K^+-ATPase; Striatum; Central nervous system (CNS); Spaceflight (Miller, J.D. (161) 165)

GM1 ganglioside; Vincristine; Choline acetyltransferase; Choline uptake (high-affinity) (Di Patre, P.L. (162) 43)

$GABA_B$ receptors; Phaclofen; Pyramidal cells (Karlsson, G. (163) 285)

9-Amino-1,2,3,4-tetrahydroacridine (THA); K^+ conductance (inwardly rectifying); Adenosine; Baclofen; 5-HT; (Alzheimer's disease) (Halliwell, J.V. (163) 369)

Ethanol; cAMP; Ca^{2+}; After-hyperpolarization; (Neuronal firing) (Benson, D.M. (164) 591)

5-HT_1 receptor subtypes; Acetylcholine release; (Electrically stimulated slices, Rat) (Maura, G. (165) 173)

Lithium; Carbamazepine; [^{3}H]Muscimol; [^{3}H](−)-Baclofen; $GABA_B$ receptors (Motohashi, N. (166) 95)

HA-966 (1-hydroxy-3-aminopyrrolidone-2); Excitatory amino acids; N-Methyl-D-aspartate (NMDA); Norepinephrine release (Keith, R.A. (166) 393)

Buspirone; 5-Hydroxytryptamine (5-HT, serotonin); Excitatory synaptic transmission (O'Connor, J.J. (167) 21)

Nicotine; Catecholamine synthesis; 5-HT synthesis; Nucleus accumbens; Hypothalamus (Mitchell, S.N. (167) 311)

Lidocaine; Carbamazepine; Phenytoin; Seizures (lidocaine-kindled); [^{3}H]Batrachotoxin binding (Zimányi, I. (167) 419)

Cromakalim (BRL 34915); K^+ channels; Tetraethylammonium; (Whole cell patch clamp) (Politi, D.M.T. (168) 7)

5-HT_1 receptors; Acetylcholine release; Minaprine (Bolanos, F. (168) 87)

Adenylate cyclase; Striatum; Ca^{2+}; Lithium (Mørk, A. (168) 347)

Buspirone; Elevated plus maze; Open field; (Microinjections) (Kostowski, W. (168) 393)

3,4-Diaminopyridine; Noradrenaline release; Phorbol ester; Protein kinase C (Huang, H.Y. (169) 115)

Benzodiazepines; 5-Hydroxytryptamine (5-HT), serotonin; GABA (Lista, A. (171) 229)

Amphetamine; Haloperidol; Dopamine; Striatum; Calmodulin translocation (Popov, N. (172) 205)

Muscarinic receptor subtypes; [^{3}H]Pirenzepine; Receptor-G protein coupling; N-Ethylmaleimide (NEM); (Agonists) (Flynn, D.D. (172) 363)

Hippocampus (ventral)
Galanin; Acetylcholine release; (Intracellular recording, Slice, Rat) (Dutar, P. (164) 355)

Histamine
Smooth muscle (intestinal); Signal-contraction coupling; Substance P; K^+ depolarization; Diacylglycerol; (Guinea-pig) (Lippe, I.T. (159) 1)

Fentanyl; 5-Hydroxytryptamine; Respiratory conductance; (Guinea-pig) (Gentil, B. (159) 181)

Hyperosmolarity; H_1 receptor antagonists; H_2 receptor antagonists; Nasal fluid secretions (Petersson, G. (161) 37)

Anaphylaxis; Airway hyperreactivity; Inflammation (Daffonchio, L. (161) 135)

Peptidoleukotrienes; Microvascular permeability (Woodward, D.F. (164) 323)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Neurotoxins; Brain; (Mouse) (Cumming, P. (166) 299)

Capsaicin; Gastric distension; Gastric acid secretion; Vagus nerve; Pentagastrin; (Cholinergic stimulation) (Raybould, H.E. (167) 237)

Kinin; Substance P; Mast cells (peritoneal) (Devillier, P. (168) 53)

Cardiac arrhythmias; Hypertension; Myocardial hypertrophy; Spontaneously hypertensive rat (SHR) (Cameron, J.S. (169) 23)

Aortic endothelial cells; Bradykinin; (Rat) (Cole, O.F. (169) 307)

Proenkephalin A; PNMT (phenylethanolamine N-methyltransferase); Gene regulation; Adrenal chromaffin cells (Wan, D.C.-C. (172) 117)

Functional antagonism; Smooth muscle (airway); Muscarinic receptor agonists; Phosphoinositide metabolism; β-Adrenergic relaxation (Van Amsterdam, R.G.M. (172) 175)

Histamine H_3 receptor agonists
(R)-α-Methylhistamine; Electrical field stimulation; Bronchi; (Human) (Ichinose, M. (163) 383)

Histamine H_1 receptor antagonists
Hyperosmolarity; Histamine; H_2 receptor antagonists; Nasal fluid secretions (Petersson, G. (161) 37)

Histamine H_2 receptor antagonists
Hyperosmolarity; Histamine; H_1 receptor antagonists; Nasal fluid secretions (Petersson, G. (161) 37)

Histamine H_1 receptors
BTM-1086; BTM-1041; Muscarinic receptor subtypes; α_1-Adrenoceptors; (Stereoselectivity) (Eltze, M. (170) 225)

Histamine receptors
L-Tyrosine; Blood pressure; Heart rate; Autonomic nervous system; Prostaglandin synthesis (Ekholm, S. (168) 145)

Histamine release
Retinoic acid; Retinal; Phorbol esters; Ca^{2+}; Mast cells (Cantwell, M.E. (160) 43)

[^{3}H]Histamine synthesis
(R)α-Methylhistamine; Thioperamide; Histamine turnover; N^τ-Methylhistamine (Garbarg, M. (164) 1)

Histamine turnover
(R)α-Methylhistamine; Thioperamide; [^{3}H]Histamine synthesis; N$^\tau$-Methylhistamine (Garbarg, M. (164) 1)

HIV-1
Protease; Protein dimer; Mutagenesis; Synthetic gene (Guenet, C. (172) 443)

HL 60 cells
N-Formylmethionine-leucyl-phenylalanine (FMLP); Guanine nucleotide-binding protein (G-protein); Na^+; Pertussis toxin (Gierschik, P. (172) 481)

Hoe 065
Acetylcholine metabolism; cGMP content; Brain; (Rat) (Wiemer, G. (166) 31)

Learning; Memory; Avoidance (inhibitory, passive); (Up-hill avoidance, Eight-arm radial maze) (Hock, F.J. (171) 79)

Homovanillic acid
Striatum; Prefrontal cortex; Haloperidol; (Tolerance) (Chang, W.-H. (162) 151)

Hot plate test
Analgesia; Formalin test; Nociception; Orphenadrine citrate; Serotonin (Hunskaar, S. (160) 83)

5-HT$_{1C}$
Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

5-HT$_{1B}$ binding sites
Sumatriptan (GR 43175); 5-HT$_{1D}$ binding sites (Peroutka, S.J. (163) 133)

5-Hydroxytryptamine (5-HT, serotonin); Smooth muscle cells (vascular); 5-HT$_2$ binding sites; (Tissue culture) (Jazayeri, A. (169) 183)

5-HT$_{1D}$ binding sites
Sumatriptan (GR 43175); 5-HT$_{1B}$ binding sites (Peroutka, S.J. (163) 133)

5-HT$_2$ binding sites
5-Hydroxytryptamine (5-HT, serotonin); Smooth muscle cells (vascular); 5-HT$_{1B}$ binding sites; (Tissue culture) (Jazayeri, A. (169) 183)

5-HT$_3$ binding sites
5-HT$_3$ receptor antagonists; Cortex; Brain; (Rat) (Wong, D.T. (166) 107)

HT29 cell-line
α_2-Adrenoceptors; [^{3}H](−)-Adrenaline; [^{3}H]Yohimbine; [^{3}H]Clonidine; Colon adenocarcinoma (Sénard, J.-M. (162) 225)

α_{2A}-Adrenoceptors; [^{3}H]RX821002; [^{3}H]Yohimbine; [^{3}H]Idazoxan; [^{3}H]UK14,304 (Langin, D. (167) 95)

HT-29 colon carcinoma cells
Muscarinic M_3 receptor subtypes; Phosphatidylinositol metabolism; AF-DX 116; Sila-hexocyclium; Hexhydro-sila-difenidol; Methoctramine (Kopp, R. (172) 397)

5-HT$_1$-like receptors
5-Hydroxytryptamine; 5-HT$_2$ receptors; Ketanserin; Coronary artery (human); GR43175 (Connor, H.E. (161) 91)

Arteriovenous anastomoses; Carotid blood flow; 5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptors; Migraine; RU 24969 (Bom, A.H. (171) 87)

5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; Methysergide; 5-HT$_2$ receptors; Renal function (Shoji, T. (171) 219)

5-HT metabolism
Odansetron (GR 38032F); 5-HT$_3$ receptors; Dopamine metabolism (Koulu, M. (169) 321)

5-HT receptor agonists
Chewing behaviour; 5-HT antagonists; Acetylcholine-5-HT interaction (Stewart, B.R. (162) 101)

5-HT receptor antagonists
Chewing behaviour; 5-HT agonists; Acetylcholine-5-HT interaction (Stewart, B.R. (162) 101)

5-HT$_{1A}$ receptor agonists
Raphe nuclei; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Motor control; (Rat) (Hillegaart, V. (160) 303)

5-HT$_{1B}$ receptor agonists; 5-HT$_2$ receptor agonists; Head twitches; Forepaw treading (Arnt, J. (161) 45)

NMDA receptor antagonists; Anxiolytic effect; Social interaction; (Elevated plus maze) (Dunn, R.W. (169) 1)

BP-554; 5-HT receptors; 8-OH-DPAT (Matsuda, T. (170) 75)

5-HT$_{1B}$ receptor agonists
5-HT$_{1A}$ receptor agonists; 5-HT$_2$ receptor agonists; Head twitches; Forepaw treading (Arnt, J. (161) 45)

5-HT$_2$ receptor agonists
5-HT$_{1A}$ receptor agonists; 5-HT$_{1B}$ receptor agonists; Head twitches; Forepaw treading (Arnt, J. (161) 45)

5-HT$_2$ receptor down-regulation; DOM (1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane) (Leysen, J.E. (163) 145)

5-HT receptor antagonism
5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; Pulmonary hypertension; Vascular effects (Le Roux, M.G.J. (169) 269)

5-HT_2 receptor antagonists
Seganserin; Sleep; EEG (human); Spectral analysis (Dijk, D.J. (171) 207)

5-HT_3 receptor antagonists
Dopamine; Antipsychotic agents; Substantia nigra; (Electrophysiology) (Sorensen, S.M. (163) 115)

5-HT_3 binding sites; Cortex; Brain; (Rat) (Wong, D.T. (166) 107)

5-HT_2 receptor down-regulation
5-HT_2 receptor agonists; DOM (1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane) (Leysen, J.E. (163) 145)

5-HT receptors
Drug discrimination; Hallucinogens; Mescaline; 5-HT_1 receptors; 5-HT_2 receptors (Appel, J.B. (159) 41)

Dopamine receptors; Na^+,K^+-ATPase; Hippocampus; Striatum; Central nervous system (CNS); Spaceflight (Miller, J.D. (161) 165)

5-Hydroxytryptamine (5-HT, serotonin); Ganglia; (Rat) (Newberry, N.R. (162) 197)

Prolactin; Quipazine (Di Renzo, G. (162) 371)

Blood platelets; Brain; [^{3}H]SCH 23390; Dopamine D-1 receptors; (Human) (De Keyser, J. (162) 437)

Coronary artery (pig); Noradrenaline release; (Presynaptic receptors) (Molderings, G.J. (164) 213)

Adrenoceptors; Blood pressure; Ketanserin; Phentolamine (Dhasmana, K.M. (168) 257)

Zacopride (benzamides); Ileum; (Binding sites, Radioligand assay, Rabbit) (Pinkus, L.M. (168) 355)

BP-554; 5-HT_{1A} receptor agonists; 8-OH-DPAT (Matsuda, T. (170) 75)

Arteriovenous anastomoses; Carotid blood flow; 5-Hydroxytryptamine (5-HT, serotonin); 5-HT_1-like receptors; Migraine; RU 24969 (Bom, A.H. (171) 87)

5-HT_1 receptors
Drug discrimination; Hallucinogens; Mescaline; 5-HT receptors; 5-HT_2 receptors (Appel, J.B. (159) 41)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); RU 24969; Morphine withdrawal; (Mouse) (Berthold, H. (162) 19)

Acetylcholine release; Minaprine; Hippocampus (Bolanos, F. (168) 87)

5-HT_{1A} receptors
[^{3}H]Rauwolscine; α_2-Adrenoceptors; Cerebral cortex membranes (human) (Convents, A. (159) 307)

Dopamine receptors (presynaptic, postsynaptic); Indolylbutylamines; Acetylcholine; Turning behaviour; Serotonin (Seyfried, C.A. (160) 31)

SK&F 104078; α_2-Adrenoceptors; 5HT_2 receptors (Kilpatrick, A.T. (166) 315)

8-OH-DPAT; Behaviour; Stereoselectivity; Partial agonists; (+)ALK-3 ((+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin); (Rat) (Hjorth, S. (170) 269)

α_1-Adrenoceptor subtypes; Niguldipine; [^{3}H]5-Methyl-urapidil (Graziadei, I. (172) 329)

5-HT_{1C} receptors
Anxiety; mCPP (1-(3-chlorophenyl)piperazine); TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine) (Kennett, G.A. (164) 445)

l-5-Hydroxytryptophan (l-5-HTP); Ritanserin; 5,7-DHT (5,7-Dihydroxytryptamine); 5-HT syndrome (Colpaert, F.C. (169) 175)

5-HT_2 receptors
Drug discrimination; Hallucinogens; Mescaline; 5-HT receptors; 5-HT_1 receptors (Appel, J.B. (159) 41)

Tetrabenazine; Imipramine; α_1-Adrenoceptors; β-Adrenoceptors; Phosphoinositide hydrolysis (Butler, P.D. (160) 93)

5-Hydroxytryptamine; Ketanserin; Coronary artery (human); 5-HT_1-like receptors; GR43175 (Connor, H.E. (161) 91)

Wet-dog shakes; 5-HT uptake inhibitors; MAO inhibition; Spinal cord; (Receptor regulation) (Koshikawa, N. (164) 595)

SK&F 104078; α_2-Adrenoceptors; 5-HT_{1A} receptors (Kilpatrick, A.T. (166) 315)

Morphine; Tolerance-dependence; Abstinence; Brain regions; Spinal cord (Gulati, A. (167) 185)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-Hydroxytryptamine (5-HT, serotonin); Pithed rat (Dabiré, H. (168) 369)

Minaprine; Cycloheximide; Serotonergic system; Cholinergic system; Amnesia; (Mouse) (Nabeshima, T. (169) 249)

DOI (1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane; (Partial agonism) (Dabiré, H. (170) 109)

5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; Methysergide; 5-HT_1-like receptors; Renal function (Shoji, T. (171) 219)

[^{125}I]7-Amino-8-iodo-ketanserin ([^{125}I]AMIK); α_1-Adrenoceptors; Release sites; (Quantitative autoradiography) (Schotte, A. (172) 99)

5-HT$_3$ receptors
BRL 43694 (endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride); 5-Hydroxytryptamine (5-HT, serotonin) (Sanger, G.J. (159) 113)

[^{3}H]GR65630; Area postrema; Vagus nerve; Brain (human); (Binding) (Kilpatrick, G.J. (159) 157)

Opiate receptors; [^{3}H]Zacopride; [^{3}H]Bremazocine; [^{3}H]Naloxone; Spinal cord; Capsaicin; (Rat) (Hamon, M. (164) 315)

Dopamine; Microdialysis; ICS 205-930; Morphine; Amphetamine (Carboni, E. (164) 515)

Odansetron (GR 38032F); Dopamine metabolism; 5-HT metabolism (Koulu, M. (169) 321)

5-Hydroxytryptamine (5-HT, serotonin); ICS 205-930; MDL 72222; Analgesia; Inflammation (Giordano, J. (170) 83)

cGMP; Neuroblastoma × glioma hybrid cells (Reiser, G. (172) 195)

Ion channels; cGMP; Adamantane derivative; Neuroblastoma × glioma hybrid cells (Reiser, G. (172) 199)

Radiation inactivation; Cerebral cortex (rat); Molecular weight; [^{3}H]Zacopride (Gozlan, H. (172) 497)

5-HT receptors (non-classical)
5-Hydroxytryptamine (5-HT); Benzamides (substituted); cAMP formation (Dumuis, A. (162) 381)

5-HT receptor subtypes
Pulmonary edema; Capillary pressure; Filtration coefficient; Ketanserin; Methysergide (Sumita, T. (164) 69)

5-HT$_1$ receptor subtypes
Acetylcholine release; Hippocampus; (Electrically stimulated slices, Rat) (Maura, G. (165) 173)

5-HT$_{1B}$ receptor subtypes
TFMPP (1-(3-trifluoromethylphenyl)piperazine); Ventral tegmental area; Forced swimming test; Desipramine; (Rat) (Cervo, L. (171) 119)

5-HT release
Botulinum A toxin; α_2-Adrenoceptors (presynaptic); Phorbol ester; Protein kinase C; Noradrenaline release (Nakov, R. (164) 45)

Mast cells; Benzodiazepine binding sites; Ca^{2+} influx; Calmodulin; BAY k 8644 (Suzuki-Nishimura, T. (167) 75)

Skin (*Pseudophryne coriacea*); Cerebral cortex (rat); Acetylcholine release; (Superfused synaptosomes) (Raiteri, M. (172) 223)

5-HT$_3$ (sites)
5-Hydroxytryptamine (5-HT, serotonin); Quipazine; Arylpiperazines; (Radioligand binding) (Glennon, R.A. (168) 387)

5-HT syndrome
MPP^+ (1-methyl-4-phenylpyridinium); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Serotonin; Microdialysis; Dopamine (Miyake, H. (166) 49)

l-5-Hydroxytryptophan (l-5-HTP); Ritanserin; 5,7-DHT (5,7-Dihydroxytryptamine); 5-HT$_{1C}$ receptors (Colpaert, F.C. (169) 175)

5-HT synthesis
Nicotine; Catecholamine synthesis; Nucleus accumbens; Hypothalamus; Hippocampus (Mitchell, S.N. (167) 311)

5-HT uptake
Ataxia; Dopamine turnover; MK-801; Phencyclidine (PCP); Stereotyped behavior; (Rat) (Hiramatsu, M. (166) 359)

[^{3}H]Cyanoimipramine binding; Brofaromine; Moclobemide; Ifoxetine; 5-HT uptake inhibitors (Waldmeier, P.C. (169) 197)

5-HT uptake inhibitors
5-HT$_2$ receptors; Wet-dog shakes; MAO inhibition; Spinal cord; (Receptor regulation) (Koshikawa, N. (164) 595)

5-HT uptake; [^{3}H]Cyanoimipramine binding; Brofaromine; Moclobemide; Ifoxetine (Waldmeier, P.C. (169) 197)

HU-211
Cisplatin; Emesis; Cannabinoid; Δ^1-Tetrahydrocannabinol; 7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl; Cupric chloride; (Pigeon) (Feigenbaum, J.J. (169) 159)

α-Human atrial natriuretic peptide (α-hANP)
Nitroglycerin; Coronary vasodilatation; (Conscious dog, Intracoronary administration) (Adachi, H. (161) 189)

Hydralazine
Norepinephrine spillover rate; Prazosin; Norepinephrine concentration (plasma); Mean arterial pressure; (Rat) (Keeton, T.K. (164) 479)

6-Hydroxydopamine (6-OHDA)
Kinins; Nociception; Spinal cord; Noradrenergic mechanism; Monoamine content (Laneuville, O. (159) 273)

Thyroid hormone; (Na^+,K^+)-ATPase; Noradrenaline (metabolic effects); Ouabain binding (Swann, A.C. (169) 275)

6-Hydroxydopamine (6-OHDA, neonatal)
MIF-1; Prolyl-leucyl-glycinamide; Apomorphine; Dopamine; (Behaviour, Development) (Kostrzewa, R.M. (163) 33)

7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl
Cisplatin; Emesis; Cannabinoid; Δ^1-Tetrahydrocannabinol; Cupric chloride; HU-211; (Pigeon) (Feigenbaum, J.J. (169) 159)

5-Hydroxyindole acetic acid (5-HIAA)
Imipramine; Pharmacokinetics (cerebral); 5-Hydroxytryptamine (5-HT, serotonin); Norepinephrine; 3-Methoxy-4-hydroxyphenylglycol (MHPG) (Sugita, S. (165) 191)

5-Hydroxytryptamine (5-HT, serotonin)
BRL 43694 (endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride); 5-HT_3 receptors (Sanger, G.J. (159) 113)

Fentanyl; Histamine; Respiratory conductance; (Guinea-pig) (Gentil, B. (159) 181)

Dopamine receptors (presynaptic, postsynaptic); Indolylbutylamines; Acetylcholine; Turning behaviour; 5-HT_{1A} receptors (Seyfried, C.A. (160) 31)

Analgesia; Formalin test; Hot plate test; Nociception; Orphenadrine citrate (Hunskaar, S. (160) 83)

β-Endorphin; Analgesia (intrathecal); Norepinephrine (Crisp, T. (160) 211)

Norepinephrine; Platelet adhesion; Eicosapentaenoic acid; Vascular reactivity (Pfister, S.L. (161) 85)

5-HT_2 receptors; Ketanserin; Coronary artery (human); 5-HT_1-like receptors; GR43175 (Connor, H.E. (161) 91)

Adrenalectomy; Corticosterone; 3,4-Methylenedioxymethamphetamine (MDMA); Tryptophan hydroxylase; (Neurotoxicity) (Johnson, M. (161) 181)

5-HT receptors; Ganglia; (Rat) (Newberry, N.R. (162) 197)

Benzamides (substituted); cAMP formation; 5-HT receptors (non-classical) (Dumuis, A. (162) 381)

Synaptosomes; α-Methyldopa; α-Methyldopamine (Wolf, W.A. (163) 43)

d-Fenfluramine; d-Norfenfluramine; p-Chloroamphetamine; L-Cysteine; Neurotoxicity (Invernizzi, R. (163) 77)

3,4-Methylenedioxymethamphetamine (MDMA); Glucocorticoid receptors; Striatum; Corticosterone; Neurotoxicity (Lowy, M.T. (163) 157)

9-Amino-1,2,3,4-tetrahydroacridine (THA); K^+ conductance (inwardly rectifying); Hippocampus; Adenosine; Baclofen; (Alzheimer's disease) (Halliwell, J.V. (163) 369)

Noradrenaline; Adrenergic nerves (vascular); α_2-Adrenoceptors (presynaptic) (Kawasaki, H. (164) 35)

Corticosterone; Hypothalamus; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); Paraventricular nucleus; (Sex differences) (Haleem, D.J. (164) 435)

Algesia; Arachidonate cyclooxygenase (inhibitors); Prostaglandins; Methysergide (Vinegar, R. (164) 497)

Intestine (small); Enterochromaffin cells; GABA receptors; Muscimol; Baclofen (Schwörer, H. (165) 29)

Imipramine; Pharmacokinetics (cerebral); 5-Hydroxyindole acetic acid (5-HIAA); Norepinephrine; 3-Methoxy-4-hydroxyphenylglycol (MHPG) (Sugita, S. (165) 191)

MPP^+ (1-methyl-4-phenylpyridinium); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Serotonin syndrome; Microdialysis; Dopamine (Miyake, H. (166) 49)

Imipramine; Antidepressants; Brain mRNA; (*Xenopus* oocytes, Current) (Tohda, M. (166) 57)

Antiemetic drugs; Autonomic ganglia; Enteric neurons; Gastrointestinal motility (Nemeth, P.R. (166) 387)

Buspirone; Hippocampus; Excitatory synaptic transmission (O'Connor, J.J. (167) 21)

Myocardial ischaemia (simulated); Coronary artery; Adenosine; Acetylcholine; U-46,619; Iloprost; (Sheep) (Kwan, Y.W. (168) 31)

Hypoxia; Cerebral artery (middle); Endothelium; BW755C; Haemolysate; (Sheep) (Klaas, M. (168) 187)

Dopamine; Voltammetry (in vivo); d,l-p-Chloroamphetamine; Amphetamine; (±)-3,4-Methylenedioxymethamphetamine (MDMA) (Gazzara, R.A. (168) 209)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2 receptors; Pithed rat (Dabiré, H. (168) 369)

5-HT_3 (sites); Quipazine; Arylpiperazines; (Radioligand binding) (Glennon, R.A. (168) 387)

Isoproterenol; Propranolol; Pulmonary circulation; (Pulmonary pressor response to 5-HT) (Takashio, T. (169) 179)

Smooth muscle cells (vascular); 5-HT_{1B} binding sites; 5-HT_2 binding sites; (Tissue culture) (Jazayeri, A. (169) 183)

Ketanserin; 5-HT receptor antagonism; Pulmonary hypertension; Vascular effects (Le Roux, M.G.J. (169) 269)

5-HT_3 receptors; ICS 205-930; MDL 72222; Analgesia; Inflammation (Giordano, J. (170) 83)

Arteriovenous anastomoses; Carotid blood flow; 5-HT receptors; 5-HT_1-like receptors; Migraine; RU 24969 (Bom, A.H. (171) 87)

Na^+ (intracellular); K^+ relaxation; Norepinephrine; Monensin; Ouabain; Smooth muscle (vascular) (Bell, D.R. (171) 189)

Ketanserin; Methysergide; 5-HT_1-like receptors; 5-HT_2 receptors; Renal function (Shoji, T. (171) 219)

Benzodiazepines; Hippocampus; GABA (Lista, A. (171) 229)

Vascular smooth muscle; Epidermal growth factor receptors; Epidermal growth factor-urogastrone; Vasopressins (Blay, J. (172) 1)

l-5-Hydroxytryptophan (l-5-HTP)
Ritanserin; 5,7-DHT (5,7-Dihydroxytryptamine); 5-HT syndrome; 5-HT_{1C} receptors (Colpaert, F.C. (169) 175)

Hyperactivity
Dopamine; Hypoactivity; (Forward progression, Movement, Rat) (Eilam, D. (161) 151)

Hyperalgesia
Corticotropin releasing factor (CRF); Analgesia; Inflammation; Pain (Hargreaves, K.M. (170) 275)

Hyperosmolarity
Histamine; H_1 receptor antagonists; H_2 receptor antagonists; Nasal fluid secretions (Petersson, G. (161) 37)

Hyperpolarization
Halothane; K^+ channels; Ca^{2+} (Scharff, O. (159) 165)

Hypertension
Histamine; Cardiac arrhythmias; Myocardial hypertrophy; Spontaneously hypertensive rat (SHR) (Cameron, J.S. (169) 23)

Muscarinic receptors; Kidney; Autoradiography; (Rat) (De Michele, M. (169) 297)

Hyperthermia
U-50,488H; Morphine; κ Opioid receptors; Tolerance; Analgesia; Hypothermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Hypnotics
Ro 15-4513; Benzodiazepine inverse agonists; Ethanol; Pentobarbital; Motor impairment (Le, A.D. (159) 25)

Hypoactivity
Dopamine; Hyperactivity; (Forward progression, Movement, Rat) (Eilam, D. (161) 151)

α_2-Adrenoceptors; Sedation; Mydriasis; MHPG (3-methoxy-4-hydroxyphenylglycol); Clonidine; Brain; Behaviour; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

Hypogastric nerve stimulation
SGB-1534; α_1-Adrenoceptor antagonists; Canine urethra (Imagawa, J.-i. (167) 167)

Hypotension
Microdialysis (in vivo); Catecholamine overflow (endogenous and methylated); MethylDOPA (Kapoor, V. (164) 531)

Hypothalamus
Prostaglandin E_2; Luteinizing hormone-releasing hormone (LHRH); Adenylyl cyclase; Guanyl-5′-yl-imidophosphate (Wisner, A. (162) 89)

Corticosterone; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); 5-Hydroxytryptamine (5-HT, serotonin); Paraventricular nucleus; (Sex differences) (Haleem, D.J. (164) 435)

Nicotine; Catecholamine synthesis; 5-HT synthesis; Nucleus accumbens; Hippocampus (Mitchell, S.N. (167) 311)

CCK receptors; (Species differences) (Miceli, M.O. (169) 215)

Hypothermia
Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Raclopride; Stereotypy; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

U-50,488H; Morphine; κ Opioid receptors; Tolerance; Analgesia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Phencyclidine (PCP); Opiates; Naloxone; Temperature; Dependence (Pechnick, R.N. (166) 295)

α_2-Adrenoceptor antagonists; Atipamezole; Idazoxan; Ethanol; Ro 15-4513; (Mouse) (Löschmann, P.-A. (166) 381)

Disulfiram; Diethylthiocarbamic acid methyl ester (Me-DTC); Ethanol; Blood pressure; (Rat, Toxicity) (Petersen, E.N. (166) 419)

Hypoxia
α-Adrenoceptor antagonists; Cell membrane permeability; Creatine kinase; High-energy phosphates; Reoxygenation; YM-12617 (Tanonaka, K. (165) 97)

Heart; ATP; Adenosine; Endothelium-derived relaxing factor (EDRF) (Hopwood, A.M. (165) 323)

Cerebral artery (middle); Endothelium; BW755C; Haemolysate; 5-Hydroxytryptamine (5-HT, serotonin); (Sheep) (Klaas, M. (168) 187)

IBMX (3-isobutyl-1-methylxanthine)
7-CET (7-(2-Chloroethyl)-theophylline); Caffeine; Behavioural effects; Fixed-interval schedules; (Squirrel monkey) (Coffin, V.L. (170) 35)

Ibopamine
Dopamine; Haemodynamics; Isovolumic relaxation; (Mathematical models) (Bernardi, L. (164) 415)

ICI 118,551
Atrial cells; Ventricular cells; Slow inward calcium current; β_2-Adrenoceptors; Procaterol (Iijima, T. (163) 357)

β-Adrenoceptor binding sites; β_1-Adrenoceptors; β_2-Adrenoceptors; [^{3}H]Dihydroalprenolol; [^{3}H]CGP 12177; CGP 20712A; (Post-mortem human brain) (De Paermentier, F. (167) 397)

Atenolol; Myocardial ischemia; Coronary stenosis; β_2-Adrenoceptors; (Regional myocardial function) (Noguchi, K. (168) 315)

ICI 154,129
Analgesia; Opioid receptors; Tail flick; Naloxonazine; β-Funaltrexamine; Opioid peptides; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

ICI 198,615
Leukotriene receptor antagonists; LTC_4; LTD_4; LTE_4 (Krell, R.D. (159) 73)

Leukotriene D_4 (LTD_4); SK&F 104353; Leukotriene receptors; Blood pressure; (Conscious rat) (Smith III, E.F. (159) 297)

Leukotrienes; Antigen; Trachea (Redkar-Brown, D.G. (165) 113)

ICS 205-930
Dopamine; Microdialysis; 5-HT_3 receptors; Morphine; Amphetamine (Carboni, E. (164) 515)

5-Hydroxytryptamine (5-HT, serotonin); 5-HT_3 receptors; MDL 72222; Analgesia; Inflammation (Giordano, J. (170) 83)

Idazoxan
Imidazolidines; Amiloride (Vigne, P. (160) 295)

Clonidine; Dopamine; Mesolimbic dopamine system; Ventral tegmental area; (Firing pattern) (Grenhoff, J. (165) 11)

α_2-Adrenoceptor antagonists; Atipamezole; Ethanol; Ro 15-4513; Hypothermia; (Mouse) (Löschmann, P.-A. (166) 381)

B-HT 920; Yohimbine; Stereotypy; Dopamine receptor agonists (Meltzer, L.T. (170) 105)

[^{3}H]Idazoxan
Imidazoline; Amiloride; α_2-Adrenoceptors; Adipocytes; (Rabbit) (Langin, D. (159) 199)

Methylphenidate; Cerebral cortex; [^{3}H]Prazosin; [^{3}H]Dihydroalprenolol; (Down-regulation) (Mathieu, J.-F. (162) 173)

Urethra (rabbit); [^{3}H]Rauwolscine; α_2-Adrenoceptors; Amiloride (Yablonsky, F. (164) 167)

α_{2A}-Adrenoceptors; [^{3}H]RX821002; [^{3}H]Yohimbine; [^{3}H]-UK14,304; HT29 cell-line (Langin, D. (167) 95)

α_2-Adrenoceptors; Adipocytes; Lipolysis; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]RX 821002; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Ifoxetine
5-HT uptake; [^{3}H]Cyanoimipramine binding; Brofaromine; Moclobemide; 5-HT uptake inhibitors (Waldmeier, P.C. (169) 197)

Ileal longitudinal muscle
Atrium; Muscarine receptors; C_7/3′-phthalimidopropyl; (Guinea-pig) (Choo, L.K. (162) 429)

Ileal motility
Submucous plexus; Substance P; (Guinea-pig) (Jin, J.-G. (161) 73)

Ileum
Thyrotropin-releasing hormone (TRH); Intestinal secretion; Submucosal neurons; (Ion transport) (Carey, H.V. (160) 183)

Angiotensin II; Receptors; Smooth muscle; (Guinea-pig, Desensitization) (Oshiro, M.E.M. (166) 411)

5-HT receptors; Zacopride (benzamides); (Binding sites, Radioligand assay, Rabbit) (Pinkus, L.M. (168) 355)

Ileum and colon (terminal)
Anaesthetics (local); Nicotinic receptors; Non-adrenergic, non-cholinergic (NANC) system; Vasoactive intestinal polypeptide (VIP); (Electrical stimulation) (Pelckmans, P.A. (170) 235)

Ileum (guinea-pig)
$GABA_B$ receptor antagonists; Benzofuran-baclofen analogues; Baclofen; Neocortex (rat) (Kerr, D.I.B. (164) 361)

Li^+; Fura-2; Ca^{2+} level (cytosolic); (Skinned fiber, Relaxation) (Hori, M. (165) 63)

Capsaicin; Ruthenium red; Primary afferent neurones; Substance P (Chahl, L.A. (169) 241)

Iloprost
Myocardial ischaemia (simulated); Coronary artery; Adenosine; 5-Hydroxytryptamine; Acetylcholine; U-46,619; (Sheep) (Kwan, Y.W. (168) 31)

Imidazole
Pyridazinone; MCI-154; Skinned fibers; Myocardium (human); Inotropic drugs (Perreault, C.L. (165) 305)

Imidazolidines
Idazoxan; Amiloride (Vigne, P. (160) 295)

Imidazoline
[^{3}H]Idazoxan; Amiloride; α_2-Adrenoceptors; Adipocytes; (Rabbit) (Langin, D. (159) 199)

Imidazoline preferring receptors
[^{3}H]Clonidine; Rilmenidine; Brain (human) (Bricca, G. (163) 373)

'Imidazoline-preferring sites'
α_2-Adrenoceptors; Adipocytes; Lipolysis; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]Idazoxan; [^{3}H]RX 821002; Fat cells; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Imidazoline receptors
α-Adrenoceptors; Blood pressure; Brainstem; Clonidine; (Binding) (Bricca, G. (162) 1)

Imipramine
Antidepressants; Thiorphan; Bestatin; Iprindole; Forced swimming test; Motor activity; Opioids (Del Carmen de Felipe, M. (159) 175)

Tetrabenazine; α_1-Adrenoceptors; β-Adrenoceptors; 5-HT$_2$ receptors; Phosphoinositide hydrolysis (Butler, P.D. (160) 93)

Pharmacokinetics (cerebral); 5-Hydroxytryptamine (5-HT, serotonin); 5-Hydroxyindole acetic acid (5-HIAA); Norepinephrine: 3-Methoxy-4-hydroxyphenylglycol (MHPG) (Sugita, S. (165) 191)

Antidepressants; 5-Hydroxytryptamine (5-HT, serotonin); Brain mRNA; (*Xenopus* oocytes, Current) (Tohda, M. (166) 57)

Dopamine D-1 receptors; Adenylate cyclase; α-Methyltyrosine (De Montis, G.M. (167) 299)

α_1-Adrenoceptors; Antidepressants; β-Adrenoceptors; S-Adenosyl-L-methionine; (Chronic treatment) (Cohen, B.M. (170) 201)

[^{3}H]Imipramine binding
Stress (acute); Phosphatidylcholine; Phosphatidylserine; Tricyclic antidepressants (Stockert, M. (160) 11)

Immobilization stress
NMDA receptor antagonists; Nucleus accumbens; Dopamine metabolism; Methyl-β-carboline-3-carboxylate (β-CCM); (In vivo voltammetry) (Serrano, A. (162) 157)

Immunoneuroendocrinology
Immunopharmacology; Appetitive behaviour; Prostaglandin; Interleukin-1; Indomethacin (Uehara, A. (170) 257)

Immunopharmacology
Immunoneuroendocrinology; Appetitive behaviour; Prostaglandin; Interleukin-1; Indomethacin (Uehara, A. (170) 257)

Indeloxazine
Passive avoidance learning; (Senescence-accelerated mice) (Yamamoto, M. (166) 345)

Indolylbutylamines
Dopamine receptors (presynaptic, postsynaptic); Acetylcholine; Turning behaviour; Serotonin; 5-HT$_{1A}$ receptors (Seyfried, C.A. (160) 31)

Indomethacin
Ca^{2+} channel blockers; Stress ulcer; Gastric secretion; Verapamil; Nitrendipine; Diltiazem; Ethanol ulcer; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Vincamine; Vinpocetine; Trachealis; Ca^{2+}; (Guinea pig) (Machová, J. (162) 387)

Trachealis; Lung parenchyma; Sensitized guinea-pig; Asthma (experimental); (Non-specific hyperresponsiveness, Guinea-pig) (Cortijo, J. (162) 467)

Platelet activating factor (PAF-acether, PAF); Alveolar macrophages; Leukotriene B_4 (LTB_4); Thromboxane B_2; BW 137C; BW 755C; 5-Lipoxygenase inhibitors (Fitzgerald, M.F. (164) 539)

Acetylcholine release; Bronchial tissue; Atropine; Prostaglandin E_2; Prostaglandin D_2 (Deckers, I.A. (167) 415)

Gastric acid secretion; Neuropeptides; Dermorphin; Corticotropin-releasing factor (CRF); Calcitonin gene-related peptide (CGKP) (Guglietta, A. (170) 87)

Immunoneuroendocrinology; Immunopharmacology; Appetitive behaviour; Prostaglandin; Interleukin-1 (Uehara, A. (170) 257)

Endothelin; Trachea (guinea-pig); Airway epithelium; Peptidase inhibitors; Captopril (Hay, D.W.P. (171) 241)

Inflammation
Aspirin; Salicylic acid; Anti-inflammatory drugs (non-steroidal); Prostaglandins; Carrageenin (Chiabrando, C. (159) 257)

Angiotensin converting enzyme inhibitors; Kinin receptors; Bradykinin; Des-Arg^9-bradykinin (Nwator, I.A.A. (160) 125)

Anaphylaxis; Airway hyperreactivity; Histamine (Daffonchio, L. (161) 135)

Platelet-activating factor (PAF-acether, PAF); Mucus; Goblet cells; Conjunctiva (Woodward, D.F. (168) 23)

5-Hydroxytryptamine (5-HT, serotonin); 5-HT_3 receptors; ICS 205-930; MDL 72222; Analgesia (Giordano, J. (170) 83)

Corticotropin releasing factor (CRF); Analgesia; Hyperalgesia; Pain (Hargreaves, K.M. (170) 275)

Bradykinin; NPC567; Carrageenan (Costello, A.H. (171) 259)

Inositol phospholipids
Depolarization; Na^+ channels; Na^+/Ca^{2+} exchange (Benuck, M. (159) 187)

Norepinephrine; Carbachol; Quisqualate; Brain (human) (Nicoletti, F. (160) 299)

Inositol polyphosphates
Muscarinic receptors; (Development) (Rooney, T.A. (172) 425)

Inositol 1,4,5-trisphosphate
Phaclofen; Neuronal cultures; GABA receptors (Michler, A. (167) 423)

D-Inositol 1,4,5-trisphosphate
Smooth muscle (airway) (Chilvers, E.R. (164) 587)

Inositol trisphosphates
Neurotensin; Fura 2; Ca^{2+} mobilization; Heterologous desensitization; NG108-15 cells (Imaizumi, T. (161) 203)

Inotropic drugs
Pyridazinone; Imidazole; MCI-154; Skinned fibers; Myocardium (human) (Perreault, C.L. (165) 305)

Inotropic effect
Atrium (guinea-pig); Field stimulation; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 37)

Atrium (guinea-pig); Field stimulation; Noradrenaline release; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 49)

Inotropic response (triphasic)
Murrayaquinone-A; Papillary muscle (guinea-pig); Mitochondrial oxidative phosphorylation; Action potential (augmented, slow) (Takeya, K. (169) 137)

Insulin
Glucagon; Somatostatin; Yohimbine; Propranolol; Vagotomy; (Secretion) (Ribes, G. (162) 207)

Pharmacodynamics; Protein phosphorylation; Guanine nucleotide-binding proteins (G-proteins) (Joost, H.G. (172) 461)

Insulin-like growth factor I (IGF-I)
Leydig cells; Testosterone; Growth hormone (Horikawa, R. (166) 87)

Insulin release
Pancreastatin; Rin m 5F cells (Lorinet, A.-M. (160) 405)

Galanin; cAMP; Rin m 5F cells (Amiranoff, B. (163) 205)

Interleukin-1
Bradykinin; Tumour necrosis factor; Synovial cells; Prostaglandin E_2 (O'Neill, L.A.J. (166) 131)

Immunoneuroendocrinology; Immunopharmacology; Appetitive behaviour; Prostaglandin; Indomethacin (Uehara, A. (170) 257)

Interleukin-1β
Vasopressin; Neurohypophysis (Christensen, J.D. (171) 233)

Internalization
β-Adrenoceptors; Down-regulation; Phenelzine; Cerebral cortex; (Rat) (Koshikawa, N. (170) 101)

Interstitial cells of Cajal
Quinidine; Quinine; Colon electrophysiology; Slow waves; Pacemaker activity (Barajas-López, C. (163) 137)

Intestinal motility
Ca^{2+} channel blockers; Electrical spike activity; Migrating myoelectric complex; (Computer analysis) (De Ponti, F. (168) 133)

Intestinal secretion
Thyrotropin-releasing hormone (TRH); Ileum; Submucosal neurons; (Ion transport) (Carey, H.V. (160) 183)

Enteric nervous system (Diener, M. (168) 219)

Intestine (small)
5-Hydroxytryptamine (5-HT, serotonin); Enterochromaffin cells; GABA receptors; Muscimol; Baclofen (Schwörer, H. (165) 29)

Intrathecal infusion
Morphine; DADLE ([D-Ala^2,D-Leu^5]enkephalin); Sufentanil; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Opioid dependence (Stevens, C.W. (166) 467)

2-[^{125}I]Iodomelatonin
Melatonin binding site (ML-1); Brain; Retina; Luzindole; (Chicken) (Dubocovich, M.L. (162) 289)

Ion channels
THA (9-amino-1,2,3,4-tetrahydroacridine); Node of Ranvier (Elinder, F. (164) 599)

Propiophenones; Ca^{2+} channel blockers; (Neurons, Snail) (Novales-Li, P. (168) 299)

Neuropeptides; Neurons; (Mollusca, Snail) (Yongsiri, A. (171) 159)

5-HT_3 receptors; cGMP; Adamantane derivative; Neuroblastoma×glioma hybrid cells (Reiser, G. (172) 199)

Ionophore complex
Axonal transport; NMDA receptors; (Autoradiography) (Cincotta, M. (160) 167)

Ion pairs
Local anesthetics (tertiary and quaternary amine); Dissociability; Lipophilicity; Neuronal membrane (site of action) (Štolc, S. (164) 249)

Iprindole
Antidepressants; Thiorphan; Bestatin; Imipramine; Forced swimming test; Motor activity; Opioids (Del Carmen de Felipe, M. (159) 175)

Iris (guinea-pig)
Muscarinic M_2 receptor subtypes; Muscarinic inhibition; Noradrenaline release; Iris (rabbit); Iris sphincter muscle (rabbit); (Pre- and postjunctional affinity constants) (Bognar, I.T. (163) 263)

Iris (rabbit)
Muscarinic M_2 receptor subtypes; Muscarinic inhibition; Noradrenaline release; Iris (guinea-pig); Iris sphincter muscle (rabbit); (Pre- and postjunctional affinity constants) (Bognar, I.T. (163) 263)

Iris sphincter muscle
Endothelin; (Pig) (Geppetti, P. (168) 119)

Iris sphincter muscle (rabbit)
Muscarinic M_2 receptor subtypes; Muscarinic inhibition; Noradrenaline release; Iris (guinea-pig); Iris (rabbit); (Pre- and postjunctional affinity constants) (Bognar, I.T. (163) 263)

Ischemia
Propranolol; Myocardium; Perfused working heart; Non-esterified fatty acids; (Rat) (Nakamura, K. (160) 61)

Nicorandil; Nipradilol; Heart (perfused, working); (Rat) (Haneda, T. (162) 81)

Nicorandil; Reperfusion; Arrhythmias; Heart; (Rat) (Kempsford, R.D. (163) 61)

Skeletal muscle; Microcirculation; Peripheral vascular disease; Torbafylline; (Performance) (Okyayuz-Baklouti, I. (166) 75)

Lidocaine; Myocardium; Heart (perfused working); Fatty acids (non-esterified); (Rat) (Nakamura, K. (169) 259)

Ischemia and reperfusion
Platelet activating factor (PAF-acether, PAF); BN 52021; Arrhythmias; Heart functions; (Rat) (Koltai, M. (164) 293)

Ischemia (cerebral)
Oligo-prostaglandin B; (Gerbil) (Von Lubitz, D.K.J.E. (164) 405)

Islet blood flow
Pancreatic islets; Pancreatic blood flow; Streptozotocin; Diabetic rats (Jansson, L. (161) 79)

Isoelectric focusing
Monoamine oxidase (MAO); MAO inhibitors (Fritze, J. (172) 147)

Isoniazid
$GABA_A$ receptors; Cl^- channels; [^{35}S]TBPS binding; (Modulators of GABAergic synapses) (Serra, M. (164) 385)

Isonicotinic acid hydrazide
THAO (5,6,7,8-tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol); Glia; GABA uptake; Seizures; Pentylenetetrazol (PTZ) (Gonsalves, S.F. (168) 265)

Isoproterenol
Heart cells; Ca^{2+} channel blockers (Briand, V. (166) 339)

Propranolol; 5-Hydroxytryptamine (5-HT, serotonin); Pulmonary circulation; (Pulmonary pressor response to 5-HT) (Takashio, T. (169) 179)

Isothiocyanates
σ Receptors; Phencyclidine receptors; Metaphit; Affinity labelling (Bluth, L.S. (161) 273)

Isovolumic relaxation
Dopamine; Ibopamine; Haemodynamics; (Mathematical models) (Bernardi, L. (164) 415)

Jaw movements
Apomorphine; Quinpirole; SCH 23390; Sulpiride; SK&F 38393 (Koshikawa, N. (163) 227)

K^+
Ca^{2+} (extra-and intra-cellular); Ca^{2+} channels (L-type and T-type); Noradrenaline; Phorbol ester; Protein kinase C; Uterine vasoconstriction (Fallgren, B. (170) 61)

Kainate receptors
Quisqualate receptors; Glutamate; GABA release; Striatal neurons; (Primary culture) (Pin, J.-P. (172) 81)

Kainic acid
N-Methyl-D-aspartic acid (NMDA); Myocardial necrosis; Neurotoxin (excitatory); Paraventricular hypothalamus; (Rat) (Rockhold, R.W. (166) 571)

KC 8857
Bradycardiac agents (selective); Hemodynamics; Myocardial dysfunction (regional); (Exercise) (Grohs, J.G. (161) 53)

K^+ channel activators
Glibenclamide; Pulmonary artery; (Guinea-pig) (Eltze, M. (165) 231)

K^+ channel blockers
Mast cell degranulating peptide; Dendrotoxin; Ca^{2+} channel antagonists; Seizures; NMDA antagonists (Gandolfo, G. (160) 173)

K^+ channels
Halothane; Hyperpolarization; Ca^{2+} (Scharff, O. (159) 165)

Quinine; Dopamine D-2 receptors; Neuroleptics; Caudate nucleus; (Patch-clamp) (Freedman, J.E. (164) 341)

Diabetes; Aorta; Cromakalim (Kamata, K. (166) 319)

Pinacidil; Trachea; Smooth muscle (vascular) (Mellemkjær, S. (167) 275)

Cromakalim (BRL 34915); Hippocampus; Tetraethylammonium; (Whole cell patch clamp) (Politi, D.M.T. (168) 7)

Endothelium; Quinine; Sulfonylureas; Pinacidil (Ramboer, I. (171) 251)

KCl contracture
Diltiazem; Ca^{2+} antagonists; Caffeine contracture; Diaphragm (rat); (Use-dependent inhibition) (Røed, A. (159) 61)

K^+ conductance
G-proteins; Transmitter release; Pyramidal cells; cAMP (Fredholm, B.B. (172) 249)

K^+ conductance (inwardly rectifying)
9-Amino-1,2,3,4-tetrahydroacridine (THA); Hippocampus; Adenosine; Baclofen; 5-HT; (Alzheimer's disease) (Halliwell, J.V. (163) 369)

K^+ currents
Vas deferens (guinea-pig); Noradrenaline; Ca^{2+} currents; Action potential (Mimata, T. (163) 181)

K^+ depolarization
Smooth muscle (intestinal); Signal-contraction coupling; Histamine; Substance P; Diacylglycerol; (Guinea-pig) (Lippe, I.T. (159) 1)

Kelatorphan
Morphine withdrawal; Naloxone; Enkephalinase inhibitors; Thiorphan (Maldonado, R. (165) 199)

Ketamine
MK-801; Phencyclidine; N-Methyl-D-aspartate (NMDA); Glutamate; Glycine; Magnesium; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

Clozapine; Dyskinesia; Tongue protrusion; Tongue retrusion; Swallow (Marco, L.A. (164) 171)

Ketanserin
5-Hydroxytryptamine; 5-HT_2 receptors; Coronary artery (human); 5-HT_1-like receptors; GR43175 (Connor, H.E. (161) 91)

5-HT receptor subtypes; Pulmonary edema; Capillary pressure; Filtration coefficient; Methysergide (Sumita, T. (164) 69)

Adrenoceptors; Blood pressure; 5-HT receptors; Phentolamine (Dhasmana, K.M. (168) 257)

5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptor antagonism; Pulmonary hypertension; Vascular effects (Le Roux, M.G.J. (169) 269)

5-Hydroxytryptamine (5-HT, serotonin); Methysergide; 5-HT_1-like receptors; 5-HT_2 receptors; Renal function (Shoji, T. (171) 219)

K^+ flux
Erythrocytes; Ca^{2+} flux; Atrial natriuretic peptide (rat) (Esparza, N. (166) 349)

K^+-free medium
Monensin; Ouabain; Noradrenaline release; Ca^{2+}-evoked contraction; Na^+/Ca^{2+} exchange transport; Vas deferens; (Guinea pig) (Katsuragi, T. (167) 147)

Kidney
Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); Heart; Endothelium; (Receptor) (Oehlenschlager, W.F. (161) 159)

Endothelin binding sites; Blood vessels; (Autoradiography) (Jones, C.R. (163) 379)

Dopamine D-1 receptors; [^{3}H]SCH 23390 (Zdilar, D. (164) 159)

Mitochondria; Succinate transport; Valproate; Membrane (Rumbach, L. (164) 577)

Autoradiography; Noradrenaline; Adrenoceptors; Renal nerve; Sympathetic nervous system (Sripairojthikoon, W. (167) 355)

Muscarinic receptors; Hypertension; Autoradiography; (Rat) (De Michele, M. (169) 297)

Kidney epithelial cell line (LLC-PK_1)
Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); cGMP (Iwata, T. (159) 321)

Kidney (isolated, rat)
Endothelin; Thromboxane analogs; Thromboxane antagonists; Glomerular hemodynamics; Tubular function (Ferrario, R.G. (171) 127)

Kidney (rat)
Vasopressin V_1 receptor antagonists (radioiodinated); [^{3}H]Vasopressin; Brain (rat); (Receptor autoradiography) (Gerstberger, R. (167) 105)

Kindling
Primidone; Phenobarbital; Epilepsy (Löscher, W. (162) 309)

Epilepsy; GABA aminotransferase; γ-Vinyl GABA (Löscher, W. (163) 1)

Kindling seizures
FG 7142; GABA (γ-aminobutyric acid); Benzodiazepines; Cl^- channels; [^{35}S]t-Butylbicyclophosphorothionate ([^{35}S]TBPS); (Autoradiography) (Lewin, E. (160) 101)

Kinin
Histamine; Substance P; Mast cells (peritoneal) (Devillier, P. (168) 53)

Kinin potentiation; Kininases; Angiotensin-converting enzyme (ACE); Endopeptidase (neutral); (Peptide) (Assreuy, J. (168) 231)

Kinin antagonists
Carotid artery; Renal artery; Endothelium; Kinins; Bradykinin; Bradykinin B_1 receptors; Bradykinin B_2 receptors; (Dog) (Rhaleb, N.-E. (162) 419)

Kininases
Kinin; Kinin potentiation; Angiotensin-converting enzyme (ACE); Endopeptidase (neutral); (Peptide) (Assreuy, J. (168) 231)

Kinin formation
Cardiotoxin; Hind-paw edema (rat); Mast cells; PMN (polymorphonuclear) leukocytes (Wang, J.-P. (161) 9)

Kinin potentiation
Kinin; Kininases; Angiotensin-converting enzyme (ACE); Endopeptidase (neutral); (Peptide) (Assreuy, J. (168) 231)

Kinin receptors
Angiotensin converting enzyme inhibitors; Inflammation; Bradykinin; Des-Arg^9-bradykinin (Nwator, I.A.A. (160) 125)

Kinins
Nociception; Spinal cord; Noradrenergic mechanism; Monoamine content; 6-Hydroxydopamine (6-OHDA) (Laneuville, O. (159) 273)

Carotid artery; Renal artery; Endothelium; Bradykinin; Bradykinin B_1 receptors; Bradykinin B_2 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

K^+ loss
Myocardial ischaemia; Coronary occlusion; Haemodynamics; Ca^{2+} antagonists; Gallopamil; Diltiazem; Nifedipine (Kirchengast, M. (160) 349)

K^+ relaxation
Na^+ (intracellular); Norepinephrine; Monensin; Ouabain; Serotonin; Smooth muscle (vascular) (Bell, D.R. (171) 189)

Kynurenate
NMDA receptors; Glycine; Glutamate; Myenteric plexus (Moroni, F. (163) 123)

Kynurenic acid
Dopamine release; Striatum; N-Methyl-D-aspartate (NMDA); Glycine; (Rat) (Krebs, M.-O. (166) 567)

NMDA receptors; MK801; HA-966; GABA release; Ca^{2+} (intracellular) (Reynolds, I.J. (172) 9)

L-364,718
Cholecystokinin antagonists; Caerulein; Anorexia (Leighton, G.E. (161) 255)

Langendorff preparation
Endothelin; Coronary circulation; Nifedipine; Vasoconstriction (Fukuda, K. (165) 301)

Learned helplessness
Gonadotropin-releasing hormone (GnRH); Antidepressants; (Rats) (Massol, J. (160) 395)

Nimodipine; BAY k 8644; Antidepressants (Martin, P. (162) 185)

Learning
Hoe 065; Memory; Avoidance (inhibitory, passive); (Up-hill avoidance, Eight-arm radial maze) (Hock, F.J. (171) 79)

Learning (latent)
Pimozide; SCH 23390; Passive avoidance response; Memory; (Mouse) (Ichihara, K. (164) 189)

Learning (maze)
AF64A; Cognitive deficits; Habituation; Acetylcholinesterase; (Histology) (Gower, A.J. (166) 271)

Lectins
Catecholamines; Corpus striatum; Glycoconjugates; Tetrabenazine; (Chromatography, Affinity) (Vincent, M.S. (172) 317)

[Leu^5]enkephalin
Opiates; [Met^5]enkephalin; (Biologically active conformation) (Gašparík, J. (172) 417)

Leukocyte accumulation
Vascular permeability; Prostaglandins; Complement depletion (Hambleton, P.T. (163) 141)

Leukotriene B_4 (LTB_4)
Platelet activating factor (PAF-acether, PAF); Alveolar macrophages; Thromboxane B_2; BW 137C; BW 755C; 5-Lipoxygenase inhibitors; Indomethacin (Fitzgerald, M.F. (164) 539)

Leukotriene C_4 (LTC_4)
Leukotriene receptor antagonists; ICI 198,615; LTD_4; LTE_4 (Krell, R.D. (159) 73)

Glutathione; Glutathione transferase; (Receptors) (Goffinet, A.M. (161) 99)

Leukotriene D_4 (LTD_4)
Leukotriene receptor antagonists; ICI 198,615; LTC_4; LTE_4 (Krell, R.D. (159) 73)

SK&F 104353; ICI 198615; Leukotriene receptors; Blood pressure; (Conscious rat) (Smith III, E.F. (159) 297)

Leukotriene E_4 (LTE_4)
Leukotriene receptor antagonists; ICI 198,615; LTC_4; LTD_4 (Krell, R.D. (159) 73)

Leukotriene receptor antagonists
ICI 198,615; LTC_4; LTD_4; LTE_4 (Krell, R.D. (159) 73)

Leukotriene receptors
Leukotriene D_4 (LTD_4); SK&F 104353; ICI 198615; Blood pressure; (Conscious rat) (Smith III, E.F. (159) 297)

Pulmonary parenchymal strips; Smooth muscle (vascular); Thromboxane B_2 (Stahl, G.L. (163) 55)

Leukotrienes
Macrophages; Prostaglandins; Malotilate; 5-Lipoxygenase (Zijlstra, F.J. (159) 291)

Vasoactive intestinal peptide (VIP); Platelet activating factor (PAF-acether, PAF); Lungs; Neuropeptides; Cyclic AMP (Di Marzo, V. (162) 115)

ICI 198,615; Antigen; Trachea (Redkar-Brown, D.G. (165) 113)

Sulfasalazine; Sulfasalazine analogues; Lipoxygenase; Cyclooxygenase; Thromboxane synthase (Tornhamre, S. (169) 225)

Levodopa
Behaviour (rotational); SKF 38393; Quinpirole; Apomorphine; (Chronic treatment) (Engber, T.M. (168) 291)

Leydig cells
Testosterone; Growth hormone; Insulin-like growth factor I (IGF-I) (Horikawa, R. (166) 87)

Li^+
Ileum (guinea-pig); Fura-2; Ca^{2+} level (cytosolic); (Skinned fiber, Relaxation) (Hori, M. (165) 63)

Carbamazepine; [^{3}H]Muscimol; [^{3}H](−)-Baclofen; $GABA_B$ receptors; Hippocampus (Motohashi, N. (166) 95)

Adenylate cyclase; Hippocampus; Striatum; Ca^{2+} (Mørk, A. (168) 347)

Li^+ clearance
[Arg^8]vasopressin; Atrial natriuretic factor; Brattleboro rats; Diuresis; Natriuresis (Palluk, R. (162) 245)

Lidocaine
Carbamazepine; Phenytoin; Seizures (lidocaine-kindled); [^{3}H]Batrachotoxin binding; Hippocampus (Zimányi, I. (167) 419)

Ischemia; Myocardium; Heart (perfused working); Fatty acids (non-esterified); (Rat) (Nakamura, K. (169) 259)

Lidocaine binding site
Antiarrhythmics; Na^+ channels; Heart; Liver (Voigt, W. (169) 103)

Lidoflazine
Nucleoside transport inhibition; Mioflazine; Mioflazine analogs; Nitrobenzylthioinosine; (Heterogeneity, Computer model) (IJzerman, A.P. (172) 273)

Limbic system
RU 24722; Eburnamine derivatives; 2-Deoxy-D-[^{14}C]-glucose; Catecholaminergic system; (Rat) (Broussolle, E. (159) 225)

Lipid peroxidation
Smooth muscle; UV light; Nitrite; Ca^{2+}; cGMP (Nelemans, A. (172) 283)

Lipolysis
α_2-Adrenoceptors; Adipocytes; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]Idazoxan; [^{3}H]RX 821002; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Lipophilicity
Local anesthetics (tertiary and quaternary amine); Dissociability; Neuronal membrane (site of action); Ion pairs (Štolc, S. (164) 249)

Lipoxygenase
Gastroprotection; Cyclooxygenase; Gastric lesions (Konturek, S.J. (164) 285)

Sulfasalazine; Sulfasalazine analogues; Leukotrienes; Cyclooxygenase; Thromboxane synthase (Tornhamre, S. (169) 225)

5-Lipoxygenase
Macrophages; Leukotrienes; Prostaglandins; Malotilate (Zijlstra, F.J. (159) 291)

5-Lipoxygenase inhibitors
Platelet activating factor (PAF-acether, PAF); Alveolar macrophages; Leukotriene B_4 (LTB_4); Thromboxane B_2; BW 137C; BW 755C; Indomethacin (Fitzgerald, M.F. (164) 539)

Liver
Antiarrhythmics; Lidocaine binding site; Na^+ channels; Heart (Voigt, W. (169) 103)

Local anesthetics (tertiary and quaternary amine)
Dissociability; Lipophilicity; Neuronal membrane (site of action); Ion pairs (Štolc, S. (164) 249)

Local cerebral glucose utilization
[^{14}C]2-Deoxyglucose; Antipsychotics; Cholinergic pathways; Desenkephalin-γ-endorphin; Glucose uptake; Org 5878; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Locomotion
CCK8; Nucleus accumbens; Exploration; (Rat) (Daugé, V. (163) 25)

Locomotor activity
Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; $5\text{-}HT_{1C}$; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Adenosine agonists; Behaviour (exploratory); (Mouse) (Durcan, M.J. (168) 285)

Locus coeruleus
α_2-Adrenoceptors; Mydriasis; Clonidine; Cocaine (Pitts, D.K. (160) 201)

Galanin; Brain slices; (Electrophysiology, Extracellular recording) (Seutin, V. (164) 373)

Loop diuretics
Furosemide; Hemodynamic response (acute); Spontaneously hypertensive rats (SHR); Sinoaortic baroreceptors (Janssen, B.J.A. (170) 1)

Loperamide
Mucus secretion; Colon; (Rat) (Loeschke, K. (170) 41)

Loxiglumide
Cholecystokinin (CCK); CCK-receptor antagonists; Bombesin; Gallbladder (Douglas, B.R. (166) 307)

Lung
Vasoactive intestinal peptide (VIP); Leukotriene; Platelet activating factor (PAF-acether, PAF); Neuropeptides; Cyclic AMP (Di Marzo, V. (162) 115)

Muscarinic receptor subtypes; Pirenzepine (Mak, J.C.W. (164) 223)

Platelet activating factor (PAF); PAF receptors; PAF antagonists (Dent, G. (169) 313)

Aging; β-Adrenoceptors; Adenylate cyclase; (Rat) (Vanscheeuwijck, P. (172) 373)

Lung parenchyma
Trachealis; Sensitized guinea-pig; Indomethacin; Asthma (experimental); (Non-specific hyperresponsiveness, Guinea-pig) (Cortijo, J. (162) 467)

Luteinizing hormone-releasing hormone (LHRH)
Prostaglandin E_2; Hypothalamus; Adenylyl cyclase; Guanyl-5′-yl-imidophosphate (Wisner, A. (162) 89)

Luzindole
Melatonin binding site (ML-1); Brain; Retina; 2-[^{125}I]Iodomelatonin; (Chicken) (Dubocovich, M.L. (162) 289)

LY171555
Atypical neuroleptics; Dopamine D-1 receptor antagonists; Dopamine D-2 receptor antagonists; Clozapine; SKF-38393; (Behavior) (Criswell, H.E. (159) 141)

Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; SCH 23390; Raclopride; Stereotypy; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

Lymphatic vessels
Adrenoceptors; (Spontaneous contractions) (Mahe, L. (167) 31)

Endothelin; Vasopressin; Arteriole; Venule (Fortes, Z.B. (170) 69)

Lymphocytes
Adenosine; Prostaglandins; Cholera toxin; Phorbol esters; (Receptors) (Nordstedt, C. (172) 51)

Macrophages
Leukotrienes; Prostaglandins; Malotilate; 5-Lipoxygenase (Zijlstra, F.J. (159) 291)

Adenylate cyclase; cAMP; Forskolin; Forskolin analogues; Guanine nucleotide regulatory proteins; Manganese; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

Macrophages (human)
β-Adrenoceptors; Adenylate cyclase (Liggett, S.B. (163) 171)

Malotilate
Macrophages; Leukotrienes; Prostaglandins; 5-Lipoxygenase (Zijlstra, F.J. (159) 291)

Manganese
Adenylate cyclase; cAMP; Forskolin; Forskolin analogues; Guanine nucleotide regulatory proteins; Macrophages; (J774 cell line) (Chambaut-Guérin, A.-M. (172) 385)

MAO inhibition
5-HT_2 receptors; Wet-dog shakes; 5-HT uptake inhibitors; Spinal cord; (Receptor regulation) (Koshikawa, N. (164) 595)

MAO inhibitors
Monoamine oxidase (MAO); Isoelectric focusing (Fritze, J. (172) 147)

Mast cell amines
Phospholipase A_2; Oedema; Anti-inflammatory drugs (Cirino, G. (166) 505)

Mast cell degranulating peptide
Dendrotoxin; K^+ channel blockers; Ca^{2+} channel antagonists; Seizures; NMDA antagonists (Gandolfo, G. (160) 173)

Mast cell degranulation
[$Thi^{5,8}$,D-Phe^7]bradykinin; Paw edema (rat) (Wang, J.-P. (161) 143)

Mast cells
Histamine release; Retinoic acid; Retinal; Phorbol esters; Ca^{2+} (Cantwell, M.E. (160) 43)

Cardiotoxin; Hind-paw edema (rat); PMN (polymorphonuclear) leukocytes; Kinin formation (Wang, J.-P. (161) 9)

Benzodiazepine binding sites; 5-HT release; Ca^{2+} influx; Calmodulin; BAY k 8644 (Suzuki-Nishimura, T. (167) 75)

Mast cells (peritoneal)
Histamine; Kinin; Substance P (Devillier, P. (168) 53)

[^{3}H]Mazindol binding
L-Deprenyl; Monoamine oxidase-B activity; Dopamine uptake carrier; Dopamine metabolism (Wiener, H.L. (163) 191)

MCI-154
Pyridazinone; Imidazole; Skinned fibers; Myocardium (human); Inotropic drugs (Perreault, C.L. (165) 305)

McN-A-343
Anococcygeus (rat); Clonidine; Methoxamine; Non-adrenergic, non-cholinergic (NANC) transmission; Rilmenidine; (Prejunctional receptors) (Li, C.G. (168) 107)

MDEA (N-ethyl-3,4-methylenedioxyamphetamine)
MDMA (methylenedioxymethamphetamine); Startle; Prepulse inhibition; (Rat) (Mansbach, R.S. (167) 49)

MDL 72222
5-Hydroxytryptamine (5-HT, serotonin); 5-HT_3 receptors; ICS 205-930; Analgesia; Inflammation (Giordano, J. (170) 83)

MDMA (3,4-methylenedioxymethamphetamine)
Adrenalectomy; Corticosterone; Serotonin (5-HT); Tryptophan hydroxylase; (Neurotoxicity) (Johnson, M. (161) 181)

Glucocorticoid receptors; 5-Hydroxytryptamine; Striatum; Corticosterone; Neurotoxicity (Lowy, M.T. (163) 157)

MDEA (N-ethyl-3,4-methylenedioxyamphetamine); Startle; Prepulse inhibition; (Rat) (Mansbach, R.S. (167) 49)

Dorsal raphe nucleus; Single unit recording; Microdialysis; Neurotransmitter release (Sprouse, J.S. (167) 375)

Apomorphine; Quinpirole; Midbrain dopamine neurons; Antidromic activation; (Electrophysiology) (Kelland, M.D. (169) 11)

MDMA neurotoxicity
MK-801; Methamphetamine; Tryptophan hydroxylase (Johnson, M. (165) 315)

Mean arterial pressure
Norepinephrine spillover rate; Prazosin; Norepinephrine concentration (plasma); Hydralazine; (Rat) (Keeton, T.K. (164) 479)

Medulla oblongata
Neuropeptide Y (NPY); α_2-Adrenoceptors; G-protein; Pertussis toxin; (Rat) (Von Euler, G. (172) 435)

Melanoma
MSH receptors; Phorbol ester; Adenylate cyclase; Cell proliferation (Gerst, J.E. (172) 29)

Melatonin binding site (ML-1)
Brain; Retina; 2-[^{125}I]Iodomelatonin; Luzindole; (Chicken) (Dubocovich, M.L. (162) 289)

Membrane
Kidney; Mitochondria; Succinate transport; Valproate (Rumbach, L. (164) 577)

Membrane fluidity
A_2C (2-[2-methoxyethoxy]-ethyl 8-[cis-2-n-octylcyclopropyl]-octanoate); Anesthetics; TBPS (t-butylbicyclophosphorothionate); Temperature; GABA-activated chloride channels (Buck, K.J. (160) 359)

Membrane potentials
Electromechanical activity; Bronchomotor tone; Catecholamines; (Action potentials, Cellular electrophysiology) (Richards, I.S. (167) 155)

Memory
Pimozide; SCH 23390; Learning (latent); Passive avoidance response; (Mouse) (Ichihara, K. (164) 189)

Hoe 065; Learning; Avoidance (inhibitory, passive); (Up-hill avoidance, Eight-arm radial maze) (Hock, F.J. (171) 79)

Memory (working)
S-Adenosyl-L-methionine; Cerebral ischemia; Scopolamine; Runway task (3-panel); Amnesia (Yatsugi, S.-i. (166) 231)

Mepirizole
Calcitonin gene-related peptide-like immunoreactivity (CGRP-li); Duodenal ulcers; Dulcerozine; Cysteamine (Evangelista, S. (164) 389)

Mesangial cells
Endothelium; Endothelin; Glomerulus; Glomerular filtration rate; Renal plasma flow; (Contraction) (López-Farré, A. (163) 187)

Mescaline
Drug discrimination; Hallucinogens; 5-HT receptors; 5-HT_1 receptors; 5-HT_2 receptors (Appel, J.B. (159) 41)

Mesenteric vasculature
Norepinephrine; Phosphatidylinositol turnover; Deoxycorticosterone acetate-salt hypertensive rats; (Contraction) (Takata, Y. (164) 365)

Mesenteric vessels
Bunazosin; Noradrenaline; Excitatory junction potential; α-Adrenoceptors (Komori, K. (164) 111)

Mesolimbic dopamine system
Clonidine; Dopamine; Idazoxan; Ventral tegmental area; (Firing pattern) (Grenhoff, J. (165) 11)

Metaphit
σ Receptors; Phencyclidine receptors; Isothiocyanates; Affinity labelling (Bluth, L.S. (161) 273)

Audiogenic seizures; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA) (Debler, E.A. (165) 155)

[Met^5]enkephalin
Enkephalinase; Thiorphan; Spinal cord; SCH 34826 (Yaksh, T.L. (167) 367)

Opiates; [Leu^5]enkephalin; (Biologically active conformation) (Gašparík, J. (172) 417)

[Met^5]enkephalin-like material
Spinal cord; Calcitonin (porcine); (Intrathecal perfusion, In vivo release) (Collin, E. (168) 201)

Methadone
Opiates; Withdrawal syndrome; Naloxone; (Rhesus monkey, Dependence) (Krystal, J.H. (160) 331)

Methamphetamine
MK-801; MDMA neurotoxicity; Tryptophan hydroxylase (Johnson, M. (165) 315)

Methiothepin
Sympathetic activity (renal); Ventrolateral pressor area; (±)-Pindolol; (±) 8-OH-DPAT (8-hydroxy-2(di-n-propylamino)tetralin) (Laubie, M. (160) 385)

Methoctramine
Drinking; Muscarinic M_1/M_2 receptors; Muscarinic receptor subtypes (Massi, M. (163) 387)

Phosphoinositide hydrolysis; Muscarinic receptors; Brain; Muscarinic receptor subtypes; Antimuscarinic agents (Lee, N.H. (167) 295)

Muscarinic receptor subtypes; Muscarinic M_3-selective antagonists; Hexahydro-sila-difenidol analogues; p-Fluoro-hexahydro-sila-difenidol; Pirenzepine; Vas deferens (rabbit); Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

Muscarinic M_3 receptor subtypes; HT-29 colon carcinoma cells; Phosphatidylinositol metabolism; AF-DX 116; Sila-hexocyclium; Hexhydro-sila-difenidol (Kopp, R. (172) 397)

Methoxamine
Anococcygeus (rat); Clonidine; McN-A-343; Non-adrenergic, non-cholinergic (NANC) transmission; Rilmenidine; (Prejunctional receptors) (Li, C.G. (168) 107)

3-Methoxytyramine
Cholecystokinin (CCK); CR 1409; Fronto-parietal cortex; Striatum; Acetylcholine; Dopamine (Cosi, C. (165) 209)

Methoxyverapamil
Noradrenaline contractions; Ryanodine; Nifedipine; Ca^{2+} mobilization; Vas deferens; (Rat) (Vesperinas, G. (165) 309)

MethylDOPA
Synaptosomes; 5-Hydroxytryptamine (5-HT); α-Methyldopamine (Wolf, W.A. (163) 43)

Microdialysis (in vivo); Catecholamine overflow (endogenous and methylated); Hypotension (Kapoor, V. (164) 531)

α-Methyldopamine
Synaptosomes; α-Methyldopa; 5-Hydroxytryptamine (5-HT) (Wolf, W.A. (163) 43)

α,β-Methylene ATP
Adrenergic/purinergic neurotransmission; α-Adrenoceptor antagonists; Resistance vessels (pre-capillary); (In vivo) (Taylor, E.M. (164) 23)

Methylene blue
Endothelin-1; BAY k 8644; Veins; Angiotensin converting enzyme (D'Orleans-Juste, P. (165) 289)

N^{τ}-Methylhistamine
(R)α-Methylhistamine; Thioperamide; Histamine turnover; [^{3}H]Histamine synthesis (Garbarg, M. (164) 1)

(R)-α-Methylhistamine
Histamine H_3-receptor agonists; Electrical field stimulation; Bronchi; (Human) (Ichinose, M. (163) 383)

Thioperamide; Histamine turnover; [^{3}H]Histamine synthesis; N^{τ}-Methylhistamine (Garbarg, M. (164) 1)

Methylmercury
Myocardium (isolated); Contractility; Transmembrane potential; Ca^{2+} action potential; Na^+,K^+-ATPase; Chlormerodrin; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Methylphenidate
Cerebral cortex; [^{3}H]Prazosin; [^{3}H]Idazoxan; [^{3}H]Dihydroalprenolol; (Down-regulation) (Mathieu, J.-F. (162) 173)

Dopamine uptake inhibitors; Dopamine metabolism; Microdialysis (in vivo); Amphetamine; Nomifensine (Hurd, Y.L. (166) 251)

[^{3}H]Methylscopolamine
SK-N-SH human neuroblastoma; SH-SY5Y human neuroblastoma; Muscarinic M_3 receptors (Lambert, D.G. (165) 71)

α-Methyl-p-tyrosine
α_2-Adrenoceptors (brain); [^{3}H]Clonidine; Reserpine; Clorgyline; Tranylcypromine; Cocaine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

Imipramine; Dopamine D-1 receptors; Adenylate cyclase (De Montis, G.M. (167) 299)

[^{3}H]5-Methyl-urapidil
α_1-Adrenoceptor subtypes; 5-HT_{1A} receptors; Niguldipine (Graziadei, I. (172) 329)

Methysergide
5-HT receptor subtypes; Pulmonary edema; Capillary pressure; Filtration coefficient; Ketanserin (Sumita, T. (164) 69)

5-Hydroxytryptamine (serotonin, 5-HT); Algesia; Arachidonate cyclooxygenase (inhibitors); Prostaglandins (Vinegar, R. (164) 497)

5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; 5-HT_1-like receptors; 5-HT_2 receptors; Renal function (Shoji, T. (171) 219)

Mg^{2+}
MK-801; Ketamine; Phencyclidine; N-Methyl-D-aspartate (NMDA); Glutamate; Glycine; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

Muscarinic acetylcholine receptors; G-proteins; Cardiac tissue; Na^+ (Hilf, G. (172) 155)

Mg^{2+} (extracellular)
Cardiac glycosides; Norepinephrine; BAY k 8644; Ca^{2+} (extracellular); Cardiac muscle; (Guinea-pig) (Kafiluddi, R. (165) 181)

MHPG (3-methoxy-4-hydroxyphenylglycol)
Imipramine; Pharmacokinetics (cerebral); 5-Hydroxytryptamine (5-HT, serotonin); 5-Hydroxyindole acetic acid (5-HIAA); Norepinephrine (Sugita, S. (165) 191)

α_2-Adrenoceptors; Hypoactivity; Sedation; Mydriasis; Clonidine; Brain; Behaviour; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

Microcirculation
Skeletal muscle; Ischaemia; Peripheral vascular disease; Torbafylline; (Performance) (Okyayuz-Baklouti, I. (166) 75)

Microdialysis
Dopamine; CY 208-243; (Release) (Imperato, A. (160) 155)

Amphetamine; Neurokinin A; Tachykinin; Nucleus accumbens; Caudate-putamen (Lindefors, N. (160) 417)

Haloperidol; Neurokinin A; Substance P; Tachykinin; Substantia nigra (Lindefors, N. (161) 95)

Dopamine release; Stereoisomers; Dopamine receptor agonists; Transdermal application; Oral administration (Timmerman, W. (162) 143)

Dopamine, 5-HT_3 receptors; ICS 205-930; Morphine; Amphetamine (Carboni, E. (164) 515)

Dopamine release; Dopamine receptor agonists; N-0437; (Stereoisomers, Slices) (Timmerman, W. (166) 1)

MPP^+ (1-methyl-4-phenylpyridinium); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Serotonin; Serotonin syndrome; Dopamine (Miyake, H. (166) 49)

MDMA (3,4-methylenedioxymethamphetamine); Dorsal raphe nucleus; Single unit recording; Neurotransmitter release (Sprouse, J.S. (167) 375)

Nucleus accumbens; Dopamine; Nicotine; Tolerance; (Rat) (Damsma, G. (168) 363)

Microdialysis (in vivo)
Catecholamine overflow (endogenous and methylated); Hypotension; MethylDOPA (Kapoor, V. (164) 531)

Dopamine uptake inhibitors; Dopamine metabolism; Amphetamine; Methylphenidate; Nomifensine (Hurd, Y.L. (166) 251)

Dopamine uptake carrier; Amphetamine; Ca^{2+}-dependent dopamine release; Dopamine metabolism (Hurd, Y.L. (166) 261)

Microtubule-associated protein
Antidepressants; cAMP-dependent phosphorylation (Perez, J. (172) 305)

Microvascular permeability
Peptidoleukotrienes; Histamine (Woodward, D.F. (164) 323)

Midazolam
βCCE (3-carboethoxy-β-carboline hydrochloride); Flumazenil; Tolerance; (Sensitization, Baboon) (Sannerud, C.A. (167) 333)

Midbrain dopamine neurons
MDMA (3,4-methylenedioxymethamphetamine); Apomorphine; Quinpirole; Antidromic activation; (Electrophysiology) (Kelland, M.D. (169) 11)

MIF-1
Prolyl-leucyl-glycinamide; Apomorphine; Dopamine; 6-Hydroxydopamine (6-OHDA, neonatal); (Behaviour, Development) (Kostrzewa, R.M. (163) 33)

Migraine
Arteriovenous anastomoses; Carotid blood flow; 5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptors; 5-HT_1-like receptors; RU 24969 (Bom, A.H. (171) 87)

Migrating myoelectric complex
Ca^{2+} channel blockers; Electrical spike activity; Intestinal motility; (Computer analysis) (De Ponti, F. (168) 133)

Milrinone
Hemodynamics; Myocardially infarcted rat; Enalapril; Cardiomegaly (compensated) (DeFelice, A. (167) 211)

Minaprine
5-HT_1 receptors; Acetylcholine release; Hippocampus (Bolanos, F. (168) 87)

Cycloheximide; Serotonergic system; Cholinergic system; 5-HT_2 receptors; Amnesia; (Mouse) (Nabeshima, T. (169) 249)

Mioflazine
Nucleoside transport inhibition; Lidoflazine; Mioflazine analogs; Nitrobenzylthioinosine; (Heterogeneity, Computer model) (IJzerman, A.P. (172) 273)

Mioflazine analogs
Nucleoside transport inhibition; Lidoflazine; Mioflazine; Nitrobenzylthioinosine; (Heterogeneity, Computer model) (IJzerman, A.P. (172) 273)

Mitochondria
Peripheral benzodiazepines; PK 11195; Ro 5-4864; Neuroblastoma cells (Larcher, J.-C. (161) 197)

ANF binding; Adrenal cortex (Heisler, S. (162) 281)

Kidney; Succinate transport; Valproate; Membrane (Rumbach, L. (164) 577)

Mitochondrial oxidative phosphorylation
Murrayaquinone-A; Papillary muscle (guinea-pig); Inotropic response (triphasic); Action potential (augmented, slow) (Takeya, K. (169) 137)

MK-801
NMDA (N-methyl-D-aspartate); CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-1-phosphonic acid); Schedule-controlled responding; Drug discrimination; (Rhesus monkey) (France, C.P. (159) 133)

Ketamine; Phencyclidine; N-Methyl-D-aspartate (NMDA); Glutamate; Glycine; Magnesium; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

Pituitary; Adrenal; ACTH; Corticosterone; Prolactin; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Methamphetamine; MDMA neurotoxicity; Tryptophan hydroxylase (Johnson, M. (165) 315)

Audiogenic seizure; Anticonvulsants; Non-competitive NMDA antagonists; Phencyclidine; Dextromethorphan (Chapman, A.G. (166) 201)

Ataxia; Dopamine turnover; Phencyclidine (PCP); 5-HT uptake; Stereotyped behavior; (Rat) (Hiramatsu, M. (166) 359)

Phencyclidine (PCP); NMDA receptor antagonists; Anticonvulsants; Drug discrimination; (Behaviour) (Tricklebank, M.D. (167) 127)

N-Methyl-D-aspartate (NMDA); Cough reflex (Kamei, J. (168) 153)

Social conflict analgesia; Periaqueductal grey; NMDA receptors; AP-7; Naloxone; (Mouse) (Siegfried, B. (168) 239)

NMDA receptors; HA-966; Kynurenic acid; GABA release; Ca^{2+} (intracellular) (Reynolds, I.J. (172) 9)

Moclobemide
5-HT uptake; [^{3}H]Cyanoimipramine binding; Brofaromine; Ifoxetine; 5-HT uptake inhibitors (Waldmeier, P.C. (169) 197)

Molecular weight
Radiation inactivation; 5-HT_3 receptors; Cerebral cortex (rat); [^{3}H]Zacopride (Gozlan, H. (172) 497)

Monensin
Ouabain; K^+-free medium; Noradrenaline release; Ca^{2+}-evoked contraction; Na^+/Ca^{2+} exchange transport; Vas deferens; (Guinea pig) (Katsuragi, T. (167) 147)

Na^+ (intracellular); K^+ relaxation; Norepinephrine; Ouabain; Serotonin; Smooth muscle (vascular) (Bell, D.R. (171) 189)

Monoamine content
Kinins; Nociception; Spinal cord; Noradrenergic mechanism; 6-Hydroxydopamine (6-OHDA) (Laneuville, O. (159) 273)

Monoamine oxidase-B activity
L-Deprenyl; Dopamine uptake carrier; [^{3}H]Mazindol binding; Dopamine metabolism (Wiener, H.L. (163) 191)

Monoamine oxidase-B (MAO-B)
Ro 19-6327; Ro 16-6491; Affinity labelling; (Mechanism-based reversible inhibition, High-affinity binding) (Cesura, A.M. (162) 457)

Monoamine oxidase (MAO)
MAO inhibitors; Isoelectric focusing (Fritze, J. (172) 147)

Monocyclic porcine analog
Endothelin (porcine); Endothelin (rat); Arterial pressure (Minkes, R.K. (164) 571)

N^G-Monomethyl-L-arginine
Endothelin-1; Vasodilatation; Nitric oxide (Gardiner, S.M. (171) 237)

Mononuclear leukocytes
β-Adrenoceptor subtypes; Cardiac muscle (Tenner, Jr., T.E. (160) 291)

Morphine
μ Opioid receptors; [^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Naltrexone; β-Funaltrexamine; κ Opioid receptors; (Receptor upregulation) (Rothman, R.B. (160) 71)

U-50,488H; κ Opioid receptors; Tolerance; Analgesia; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Bronchi; Neuropeptide Y; UK 14,304; α-Adrenoceptors; Cholinergic contraction; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Noradrenaline; (Guinea-pig) (Matran, R. (163) 15)

Calcitonin; Analgesia; Withdrawal syndrome; Ca^{2+} (Clementi, G. (163) 175)

Reticular formation; Pain (Bing, Z. (164) 85)

Dopamine; Microdialysis; 5-HT_3 receptors; ICS 205-930; Amphetamine (Carboni, E. (164) 515)

Enkephalin analog; Reinforcing effects; Self-administration (Nishida, N. (166) 453)

DADLE ([D-Ala^2,D-Leu^5]enkephalin); Sufentanil; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Opioid dependence; Intrathecal infusion (Stevens, C.W. (166) 467)

Tolerance-dependence; Abstinence; 5-HT_2 receptors; Brain regions; Spinal cord (Gulati, A. (167) 185)

β-Endorphin; Analgesia; Pain control systems (descending) (Suh, H.H. (168) 61)

Spinal cord; Tolerance; Opioids; Naloxone; Withdrawal (Bell, J.A. (168) 101)

Dependence; U-50,488H; κ-Opioid agonists (Fukagawa, Y. (170) 47)

Bromocriptine; (Mouse) (Gomaa, A.A. (170) 129)

Opioids; Naltrexone; Upregulation; Supersensitivity; Analgesia; (Dose dependence) (Yoburn, B.C. (170) 193)

Morphine analgesia
Adrenalectomy; (Tissue content-effect correlation, Sensitivity to morphine, Subcutaneous, Intracerebroventricular, Rat) (Miyamoto, Y. (167) 11)

Morphine dependence
α_2-Adrenoceptors; Morphine withdrawal; Hippocampal slices; [^{3}H]Clonidine binding; Brain; (Field stimulation, Rat) (Smith, C.B. (161) 111)

Butorphanol; Withdrawal; Naloxone (Horan, P. (170) 265)

Morphine withdrawal
α_2-Adrenoceptors; Morphine dependence; Hippocampal slices; [^{3}H]Clonidine binding; Brain; (Field stimulation, Rat) (Smith, C.B. (161) 111)

5-HT_1 receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); RU 24969; (Mouse) (Berthold, H. (162) 19)

Naloxone; Enkephalinase inhibitors; Kelatorphan; Thiorphan (Maldonado, R. (165) 199)

Motor activity
Antidepressants; Thiorphan; Bestatin; Iprindole; Imipramine;

Forced swimming test; Opioids (Del Carmen de Felipe, M. (159) 175)

Muscarinic receptors; Quinuclidinyl benzilate (QNB); Phencyclidine (PCP) (Boggan, W. (166) 123)

GBR 12909; Dopamine; Reinforcement (conditioned); (Sensitization, Fixed-interval) (Kelley, A.E. (167) 385)

Motor control
Raphe nuclei; 5-HT_{1A} agonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Hillegaart, V. (160) 303)

Motor impairment
Ro 15-4513; Benzodiazepine inverse agonists; Ethanol; Pentobarbital; Hypnotics (Le, A.D. (159) 25)

Motor incoordination
Dilazep; Dilazep metabolites; Ethanol; (Intracerebroventricularly) (Dar, M.S. (164) 303)

Motor nerve terminal
Stannous chloride; Ca^{2+} entry; Ca^{2+} channel; Transmitter release; (Frog) (Hattori, T. (166) 527)

MPP^+ (1-methyl-4-phenylpyridinium ion)
Catecholamine uptake; Dopamine; Diethyldithiocarbamate; Disulfiram (Di Monte, D. (166) 23)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Serotonin; Serotonin syndrome; Microdialysis; Dopamine (Miyake, H. (166) 49)

Dopamine uptake; Striatal synaptosomes; (Neurotoxicity) (Johnson, E.A. (166) 65)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
MPP^+ (1-methyl-4-phenylpyridinium); Serotonin; Serotonin syndrome; Microdialysis; Dopamine (Miyake, H. (166) 49)

Histamine; Neurotoxins; Brain; (Mouse) (Cumming, P. (166) 299)

Dopamine; Dopamine uptake inhibitors; (Mouse) (Kilbourn, M.R. (166) 331)

Parkinsonism; Dopamine D-2 agonists; N-0437; (Transdermal administration, Common marmoset) (Löschmann, P.-A. (166) 373)

Nigrostriatal dopaminergic neurons; GM1 ganglioside; Dopamine receptors (Hadjiconstantinou, M. (168) 261)

Striatum; [^{3}H]Dopamine release; [^{3}H]Acetylcholine release; [^{3}H]Spiroperidol binding; (Rat) (Kurstjens, N.P. (169) 147)

MR-2266
κ Opioid receptor agonists; U-62,066E; κ Opioid receptor antagonists; [Arg^8]vasopressin; Diuresis; Collecting duct; Water permeability (Imai, K.Y.M. (160) 229)

MSH receptors
Phorbol ester; Adenylate cyclase; Melanoma; Cell proliferation (Gerst, J.E. (172) 29)

Mucus
Platelet-activating factor (PAF-acether, PAF); Inflammation; Goblet cells; Conjunctiva (Woodward, D.F. (168) 23)

Mucus secretion
Loperamide; Colon; (Rat) (Loeschke, K. (170) 41)

Murrayaquinone-A
Papillary muscle (guinea-pig); Mitochondrial oxidative phosphorylation; Inotropic response (triphasic); Action potential (augmented, slow) (Takeya, K. (169) 137)

Muscarinic acetylcholine receptors
G-proteins; Cardiac tissue; Mg^{2+}; Na^+ (Hilf, G. (172) 155)

Muscarinic acetylcholine receptor subtypes
Cardiac M_2 receptors; Phosphoinositide hydrolysis (Mizushima, A. (168) 375)

Muscarinic inhibition
Muscarinic M_2 receptor subtypes; Noradrenaline release; Iris (guinea-pig); Iris (rabbit); Iris sphincter muscle (rabbit); (Pre- and postjunctional affinity constants) (Bognar, I.T. (163) 263)

Muscarinic K^+ channels
AN-132; Anticholinergic effect; Acetylcholine; Atrial myocyte (Kurachi, Y. (165) 319)

Muscarinic M_1/M_2 receptors
Methoctramine; Drinking; Muscarinic receptor subtypes (Massi, M. (163) 387)

Muscarinic M_2 receptor subtypes
Muscarinic inhibition; Noradrenaline release; Iris (guinea-pig); Iris (rabbit); Iris sphincter muscle (rabbit); (Pre- and postjunctional affinity constants) (Bognar, I.T. (163) 263)

Muscarinic M_1 receptors
SR 95639A; Sympathetic ganglion; Turning behaviour (Schumacher, C. (166) 139)

Hexahydrodifenidol (Freedman, S.B. (167) 411)

Muscarinic M_3 receptors
SK-N-SH human neuroblastoma; SH-SY5Y human neuroblastoma; [^{3}H]Methylscopolamine (Lambert, D.G. (165) 71)

Muscarinic M_3 receptor subtypes
HT-29 colon carcinoma cells; Phosphatidylinositol metabolism; AF-DX 116; Sila-hexocyclium; Hexhydro-sila-difenidol; Methoctramine (Kopp, R. (172) 397)

Muscarinic M_3-selective antagonists
Muscarinic receptor subtypes; Hexahydro-sila-difenidol analogues; p-Fluoro-hexahydro-sila-difenidol; Pirenzepine; Methoctramine; Vas deferens (rabbit); Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

Muscarinic receptor agonists
α_2-Adrenoceptors; Muscarinic receptor antagonists; [^{3}H]Clonidine binding; Brain (rat) (Hollingsworth, P.J. (168) 159)

Functional antagonism; Smooth muscle (airway); Histamine; Phosphoinositide metabolism; β-Adrenergic relaxation (Van Amsterdam, R.G.M. (172) 175)

Muscarinic receptor antagonists
α_2-Adrenoceptors; Muscarinic receptor agonists; [^{3}H]Clonidine binding; Brain (rat) (Hollingsworth, P.J. (168) 159)

Muscarinic receptors
Heart; Cerebral cortex (rat); Bretylium tosylate (Gillard, M. (160) 117)

Atrium; Ileal longitudinal muscle; C_7/3′-phthalimidopropyl; (Guinea-pig) (Choo, L.K. (162) 429)

OM-853; Dopamine release; Striatum (Koda, H. (162) 501)

Sympathetic ganglia; (Rat) (Newberry, N.R. (163) 237)

Smooth muscle (human, airway); Phosphoinositide metabolism (Meurs, H. (164) 369)

Sprague-Dawley rat (SD); Wistar-Kyoto rat (WKY); Spontaneously hypertensive rat (SHR); Cholinesterase; Dopamine receptors (Lim, D.K. (165) 279)

Motor activity; Quinuclidinyl benzilate (QNB); Phencyclidine (PCP) (Boggan, W. (166) 123)

4-DAMP (4-diphenylacetoxy-N-methyl-piperidine methiodide); Submaxillary gland; Cortex; Heart (Michel, A.D. (166) 459)

Telenzepine; Sympathetic ganglion; EPSP (slow); (Ligand binding) (Galvan, M. (167) 1)

Methoctramine; Phosphoinositide hydrolysis; Brain; Muscarinic receptor subtypes; Antimuscarinic agents (Lee, N.H. (167) 295)

Hypertension; Kidney; Autoradiography; (Rat) (De Michele, M. (169) 297)

Inositol polyphosphates; (Development) (Rooney, T.A. (172) 425)

Muscarinic receptor subtypes
Cultured explants; Hippocampus; Septum; Cholinergic reinnervation; (Up-regulation, Down-regulation) (Rimvall, K. (160) 1)

Methoctramine; Drinking; Muscarinic M_1/M_2 receptors (Massi, M. (163) 387)

Lung; Pirenzepine (Mak, J.C.W. (164) 223)

Telenzepine; Pirenz-pine; Ulcer model (Schudt, C. (165) 87)

Methoctramine; Phosphoinositide hydrolysis; Muscarinic receptors; Brain; Antimuscarinic agents (Lee, N.H. (167) 295)

Muscarinic M_3-selective antagonists; Hexahydro-sila-difenidol analogues; p-Fluoro-hexahydro-sila-difenidol; Pirenzepine; Methoctramine; Vas deferens (rabbit); Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

BTM-1086; BTM-1041; Histamine H_1 receptors; α_1-Adrenoceptors; (Stereoselectivity) (Eltze, M. (170) 225)

Ventricle (bovine, left); Smooth muscle (bovine, tracheal); (Allosteric modulation) (Roffel, A.F. (172) 61)

[^{3}H]Pirenzepine; Hippocampus; Receptor-G protein coupling; N-Ethylmaleimide (NEM); (Agonists) (Flynn, D.D. (172) 363)

Muscarinic stimulation
Trachea; Cigarette smoke; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2; Cortisol; Ca^{2+} (Jeremy, J.Y. (160) 107)

Muscimol
5-Hydroxytryptamine (5-HT, serotonin); Intestine (small); Enterochromaffin cells; GABA receptors; Baclofen (Schwörer, H. (165) 29)

$GABA_B$ autoreceptors; [^{3}H]GABA release; (−)-Baclofen; Phaclofen; (Superfused synaptosomes) (Bonanno, G. (172) 41)

[^{3}H]Muscimol
Lithium; Carbamazepine; [^{3}H](−)-Baclofen; $GABA_B$ receptors; Hippocampus (Motohashi, N. (166) 95)

[^{3}H]Muscimol binding
$GABA_A$ receptors; Gastric ulcer; Gastric mucoprotection; Stomach; [^{3}H]GABA binding; (Rat) (Erdö, S.L. (165) 79)

Muscle relaxants (central)
Benzodiazepine; Spinal cord; GABA; Cerebellar Purkinje cells; (Unit activity) (Tarnawa, I. (167) 193)

Muscle twitch
Diltiazem; Neuromuscular junction; Nicotinic receptor-ion channel complex (Baños, J. (165) 151)

Mutagenesis
HIV-1; Protease; Protein dimer; Synthetic gene (Guenet, C. (172) 443)

Mydriasis
Locus coeruleus; α_2-Adrenoceptors; Clonidine; Cocaine (Pitts, D.K. (160) 201)

α-Adrenoceptors; Central nervous system (CNS); Clonidine; (Functional model, Mouse) (Heal, D.J. (170) 11)

α_2-Adrenoceptors; Hypoactivity; Sedation; MHPG (3-methoxy-4-hydroxyphenylglycol); Clonidine; Brain; Behaviour; (Presynaptic α_2-adrenoceptors, Postsynaptic α_2-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

Myenteric plexus
NMDA receptors; Glycine; Kynurenate; Glutamate (Moroni, F. (163) 123)

Galanin; Small intestine; (Circular muscle contraction, Guinea-pig) (Kuwahara, A. (164) 175)

Glycine; NMDA (N-methyl-D-aspartate); 7-Chlorokynurenic acid (Reggiani, A. (168) 123)

Myocardial depressant factor
Peptidoleukotriene; Splanchnic artery occlusion; SK&F 104353; Hematocrit; Cathepsin D (Lento, P.H. (165) 241)

Myocardial dysfunction (regional)
KC 8857; Bradycardiac agents (selective); Hemodynamics; (Exercise) (Grohs, J.G. (161) 53)

Myocardial hypertrophy
Histamine; Cardiac arrhythmias; Hypertension; Spontaneously hypertensive rat (SHR) (Cameron, J.S. (169) 23)

Myocardial ischemia
Coronary occlusion; K^+ loss; Haemodynamics; Ca^{2+} antagonists; Gallopamil; Diltiazem; Nifedipine (Kirchengast, M. (160) 349)

Noradrenaline; Converting enzyme inhibitors; (Rat) (Carlsson, L. (166) 157)

ICI 118,551; Atenolol; Coronary stenosis; β_2-Adrenoceptors; (Regional myocardial function) (Noguchi, K. (168) 315)

Myocardial ischemia (simulated)
Coronary artery; Adenosine; 5-Hydroxytryptamine; Acetylcholine; U-46,619; Iloprost; (Sheep) (Kwan, Y.W. (168) 31)

Myocardially infarcted rat
Hemodynamics; Milrinone; Enalapril; Cardiomegaly (compensated) (DeFelice, A. (167) 211)

Myocardial necrosis
Kainic acid; N-Methyl-D-aspartic acid (NMDA); Neurotoxin (excitatory); Paraventricular hypothalamus; (Rat) (Rockhold, R.W. (166) 571)

Myocardial uptake
Acidosis; Disopyramide; ECG effects (Bova, S. (168) 179)

Myocardium
Propranolol; Ischemia; Perfused working heart; Non-esterified fatty acids; (Rat) (Nakamura, K. (160) 61)

Contractility; Adenosine; Alinidine; Heart rate; (Action potential) (Lang, U. (164) 13)

Lidocaine; Ischemia; Heart (perfused working); Fatty acids (non-esterified); (Rat) (Nakamura, K. (169) 259)

Myocardium (human)
Pyridazinone; Imidazole; MCI-154; Skinned fibers; Inotropic drugs (Perreault, C.L. (165) 305)

Myocardium (isolated)
R56865; Ouabain; Digitalis toxicity; Na^+ pump; (Rat) (Finet, M. (164) 555)

Contractility; Transmembrane potential; Ca^{2+} action potential; Na^+,K^+-ATPase; Methylmercury; Chlormerodrin; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Myocardium (reperfused, dog)
Nitroglycerin; O_2 supply; O_2 consumption (Joselevitz-Goldman, J. (166) 283)

Myocytes (ventricular)
α_1-Adrenoceptors; Cardiac action potential; Epinephrine; Prazosin; β-Adrenoceptor blockade; (Adult rat) (Vogel, S.M. (164) 231)

Myogenic tone
Hemolysate; Cerebral artery; Vasospasm; Ca^{2+} antagonists; Endothelium (Nakayama, K. (169) 33)

Myosin light-chain kinase
Ca^{2+} entry blockers; Protein kinase C; Smooth muscle contraction (vascular) (Schächtele, C. (163) 151)

N-0434
Dopamine D-2 receptors; Affinity chromatography; (Purification) (Bosker, F.J. (163) 319)

N-0437
Microdialysis; Dopamine release; Dopamine receptor agonists; (Stereoisomers, Slices) (Timmerman, W. (166) 1)

MPTP; Parkinsonism; Dopamine D-2 agonists; (Transdermal administration, Common marmoset) (Löschmann, P.-A. (166) 373)

^{22}Na
Submandibular acini; [^{3}H]QNB binding; Amiloride; Furosemide (Martinez, J.R. (164) 335)

Na^+
Muscarinic acetylcholine receptors; G-proteins; Cardiac tissue; Mg^{2+} (Hilf, G. (172) 155)

N-Formylmethionine-leucyl-phenylalanine (FMLP); Guanine nucleotide-binding protein (G-protein); Pertussis toxin; HL 60 cells (Gierschik, P. (172) 481)

Na^+/Ca^{2+} exchange
Inositol phospholipids; Depolarization; Na^+ channels (Benuck, M. (159) 187)

Quinacrine; Slow inward current; Force (Yang, L. (170) 261)

Ca^{2+} (intracellular); Na^+ channels (Briggs, G.M. (170) 281)

Na^+/Ca^{2+} exchange transport
Monensin; Ouabain; K^+-free medium; Noradrenaline release; Ca^{2+}-evoked contraction; Vas deferens; (Guinea pig) (Katsuragi, T. (167) 147)

Na^+ channel modifiers
Cardiac Na^+ channels (non-inactivating); (±)-DPI 201-106 (Kohlhardt, M. (168) 115)

Na^+ channels
Inositol phospholipids; Depolarization; Na^+/Ca^{2+} exchange (Benuck, M. (159) 187)

GBR 12909 (1-(2-(bis(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenylpropyl)piperazine); Dopamine uptake; Piperazine site; (Neurochemical properties, Voltage-dependent) (Andersen, P.H. (166) 493)

Antiarrhythmics; Lidocaine binding site; Heart; Liver (Voigt, W. (169) 103)

Ca^{2+} (intracellular); Na^+/Ca^{2+} exchange (Briggs, G.M. (170) 281)

Na^+ channels (voltage-sensitive)
$^{22}Na^+$ uptake (synaptosomal); Veratridine; [^{3}H]Batrachotoxin binding; [^{3}H]TCP binding; PCP-like drugs; PCP receptors; Anaesthetics (Allaoua, H. (163) 327)

Na^+/H^+ exchanger
Endothelin; Sarafotoxin S6b; Ca^{2+} antagonists; BAY k 8644; ω-Conotoxin (Gu, X.-H. (167) 281)

Na^+ (intracellular)
K^+ relaxation; Norepinephrine; Monensin; Ouabain; Serotonin; Smooth muscle (vascular) (Bell, D.R. (171) 189)

Na^+ ions
Dynorphin A; μ-Opioid receptors; κ-Opioid receptors; 5′-Guanylyl amidodiphosphate (Gpp(NH)p) sensitivity; (Agonist peptides); (Antagonist peptides) (Gairin, J.-E. (172) 381)

Na^+,K^+-ATPase
5-HT receptors; Dopamine receptors; Hippocampus; Striatum; Central nervous system (CNS); Spaceflight (Miller, J.D. (161) 165)

Myocardium (isolated); Contractility; Transmembrane potential; Ca^{2+} action potential; Methylmercury; Chlormerodrin; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

[^{3}H]Ouabain binding; Ventricles; Renal hypertension; DOCA/NaCl hypertension (Chen, C.-C. (169) 67)

Thyroid hormone; Noradrenaline (metabolic effects); Ouabain binding; 6-Hydroxydopamine (Swann, A.C. (169) 275)

Nalbuphine
Reward threshold; Brain stimulation reward; Tripelennamine; Pentazocine; Physical dependence (Huston-Lyons, D. (169) 153)

Naloxonazine
Analgesia; Opioid receptors; Tail flick; ICI 154,129; β-Funaltrexamine; Opioid peptides; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

Opioid antinociception; μ Opioid receptors; δ Opioid receptors; β-Funaltrexamine (β-FNA); (Intracerebroventricular, Mouse) (Heyman, J.S. (169) 43)

Naloxone
Opiates; Withdrawal syndrome; Methadone; (Rhesus monkey, Dependence) (Krystal, J.H. (160) 331)

Antiarrhythmic activity; Purkinje fibers; Oscillatory afterpotentials; (Triggered activity) (Cerbai, E. (162) 491)

Morphine withdrawal; Enkephalinase inhibitors; Kelatorphan; Thiorphan (Maldonado, R. (165) 199)

Bremazocine; Opiates; Oxytocin; (In vitro, In vivo) (Grell, S. (166) 41)

Phencyclidine (PCP); Opiates; Temperature; Hypothermia; Dependence (Pechnick, R.N. (166) 295)

Morphine; Spinal cord; Tolerance; Opioids; Withdrawal (Bell, J.A. (168) 101)

Social conflict analgesia; Periaqueductal grey; NMDA receptors; AP-7; MK-801; (Mouse) (Siegfried, B. (168) 239)

Butorphanol; Withdrawal; Morphine dependence (Horan, P. (170) 265)

[^{3}H]Naloxone
5-HT_3 receptors; Opiate receptors; [^{3}H]Zacopride; [^{3}H]-Bremazocine; Spinal cord; Capsaicin; (Rat) (Hamon, M. (164) 315)

Naltrexone
μ Opioid receptors; [^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Morphine; β-Funaltrexamine; κ Opioid receptors; (Receptor upregulation) (Rothman, R.B. (160) 71)

Opioids; Upregulation; Supersensitivity; Analgesia; Morphine; (Dose dependence) (Yoburn, B.C. (170) 193)

Na^+ pump
R56865; Ouabain; Digitalis toxicity; Myocardium (isolated); (Rat) (Finet, M. (164) 555)

Narcotic analgesia
Heroin; Self-administration; Physical dependence; (Unit dose, Intraventricular, Rat) (De Vry, J. (161) 19)

Nasal fluid secretions
Hyperosmolarity; Histamine; H_1 receptor antagonists; H_2 receptor antagonists (Petersson, G. (161) 37)

Nasal vasculature
Noradrenaline; Neuropeptide Y (NPY); ATP; α-Adrenoceptors; (Denervation) (Lacroix, J.-S. (169) 125)

Natriuresis
[Arg^8]vasopressin; Atrial natriuretic factor; Brattleboro rats; Diuresis; Lithium clearance (Palluk, R. (162) 245)

$^{22}Na^+$ uptake (synaptosomal)
Na^+ channels (voltage-sensitive); Veratridine; [^{3}H]-Batrachotoxin binding; [^{3}H]TCP binding; PCP-like drugs; PCP receptors; Anaesthetics (Allaoua, H. (163) 327)

Nebivolol
β_1-Adrenoceptor blockade; Pindolol; Practolol; Reserpinized animals; Atria (isolated); Blood vessels (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

β-Adrenoceptor-mediated cAMP accumulation; Cardiac cells; β-Adrenoceptor antagonist; (Rat) (Pauwels, P.J. (172) 471)

NECA (5′-*N*-ethylcarboxamideadenosine)
Adenosine; Negative inotropic effect; Heart; Adenylate cyclase; cAMP content; (−)-N^6-Phenylisopropyladenosine (PIA); (Guinea-pig) (Heller, T. (164) 179)

Negative inotropic effect
Adenosine; 5′-N-Ethylcarboxamideadenosine (NECA); Heart; Adenylate cyclase; cAMP content; (−)-N^6-Phenylisopropyladenosine (PIA); (Guinea-pig) (Heller, T. (164) 179)

Neocortex (rat)
$GABA_B$ receptor antagonists; Benzofuran-baclofen analogues; Baclofen; Ileum (guinea-pig) (Kerr, D.I.B. (164) 361)

Neuroblastoma cells
Peripheral benzodiazepines; PK 11195; Ro 5-4864; Mitochondrion (Larcher, J.-C. (161) 197)

Somatostatin receptors; Cyclic AMP (McKinney, M. (162) 397)

Neuroblastoma × glioma hybrid cells
5-HT_3 receptors; cGMP (Reiser, G. (172) 195)

5-HT_3 receptors; Ion channels; cGMP; Adamantane derivative (Reiser, G. (172) 199)

Neurogenic inflammation
Antiinflammatory drugs; Dura mater; Trigeminal ganglion (Buzzi, M.G. (165) 251)

Neurohypophysis
Vasopressin; Interleukin-1β (Christensen, J.D. (171) 233)

Neurokinin A
Amphetamine; Tachykinin; Nucleus accumbens; Caudate-putamen; Microdialysis (Lindefors, N. (160) 417)

Haloperidol; Substance P; Tachykinin; Substantia nigra; Microdialysis (Lindefors, N. (161) 95)

Substance P; γ-PPT-(72-92)-NH_2; Neuropeptide K; Tachykinins; Salivation (Takeda, Y. (161) 267)

Gallbladder; Tachykinins; Capsaicin; Substance P; Tachykinin receptors; Thiorphan; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Trachea; Tachykinins; Substance P; Neurokinin B; Tachykinin receptors; (Hamster) (Maggi, C.A. (166) 435)

Neurokinin B
Trachea; Tachykinins; Substance P; Neurokinin A; Tachykinin receptors; (Hamster) (Maggi, C.A. (166) 435)

Neuroleptics
Neurotensin; Operant responding; 'Anhedonia'; Central nervous system (CNS); (Dose-response curve) (Rossitch, Jr., E. (163) 119)

Quinine; K^+ channels; Dopamine D-2 receptors; Caudate nucleus; (Patch-clamp) (Freedman, J.E. (164) 341)

Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; (Receptor binding) (Kerkman, D.J. (166) 481)

Neuroleptic sensitization
Tardive dyskinesia; Oral dyskinesia; Haloperidol (intermittent); Amygdala kindling; (Drug holidays, Rat) (Glenthøj, B. (164) 393)

Neuromedin U
Gut motility; (Turtle) (Bockman, C.S. (171) 255)

Neuromuscular junction
4-Aminopyridine; Polymyxin B; (End-plate receptor desensitization) (Vital Brazil, O. (159) 47)

Adenosine; Diazepam; Sartorius muscle; Nucleoside uptake; Dipyridamole; (Frog) (De Mendonça, A. (164) 347)

Diltiazem; Nicotinic receptor-ion channel complex; Muscle twitch (Baños, J. (165) 151)

Endothelin; Heart; Blood vessels; Uterus; Trachea; Vas deferens; Platelets; Chromaffin cells; Neutrophils (Borges, R. (165) 223)

Neuromuscular transmission
Post-tetanic potentiation (Tsai, M.-C. (160) 133)

Neuronal cultures
Phaclofen; Inositol 1,4,5-triphosphate; GABA receptors (Michler, A. (167) 423)

Neuronal membrane (site of action)
Local anesthetics (tertiary and quaternary amine); Dissociability; Lipophilicity; Ion pairs (Štolc, S. (164) 249)

Neurons
Neuropeptides; Ion channels; (Mollusca, Snail) (Yongsiri, A. (171) 159)

Neuropeptide K
Substance P; Neurokinin A; γ-PPT-(72-92)-NH_2; Tachykinins; Salivation (Takeda, Y. (161) 267)

Neuropeptides
Vasoactive intestinal peptide (VIP); Leukotriene; Platelet activating factor (PAF-acether, PAF); Lungs; Cyclic AMP (Di Marzo, V. (162) 115)

Gastric acid secretion; Indomethacin; Dermorphin; Corticotropin-releasing factor (CRF); Calcitonin gene-related peptide (CGKP) (Guglietta, A. (170) 87)

Ion channels; Neurons; (Mollusca, Snail) (Yongsiri, A. (171) 159)

Neuropeptide Y
Bronchi; UK 14,304; α-Adrenoceptors; Cholinergic contraction; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Noradrenaline; Morphine; (Guinea-pig) (Matran, R. (163) 15)

Noradrenaline; Spleen; Adrenoceptors; Vasoconstriction; (Transmitter release) (Lundberg, J.M. (163) 103)

Coronary regulation; Catecholamines (potentiation of); Coronary vasoconstriction; Coronary arteries (isolated) (Macho, P. (167) 67)

Endothelium; Adrenergic nerve stimulation; Ear artery; (Rabbit) (Budai, D. (168) 97)

Noradrenaline; ATP; Nasal vasculature; α-Adrenoceptors; (Denervation) (Lacroix, J.-S. (169) 125)

α_2-Adrenoceptors; G-protein; Pertussis toxin; Medulla oblongata; (Rat) (Von Euler, G. (172) 435)

Neurotensin
Basal ganglia; Cocaine; Dopamine; GBR 12909; Substantia nigra; Striatum (Hanson, G.R. (160) 23)

Dopamine receptors; Striatum; Nucleus accumbens (Merchant, K.M. (160) 409)

Fura 2; Ca^{2+} mobilization; Inositol trisphosphate; Heterologous desensitization; NG108-15 cells (Imaizumi, T. (161) 203)

Neuroleptics; Operant responding; 'Anhedonia'; Central nervous system (CNS); (Dose-response curve) (Rossitch, Jr., E. (163) 119)

Haloperidol; Atropine; Scopolamine; Nucleus accumbens; Caudate nucleus (Levant, B. (165) 327)

Neurotoxicity
d-Fenfluramine; d-Norfenfluramine; p-Chloroamphetamine; L-Cysteine; Serotonin (Invernizzi, R. (163) 77)

3,4-Methylenedioxymethamphetamine (MDMA); Glucocorticoid receptors; 5-Hydroxytryptamine; Striatum; Corticosterone (Lowy, M.T. (163) 157)

Neurotoxin (excitatory)
Kainic acid; N-Methyl-D-aspartic acid (NMDA); Myocardial necrosis; Paraventricular hypothalamus; (Rat) (Rockhold, R.W. (166) 571)

Neurotoxins
Histamine; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Brain; (Mouse) (Cumming, P. (166) 299)

Neurotransmitter release
MDMA (3,4-methylenedioxymethamphetamine); Dorsal raphe nucleus; Single unit recording; Microdialysis (Sprouse, J.S. (167) 375)

δ Opioid receptors; Enkephalin analogues; Adenylate cyclase; Brain slices; (Rat) (De Vries, T.J. (170) 137)

Neutrophils
Endothelin; Heart; Blood vessels; Uterus; Trachea; Vas deferens; Platelets; Chromaffin cells; Neuromuscular junction (Borges, R. (165) 223)

NG108-15 cells
Neurotensin; Fura 2; Ca^{2+} mobilization; Inositol trisphosphate; Heterologous desensitization (Imaizumi, T. (161) 203)

Nicorandil
Ischemia; Nipradilol; Heart (perfused, working); (Rat) (Haneda, T. (162) 81)

Ischemia; Reperfusion; Arrhythmias; Heart; (Rat) (Kempsford, R.D. (163) 61)

Nicotine
Cardiac nerves (intrinsic); Cardiac muscle (isolated); Cardiac contractility; Acetylcholine; (Denervation, Supersensitivity) (Smith, D.C. (161) 249)

Gastric motility; Vagus nerve; Nicotinic receptors (central) (Nagata, M. (163) 85)

Catecholamine synthesis; 5-HT synthesis; Nucleus accumbens; Hypothalamus; Hippocampus (Mitchell, S.N. (167) 311)

Microdialysis; Nucleus accumbens; Dopamine; Tolerance; (Rat) (Damsma, G. (168) 363)

Nicotine (acute, repeated)
Dopamine; Dopamine metabolism; Nucleus accumbens; Caudate nucleus; Olfactory tubercle (Lapin, E.P. (160) 53)

Nicotinic acetylcholine receptors
(Receptor proteins, Biospecific ligands, Affinity chromatography) (Waser, P.G. (172) 231)

Nicotinic receptor-ion channel complex
Diltiazem; Neuromuscular junction; Muscle twitch (Baños, J. (165) 151)

Nicotinic receptors
Ileum and colon (terminal); Anaesthetics (local); Non-adrenergic, non-cholinergic (NANC) system; Vasoactive intestinal polypeptide (VIP); (Electrical stimulation) (Pelckmans, P.A. (170) 235)

Nicotinic receptors (central)
Nicotine; Gastric motility; Vagus nerve (Nagata, M. (163) 85)

Nifedipine
Blood flow (gastric, hepatic, intestinal, kidney); Arterial pressure; Heart rate (Van Berlo, C.L.H. (160) 17)

Purinergic transmission (sympathetic); Adrenergic transmission; Artery (Omote, S. (160) 239)

Myocardial ischaemia; Coronary occlusion; K^+ loss; Haemodynamics; Ca^{2+} antagonists; Gallopamil; Diltiazem (Kirchengast, M. (160) 349)

Colon (distal); Galanin; (Contraction, Mouse) (Fontaine, J. (164) 583)

Endothelin; Coronary circulation; Langendorff preparation; Vasoconstriction (Fukuda, K. (165) 301)

Noradrenaline contractions; Ryanodine; Ca^{2+} mobilization; Vas deferens; Methoxyverapamil; (Rat) (Vesperinas, G. (165) 309)

Cromakalim; Pinacidil; Renal blood flow; Renin activity (plasma); (Cat) (Clapham, J.C. (171) 109)

Nigrostriatal dopamine neurons
Dopamine neurons; d-Amphetamine; Apomorphine; Quinpirole; SCH 23390 (Pitts, D.K. (162) 167)

MPTP; GM1 ganglioside; Dopamine receptors (Hadjiconstantinou, M. (168) 261)

Niguldipine
1,4-Dihydropyridine; α_1-Adrenoceptors; (Subtype, bivalent ligands) (Boer, R. (172) 131)

α_1-Adrenoceptor subtypes; 5-HT_{1A} receptors; [^{3}H]5-Methylurapidil (Graziadei, I. (172) 329)

Nimodipine
BAY k 8644; Antidepressants; Learned helplessness (Martin, P. (162) 185)

Flunarizine; Diltiazem; Ca^{2+} channel antagonists; Seizures; Dihydropyridines (Morón, M.A. (163) 299)

Nipradilol
Ischemia; Nicorandil; Heart (perfused, working); (Rat) (Haneda, T. (162) 81)

Nisoldipine
Adrenergic responses; α_1-Adrenoceptors; α_2-Adrenoceptors; Vascular bed (hindquarters) (Minkes, R.K. (165) 259)

Nitrates
Smooth muscle (relaxation); Vasodilation; Endothelium; cGMP; Nitric oxide (Buga, G.M. (161) 61)

Nitrendipine
Ca^{2+} channel blockers; Stress ulcer; Gastric secretion; Verapamil; Diltiazem; Ethanol ulcer; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Nitric oxide
Smooth muscle (relaxation); Vasodilation; Endothelium; cGMP; Nitrates (Buga, G.M. (161) 61)

Endothelin-1; Vasodilatation; N^G-Monomethyl-L-arginine (Gardiner, S.M. (171) 237)

NMDA receptors; Arginine; cGMP (Garthwaite, J. (172) 413)

Nitrite
Smooth muscle; UV light; Lipid peroxidation; Ca^{2+}; cGMP (Nelemans, A. (172) 283)

Nitrobenzylthioinosine
Adenosine; Nucleoside transport; Autoradiography (quantitative); Heart; (Guinea-pig) (Parkinson, F.E. (163) 69)

Nucleoside transport inhibition; Lidoflazine; Mioflazine; Mioflazine analogs; (Heterogeneity, Computer model) (IJzerman, A.P. (172) 273)

Nitroglycerin
α-Human atrial natriuretic peptide (α-hANP); Coronary vasodilatation; (Conscious dog, Intracoronary administration) (Adachi, H. (161) 189)

O_2 supply; O_2 consumption; Myocardium (reperfused, dog) (Joselevitz-Goldman, J. (166) 283)

NMDA (N-methyl-D-aspartate)
MK-801; CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-1-phosphonic acid); Schedule-controlled responding; Drug discrimination; (Rhesus monkey) (France, C.P. (159) 133)

MK-801; Ketamine; Phencyclidine; Glutamate; Glycine; Magnesium; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

MK-801; Pituitary; Adrenal; ACTH; Corticosterone; Prolactin; Phencyclidine (PCP); (Hormone) (Pechnick, R.N. (164) 257)

Metaphit; Audiogenic seizures; Phencyclidine (PCP) (Debler, E.A. (165) 155)

HA-966 (1-hydroxy-3-aminopyrrolidone-2); Excitatory amino acids; Hippocampus; Norepinephrine release (Keith, R.A. (166) 393)

Dopamine release; Striatum; Glycine; Kynurenic acid; (Rat) (Krebs, M.-O. (166) 567)

Kainic acid; Myocardial necrosis; Neurotoxin (excitatory); Paraventricular hypothalamus; (Rat) (Rockhold, R.W. (166) 571)

Glycine; 1-Aminocyclobutane-1-carboxylate (ACBC); HA-966 (1-hydroxy-3-aminopyrrolidone-2); D-AP-7 (D-2-Amino-7-phosphonoheptanoate); Oocytes (*Xenopus*) (Watson, G.B. (167) 291)

Myenteric plexus; Glycine; 7-Chlorokynurenic acid (Reggiani, A. (168) 123)

Cough reflex; MK-801 (Kamei, J. (168) 153)

NMDA-receptor complex; 3-(±)-2-(Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP); TCP (N-1[2-thienyl]cyclohexyl)3,4-piperidine; Glycine; (Molecular target size, Receptors) (Honoré, T. (172) 239)

NMDA receptor antagonists
Mast cell degranulating peptide; Dendrotoxin; K^+ channel blockers; Ca^{2+} channel antagonists; Seizures (Gandolfo, G. (160) 173)

Nucleus accumbens; Dopamine metabolism; Immobilization stress; Methyl-β-carboline-3-carboxylate (β-CCM); (In vivo voltammetry) (Serrano, A. (162) 157)

MK-801; Phencyclidine (PCP); Anticonvulsants; Drug discrimination; (Behaviour) (Tricklebank, M.D. (167) 127)

5-HT_{1A} receptor agonists; Anxiolytic effect; Social interaction; (Elevated plus maze) (Dunn, R.W. (169) 1)

NMDA receptor antagonists (non-competitive)
High pressure neurological syndrome; NMDA receptor channel complex (Wardley-Smith, B. (165) 107)

Audiogenic seizure; Anticonvulsants; Phencyclidine; MK-801; Dextromethorphan (Chapman, A.G. (166) 201)

NMDA receptor channel complex
NMDA receptor antagonists (non-competitive); High pressure neurological syndrome (Wardley-Smith, B. (165) 107)

NMDA-receptor complex
N-Methyl-D-aspartate (NMDA); 3-(±)-2-(Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP); TCP (N-1[2-thienyl]cyclohexyl)3,4-piperidine; Glycine; (Molecular target size, Receptors) (Honoré, T. (172) 239)

NMDA receptors
Axonal transport; Ionophore complex; (Autoradiography) (Cincotta, M. (160) 167)

Glycine; Kynurenate; Glutamate; Myenteric plexus (Moroni, F. (163) 123)

Social conflict analgesia; Periaqueductal grey; AP-7; MK-801; Naloxone; (Mouse) (Siegfried, B. (168) 239)

MK801; HA-966; Kynurenic acid; GABA release; Ca^{2+} (intracellular) (Reynolds, I.J. (172) 9)

Nitric oxide; Arginine; cGMP (Garthwaite, J. (172) 413)

σ Sites; Target size analysis (Wong, E.H.F. (172) 493)

Nociception
Kinins; Spinal cord; Noradrenergic mechanism; Monoamine content; 6-Hydroxydopamine (6-OHDA) (Laneuville, O. (159) 273)

Analgesia; Formalin test; Hot plate test; Orphenadrine citrate; Serotonin (Hunskaar, S. (160) 83)

Node of Ranvier
THA (9-amino-1,2,3,4-tetrahydroacridine); Ion channels (Elinder, F. (164) 599)

Nomifensine
Dopamine uptake inhibitors; Dopamine metabolism; Microdialysis (in vivo); Amphetamine; Methylphenidate (Hurd, Y.L. (166) 251)

Non-adrenergic, non-cholinergic (NANC)
Vasoactive intestinal peptide (VIP); Trachea; Epithelium; Endopeptidase (neutral) (Rhoden, K.J. (171) 247)

Non-adrenergic, non-cholinergic (NANC) contraction (excitatory)
Bronchi; Neuropeptide Y; UK 14,304; α-Adrenoceptors; Cholinergic contraction; Noradrenaline; Morphine; (Guinea-pig) (Matran, R. (163) 15)

Non-adrenergic, non-cholinergic (NANC) transmission
Anococcygeus (rat); Clonidine; McN-A-343; Methoxamine; Rilmenidine; (Prejunctional receptors) (Li, C.G. (168) 107)

Non-adrenergic, non-cholinergic (NANC) system
Ileum and colon (terminal); Anaesthetics (local); Nicotinic receptors; Vasoactive intestinal polypeptide (VIP); (Electrical stimulation) (Pelckmans, P.A. (170) 235)

Non-esterified fatty acids
Propranolol; Ischemia; Myocardium; Perfused working heart; (Rat) (Nakamura, K. (160) 61)

Noradrenaline
Bronchi; Neuropeptide Y; UK 14,304; α-Adrenoceptors; Cholinergic contraction; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Morphine; (Guinea-pig) (Matran, R. (163) 15)

Neuropeptide Y; Spleen; Adrenoceptors; Vasoconstriction; (Transmitter release) (Lundberg, J.M. (163) 103)

Vas deferens (guinea-pig); Ca^{2+} currents; K^+ currents; Action potential (Mimata, T. (163) 181)

5-Hydroxytryptamine; Adrenergic nerves (vascular); α_2-Adrenoceptors (presynaptic) (Kawasaki, H. (164) 35)

Bunazosin; Mesenteric vessels; Excitatory junction potential; α-Adrenoceptors (Komori, K. (164) 111)

Myocardial ischemia; Converting enzyme inhibitors; (Rat) (Carlsson, L. (166) 157)

Aorta; Electrophysiological properties; Electromechanical coupling; α-Adrenoceptors; Angiotensin II; (Rabbit) (Haeusler, G. (166) 175)

Autoradiography; Kidney; Adrenoceptors; Renal nerve; Sympathetic nervous system (Sripairojthikoon, W. (167) 355)

Adrenaline; Adrenoceptors; (Desensitisation) (Deighton, N.M. (169) 95)

Neuropeptide Y (NPY); ATP; Nasal vasculature; α-Adrenoceptors; (Denervation) (Lacroix, J.-S. (169) 125)

Ca^{2+} (extra-and intra-cellular); Ca^{2+} channels (L-type and T-type); Phorbol ester; K^+; Protein kinase C; Uterine vasoconstriction (Fallgren, B. (170) 61)

β-Adrenoceptor antagonists; Sympathomimetic activity (intrinsic); β_1 Selectivity; Heart cells (Reithmann, C. (170) 243)

Adenylate cyclase; Guanine nucleotide-binding protein; Heart cells; (Desensitization) (Reithmann, C. (172) 211)

Noradrenaline contractions
Ryanodine; Nifedipine; Ca^{2+} mobilization; Vas deferens; Methoxyverapamil; (Rat) (Vesperinas, G. (165) 309)

Noradrenaline (metabolic effects)
Thyroid hormone; (Na^+,K^+)-ATPase; Ouabain binding; 6-Hydroxydopamine (Swann, A.C. (169) 275)

Noradrenaline release
Muscarinic M_2 receptor subtypes; Muscarinic inhibition; Iris (guinea-pig); Iris (rabbit); Iris sphincter muscle (rabbit); (Pre- and postjunctional affinity constants) (Bognar, I.T. (163) 263)

Botulinum A toxin; α_2-Adrenoceptors (presynaptic); Phorbol ester; Protein kinase C; 5-HT release (Nakov, R. (164) 45)

Pentazocine; Brain; Opioid receptor subtypes; Dynorphin A-(1-13); (Guinea-pig) (Kinouchi, K. (164) 63)

5-HT receptors; Coronary artery (pig); (Presynaptic receptors) (Molderings, G.J. (164) 213)

Monensin; Ouabain; K^+-free medium; Ca^{2+}-evoked contraction; Na^+/Ca^{2+} exchange transport; Vas deferens; (Guinea pig) (Katsuragi, T. (167) 147)

α_2-Adrenoceptors; Spinal cord; DSP-4; (Slices, Rat) (Reimann, W. (167) 161)

3,4-Diaminopyridine; Hippocampus; Phorbol ester; Protein kinase C (Huang, H.Y. (169) 115)

α-Adrenoceptors (prejunctional); Renal nerves (Murphy, T.V. (169) 285)

Atrium (guinea-pig); Field stimulation; Inotropic effect; α_2-Adrenoceptors; Presynaptic autoinhibition (Brasch, H. (171) 49)

Noradrenergic mechanism
Kinins; Nociception; Spinal cord; Monoamine content; 6-Hydroxydopamine (6-OHDA) (Laneuville, O. (159) 273)

Noradrenergic transmission
Endothelin; Atrium (isolated); (Rat, Guinea-pig) (Reid, J.J. (168) 93)

Norepinephrine
β-Endorphin; Analgesia (intrathecal); Serotonin (Crisp, T. (160) 211)

Carbachol; Quisqualate; Inositol phospholipids; Brain (human) (Nicoletti, F. (160) 299)

Serotonin; Platelet adhesion; Eicosapentaenoic acid; Vascular reactivity (Pfister, S.L. (161) 85)

Phosphatidylinositol turnover; Deoxycorticosterone acetate-salt hypertensive rats; Mesenteric vasculature; (Contraction) (Takata, Y. (164) 365)

Benzodiazepines; Sympathetic neurotransmission; Atrial responses; (Peripheral effects) (Elgoyhen, B. (164) 467)

Cardiac glycosides; BAY k 8644; Ca^{2+} (extracellular); Mg^{2+} (extracellular); Cardiac muscle; (Guinea-pig) (Kafiluddi, R. (165) 181)

Imipramine; Pharmacokinetics (cerebral); 5-Hydroxytryptamine (5-HT, serotonin); 5-Hydroxyindole acetic acid (5-HIAA); 3-Methoxy-4-hydroxyphenylglycol (MHPG) (Sugita, S. (165) 191)

Epinephrine; Sympathetic nervous system; α_2-Adrenoceptors (Szemeredi, K. (170) 53)

Na^+ (intracellular); K^+ relaxation; Monensin; Ouabain; Serotonin; Smooth muscle (vascular) (Bell, D.R. (171) 189)

Norepinephrine concentration (plasma)
Norepinephrine spillover rate; Prazosin; Hydralazine; Mean arterial pressure; (Rat) (Keeton, T.K. (164) 479)

Norepinephrine release
HA-966 (1-hydroxy-3-aminopyrrolidone-2); Excitatory amino acids; N-Methyl-D-aspartate (NMDA); Hippocampus (Keith, R.A. (166) 393)

Norepinephrine spillover rate
Prazosin; Norepinephrine concentration (plasma); Hydralazine; Mean arterial pressure; (Rat) (Keeton, T.K. (164) 479)

d-Norfenfluramine
d-Fenfluramine; p-Chloroamphetamine; L-Cysteine; Serotonin; Neurotoxicity (Invernizzi, R. (163) 77)

l-Norfenfluramine
l-Fenfluramine; Dopamine metabolism; Acetylcholine release in vivo; Striatum; Nucleus accumbens (Invernizzi, R. (164) 241)

NPC567
Inflammation; Bradykinin; Carrageenan (Costello, A.H. (171) 259)

N^6 region
Adenosine A_1 receptors; Computer graphics (J.M. Van Galen, P. (172) 19)

Nucleoside transport
Adenosine; Nitrobenzylthioinosine; Autoradiography (quantitative); Heart; (Guinea-pig) (Parkinson, F.E. (163) 69)

Nucleoside transport inhibition
Lidoflazine; Mioflazine; Mioflazine analogs; Nitrobenzylthioinosine; (Heterogeneity, Computer model) (IJzerman, A.P. (172) 273)

Nucleoside uptake
Adenosine; Diazepam; Neuromuscular junction; Sartorius muscle; Dipyridamole; (Frog) (De Mendonça, A. (164) 347)

Nucleus accumbens
Dopamine; Dopamine metabolism; Nicotine (acute, repeated); Caudate nucleus; Olfactory tubercle (Lapin, E.P. (160) 53)

Neurotensin; Dopamine receptors; Striatum (Merchant, K.M. (160) 409)

Amphetamine; Neurokinin A; Tachykinin; Caudate-putamen; Microdialysis (Lindefors, N. (160) 417)

NMDA receptor antagonists; Dopamine metabolism; Immobilization stress; Methyl-β-carboline-3-carboxylate (β-CCM); (In vivo voltammetry) (Serrano, A. (162) 157)

CCK8; Locomotion; Exploration; (Rat) (Daugé, V. (163) 25)

l-Fenfluramine; l-Norfenfluramine; Dopamine metabolism; Acetylcholine release in vivo; Striatum (Invernizzi, R. (164) 241)

Neurotensin; Haloperidol; Atropine; Scopolamine; Caudate nucleus (Levant, B. (165) 327)

Prolactin; Tyrosine hydroxylase; DOPA (2,4-dihydroxyphenylalanine); DOPAC (3,4-dihydroxyphenylacetic acid); Striatum (Chen, J.-C. (166) 473)

Nicotine; Catecholamine synthesis; 5-HT synthesis; Hypothalamus; Hippocampus (Mitchell, S.N. (167) 311)

Microdialysis; Dopamine; Nicotine; Tolerance; (Rat) (Damsma, G. (168) 363)

O_2 consumption
Cis-chlorprothixene; Xerostomia; Cytosolic free Ca^{2+}; Cl^- loss (Undén, M. (164) 129)

Nitroglycerin; O_2 supply; Myocardium (reperfused, dog) (Joselevitz-Goldman, J. (166) 283)

p-Octopamine
Analgesia (non-opioid); Spinal; Supraspinal; (Mouse) (Raffa, R.B. (169) 317)

Odansetron (GR 38032F)
5-HT_3 receptors; Dopamine metabolism; 5-HT metabolism (Koulu, M. (169) 321)

Oedema
Phospholipase A_2; Mast cell amines; Anti-inflammatory drugs (Cirino, G. (166) 505)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)
Raphe nuclei; 5-HT_{1A} agonists; Motor control; (Rat) (Hillegaart, V. (160) 303)

5-HT_1 receptors; RU 24969; Morphine withdrawal; (Mouse) (Berthold, H. (162) 19)

Corticosterone; Hypothalamus; 5-Hydroxytryptamine (5-HT, serotonin); Paraventricular nucleus; (Sex differences) (Haleem, D.J. (164) 435)

BP-554; 5-HT_{1A} receptor agonists; 5-HT receptors (Matsuda, T. (170) 75)

5-HT_{1A} receptors; Behaviour; Stereoselectivity; Partial agonists; (+)ALK-3 ((+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin); (Rat) (Hjorth, S. (170) 269)

1-Oleyl-2-acetyl glycerol (OAG)
Pituitary; Ca^{2+} mobilization; Diacylglycerol; Thyrotropin releasing hormone (TRH); R59022 (Mollard, P. (172) 71)

Olfactory tubercle
Dopamine; Dopamine metabolism; Nicotine (acute, repeated); Nucleus accumbens; Caudate nucleus (Lapin, E.P. (160) 53)

Dopamine; Electrochemistry; (Electrical stimulation, Drug effects) (Suaud-Chagny, M.-F. (164) 273)

Oligo-prostaglandin B
Ischemia (cerebral); (Gerbil) (Von Lubitz, D.K.J.E. (164) 405)

OM-853
Dopamine release; Muscarinic receptors; Striatum (Koda, H. (162) 501)

Oocytes (*Xenopus*)
N-Methyl-D-aspartate (NMDA); Glycine; 1-Aminocyclobutane-1-carboxylate (ACBC); HA-966 (1-hydroxy-3-aminopyrrolidone-2); D-AP-7 (D-2-Amino-7-phosphonoheptanoate) (Watson, G.B. (167) 291)

OPC-8212
Sotalol; Antiarrhythmics (class III); Action potential duration; (Rate-dependent effects) (Lathrop, D.A. (164) 487)

Open field
Buspirone; Hippocampus; Elevated plus maze; (Microinjections) (Kostowski, W. (168) 393)

Operant responding
Neurotensin; Neuroleptics; 'Anhedonia'; Central nervous system (CNS); (Dose-response curve) (Rossitch, Jr., E. (163) 119)

Opiate receptors
5-HT_3 receptors; [^{3}H]Zacopride; [^{3}H]Bremazocine; [^{3}H]Naloxone; Spinal cord; Capsaicin; (Rat) (Hamon, M. (164) 315)

Brain; κ Opioid receptors; (Autoradiography, Guinea-pig) (Lahti, R.A. (166) 563)

κ Opioid receptors; U-50,488; U-69,593; (Enantiomers, cis diastereomer of U-50,488) (Rothman, R.B. (167) 345)

Opiates
Withdrawal syndrome; Methadone; Naloxone; (Rhesus monkey, Dependence) (Krystal, J.H. (160) 331)

Bremazocine; Naloxone; Oxytocin; (In vitro, In vivo) (Grell, S. (166) 41)

Phencyclidine (PCP); Naloxone; Temperature; Hypothermia; Dependence (Pechnick, R.N. (166) 295)

[Met^5]enkephalin; [Leu^5]enkephalin; (Biologically active conformation) (Gašparík, J. (172) 417)

Opioid antinociception
μ Receptors; δ Receptors; (Intracerebroventricular, Mouse) (Heyman, J.S. (165) 1)

μ Opioid receptors; δ Opioid receptors; β-Funaltrexamine (β-FNA); Naloxonazine; (Intracerebroventricular, Mouse) (Heyman, J.S. (169) 43)

Opioid binding sites
Periaqueductal gray; Analgesia (Fedynyshyn, J.P. (159) 83)

μ, δ, κ Opioid binding sites
Brain regions; (Binding capacities, Binding affinities, Rabbit) (Petrillo, P. (166) 213)

Opioid dependence
Morphine; DADLE ([D-Ala^2,D-Leu^5]enkephalin); Sufentanil; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Intrathecal infusion (Stevens, C.W. (166) 467)

δ Opioid ligands
Opioid receptors; μ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; RB38A; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

μ Opioid ligands
Opioid receptors; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; RB38A; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Opioid peptides
γ-Endorphin; β-Endorphin; Stress (chronic) (Young, E.A. (167) 229)

Analgesia; Opioid receptors; Tail flick; Naloxonazine; ICI 154,129; β-Funaltrexamine; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

Opioid receptor agonists
Dopamine receptor agonists; Dopamine receptor antagonists; Antinociception (Rooney, K.F. (168) 329)

δ Opioid receptor agonists
Deltorphin; (Isolation, Sequencing) (Kreil, G. (162) 123)

κ Opioid receptor agonists
U-62,066E; κ Opioid receptor antagonists; MR-2266; [Arg^8]vasopressin; Diuresis; Collecting duct; Water permeability (Imai, K.Y.M. (160) 229)

Dependence; Morphine; U-50,488H (Fukagawa, Y. (170) 47)

Globus pallidus; Opioid receptors; μ-Opioid receptor agonists; Benzomorphans; Dynorphin A-(1-13); (Microiontophoresis) (Huffman, R.D. (170) 179)

μ Opioid receptor agonists
Globus pallidus; Opioid receptors; κ-Opioid receptor agonists; Benzomorphans; Dynorphin A-(1-13); (Microiontophoresis) (Huffman, R.D. (170) 179)

κ Opioid receptor antagonists
κ Opioid receptor agonists; U-62,066E; MR-2266; [Arg^8]vasopressin; Diuresis; Collecting duct; Water permeability (Imai, K.Y.M. (160) 229)

Opioid receptors
Prostaglandins; Dynorphin; Heart (Ledda, F. (162) 323)

N-Ethylmaleimide; Opioids; Supraspinal analgesia; (Agonist efficacy) (Sánchez-Blázquez, P. (166) 193)

Hemorphin-4; Cytochrophin-4; κ Sites; β-Casomorphins (Liebmann, C. (166) 523)

Analgesia; Tail flick; Naloxonazine; ICI 154,129; β-Funaltrexamine; Opioid peptides; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

Globus pallidus; κ Opioid receptor agonists; μ Opioid receptor agonists; Benzomorphans; Dynorphin A-(1-13); (Microiontophoresis) (Huffman, R.D. (170) 179)

μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; RB38A; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

δ Opioid receptors
Opioid antinociception; μ Opioid receptors; β-Funaltrexamine (β-FNA); Naloxonazine; (Intracerebroventricular, Mouse) (Heyman, J.S. (169) 43)

Enkephalin analogues; Neurotransmitter release; Adenylate cyclase; Brain slices; (Rat) (De Vries, T.J. (170) 137)

κ Opioid receptors
Analgesia; Pregnancy; Spinal cord; Dynorphin A (Sander, H.W. (159) 205)

μ Opioid receptors; [^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Morphine; Naltrexone; β-Funaltrexamine; (Receptor upregulation) (Rothman, R.B. (160) 71)

U-50,488H; Morphine; Tolerance; Analgesia; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Opiate receptors; Brain; (Autoradiography, Guinea-pig) (Lahti, R.A. (166) 563)

Opiate receptors; U-50,488; U-69,593; (Enantiomers, cis diastereomer of U-50,488) (Rothman, R.B. (167) 345)

Dynorphin A; μ-Opioid receptors; Na^+ ions; 5′-Guanylyl amidodiphosphate (Gpp(NH)p) sensitivity; (Agonist peptides); (Antagonist peptides) (Gairin, J.-E. (172) 381)

μ Opioid receptors
[^{3}H][D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Morphine; Naltrexone; β-Funaltrexamine; κ Opioid receptors; (Receptor upregulation) (Rothman, R.B. (160) 71)

[^{3}H]Carfentanil; PET (positron emission tomography) scanning (Titeler, M. (167) 221)

Opioid antinociception; δ Opioid receptors; β-Funaltrexamine (β-FNA); Naloxonazine; (Intracerebroventricular, Mouse) (Heyman, J.S. (169) 43)

GTP-binding protein; Pertussis toxin; Adenylyl cyclase (Frey, E.A. (172) 347)

Dynorphin A; κ-Opioid receptors; Na^+ ions; 5′-Guanylyl amidodiphosphate (Gpp(NH)p) sensitivity; (Agonist peptides); (Antagonist peptides) (Gairin, J.-E. (172) 381)

μ_1 Opioid receptors
Analgesia; Opioid receptors; Tail flick; Naloxonazine; ICI 154,129; β-Funaltrexamine; Opioid peptides; μ_2 Opioid receptors (Paul, D. (168) 307)

μ_2 Opioid receptors
Analgesia; Opioid receptors; Tail flick; Naloxonazine; ICI 154,129; β-Funaltrexamine; Opioid peptides; μ_1 Opioid receptors (Paul, D. (168) 307)

Opioid receptor subtypes
Pentazocine; Noradrenaline release; Brain; Dynorphin A-(1-13); (Guinea-pig) (Kinouchi, K. (164) 63)

Opioids
β-Funaltrexamine; Supraspinal analgesia; Periaqueductal gray; δ Receptors; μ Receptors; (Binding) (Sánchez-Blázquez, P. (159) 9)

Antidepressants; Thiorphan; Bestatin; Iprindole; Imipramine; Forced swimming test; Motor activity (Del Carmen de Felipe, M. (159) 175)

Pindolol; β-Adrenoceptor antagonists; α_2-Adrenoceptors (Jones, L.F. (165) 123)

N-Ethylmaleimide; Supraspinal analgesia; Opioid receptors; (Agonist efficacy) (Sánchez-Blázquez, P. (166) 193)

Morphine; Spinal cord; Tolerance; Naloxone; Withdrawal (Bell, J.A. (168) 101)

Naltrexone; Upregulation; Supersensitivity; Analgesia; Morphine; (Dose dependence) (Yoburn, B.C. (170) 193)

Optic tectum
γ-Aminobutyric acid (GABA); Picrotoxin; Bicuculline; Pentobarbitone; Benzodiazepines (Sivilotti, L. (164) 205)

Oral administration
Microdialysis; Dopamine release; Stereoisomers; Dopamine receptor agonists; Transdermal application (Timmerman, W. (162) 143)

Oral dyskinesia
Tardive dyskinesia; Haloperidol (intermittent); Neuroleptic sensitization; Amygdala kindling; (Drug holidays, Rat) (Glenthøj, B. (164) 393)

Org 5878
[^{14}C]2-Deoxyglucose; Antipsychotics; Cholinergic pathways; Desenkephalin-γ-endorphin; Glucose uptake; Local cerebral glucose utilization; Ventral tegmental area; (Neuropeptides) (Room, P. (171) 69)

Orphenadrine citrate
Analgesia; Formalin test; Hot plate test; Nociception; Serotonin (Hunskaar, S. (160) 83)

Oscillatory afterpotentials
Naloxone; Antiarrhythmic activity; Purkinje fibers; (Triggered activity) (Cerbai, E. (162) 491)

O_2 supply
Nitroglycerin; O_2 consumption; Myocardium (reperfused, dog) (Joselevitz-Goldman, J. (166) 283)

Ouabain
Dantrolene sodium; Antiarrhythmia agents; Cardiac arrhythmia models; Coronary artery ligation; Ventricular fibrillation threshold; Aconitine (Brooks, R.R. (164) 521)

R56865; Digitalis toxicity; Na^+ pump; Myocardium (isolated); (Rat) (Finet, M. (164) 555)

Monensin; K^+-free medium; Noradrenaline release; Ca^{2+}-evoked contraction; Na^+/Ca^{2+} exchange transport; Vas deferens; (Guinea pig) (Katsuragi, T. (167) 147)

Rhythmicity; Coronary artery (human); Prostaglandin $F_{2\alpha}$; Adenosine receptors (Sabouni, M.H. (168) 271)

Na^+ (intracellular); K^+ relaxation; Norepinephrine; Monensin; Serotonin; Smooth muscle (vascular) (Bell, D.R. (171) 189)

Ouabain binding
Thyroid hormone; (Na^+,K^+)-ATPase; Noradrenaline (metabolic effects); 6-Hydroxydopamine (Swann, A.C. (169) 275)

[^{3}H]Ouabain binding
Na^+,K^+-ATPase; Ventricles; Renal hypertension; DOCA/NaCl hypertension (Chen, C.-C. (169) 67)

Ouabain-induced ventricular tachycardia
Flunarizine; After-depolarizations (delayed); (Conscious dog, Triggered activity) (Vos, M.A. (165) 139)

2-Oxo-quazepam
Benzodiazepine receptor subtypes; Spinal cord; GABA receptors (Corda, M.G. (169) 205)

Oxytocin
Apomorphine; Oxytocin antagonists; Penile erection; Yawning; (Rat) (Melis, M.R. (164) 565)

Bremazocine; Naloxone; Opiates; (In vitro, In vivo) (Grell, S. (166) 41)

Ca^{2+} channel inhibitors; Penile erection; Yawning; Apomorphine; (Rat) (Argiolas, A. (166) 515)

Testicular capsule; Ca^{2+} channel blockers; Calmodulin antagonists; (Intracellular calcium antagonists) (Sánchez, M. (168) 169)

Oxytocin antagonists
Apomorphine; Oxytocin; Penile erection; Yawning; (Rat) (Melis, M.R. (164) 565)

Pacemaker activity
Quinidine; Quinine; Colon electrophysiology; Interstitial cells of Cajal; Slow waves (Barajas-López, C. (163) 137)

PAF receptor antagonists
Platelet-activating factor (PAF-acether, PAF); PAF receptors; Retina; Retinal membrane; (Rat) (Thierry, A. (163) 97)

Platelet activating factor (PAF); PAF receptors; Lung (Dent, G. (169) 313)

YM-461; Airway hyperresponsiveness; (*Ascaris suum*, Late response, Allergic sheep) (Tomioka, K. (170) 209)

PAF receptors
Platelet-activating factor (PAF-acether, PAF); Retina; Retinal membrane; PAF antagonists; (Rat) (Thierry, A. (163) 97)

Platelet activating factor (PAF); PAF antagonists; Lung (Dent, G. (169) 313)

Pain
Analgesia; Bicuculline; (Descending inhibition, Rat) (Sandkühler, J. (160) 163)

Reticular formation; Morphine (Bing, Z. (164) 85)

Corticotropin releasing factor (CRF); Analgesia; Inflammation; Hyperalgesia (Hargreaves, K.M. (170) 275)

Pain control systems (descending)
β-Endorphin; Morphine; Analgesia (Suh, H.H. (168) 61)

Pancreastatin
Insulin release; Rin m 5F cells (Lorinet, A.-M. (160) 405)

Pancreatic blood flow
Pancreatic islets; Islet blood flow; Streptozotocin; Diabetic rats (Jansson, L. (161) 79)

Pancreatic growth
Cholecystokinin; Bombesin; (Receptor antagonist, Rat, Hamster) (Douglas, B.R. (161) 209)

Pancreatic islets
Islet blood flow; Pancreatic blood flow; Streptozotocin; Diabetic rats (Jansson, L. (161) 79)

Papaverine
Cerebral ischemia; Baroreflex; Flunarizine; (Cerebral protection) (Kurihara, J. (165) 147)

Papillary muscle
Endothelin; (Contraction, Ferret) (Shah, A.M. (163) 365)

Papillary muscle (guinea-pig)
Murrayaquinone-A; Mitochondrial oxidative phosphorylation; Inotropic response (triphasic); Action potential (augmented, slow) (Takeya, K. (169) 137)

Parathyroid hormone (PTH)
Gastric acid secretion; Gastric ulcers; CNS (Clementi, G. (166) 549)

Paraventricular hypothalamus
Kainic acid; N-Methyl-D-aspartic acid (NMDA); Myocardial necrosis; Neurotoxin (excitatory); (Rat) (Rockhold, R.W. (166) 571)

Paraventricular nucleus
Corticosterone; Hypothalamus; 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT); 5-Hydroxytryptamine (5-HT, serotonin); (Sex differences) (Haleem, D.J. (164) 435)

Parkinsonism
MPTP; Dopamine D-2 agonists; N-0437; (Transdermal administration, Common marmoset) (Löschmann, P.-A. (166) 373)

Partial agonists
8-OH-DPAT; $5\text{-}HT_{1A}$ receptors; Behaviour; Stereoselectivity; (+)ALK-3 ((+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin); (Rat) (Hjorth, S. (170) 269)

Passive avoidance behaviour
Acetyl-vasopressin; [Cyt^6]vasopressin-(5-9); Vasopressin; Exploratory behavior; Body temperature (Kovács, G.L. (161) 27)

Passive avoidance learning
Indeloxazine; (Senescence-accelerated mice) (Yamamoto, M. (166) 345)

Passive avoidance response
Pimozide; SCH 23390; Learning (latent); Memory; (Mouse) (Ichihara, K. (164) 189)

Paw edema (rat)
[Thi^{5,8},D-Phe^{7}]bradykinin; Mast cell degranulation (Wang, J.-P. (161) 143)

PC12 cells
σ Receptors; PCP receptors; Chromaffin cells; Adrenal medulla (Yang, Z.W. (164) 607)

Penile erection
Apomorphine; Oxytocin; Oxytocin antagonists; Yawning; (Rat) (Melis, M.R. (164) 565)

Ca^{2+} channel inhibitors; Yawning; Apomorphine; Oxytocin; (Rat) (Argiolas, A. (166) 515)

Pentagastrin
Capsaicin; Gastric distension; Gastric acid secretion; Vagus nerve; Histamine; (Cholinergic stimulation) (Raybould, H.E. (167) 237)

Pentazocine
Flupirtine; Antinociception; Flexor reflex; Skin twitch reflex (Vaupel, D.B. (162) 447)

Noradrenaline release; Brain; Opioid receptor subtypes; Dynorphin A-(1-13); (Guinea-pig) (Kinouchi, K. (164) 63)

Reward threshold; Brain stimulation reward; Tripelennamine; Nalbuphine; Physical dependence (Huston-Lyons, D. (169) 153)

Pentobarbital
Ro 15-4513; Benzodiazepine inverse agonists; Ethanol; Motor impairment; Hypnotics (Le, A.D. (159) 25)

Delta sleep-inducing peptide; Antidepressants; Haloperidol; Brain regions; Adrenalectomy; (Rat) (Wahlestedt, C. (159) 285)

Anesthetics; Barbiturates; Endothelium; Phosphatidylinositol hydrolysis; Phosphatidylinositol (Robinson-White, A.J. (172) 291)

Pentobarbitone
γ-Aminobutyric acid (GABA); Picrotoxin; Bicuculline; Benzodiazepines; Optic tectum (Sivilotti, L. (164) 205)

Pentobarbitone anaesthesia
Taurine; Blood pressure; Heart rate; Ventilation (Petty, M.A. (162) 359)

Pentylenetetrazol (PTZ)
THAO (5,6,7,8-tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol); Glia; GABA uptake; Seizures; Isonicotinic acid hydrazide (Gonsalves, S.F. (168) 265)

Peptidase inhibitors
Opioid receptors; μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Thiorphan; RB38A; Enkephalin metabolism; [D-Thr^{2},Leu^{5}]enkephalyl-Thr (DTLET); [D-Ala^{2},MePhe^{4},Gly-ol^{5}]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Endothelin; Trachea (guinea-pig); Airway epithelium; Indomethacin; Captopril (Hay, D.W.P. (171) 241)

Peptidoleukotrienes
Microvascular permeability; Histamine (Woodward, D.F. (164) 323)

Splanchnic artery occlusion; SK&F 104353; Myocardial depressant factor; Hematocrit; Cathepsin D (Lento, P.H. (165) 241)

Periaqueductal gray
β-Funaltrexamine; Opioids; Supraspinal analgesia; δ Receptors; μ Receptors; (Binding) (Sánchez-Blázquez, P. (159) 9)

Opioid binding sites; Analgesia (Fedynyshyn, J.P. (159) 83)

Social conflict analgesia; NMDA receptors; AP-7; MK-801; Naloxone; (Mouse) (Siegfried, B. (168) 239)

Peripheral benzodiazepines
PK 11195; Ro 5-4864; Mitochondrion; Neuroblastoma cells (Larcher, J.-C. (161) 197)

Peripheral vascular disease
Skeletal muscle; Ischaemia; Microcirculation; Torbafylline; (Performance) (Okyayuz-Baklouti, I. (166) 75)

Pertussis toxin (IAP)
Thromboxane A_2 receptors; Phosphoinositide hydrolysis; GTP binding protein (Nakahata, N. (162) 407)

Pertussis toxins
Sympathetic ganglion; GABA receptors; (Rat) (Newberry, N.R. (163) 245)

cAMP; Prostacyclin; Angiotensin II; Vasopressin (Vallotton, M.B. (166) 219)

μ-Opioid receptors; GTP-binding protein; Adenylyl cyclase (Frey, E.A. (172) 347)

Adenosine; A_1 adenosine receptors; Heart (human); G proteins; Heart failure (Böhm, M. (172) 407)

Neuropeptide Y (NPY); α_2-Adrenoceptors; G-protein; Medulla oblongata; (Rat) (Von Euler, G. (172) 435)

N-Formylmethionine-leucyl-phenylalanine (FMLP); Guanine nucleotide-binding protein (G-protein); Na^{+}; HL 60 cells (Gierschik, P. (172) 481)

PET (positron emission tomography) scanning
[^{3}H]Carfentanil; μ Opioid receptors (Titeler, M. (167) 221)

Phaclofen
$GABA_B$ receptors; Hippocampus; Pyramidal cells (Karlsson, G. (163) 285)

Inositol 1,4,5-triphosphate; Neuronal cultures; GABA receptors (Michler, A. (167) 423)

$GABA_B$ autoreceptors; [^{3}H]GABA release; (−)-Baclofen; Muscimol; (Superfused synaptosomes) (Bonanno, G. (172) 41)

Pharmacodynamics
Insulin; Protein phosphorylation; Guanine nucleotide-binding proteins (G-proteins) (Joost, H.G. (172) 461)

Pharmacokinetics (cerebral)
Imipramine; 5-Hydroxytryptamine (5-HT, serotonin); 5-Hydroxyindole acetic acid (5-HIAA); Norepinephrine; 3-Methoxy-4-hydroxyphenylglycol (MHPG) (Sugita, S. (165) 191)

Phencyclidine
MK-801; Ketamine; N-Methyl-D-aspartate (NMDA); Glutamate; Glycine; Magnesium; (Post-mortem human brain, Receptor) (Kornhuber, J. (162) 483)

MK-801; Pituitary; Adrenal; ACTH; Corticosterone; Prolactin; N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Metaphit; Audiogenic seizures; N-Methyl-D-aspartate (NMDA) (Debler, E.A. (165) 155)

Muscarinic receptors; Motor activity; Quinuclidinyl benzilate (QNB) (Boggan, W. (166) 123)

Audiogenic seizure; Anticonvulsants; Non-competitive NMDA antagonists; MK-801; Dextromethorphan (Chapman, A.G. (166) 201)

Opiates; Naloxone; Temperature; Hypothermia; Dependence (Pechnick, R.N. (166) 295)

Ataxia; Dopamine turnover; MK-801; 5-HT uptake; Stereotyped behavior; (Rat) (Hiramatsu, M. (166) 359)

MK-801; NMDA receptor antagonists; Anticonvulsants; Drug discrimination; (Behaviour) (Tricklebank, M.D. (167) 127)

Phencyclidine-like drugs
Na^+ channels (voltage-sensitive); $^{22}Na^+$ uptake (synaptosomal); Veratridine; [^{3}H]Batrachotoxin binding; [^{3}H]TCP binding; PCP receptors; Anaesthetics (Allaoua, H. (163) 327)

Phencyclidine receptors
Antinociception; Substance P; Excitatory amino acids (DeLander, G.E. (159) 149)

σ Receptors; Metaphit; Isothiocyanates; Affinity labelling (Bluth, L.S. (161) 273)

Na^+ channels (voltage-sensitive); $^{22}Na^+$ uptake (synaptosomal); Veratridine; [^{3}H]Batrachotoxin binding; [^{3}H]TCP binding; PCP-like drugs; Anaesthetics (Allaoua, H. (163) 327)

σ Receptors; PC12 cells; Chromaffin cells; Adrenal medulla (Yang, Z.W. (164) 607)

Phenelzine
β-Adrenoceptors; Down-regulation; Internalization; Cerebral cortex; (Rat) (Koshikawa, N. (170) 101)

Phenethylamine
Phenylalanine; Tyrosine; Arterial pressure (mean); Heart rate; (Rat) (Yourick, D.L. (160) 219)

Phenobarbital
Primidone; Kindling; Epilepsy (Löscher, W. (162) 309)

Benzodiazepine receptors (central and peripheral types); [^{3}H]PK 11195; [^{3}H]Flunitrazepam (Weizman, A. (169) 235)

Phentolamine
Adrenoceptors; Blood pressure; 5-HT receptors; Ketanserin (Dhasmana, K.M. (168) 257)

Phenylalanine
Tyrosine; Arterial pressure (mean); Heart rate; Phenethylamine; (Rat) (Yourick, D.L. (160) 219)

Phenylalkylamine
Ca^{2+} channels; Smooth muscle (vascular); Portal vein; (Binding study, Patch-clamp) (Loirand, G. (167) 265)

Phenylephrine
Antidepressants; α_1-Adrenoceptors; Hippocampal slice (Bijak, M. (166) 183)

Tetramethylpyrazine; Aorta; Endothelium; (High potassium, Rat) (Wu, C.-C. (169) 189)

Phenytoin
Lidocaine; Carbamazepine; Seizures (lidocaine-kindled); [^{3}H]Batrachotoxin binding; Hippocampus (Zimányi, I. (167) 419)

Cerebellum; $GABA_A$ binding sites; Benzodiazepine binding sites; β-Adrenoceptors; (Development) (Ruiz, G. (168) 251)

Phorbol esters
Histamine release; Retinoic acid; Retinal; Ca^{2+}; Mast cells (Cantwell, M.E. (160) 43)

Ca^{2+} channels; Dihydropyridines; ω-Conotoxin (Adamson, P. (162) 59)

Botulinum A toxin; α_2-Adrenoceptors (presynaptic); Protein kinase C; Noradrenaline release; 5-HT release (Nakov, R. (164) 45)

3,4-Diaminopyridine; Noradrenaline release; Hippocampus; Protein kinase C (Huang, H.Y. (169) 115)

Ca^{2+} (extra-and intra-cellular); Ca^{2+} channels (L-type and T-type); Noradrenaline; K^+; Protein kinase C; Uterine vasoconstriction (Fallgren, B. (170) 61)

MSH receptors; Adenylate cyclase; Melanoma; Cell proliferation (Gerst, J.E. (172) 29)

Adenosine; Prostaglandins; Lymphocytes; Cholera toxin; (Receptors) (Nordstedt, C. (172) 51)

Phosphatidylcholine
Stress (acute); [^{3}H]Imipramine binding; Phosphatidylserine; Tricyclic antidepressants (Stockert, M. (160) 11)

Phosphatidylinositol hydrolysis
Anesthetics; Barbiturates; Endothelium; Pentobarbital; Phosphatidylinositol (Robinson-White, A.J. (172) 291)

Phosphatidylinositol metabolism
Muscarinic M_3 receptor subtypes; HT-29 colon carcinoma cells; AF-DX 116; Sila-hexocyclium; Hexhydro-sila-difenidol; Methoctramine (Kopp, R. (172) 397)

Phosphatidylinositols
Vasodilators; Protein phosphorylation; cAMP; cGMP; Platelets (Waldmann, R. (159) 317)

Anesthetics; Barbiturates; Endothelium; Pentobarbital; Phosphatidylinositol hydrolysis (Robinson-White, A.J. (172) 291)

Phosphatidylinositol turnover
Diabetic rats; Ca^{2+} channels; α_1-Adrenoceptors; (Hyper-reactivity) (Sakai, Y. (162) 475)

Norepinephrine; Deoxycorticosterone acetate-salt hypertensive rats; Mesenteric vasculature; (Contraction) (Takata, Y. (164) 365)

Phosphatidylserine
Stress (acute); [^{3}H]Imipramine binding; Phosphatidylcholine; Tricyclic antidepressants (Stockert, M. (160) 11)

Phosphoinositide hydrolysis
Tetrabenazine; Imipramine; α_1-Adrenoceptors; β-Adrenoceptors; 5-HT_2 receptors (Butler, P.D. (160) 93)

Thromboxane A_2 receptors; GTP binding protein; Pertussis toxin (IAP) (Nakahata, N. (162) 407)

Methoctramine; Muscarinic receptors; Brain; Muscarinic receptor subtypes; Antimuscarinic agents (Lee, N.H. (167) 295)

Muscarinic acetylcholine receptor subtypes; Cardiac M_2 receptors (Mizushima, A. (168) 375)

Phosphoinositide metabolism
Muscarinic receptors; Smooth muscle (human, airway) (Meurs, H. (164) 369)

Functional antagonism; Smooth muscle (airway); Muscarinic receptor agonists; Histamine; β-Adrenergic relaxation (Van Amsterdam, R.G.M. (172) 175)

Phospholipase A_2
Oedema; Mast cell amines; Anti-inflammatory drugs (Cirino, G. (166) 505)

Phospholipase C
Angiotensin II; Uterus; Pregnancy; (Receptors, Rat) (Varol, F.G. (162) 37)

Photoaffinity labelling
L-Glutamate; (Binding sites) (Voukelatou, G. (162) 179)

Benzodiazepine receptors; β-Carboline; Diazepam (Dellouve-Courillon, C. (166) 557)

Physical dependence
Heroin; Self-administration; Narcotic analgesia; (Unit dose, Intraventricular, Rat) (De Vry, J. (161) 19)

Reward threshold; Brain stimulation reward; Tripelennamine; Pentazocine; Nalbuphine (Huston-Lyons, D. (169) 153)

Picrotoxin
γ-Aminobutyric acid (GABA); Bicuculline; Pentobarbitone; Benzodiazepines; Optic tectum (Sivilotti, L. (164) 205)

Pimozide
SCH 23390; Learning (latent); Passive avoidance response; Memory; (Mouse) (Ichihara, K. (164) 189)

Pinacidil
K^+ channels; Trachea; Smooth muscle (vascular) (Mellemkjær, S. (167) 275)

Cromakalim; Nifedipine; Renal blood flow; Renin activity (plasma); (Cat) (Clapham, J.C. (171) 109)

K^+ channels; Endothelium; Quinine; Sulfonylureas (Ramboer, I. (171) 251)

Pindolol
β_1-Adrenoceptor blockade; Nebivolol; Practolol; Reserpinized animals; Atria (isolated); Blood vessels (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

β-Adrenoceptor antagonists; Opioids; α_2-Adrenoceptors (Jones, L.F. (165) 123)

(±)-Pindolol
Sympathetic activity (renal); Ventrolateral pressor area; Methiothepin; (±) 8-OH-DPAT (8-hydroxy-2(di-n-propylamino)tetralin) (Laubie, M. (160) 385)

Piperazine site
GBR 12909 (1-(2-(bis(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenylpropyl)piperazine); Dopamine uptake; Na^+ channels; (Neurochemical properties, Voltage-dependent) (Andersen, P.H. (166) 493)

cis-2,3-Piperidine dicarboxylic acid (PDA)
2-Amino-4-phosphonobutyrate (APB); Glutamate; Retina; Acetylcholine; Glycine; (ON channel, OFF channel, Receptive field, Frog) (Jardon, B. (162) 215)

Pirenzepine
Lung; Muscarinic receptor subtypes (Mak, J.C.W. (164) 223)

Muscarinic receptor subtypes; Telenzepine; Ulcer model (Schudt, C. (165) 87)

Muscarinic receptor subtypes; Muscarinic M_3-selective antagonists; Hexahydro-sila-difenidol analogues; p-Fluorohexahydro-sila-difenidol; Methoctramine; Vas deferens (rabbit); Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

[^{3}H]Pirenzepine
Muscarinic receptor subtypes; Hippocampus; Receptor-G protein coupling; N-Ethylmaleimide (NEM); (Agonists) (Flynn, D.D. (172) 363)

Piroxicam
Endothelin; Platelet aggregation; Haemodynamics; Cyclooxygenase; (Rabbit) (Lidbury, P.S. (166) 335)

Pithed rat
Thioridazine; α_1-Adrenoceptors; α_2-Adrenoceptors (Cuffi, M.L. (168) 111)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2 receptors; 5-Hydroxytryptamine (5-HT, serotonin) (Dabiré, H. (168) 369)

Pituitary
MK-801; Adrenal; ACTH; Corticosterone; Prolactin; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Progesterone metabolites; Barbiturate site; $GABA_A$ receptor complex; Prolactin (Vincens, M. (168) 15)

Ca^{2+} mobilization; Diacylglycerol; Thyrotropin releasing hormone (TRH); 1-Oleyl-2-acetyl glycerol (OAG); R59022 (Mollard, P. (172) 71)

Pituitary cells
Vasopressin; ACTH; cAMP; cGMP; AtT-20 corticotrophs; Corticotropin-releasing factor (CRF) (Koch, B. (158) 53)

Pituitary gland
Atrial natriuretic peptide (ANP); Thymus gland; (Receptor, classification, Olfactory bulb) (Agui, T. (162) 301)

PK 11195
Peripheral benzodiazepines; Ro 5-4864; Mitochondrion; Neuroblastoma cells (Larcher, J.-C. (161) 197)

[^{3}H]PK 11195
Benzodiazepine receptors (central and peripheral types); Phenobarbital; [^{3}H]Flunitrazepam (Weizman, A. (169) 235)

Planar lipid bilayer
Aorta; Ca^{2+}-activated K^+ channels; $[Ca^{2+}]_i$ sensitivity; Cromakalim; (Rabbit) (Gelband, C.H. (167) 201)

Platelet actions
S-145; Thromboxane A_2 receptor antagonists; Vascular actions; (Kinetic binding parameters) (Mihara, S. (171) 179)

Platelet-activating factor (PAF-acether, PAF)
Vasoactive intestinal peptide (VIP); Leukotriene; Lungs; Neuropeptides; Cyclic AMP (Di Marzo, V. (162) 115)

PAF receptors; Retina; Retinal membrane; PAF antagonists; (Rat) (Thierry, A. (163) 97)

Bradykinin; Colonic epithelium; Cl^- channels; Prostaglandins (Buckley, T.L. (163) 275)

BN 52021; Arrhythmias; Heart functions; Ischemia and reperfusion; (Rat) (Koltai, M. (164) 293)

Alveolar macrophages; Leukotriene B_4 (LTB_4); Thromboxane B_2; BW 137C; BW 755C; 5-Lipoxygenase inhibitors; Indomethacin (Fitzgerald, M.F. (164) 539)

Bronchoconstriction; Doxofylline (Franzone, J.S. (165) 269)

Inflammation; Mucus; Goblet cells; Conjunctiva (Woodward, D.F. (168) 23)

PAF receptors; PAF antagonists; Lung (Dent, G. (169) 313)

Platelet adhesion
Serotonin; Norepinephrine; Eicosapentaenoic acid; Vascular reactivity (Pfister, S.L. (161) 85)

Platelet aggregation
Thromboxane A_2/prostaglandin H_2 receptors (pig); Vascular system; Platelets; Coronary artery (contraction); (Ligand binding) (Mihara, S. (160) 313)

Thromboxane A_2/prostaglandin endoperoxide receptor; Coronary thrombosis; Thromboxane A_2/prostaglandin endoperoxide antagonists (Kondo, K. (163) 253)

Endothelium-derived relaxing factor (EDRF); Prostacyclin; cAMP; cGMP (Alheid, U. (164) 103)

Endothelin; Haemodynamics; Piroxicam; Cyclo-oxygenase; (Rabbit) (Lidbury, P.S. (166) 335)

Platelets
Vasodilators; Protein phosphorylation; cAMP; cGMP; Phosphatidylinositols (Waldmann, R. (159) 317)

Thromboxane A_2/prostaglandin H_2 receptors (pig); Vascular system; Coronary artery (contraction); Platelet aggregation; (Ligand binding) (Mihara, S. (160) 313)

Endothelin; Heart; Blood vessels; Uterus; Trachea; Vas deferens; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Thromboxane A_2; Prostaglandins; (Receptors) (Modesti, P.A. (169) 85)

PMN (polymorphonuclear) leukocytes
Cardiotoxin; Hind-paw edema (rat); Mast cells; Kinin formation (Wang, J.-P. (161) 9)

PNMT (phenylethanolamine N-methyltransferase)
Chromaffin cells; Proenkephalin; mRNA; Glucocorticoids; Dexamethasone; Gene expression (Wan, D.C.-C. (172) 107)

Histamine; Proenkephalin A; Gene regulation; Adrenal chromaffin cells (Wan, D.C.-C. (172) 117)

Polyethylene glycol
Dopamine D-1 receptors (solubilized); [^{3}H]SCH 23390; Guanine nucleotide (GTP); Striatum; (Rat) (Zhang, X. (166) 401)

Polymyxin B
4-Aminopyridine; Neuromuscular junction; (End-plate receptor desensitization) (Vital Brazil, O. (159) 47)

Portal vein
Ca^{2+} channels; Phenylalkylamine; Smooth muscle (vascular); (Binding study, Patch-clamp) (Loirand, G. (167) 265)

Portal vein (rat)
Purinergic modulation; Spontaneously hypertensive rat (SHR); Wistar-Kyoto rat (WKY) (Reilly, W.M. (160) 283)

Positive inotropic effects
DPI 201-106; Hemodynamic effects; Contractility; Heart rate; (Conscious dog) (Gerard, J.-L. (165) 39)

Endothelin; Vasoconstriction; (Anesthetized dogs) (Kitayoshi, T. (166) 519)

Positive inotropism
Theophylline; Positive staircase; Ca^{2+}; (Post-rest potentiation) (Zavecz, J.H. (160) 187)

Positive staircase
Theophylline; Positive inotropism; Ca^{2+}; (Post-rest potentiation) (Zavecz, J.H. (160) 187)

Post-tetanic potentiation
Neuromuscular transmission (Tsai, M.-C. (160) 133)

[^{3}H]3-PPP binding in vivo
σ Receptors; 3-PPP (3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); 3-PPPP (3-(3-hydroxyphenyl)-N-(3-phenyl-1-propyl)piperidine) (Koe, B.K. (161) 263)

3-PPP (3-(3-hydroxyphenyl)-N-(1-propyl)piperidine)
σ Receptors; [^{3}H]3-PPP binding in vivo; 3-PPPP (3-(3-hydroxyphenyl)-N-(3-phenyl-1-propyl)piperidine) (Koe, B.K. (161) 263)

σ Receptors; BMY 14802; Dopamine neurons (Steinfels, G.F. (163) 167)

σ Receptors; Haloperidol; Psychotomimetic (+)-benzomorphans; 1,3-Di-o-tolylguanidine; (Allosteric interaction) (Bowen, W.D. (163) 309)

3-PPPP (3-(3-hydroxyphenyl)-N-(3-phenyl-1-propyl)piperidine)
σ Receptors; 3-PPP (3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); [^{3}H]3-PPP binding in vivo (Koe, B.K. (161) 263)

γ-PPT-(72-92)-NH_2
Substance P; Neurokinin A; Neuropeptide K; Tachykinins; Salivation (Takeda, Y. (161) 267)

P_2 purinoceptors
Bradykinin; Vas deferens; ATP receptors; Bradykinin B_2 receptors; Bradykinin antagonists (Donoso, M.V. (160) 263)

Vasodilatation; Vasoconstriction; Reactive blue 2; (In vivo) (Taylor, E.M. (161) 121)

Quin-2; Ca^{2+}; Prostacyclin; Endothelium (Raspe, E. (163) 345)

ATP; Ca^{2+} antagonists; Vas deferens; (Guinea-pig) (Morishita, H. (164) 507)

Smooth muscle; α_1-Adrenoceptors; Suramin (Den Hertog, A. (166) 531)

Practolol
β_1-Adrenoceptor blockade; Nebivolol; Pindolol; Reserpinized animals; Atria (isolated); Blood vessels (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

Prazosin
α_1-Adrenoceptors; Cardiac action potential; Epinephrine; β-Adrenoceptor blockade; Myocytes (ventricular); (Adult rat) (Vogel, S.M. (164) 231)

Norepinephrine spillover rate; Norepinephrine concentration (plasma); Hydralazine; Mean arterial pressure; (Rat) (Keeton, T.K. (164) 479)

[^{3}H]Prazosin
Methylphenidate; Cerebral cortex; [^{3}H]Idazoxan; [^{3}H]Dihydroalprenolol; (Down-regulation) (Mathieu, J.-F. (162) 173)

[^{3}H]Prazosin binding
α-Adrenoceptors; α_1-Adrenoceptor subtypes; Brain (human); Cerebral cortex (Gross, G. (169) 325)

Prefrontal cortex
Homovanillic acid; Striatum; Haloperidol; (Tolerance) (Chang, W.-H. (162) 151)

Pregnancy
Analgesia; Spinal cord; κ Opioid receptors; Dynorphin A (Sander, H.W. (159) 205)

Angiotensin II; Uterus; Phospholipase C; (Receptors, Rat) (Varol, F.G. (162) 37)

Prepulse inhibition
MDEA (N-ethyl-3,4-methylenedioxyamphetamine); MDMA (methylenedioxymethamphetamine); Startle; (Rat) (Mansbach, R.S. (167) 49)

Presynaptic autoinhibition
Atrium (guinea-pig); Field stimulation; Inotropic effect; α_2-Adrenoceptors (Brasch, H. (171) 37)

Atrium (guinea-pig); Field stimulation; Noradrenaline release; Inotropic effect; α_2-Adrenoceptors (Brasch, H. (171) 49)

Primary afferent neurones
Capsaicin; Ruthenium red; Substance P; Ileum (guinea-pig) (Chahl, L.A. (169) 241)

Primidone
Phenobarbital; Kindling; Epilepsy (Löscher, W. (162) 309)

Procaterol
Atrial cells; Ventricular cells; Slow inward calcium current; β_2-Adrenoceptors; ICI-118551 (Iijima, T. (163) 357)

Proconflict effect
Ro 15-4513; β-Carbolines; Benzodiazepine recognition sites; Anxiety; Convulsions; [^{3}H]GABA binding (Corda, M.G. (159) 233)

Proenkephalin
Chromaffin cells; PNMT (phenylethanolamine N-methyltransferase); mRNA; Glucocorticoids; Dexamethasone; Gene expression (Wan, D.C.-C. (172) 107)

Proenkephalin A
Histamine; PNMT (phenylethanolamine N-methyltransferase); Gene regulation; Adrenal chromaffin cells (Wan, D.C.-C. (172) 117)

Progesterone metabolites
Anticonvulsants; Seizures; Steroids; GABA receptors; Cl^- ionophore (Belelli, D. (166) 325)

Chloride ionophore; Benzodiazepines; GABA receptors; Steroids; Clonazepam; (Partial agonists) (Belelli, D. (167) 173)

Barbiturate site; $GABA_A$ receptor complex; Prolactin; Pituitary (Vincens, M. (168) 15)

Prolactin
5-HT receptors; Quipazine (Di Renzo, G. (162) 371)

MK-801; Pituitary; Adrenal; ACTH; Corticosterone; Phencyclidine (PCP); N-Methyl-D-aspartate (NMDA); (Hormone) (Pechnick, R.N. (164) 257)

Tyrosine hydroxylase; DOPA (2,4-dihydroxyphenylalanine); DOPAC (3,4-dihydroxyphenylacetic acid); Striatum; Nucleus accumbens (Chen, J.-C. (166) 473)

Progesterone metabolites; Barbiturate site; $GABA_A$ receptor complex; Pituitary (Vincens, M. (168) 15)

Prolactin receptors
S-Adenosyl-L-methionine; Brain; Aging (Muccioli, G. (166) 223)

Prolactin-stimulated mitogenesis
Benzodiazepine receptors (peripheral type); Cell cycle regulation (Laird II, H.E. (171) 25)

Prolyl-leucyl-glycinamide
MIF-1; Apomorphine; Dopamine; 6-Hydroxydopamine (6-OHDA, neonatal); (Behaviour, Development) (Kostrzewa, R.M. (163) 33)

Propiophenones
Ca^{2+} channel blockers; Ion channels; (Neurons, Snail) (Novales-Li, P. (168) 299)

Propranolol
Ischemia; Myocardium; Perfused working heart; Non-esterified fatty acids; (Rat) (Nakamura, K. (160) 61)

Insulin; Glucagon; Somatostatin; Yohimbine; Vagotomy; (Secretion) (Ribes, G. (162) 207)

Isoproterenol; 5-Hydroxytryptamine (5-HT, serotonin); Pulmonary circulation; (Pulmonary pressor response to 5-HT) (Takashio, T. (169) 179)

Prostacyclin
Quin-2; Ca^{2+}; Endothelium; P_2 purinoceptors (Raspe, E. (163) 345)

Endothelium-derived relaxing factor (EDRF); Platelet aggregation; cAMP; cGMP (Alheid, U. (164) 103)

cAMP; Pertussis toxin; Angiotensin II; Vasopressin (Vallotton, M.B. (166) 219)

Prostaglandin D_2
Acetylcholine release; Bronchial tissue; Atropine; Indomethacin; Prostaglandin E_2 (Deckers, I.A. (167) 415)

Prostaglandin E_2
Trachea; Cigarette smoke; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Thromboxane A_2; Cortisol; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Luteinizing hormone-releasing hormone (LHRH); Hypothalamus; Adenylyl cyclase; Guanyl-5′-yl-imidophosphate (Wisner, A. (162) 89)

Adrenergic neurotransmission; Purinergic neurotransmission; Guanabenz; Guanethidine; (Neuromodulators) (Trachte, G.J. (164) 425)

Bronchus (in vitro, human); Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Thromboxane A_2 receptors; Thromboxane A_2 antagonists (Armour, C.L. (165) 215)

Interleukin-1; Bradykinin; Tumour necrosis factor; Synovial cells (O'Neill, L.A.J. (166) 131)

Acetylcholine release; Bronchial tissue; Atropine; Indomethacin; Prostaglandin D_2 (Deckers, I.A. (167) 415)

Endothelin; Prostaglandin I_2; Renal blood flow (Miura, K. (170) 91)

Prostaglandin $F_{1\alpha}$
Aorta; Acetylcholine; Endothelium; Glyceryl trinitrate; 6-keto-Prostaglandin $F_{1\alpha}$; (Radioimmunoassay, Rat) (Bossaller, C. (165) 165)

6-keto-Prostaglandin $F_{1\alpha}$
Aorta; Acetylcholine; Endothelium; Glyceryl trinitrate; Prostaglandin $F_{1\alpha}$; (Radioimmunoassay, Rat) (Bossaller, C. (165) 165)

Prostaglandin $F_{2\alpha}$
Adenosine receptors; Ca^{2+}; Coronary circulation; Smooth muscle (vascular) (Ramagopal, M.V. (159) 33)

Trachea; Cigarette smoke; Prostaglandin I_2; Prostaglandin E_2; Thromboxane A_2; Cortisol; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Bronchus (in vitro, human); Thromboxane A_2; Prostaglandin E_2; Thromboxane A_2 receptors; Thromboxane A_2 antagonists (Armour, C.L. (165) 215)

Rhythmicity; Coronary artery (human); Adenosine receptors; Ouabain (Sabouni, M.H. (168) 271)

Prostaglandin I_2
Trachea; Cigarette smoke; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2; Cortisol; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Endothelin; Prostaglandin E_2; Renal blood flow (Miura, K. (170) 91)

Prostaglandins
Aspirin; Salicylic acid; Anti-inflammatory drugs (non-steroidal); Inflammation; Carrageenin (Chiabrando, C. (159) 257)

Macrophages; Leukotrienes; Malotilate; 5-Lipoxygenase (Zijlstra, F.J. (159) 291)

Calcitonin gene-related peptide (CGRP); Ca^{2+} channels; Stomach; (Rat, Guinea pig) (Katsoulis, S. (161) 129)

Opioid receptors; Dynorphin; Heart (Ledda, F. (162) 323)

Leukocyte accumulation; Vascular permeability; Complement depletion (Hambleton, P.T. (163) 141)

Platelet activating factor (PAF-acether, PAF); Bradykinin; Colonic epithelium; Cl^- channels (Buckley, T.L. (163) 275)

5-Hydroxytryptamine (serotonin, 5-HT); Algesia; Arachidonate cyclooxygenase (inhibitors); Methysergide (Vinegar, R. (164) 497)

Platelets; Thromboxane A_2; (Receptors) (Modesti, P.A. (169) 85)

Des-Arg^9-bradykinin; Bradykinin receptors; Vasorelaxation (Nwator, I.A.A. (170) 29)

Immunoneuroendocrinology; Immunopharmacology; Appetitive behaviour; Interleukin-1; Indomethacin (Uehara, A. (170) 257)

Adenosine; Lymphocytes; Cholera toxin; Phorbol esters; (Receptors) (Nordstedt, C. (172) 51)

Prostaglandin synthesis
L-Tyrosine; Blood pressure; Heart rate; Autonomic nervous system; Histamine receptors (Ekholm, S. (168) 145)

Protease
HIV-1; Protein dimer; Mutagenesis; Synthetic gene (Guenet, C. (172) 443)

Protein dimer
HIV-1; Protease; Mutagenesis; Synthetic gene (Guenet, C. (172) 443)

Protein kinase C
Ca^{2+} entry blockers; Myosin light-chain kinase; Smooth muscle contraction (vascular) (Schächtele, C. (163) 151)

Botulinum A toxin; α_2-Adrenoceptors (presynaptic); Phorbol ester; Noradrenaline release; 5-HT release (Nakov, R. (164) 45)

Corticotropin-releasing factor; Dopamine synthesis; Synaptosomes; Ca^{2+}; Striatum; (Rat) (Olianas, M.C. (166) 165)

3,4-Diaminopyridine; Noradrenaline release; Hippocampus; Phorbol ester (Huang, H.Y. (169) 115)

Ca^{2+} (extra-and intra-cellular); Ca^{2+} channels (L-type and T-type); Noradrenaline; Phorbol ester; K^+; Uterine vasoconstriction (Fallgren, B. (170) 61)

Protein phosphorylation
Vasodilators; cAMP; cGMP; Platelets; Phosphatidylinositols (Waldmann, R. (159) 317)

Striatum; DARPP-32; Dopamine D-1 receptor; (Pharmacological modulation) (Di Luca, M. (172) 321)

Insulin; Pharmacodynamics; Guanine nucleotide-binding proteins (G-proteins) (Joost, H.G. (172) 461)

Protriptyline
α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Clorgyline; Tranylcypromine; Cocaine; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

Psychotomimetic (+)-benzomorphans
σ Receptors; Haloperidol; 1,3-Di-o-tolylguanidine; (+)-3-(3-Hydroxyphenyl)-N-(1-propyl)piperidine; (Allosteric interaction) (Bowen, W.D. (163) 309)

Pulmonary artery
Endothelium; Endothelium-derived relaxing factor (EDRF); Hemoglobin; (Modulation of contraction) (Yamaguchi, T. (161) 259)

Smooth muscle (vascular); Pulmonary veins; Endothelium; Endothelium-derived relaxing factor (EDRF); Adrenergic neurotransmission (Greenberg, S. (162) 67)

K^+ channel activators; Glibenclamide; (Guinea-pig) (Eltze, M. (165) 231)

Aorta; Endothelin; Endothelium; (Rat) (Rodman, D.M. (165) 297)

Pulmonary β-adrenoceptors
Haemophilus influenzae; Atopic guinea-pig; (Autoradiography) (Engels, F. (164) 139)

Pulmonary circulation
Isoproterenol; Propranolol; 5-Hydroxytryptamine (5-HT, serotonin); (Pulmonary pressor response to 5-HT) (Takashio, T. (169) 179)

Pulmonary edema
5-HT receptor subtypes; Capillary pressure; Filtration coefficient; Ketanserin; Methysergide (Sumita, T. (164) 69)

Pulmonary hypertension
5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; 5-HT receptor antagonism; Vascular effects (Le Roux, M.G.J. (169) 269)

Pulmonary parenchymal strips
Smooth muscle (vascular); Leukotriene receptors; Thromboxane B_2 (Stahl, G.L. (163) 55)

Pulmonary veins
Smooth muscle (vascular); Pulmonary arteries; Endothelium; Endothelium-derived relaxing factor (EDRF); Adrenergic neurotransmission (Greenberg, S. (162) 67)

Purinergic action (central)
Dilazep; Clonidine; Aggressive behaviour (Ushijima, I. (161) 245)

Purinergic modulation
Spontaneously hypertensive rat (SHR); Wistar-Kyoto rat (WKY); Portal vein (rat) (Reilly, W.M. (160) 283)

Purinergic neurotransmission
Adrenergic neurotransmission; PGE_2; Guanabenz; Guanethidine; (Neuromodulators) (Trachte, G.J. (164) 425)

Purinergic transmission (sympathetic)
Nifedipine; Adrenergic transmission; Artery (Omote, S. (160) 239)

Purkinje fibers
Naloxone; Antiarrhythmic activity; Oscillatory afterpotentials; (Triggered activity) (Cerbai, E. (162) 491)

Pyramidal cells
$GABA_B$ receptors; Phaclofen; Hippocampus (Karlsson, G. (163) 285)

G-proteins; Transmitter release; K^+ conductance; cAMP (Fredholm, B.B. (172) 249)

Pyridazinone
Imidazole; MCI-154; Skinned fibers; Myocardium (human); Inotropic drugs (Perreault, C.L. (165) 305)

Quaternary ammonium compounds
Acetylcholinesterase (EC 3.1.1.7); Esteratic subsite; (Active site) (Thanei-Wyss, P. (172) 165)

Quin-2
Ca^{2+}; Prostacyclin; Endothelium; P_2 purinoceptors (Raspe, E. (163) 345)

Quinacrine
Slow inward current; Na^+/Ca^{2+} exchange; Force (Yang, L. (170) 261)

Quinidine
Quinine; Colon electrophysiology; Interstitial cells of Cajal; Slow waves; Pacemaker activity (Barajas-López, C. (163) 137)

Quinine
Quinidine; Colon electrophysiology; Interstitial cells of Cajal; Slow waves; Pacemaker activity (Barajas-López, C. (163) 137)

K^+ channels; Dopamine D-2 receptors; Neuroleptics; Caudate nucleus; (Patch-clamp) (Freedman, J.E. (164) 341)

K^+ channels; Endothelium; Sulfonylureas; Pinacidil (Ramboer, I. (171) 251)

Quinpirole
Dopamine neurons; d-Amphetamine; Apomorphine; SCH 23390; Nigrostriatal dopamine neurons (Pitts, D.K. (162) 167)

Apomorphine; SCH 23390; Sulpiride; SK&F 38393; Jaw movements (Koshikawa, N. (163) 227)

BHT-920; Dopamine D-1 receptors; Dopamine D-2 receptors; Striatum; (Rat) (Ferré, S. (166) 303)

Levodopa; Behaviour (rotational); SKF 38393; Apomorphine; (Chronic treatment) (Engber, T.M. (168) 291)

MDMA (3,4-methylenedioxymethamphetamine); Apomorphine; Midbrain dopamine neurons; Antidromic activation; (Electrophysiology) (Kelland, M.D. (169) 11)

Sleep; Wakefulness; REM (rapid eye movement) sleep; YM-09151-2; Dopamine D-2 receptors (Monti, J.M. (169) 61)

Quinuclidinyl benzilate (QNB)
Muscarinic receptors; Motor activity; Phencyclidine (PCP) (Boggan, W. (166) 123)

Quipazine
5-HT receptors; Prolactin (Di Renzo, G. (162) 371)

5-Hydroxytryptamine (5-HT, serotonin); $5\text{-}HT_3$ (sites); Arylpiperazines; (Radioligand binding) (Glennon, R.A. (168) 387)

Quisqualate
Norepinephrine; Carbachol; Inositol phospholipids; Brain (human) (Nicoletti, F. (160) 299)

Quisqualate receptors
Kainate receptors; Glutamate; GABA release; Striatal neurons; (Primary culture) (Pin, J.-P. (172) 81)

[^{3}H]QNB binding
Submandibular acini; ^{22}Na; Amiloride; Furosemide (Martinez, J.R. (164) 335)

R56865
Ouabain; Digitalis toxicity; Na^+ pump; Myocardium (isolated); (Rat) (Finet, M. (164) 555)

R59022
Pituitary; Ca^{2+} mobilization; Diacylglycerol; Thyrotropin releasing hormone (TRH); 1-Oleyl-2-acetyl glycerol (OAG) (Mollard, P. (172) 71)

Raclopride
Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Stereotypy; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

[^{3}H]Raclopride
Amphetamine discrimination; Dopamine D-1 receptors; Dopamine D-2 receptors; [^{3}H]SCH 23390; Dopamine (Nielsen, E.B. (160) 253)

Radiation inactivation
$5\text{-}HT_3$ receptors; Cerebral cortex (rat); Molecular weight; [^{3}H]Zacopride (Gozlan, H. (172) 497)

Raphe nuclei
$5\text{-}HT_{1A}$ agonists; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Motor control; (Rat) (Hillegaart, V. (160) 303)

[^{3}H]Rauwolscine
α_2-Adrenoceptors; $5\text{-}HT_{1A}$ receptors; Cerebral cortex membranes (human) (Convents, A. (159) 307)

Urethra (rabbit); [^{3}H]Idazoxan; α_2-Adrenoceptors; Amiloride (Yablonsky, F. (164) 167)

[^{3}H]Rauwolscine binding
α_2-Adrenoceptors; (Heterogeneity) (Young, P. (168) 381)

RB38A
Opioid receptors; μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; Thiorphan; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Reactive blue 2
P_2 purinoceptors; Vasodilatation; Vasoconstriction; (In vivo) (Taylor, E.M. (161) 121)

Receptor-G-protein coupling
Muscarinic receptor subtypes; [^{3}H]Pirenzepine; Hippocampus; N-Ethylmaleimide (NEM); (Agonists) (Flynn, D.D. (172) 363)

Receptors
Angiotensin II; Smooth muscle; Ileum; (Guinea-pig, Desensitization) (Oshiro, M.E.M. (166) 411)

δ Receptors
β-Funaltrexamine; Opioids; Supraspinal analgesia; Periaqueductal gray; μ Receptors; (Binding) (Sánchez-Blázquez, P. (159) 9)

Opioid antinociception; μ Receptors; (Intracerebroventricular, Mouse) (Heyman, J.S. (165) 1)

μ Receptors
β-Funaltrexamine; Opioids; Supraspinal analgesia; Periaqueductal gray; δ Receptors; (Binding) (Sánchez-Blázquez, P. (159) 9)

Opioid antinociception; δ Receptors; (Intracerebroventricular, Mouse) (Heyman, J.S. (165) 1)

σ Receptors
3-PPP (3-(3-hydroxyphenyl)-N-(1-propyl)piperidine); [^{3}H]3-PPP binding in vivo; 3-PPPP (3-(3-hydroxyphenyl)-N-(3-phenyl-1-propyl)piperidine) (Koe, B.K. (161) 263)

Phencyclidine receptors; Metaphit; Isothiocyanates; Affinity labelling (Bluth, L.S. (161) 273)

(+)-3-PPP; BMY 14802; Dopamine neurons (Steinfels, G.F. (163) 167)

Haloperidol; Psychotomimetic (+)-benzomorphans; 1,3-Di-o-tolylguanidine; (+)-3-(3-Hydroxyphenyl)-N-(1-propyl)piperidine; (Allosteric interaction) (Bowen, W.D. (163) 309)

PCP receptors; PC12 cells; Chromaffin cells; Adrenal medulla (Yang, Z.W. (164) 607)

Recombinant DNA
cAMP-dependent protein kinase; Regulatory subunit; Catalytic subunit; Expression vector; (*E. coli*) (Kuno, T. (172) 263)

Red blood cells
Endothelium-derived relaxing factor (EDRF); Haemoglobin (Evans, H.G. (163) 361)

Regulatory subunit
cAMP-dependent protein kinase; Catalytic subunit; Recombinant DNA; Expression vector; (*E. coli*) (Kuno, T. (172) 263)

Reinforcement (conditioned)
GBR 12909; Motor activity; Dopamine; (Sensitization, Fixed-interval) (Kelley, A.E. (167) 385)

Reinforcing effects
Enkephalin analog; Self-administration; Morphine (Nishida, N. (166) 453)

Release sites
[^{125}I]7-Amino-8-iodo-ketanserin ([^{125}I]AMIK); 5-HT_2 receptors; α_1-Adrenoceptors; (Quantitative autoradiography) (Schotte, A. (172) 99)

REM (rapid eye movement) sleep
Sleep; Wakefulness; Quinpirole; YM-09151-2; Dopamine D-2 receptors (Monti, J.M. (169) 61)

Renal artery
Carotid artery; Endothelium; Kinins; Bradykinin; Bradykinin B_1 receptors; Bradykinin B_2 receptors; Kinin antagonists; (Dog) (Rhaleb, N.-E. (162) 419)

Renal blood flow
Endothelin; Renal cortex; Renal medulla (Tsuchiya, K. (166) 541)

Endothelin; Prostaglandin E_2; Prostaglandin I_2 (Miura, K. (170) 91)

Cromakalim; Pinacidil; Nifedipine; Renin activity (plasma); (Cat) (Clapham, J.C. (171) 109)

Renal cortex
Endothelin; Renal blood flow; Renal medulla (Tsuchiya, K. (166) 541)

Renal function
Endothelin; Urine formation; Renin secretion; (Anesthetized rat) (Matsumura, Y. (166) 577)

Atrial natriuretic peptide (ANP); Urinary kallikrein excretion (Lòpez, C. (168) 1)

5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; Methysergide; 5-HT_1-like receptors; 5-HT_2 receptors (Shoji, T. (171) 219)

Renal hypertension
Na^+,K^+-ATPase; [^{3}H]Ouabain binding; Ventricles; DOCA/NaCl hypertension (Chen, C.-C. (169) 67)

Renal medulla
Endothelin; Renal blood flow; Renal cortex (Tsuchiya, K. (166) 541)

Renal nerves
Autoradiography; Kidney; Noradrenaline; Adrenoceptors; Sympathetic nervous system (Sripairojthikoon, W. (167) 355)

α-Adrenoceptors (prejunctional); Noradrenaline release (Murphy, T.V. (169) 285)

Renal plasma flow
Endothelium; Endothelin; Glomerulus; Glomerular filtration rate; Mesangial cells; (Contraction) (López-Farré, A. (163) 187)

Renal tubular basolateral membrane
Chlorpropamide; [Arg^8]vasopressin receptor; [^{3}H]-[Arg^8]vasopressin; (Rat) (Muta, T. (159) 191)

Renin activity (plasma)
Cromakalim; Pinacidil; Nifedipine; Renal blood flow; (Cat) (Clapham, J.C. (171) 109)

Renin secretion
Endothelin; Renal function; Urine formation; (Anesthetized rat) (Matsumura, Y. (166) 577)

Reoxygenation
α-Adrenoceptor antagonists; Cell membrane permeability; Creatine kinase; High-energy phosphates; Hypoxia; YM-12617 (Tanonaka, K. (165) 97)

Reperfusion
Nicorandil; Ischemia; Arrhythmias; Heart; (Rat) (Kempsford, R.D. (163) 61)

Reserpine
α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Clorgyline; Tranylcypromine; Cocaine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

α-Adrenoceptor subtypes (postsynaptic); Tail artery (rat); Ca^{2+} influx (Abe, K. (171) 59)

Reserpinized animals
β_1-Adrenoceptor blockade; Nebivolol; Pindolol; Practolol; Atria (isolated); Blood vessels (isolated); (Intrinsic sympathomimetic activity) (Janssens, W.J. (159) 89)

Resistance vessels (pre-capillary)
Adrenergic/purinergic neurotransmission; α-Adrenoceptor antagonists; α,β-Methylene ATP; (In vivo) (Taylor, E.M. (164) 23)

Respiratory conductance
Fentanyl; 5-Hydroxytryptamine; Histamine; (Guinea-pig) (Gentil, B. (159) 181)

Reticular formation
Pain; Morphine (Bing, Z. (164) 85)

Reticulocytes
Heterologous desensitization; Adenylate cyclase; G_s proteins; β-Adrenoceptor agonists; (Rat) (Yamashita, A. (159) 247)

Retina
2-Amino-4-phosphonobutyrate (APB); Cis-2,3-piperidine dicarboxylic acid (PDA); Glutamate; Acetylcholine; Glycine; (ON channel, OFF channel, Receptive field, Frog) (Jardon, B. (162) 215)

Melatonin binding site (ML-1); Brain; 2-[^{125}I]Iodomelatonin; Luzindole; (Chicken) (Dubocovich, M.L. (162) 289)

Platelet-activating factor (PAF-acether, PAF); PAF receptors; Retinal membrane; PAF antagonists; (Rat) (Thierry, A. (163) 97)

Retinal
Histamine release; Retinoic acid; Phorbol esters; Ca^{2+}; Mast cells (Cantwell, M.E. (160) 43)

Retinal ganglion cell
CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); DNQX (dinitroquinoxaline-2,3-dione); CPP (3-(±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); Excitatory amino acids (Kay, C.D. (164) 381)

Retinal membrane
Platelet-activating factor (PAF-acether, PAF); PAF receptors; Retina; PAF antagonists; (Rat) (Thierry, A. (163) 97)

Retinoic acid
Histamine release; Retinal; Phorbol esters; Ca^{2+}; Mast cells (Cantwell, M.E. (160) 43)

Reward threshold
Brain stimulation reward; Tripelennamine; Pentazocine; Nalbuphine; Physical dependence (Huston-Lyons, D. (169) 153)

Rhythmicity
Coronary artery (human); Prostaglandin $F_{2\alpha}$; Adenosine receptors; Ouabain (Sabouni, M.H. (168) 271)

Rilmenidine
[^{3}H]Clonidine; Imidazoline preferring receptors; Brain (human) (Bricca, G. (163) 373)

Anococcygeus (rat); Clonidine; McN-A-343; Methoxamine; Non-adrenergic, non-cholinergic (NANC) transmission; (Prejunctional receptors) (Li, C.G. (168) 107)

Rin m 5F cells
Pancreastatin; Insulin release (Lorinet, A.-M. (160) 405)

Galanin; Insulin release; cAMP (Amiranoff, B. (163) 205)

Ritanserin
l-5-Hydroxytryptophan (l-5-HTP); 5,7-DHT (5,7-Dihydroxytryptamine); 5-HT syndrome; 5-HT_{1C} receptors (Colpaert, F.C. (169) 175)

mRNA
Chromaffin cells; Proenkephalin; PNMT (phenylethanolamine N-methyltransferase); Glucocorticoids; Dexamethasone; Gene expression (Wan, D.C.-C. (172) 107)

Ro 5-4864
Peripheral benzodiazepines; PK 11195; Mitochondrion; Neuroblastoma cells (Larcher, J.-C. (161) 197)

Ro 15-1788
Benzodiazepine binding; GABA; (Chronic treatment) (Urbancic, M. (171) 1)

Ro 15-4513
Benzodiazepine inverse agonists; Ethanol; Pentobarbital; Motor impairment; Hypnotics (Le, A.D. (159) 25)

β-Carbolines; Benzodiazepine recognition sites; Proconflict effect; Anxiety; Convulsions; [^{3}H]GABA binding (Corda, M.G. (159) 233)

Ethanol; General depressants; Ethanol reduction (Bishop, B.E. (162) 265)

α_2-Adrenoceptor antagonists; Atipamezole; Idazoxan; Ethanol; Hypothermia; (Mouse) (Löschmann, P.-A. (166) 381)

Ro 16-6491
Monoamine oxidase-B (MAO-B); Ro 19-6327; Affinity labelling; (Mechanism-based reversible inhibition, High-affinity binding) (Cesura, A.M. (162) 457)

Ro 17-1812
Anticonvulsant tolerance; Diazepam; RU 32698; (Partial agonists) (Feely, M. (164) 377)

Ro 19-6327
Monoamine oxidase-B (MAO-B); Ro 16-6491; Affinity labelling; (Mechanism-based reversible inhibition, High-affinity binding) (Cesura, A.M. (162) 457)

Ro 15-4513 binding
Granule cells; Cerebellum; GABA (γ-aminobutyric acid); Diazepam; Ethanol (Malminiemi, O. (169) 53)

Rotation
Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; DOPA accumulation; Catalepsy; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

RU 24722
Eburnamine derivatives; 2-Deoxy-D-[^{14}C]-glucose; Catecholaminergic system; Limbic system; (Rat) (Broussolle, E. (159) 225)

RU 24969
5-HT_1 receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Morphine withdrawal; (Mouse) (Berthold, H. (162) 19)

Arteriovenous anastomoses; Carotid blood flow; 5-Hydroxytryptamine (5-HT, serotonin); 5-HT receptors; 5-HT_1-like receptors; Migraine (Bom, A.H. (171) 87)

RU 32698
Anticonvulsant tolerance; Diazepam; Ro 17-1812; (Partial agonists) (Feely, M. (164) 377)

Runway task (3-panel)
S-Adenosyl-L-methionine; Cerebral ischemia; Scopolamine; Memory (working); Amnesia (Yatsugi, S.-i. (166) 231)

Ruthenium red
Capsaicin; Primary afferent neurones; Substance P; Ileum (guinea-pig) (Chahl, L.A. (169) 241)

Capsaicin sensitive sensory nerves ('efferent' function of); Bronchi; Atrium; (Guinea-pig) (Maggi, C.A. (170) 167)

[^{3}H]RX821002
α_{2A}-Adrenoceptors; [^{3}H]Yohimbine; [^{3}H]Idazoxan; [^{3}H]-UK14,304; HT29 cell-line (Langin, D. (167) 95)

α_2-Adrenoceptors; Adipocytes; Lipolysis; [^{3}H]Yohimbine; [^{3}H]UK 14304; [^{3}H]Idazoxan; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Ryanodine
Noradrenaline contractions; Nifedipine; Ca^{2+} mobilization; Vas deferens; Methoxyverapamil; (Rat) (Vesperinas, G. (165) 309)

S-145
Thromboxane A_2 receptor antagonists; Vascular actions; Platelet actions; (Kinetic binding parameters) (Mihara, S. (171) 179)

Salicylic acid
Aspirin; Anti-inflammatory drugs (non-steroidal); Prostaglandins; Inflammation; Carrageenin (Chiabrando, C. (159) 257)

Salivary secretion
Substance P; Tachykinins; (Dimeric analogue) (Higuchi, Y. (160) 413)

Salivation
Substance P; Neurokinin A; γ-PPT-(72-92)-NH_2; Neuropeptide K; Tachykinins (Takeda, Y. (161) 267)

Sarafotoxin S6b
Endothelin; Ca^{2+} antagonists; BAY k 8644; ω-Conotoxin; Na^+/H^+ exchanger (Gu, X.-H. (167) 281)

Sartorius muscle
Adenosine; Diazepam; Neuromuscular junction; Nucleoside uptake; Dipyridamole; (Frog) (De Mendonça, A. (164) 347)

Sauvagine
Corticotropin-releasing factor (CRF); Urotensin I; CRF-(9-41) antagonist (α-helical); Anti-inflammatory response; Thermal injury; Vascular permeability (Wei, E.T. (168) 81)

SCH 23390
Dopamine receptors; Aggression (intraspecies); Clozapine; Haloperidol (McMillen, B.A. (160) 149)

Haloperidol; Dopamine; Depolarization block; (Electrophysiology, Rat) (Esposito, E. (162) 109)

Dopamine neurons; d-Amphetamine; Apomorphine; Quinpirole; Nigrostriatal dopamine neurons (Pitts, D.K. (162) 167)

Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; Raclopride; Stereotypy; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

Apomorphine; Quinpirole; Sulpiride; SK&F 38393; Jaw movements (Koshikawa, N. (163) 227)

Pimozide; Learning (latent); Passive avoidance response; Memory; (Mouse) (Ichihara, K. (164) 189)

Apomorphine; Dopamine; Dopamine DA2 receptors; Heart rate; Domperidone; Vagus nerve (Montastruc, P. (166) 511)

[^{3}H]SCH 23390
Amphetamine discrimination; Dopamine D-1 receptors; Dopamine D-2 receptors; [^{3}H]Raclopride; Dopamine (Nielsen, E.B. (160) 253)

5-HT receptors; Blood platelets; Brain; Dopamine D-1 receptors; (Human) (De Keyser, J. (162) 437)

Dopamine D-1 receptors; Kidney (Zdilar, D. (164) 159)

Dopamine D-1 receptors (solubilized); Polyethylene glycol; Guanine nucleotide (GTP); Striatum; (Rat) (Zhang, X. (166) 401)

SCH 34826
Enkephalinase; Thiorphan; Spinal cord; [Met^5]enkephalin (Yaksh, T.L. (167) 367)

Schedule-controlled behaviour
FG 7142; β-Carbolines; Benzodiazepines; CGS 8216; (Primates) (Wettstein, J.G. (163) 219)

Schedule-controlled responding
NMDA (N-methyl-D-aspartate); MK-801; CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-1-phosphonic acid); Drug discrimination; (Rhesus monkey) (France, C.P. (159) 133)

Schedule-induced wheelrunning
Adrenalectomy; Corticosterone; Dexamethasone; (Rat) (Lin, W. (171) 9)

Scopolamine
Neurotensin; Haloperidol; Atropine; Nucleus accumbens; Caudate nucleus (Levant, B. (165) 327)

S-Adenosyl-L-methionine; Cerebral ischemia; Runway task (3-panel); Memory (working); Amnesia (Yatsugi, S.-i. (166) 231)

Sedation
Benzodiazepine receptors; Seizures; Bicuculline; β-CMC (3-(methoxycarbonyl)-amino-β-carboline (Nutt, D.J. (165) 135)

$α_2$-Adrenoceptors; Hypoactivity; Mydriasis; MHPG (3-methoxy-4-hydroxyphenylglycol); Clonidine; Brain; Behaviour; (Presynaptic $α_2$-adrenoceptors, Postsynaptic $α_2$-adrenoceptors, Mouse) (Heal, D.J. (170) 19)

Seganserin
5-HT_2 receptor antagonists; Sleep; EEG (human); Spectral analysis (Dijk, D.J. (171) 207)

Seizures
Mast cell degranulating peptide; Dendrotoxin; K^+ channel blockers; Ca^{2+} channel antagonists; NMDA antagonists (Gandolfo, G. (160) 173)

Nimodipine; Flunarizine; Diltiazem; Ca^{2+} channel antagonists; Dihydropyridines (Morón, M.A. (163) 299)

Benzodiazepine receptors; Sedation; Bicuculline; β-CMC (3-(methoxycarbonyl)-amino-β-carboline (Nutt, D.J. (165) 135)

Anticonvulsants; Steroids; Progesterone metabolite; GABA receptors; Cl^- ionophore (Belelli, D. (166) 325)

THAO (5,6,7,8-tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol); Glia; GABA uptake; Pentylenetetrazol (PTZ); Isonicotinic acid hydrazide (Gonsalves, S.F. (168) 265)

Seizures (lidocaine-kindled)
Lidocaine; Carbamazepine; Phenytoin; [^{3}H]Batrachotoxin binding; Hippocampus (Zimányi, I. (167) 419)

$β_1$ Selectivity
β-Adrenoceptor antagonists; Sympathomimetic activity (intrinsic); Noradrenaline; Heart cells (Reithmann, C. (170) 243)

Selenite-induced contracture
Diaphragm; Ca^{2+} release (Lin-Shiau, S.-Y. (167) 137)

Self-administration
Heroin; Narcotic analgesia; Physical dependence; (Unit dose, Intraventricular, Rat) (De Vry, J. (161) 19)

Enkephalin analog; Reinforcing effects; Morphine (Nishida, N. (166) 453)

Sensitized guinea-pig
Trachealis; Lung parenchyma; Indomethacin; Asthma (experimental); (Non-specific hyperresponsiveness, Guinea-pig) (Cortijo, J. (162) 467)

Sensory nerves
Heart; [D-Ala^2,D-Leu^5]enkephalin (DADLE); [D-Ala^2,N-Me-Phe^4,Gly^5-ol]enkephalin (DAGO); Capsaicin (Mantelli, L. (170) 217)

Sensory nerves ('efferent' function of)
Capsaicin; Galanin; Bronchi; Atrium; (Guinea-pig) (Giuliani, S. (163) 91)

Sensory neuron
Amino-γ-carboline; γ-Aminobutyric acid; (Whole cell clamp, Mouse) (Kanai, Y. (166) 553)

Septum
Cultured explants; Hippocampus; Cholinergic reinnervation; Muscarinic receptor subtypes; (Up-regulation, Down-regulation) (Rimvall, K. (160) 1)

Serotonergic system
Minaprine; Cycloheximide; Cholinergic system; 5-HT_2 receptors; Amnesia; (Mouse) (Nabeshima, T. (169) 249)

SGB-1534
α_1-Adrenoceptor antagonists; Canine urethra; Hypogastric nerve stimulation (Imagawa, J.-i. (167) 167)

SH-SY5Y human neuroblastoma
SK-N-SH human neuroblastoma; [^{3}H]Methylscopolamine; Muscarinic M_3 receptors (Lambert, D.G. (165) 71)

Signal-contraction coupling
Smooth muscle (intestinal); Histamine; Substance P; K^+ depolarization; Diacylglycerol; (Guinea-pig) (Lippe, I.T. (159) 1)

Sila-hexocyclium
Muscarinic M_3 receptor subtypes; HT-29 colon carcinoma cells; Phosphatidylinositol metabolism; AF-DX 116; Hexhydro-sila-difenidol; Methoctramine (Kopp, R. (172) 397)

Single unit recording
MDMA (3,4-methylenedioxymethamphetamine); Dorsal raphe nucleus; Microdialysis; Neurotransmitter release (Sprouse, J.S. (167) 375)

Sinoaortic baroreceptors
Furosemide; Loop diuretics; Hemodynamic response (acute); Spontaneously hypertensive rats (SHR) (Janssen, B.J.A. (170) 1)

Sinoatrial conduction
Sinus automaticity; Bepridil; Verapamil; Diltiazem; Disopyramide (Kirchhof, C.J.H.J. (160) 369)

Sinus automaticity
Sinoatrial conduction; Bepridil; Verapamil; Diltiazem; Disopyramide (Kirchhof, C.J.H.J. (160) 369)

Sinus node pacemaker activity
Sympathetic-parasympathetic interaction; Atrial contractility; cAMP; Ca^{2+} channels; Atrium (isolated, canine) (Furukawa, Y. (161) 1)

κ Sites
Opioid receptors; Hemorphin-4; Cytochrophin-4; β-Casomorphins (Liebmann, C. (166) 523)

σ Sites
NMDA receptors; Target size analysis (Wong, E.H.F. (172) 493)

Skeletal muscle
Ischaemia; Microcirculation; Peripheral vascular disease; Torbafylline; (Performance) (Okyayuz-Baklouti, I. (166) 75)

Amiloride; Voltage clamp; Ca^{2+}-dependent K^+ currents; (Frog) (Nasri-Sebdani, M. (171) 97)

SK&F 38393
Atypical neuroleptics; Dopamine D-1 receptor antagonists; Dopamine D-2 receptor antagonists; Clozapine; LY-171555; (Behavior) (Criswell, H.E. (159) 141)

Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; LY171555; SCH 23390; Raclopride; Stereotypy; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

Apomorphine; Quinpirole; SCH 23390; Sulpiride; Jaw movements (Koshikawa, N. (163) 227)

Levodopa; Behaviour (rotational); Quinpirole; Apomorphine; (Chronic treatment) (Engber, T.M. (168) 291)

SK&F 104078
α_2-Adrenoceptors; 5-HT_{1A} receptors; 5HT_2 receptors (Kilpatrick, A.T. (166) 315)

SK&F 104353
Leukotriene D_4 (LTD_4); ICI 198615; Leukotriene receptors; Blood pressure; (Conscious rat) (Smith III, E.F. (159) 297)

Peptidoleukotriene; Splanchnic artery occlusion; Myocardial depressant factor; Hematocrit; Cathepsin D (Lento, P.H. (165) 241)

Skinned fibers
Pyridazinone; Imidazole; MCI-154; Myocardium (human); Inotropic drugs (Perreault, C.L. (165) 305)

Skin (*Pseudophryne coriacea*)
Cerebral cortex (rat); Acetylcholine release; 5-HT release; (Superfused synaptosomes) (Raiteri, M. (172) 223)

Skin twitch reflex
Flupirtine; Pentazocine; Antinociception; Flexor reflex (Vaupel, D.B. (162) 447)

SK-N-SH human neuroblastoma
SH-SY5Y human neuroblastoma; [^{3}H]Methylscopolamine; Muscarinic M_3 receptors (Lambert, D.G. (165) 71)

Sleep
Wakefulness; REM (rapid eye movement) sleep; Quinpirole; YM-09151-2; Dopamine D-2 receptors (Monti, J.M. (169) 61)

Seganserin; 5-HT_2 receptor antagonists; EEG (human); Spectral analysis (Dijk, D.J. (171) 207)

Slow inward calcium current
Atrial cells; Ventricular cells; β_2-Adrenoceptors; Procaterol; ICI-118551 (Iijima, T. (163) 357)

Slow inward current
Quinacrine; Na^+/Ca^{2+} exchange; Force (Yang, L. (170) 261)

Slow waves
Quinidine; Quinine; Colon electrophysiology; Interstitial cells of Cajal; Pacemaker activity (Barajas-López, C. (163) 137)

Small intestine
Galanin; Myenteric plexus; (Circular muscle contraction, Guinea-pig) (Kuwahara, A. (164) 175)

Smooth muscle
Stomach; Capsaicin (8-methyl-N-vanillyl-6-nonenamide); Tachykinins; Calcitonin gene-related peptide (CGRP) (Holzer-Petsche, U. (162) 29)

Strontium; Acetylcholine receptors (Macara, B. (162) 51)

Angiotensin II; Receptors; Ileum; (Guinea-pig, Desensitization) (Oshiro, M.E.M. (166) 411)

P_2-purinoceptors; α_1-Adrenoceptors; Suramin (Den Hertog, A. (166) 531)

UV light; Lipid peroxidation; Nitrite; Ca^{2+}; cGMP (Nelemans, A. (172) 283)

Smooth muscle (airway)
D-Inositol(1,4,5)trisphosphate (Chilvers, E.R. (164) 587)

Functional antagonism; Muscarinic receptor agonists; Histamine; Phosphoinositide metabolism; β-Adrenergic relaxation (Van Amsterdam, R.G.M. (172) 175)

Smooth muscle (bovine, tracheal)
Ventricle (bovine, left); Muscarine receptor subtypes; (Allosteric modulation) (Roffel, A.F. (172) 61)

Smooth muscle cells (vascular)
Atrial natriuretic peptide (ANP); (Vasoconstrictor, Receptor down-regulation) (Hirata, Y. (164) 603)

5-Hydroxytryptamine (5-HT, serotonin); 5-HT_{1B} binding sites; 5-HT_2 binding sites; (Tissue culture) (Jazayeri, A. (169) 183)

Smooth muscle contraction (vascular)
Ca^{2+} entry blockers; Myosin light-chain kinase; Protein kinase C (Schächtele, C. (163) 151)

Smooth muscle (human, airway)
Muscarinic receptors; Phosphoinositide metabolism (Meurs, H. (164) 369)

Smooth muscle (intestinal)
Signal-contraction coupling; Histamine; Substance P; K^+ depolarization; Diacylglycerol; (Guinea-pig) (Lippe, I.T. (159) 1)

Smooth muscle (non-vascular)
Adenosine agonists; Vas deferens (rat); Contractions (electrically evoked); (Presynaptic) (Major, T.C. (167) 323)

Smooth muscle (relaxation)
Vasodilation; Endothelium; cGMP; Nitric oxide; Nitrates (Buga, G.M. (161) 61)

Smooth muscle (vascular)
Adenosine receptors; Ca^{2+}; Coronary circulation; Prostaglandin $F_{2\alpha}$ (Ramagopal, M.V. (159) 33)

Pulmonary arteries; Pulmonary veins; Endothelium; Endothelium-derived relaxing factor (EDRF); Adrenergic neurotransmission (Greenberg, S. (162) 67)

Pulmonary parenchymal strips; Leukotriene receptors; Thromboxane B_2 (Stahl, G.L. (163) 55)

Vasoconstriction; Vasoactive peptide; Vasodilatation (Winquist, R.J. (163) 199)

Dithiothreitol; Sulfhydryl compounds; Coronary artery; Ca^{2+} ion; (Dog) (Fujioka, H. (166) 13)

Bepridil isomers; Ca^{2+} antagonists; Calmodulin antagonists (Winslow, E. (166) 241)

Ca^{2+} channels; Phenylalkylamine; Portal vein; (Binding study, Patch-clamp) (Loirand, G. (167) 265)

Pinacidil; K^+ channels; Trachea (Mellemkjær, S. (167) 275)

Epidermal growth factor-urogastrone; Autoradiography (Siang Gan, B. (167) 407)

Ethanol; Clonidine; Aorta; Endothelium; Vasorelaxation; (Rat) (Hatake, K. (168) 277)

Na^+ (intracellular); K^+ relaxation; Norepinephrine; Monensin; Ouabain; Serotonin (Bell, D.R. (171) 189)

Social conflict analgesia
Periaqueductal grey; NMDA receptors; AP-7; MK-801; Naloxone; (Mouse) (Siegfried, B. (168) 239)

Social interaction
5-HT_{1A} receptor agonists; NMDA receptor antagonists; Anxiolytic effect; (Elevated plus maze) (Dunn, R.W. (169) 1)

Somatostatin
Insulin; Glucagon; Yohimbine; Propranolol; Vagotomy; (Secretion) (Ribes, G. (162) 207)

Somatostatin receptors
Neuroblastoma cells; Cyclic AMP (McKinney, M. (162) 397)

Sotalol
OPC-8212; Antiarrhythmics (class III); Action potential duration; (Rate-dependent effects) (Lathrop, D.A. (164) 487)

Spaceflight
5-HT receptors; Dopamine receptors; Na^+,K^+-ATPase; Hippocampus; Striatum; Central nervous system (CNS) (Miller, J.D. (161) 165)

Spectral analysis
Seganserin; 5-HT_2 receptor antagonists; Sleep; EEG (human) (Dijk, D.J. (171) 207)

Spinal
p-Octopamine; Analgesia (non-opioid); Supraspinal; (Mouse) (Raffa, R.B. (169) 317)

Spinal cord
Analgesia; Pregnancy; κ Opioid receptors; Dynorphin A (Sander, H.W. (159) 205)

Kinins; Nociception; Noradrenergic mechanism; Monoamine content; 6-Hydroxydopamine (6-OHDA) (Laneuville, O. (159) 273)

U-50,488H; Morphine; κ Opioid receptors; Tolerance; Analgesia; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain (Bhargava, H.N. (162) 257)

5-HT_3 receptors; Opiate receptors; [^{3}H]Zacopride; [^{3}H]-Bremazocine; [^{3}H]Naloxone; Capsaicin; (Rat) (Hamon, M. (164) 315)

5-HT_2 receptors; Wet-dog shakes; 5-HT uptake inhibitors; MAO inhibition; (Receptor regulation) (Koshikawa, N. (164) 595)

Noradrenaline release; α_2-Adrenoceptors; DSP-4; (Slices, Rat) (Reimann, W. (167) 161)

Morphine; Tolerance-dependence; Abstinence; 5-HT_2 receptors; Brain regions (Gulati, A. (167) 185)

Benzodiazepine; Muscle relaxants (central); GABA; Cerebellar Purkinje cells; (Unit activity) (Tarnawa, I. (167) 193)

Enkephalinase; Thiorphan; [Met^5]enkephalin; SCH 34826 (Yaksh, T.L. (167) 367)

Morphine; Tolerance; Opioids; Naloxone; Withdrawal (Bell, J.A. (168) 101)

[Met^5]enkephalin-like material; Calcitonin (porcine); (Intrathecal perfusion, In vivo release) (Collin, E. (168) 201)

Benzodiazepine receptor subtypes; 2-Oxo-quazepam; GABA receptors (Corda, M.G. (169) 205)

[^{3}H]Spiroperidol binding
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatum; [^{3}H]Dopamine release; [^{3}H]Acetylcholine release; (Rat) (Kurstjens, N.P. (169) 147)

Splanchnic artery occlusion
Peptidoleukotriene; SK&F 104353; Myocardial depressant factor; Hematocrit; Cathepsin D (Lento, P.H. (165) 241)

Spleen
Noradrenaline; Neuropeptide Y; Adrenoceptors; Vasoconstriction; (Transmitter release) (Lundberg, J.M. (163) 103)

Spontaneously hypertensive rat (SHR)
Purinergic modulation; Wistar-Kyoto rat (WKY); Portal vein (rat) (Reilly, W.M. (160) 283)

Sprague-Dawley rat (SD); Wistar-Kyoto rat (WKY); Cholinesterase; Muscarinic receptors; Dopamine receptors (Lim, D.K. (165) 279)

Histamine; Cardiac arrhythmias; Hypertension; Myocardial hypertrophy (Cameron, J.S. (169) 23)

Thromboxane synthetase inhibitor; Cerebral ischemia; Cerebral metabolism (Sadoshima, S. (169) 75)

Furosemide; Loop diuretics; Hemodynamic response (acute); Sinoaortic baroreceptors (Janssen, B.J.A. (170) 1)

Sprague-Dawley rat (SD)
Wistar-Kyoto rat (WKY); Spontaneously hypertensive rat (SHR); Cholinesterase; Muscarinic receptors; Dopamine receptors (Lim, D.K. (165) 279)

SR 95639A
Muscarinic M_1 receptors; Sympathetic ganglion; Turning behaviour (Schumacher, C. (166) 139)

Stannous chloride
Ca^{2+} entry; Ca^{2+} channel; Motor nerve terminal; Transmitter release; (Frog) (Hattori, T. (166) 527)

Startle
MDEA (N-ethyl-3,4-methylenedioxyamphetamine); MDMA (methylenedioxymethamphetamine); Prepulse inhibition; (Rat) (Mansbach, R.S. (167) 49)

Stereoisomers
Microdialysis; Dopamine release; Dopamine receptor agonists; Transdermal application; Oral administration (Timmerman, W. (162) 143)

Stereoselectivity
8-OH-DPAT; $5\text{-}HT_{1A}$ receptors; Behaviour; Partial agonists; (+)ALK-3 ((+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin); (Rat) (Hjorth, S. (170) 269)

Stereotyped behaviour
Ataxia; Dopamine turnover; MK-801; Phencyclidine (PCP); 5-HT uptake; (Rat) (Hiramatsu, M. (166) 359)

Stereotypy
Dopamine D-1 receptor subtypes; Dopamine D-2 receptor subtypes; SK&F 38393; LY171555; SCH 23390; Raclopride; Hypothermia; Adrenocortical hormones; Adrenalectomy; (Rat) (Faunt, J.E. (162) 237)

Dopamine D-1 receptor antagonists; A-69024; Tetrahydroisoquinoline; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; $5\text{-}HT_{1C}$; DOPA accumulation; Catalepsy; Rotation; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

γ-Aminobutyric acid (GABA); Dopamine; Haloperidol treatment; Convulsions (Sandoval, M.R.L. (167) 117)

B-HT 920; Yohimbine; Idazoxan; Dopamine receptor agonists (Meltzer, L.T. (170) 105)

Steroids
Anticonvulsants; Seizures; Progesterone metabolite; GABA receptors; Cl^- ionophore (Belelli, D. (166) 325)

Chloride ionophore; Benzodiazepines; GABA receptors; Progesterone metabolites; Clonazepam; (Partial agonists) (Belelli, D. (167) 173)

Flunitrazepam; Forebrain; Autoradiography (quantitative) (Canonaco, M. (170) 95)

Stomach
Calcitonin gene-related peptide (CGRP); Ca^{2+} channels; Prostaglandins; (Rat, Guinea pig) (Katsoulis, S. (161) 129)

Smooth muscle; Capsaicin (8-methyl-N-vanillyl-6-nonenamide); Tachykinins; Calcitonin gene-related peptide (CGRP) (Holzer-Petsche, U. (162) 29)

$GABA_A$ receptors; Gastric ulcer; Gastric mucoprotection; [^{3}H]GABA binding; [^{3}H]Muscimol binding; (Rat) (Erdö, S.L. (165) 79)

Streptozotocin
Pancreatic islets; Islet blood flow; Pancreatic blood flow; Diabetic rats (Jansson, L. (161) 79)

Stress (acute)
[^{3}H]Imipramine binding; Phosphatidylcholine; Phosphatidylserine; Tricyclic antidepressants (Stockert, M. (160) 11)

Stress (chronic)
γ-Endorphin; β-Endorphin; Opioid peptides (Young, E.A. (167) 229)

Stress ulcer
Ca^{2+} channel blockers; Gastric secretion; Verapamil; Nitrendipine; Diltiazem; Ethanol ulcer; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Striatal neurons
Quisqualate receptors; Kainate receptors; Glutamate; GABA release; (Primary culture) (Pin, J.-P. (172) 81)

Striatal slices
γ-Aminobutyric acid (GABA); Aspartate; Glutamate; Apomorphine; Haloperidol; (K^+-evoked endogenous release) (Umeda, Y. (163) 291)

Striatal synaptosomes
MPP^+ (1-methyl-4-phenylpyridinium); Dopamine uptake; (Neurotoxicity) (Johnson, E.A. (166) 65)

Striatum
Basal ganglia; Cocaine; Dopamine; GBR 12909; Neurotensin; Substantia nigra (Hanson, G.R. (160) 23)

Neurotensin; Dopamine receptors; Nucleus accumbens (Merchant, K.M. (160) 409)

5-HT receptors; Dopamine receptors; Na^+,K^+-ATPase; Hippocampus; Central nervous system (CNS); Spaceflight (Miller, J.D. (161) 165)

Homovanillic acid; Prefrontal cortex; Haloperidol; (Tolerance) (Chang, W.-H. (162) 151)

OM-853; Dopamine release; Muscarinic receptors (Koda, H. (162) 501)

3,4-Methylenedioxymethamphetamine (MDMA); Glucocorticoid receptors; 5-Hydroxytryptamine; Corticosterone; Neurotoxicity (Lowy, M.T. (163) 157)

l-Fenfluramine; l-Norfenfluramine; Dopamine metabolism; Acetylcholine release in vivo; Nucleus accumbens (Invernizzi, R. (164) 241)

Cholecystokinin (CCK); CR 1409; Fronto-parietal cortex; Acetylcholine; Dopamine; 3-Methoxytyramine (Cosi, C. (165) 209)

Catecholestrogens; Estrogens; Antiestrogens; Tamoxifen; Dopamine receptor supersensitivity (Ferretti, C. (166) 149)

Corticotropin-releasing factor; Dopamine synthesis; Synaptosomes; Ca^{2+}; Protein kinase C; (Rat) (Olianas, M.C. (166) 165)

BHT-920; Quinpirole; Dopamine D-1 receptors; Dopamine D-2 receptors; (Rat) (Ferré, S. (166) 303)

Dopamine D-1 receptors (solubilized); Polyethylene glycol; [^{3}H]SCH 23390; Guanine nucleotide (GTP); (Rat) (Zhang, X. (166) 401)

Dopamine release; N-Methyl-D-aspartate (NMDA); Glycine; Kynurenic acid; (Rat) (Krebs, M.-O. (166) 567)

Acetylcholine; Dopamine; (Recovery of function, Release, Slices) (MacKenzie, R.G. (168) 43)

Adenosine; Adenosine A_2 receptors; Autoradiography (Jarvis, M.F. (168) 243)

Adenylate cyclase; Hippocampus; Ca^{2+}; Lithium (Mørk, A. (168) 347)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); [^{3}H]-Dopamine release; [^{3}H]Acetylcholine release; [^{3}H]Spiroperidol binding; (Rat) (Kurstjens, N.P. (169) 147)

Amphetamine; Haloperidol; Dopamine; Hippocampus; Calmodulin translocation (Popov, N. (172) 205)

Protein phosphorylation; DARPP-32; Dopamine D-1 receptor; (Pharmacological modulation) (Di Luca, M. (172) 321)

Strontium
Smooth muscle; Acetylcholine receptors (Macara, B. (162) 51)

Submandibular acini
^{22}Na; [^{3}H]QNB binding; Amiloride; Furosemide (Martinez, J.R. (164) 335)

Submaxillary gland
4-DAMP (4-diphenylacetoxy-N-methyl-piperidine methiodide); Muscarinic receptors; Cortex; Heart (Michel, A.D. (166) 459)

Submucosal neurons
Thyrotropin-releasing hormone (TRH); Intestinal secretion; Ileum; (Ion transport) (Carey, H.V. (160) 183)

Submucous plexus
Ileal motility; Substance P; (Guinea-pig) (Jin, J.-G. (161) 73)

Substance P
Smooth muscle (intestinal); Signal-contraction coupling; Histamine; K^+ depolarization; Diacylglycerol; (Guinea-pig) (Lippe, I.T. (159) 1)

Antinociception; Excitatory amino acids; Phencyclidine receptors (DeLander, G.E. (159) 149)

Salivary secretion; Tachykinins; (Dimeric analogue) (Higuchi, Y. (160) 413)

Ileal motility; Submucous plexus; (Guinea-pig) (Jin, J.-G. (161) 73)

Haloperidol; Neurokinin A; Tachykinin; Substantia nigra; Microdialysis (Lindefors, N. (161) 95)

Neurokinin A; γ-PPT-(72-92)-NH_2; Neuropeptide K; Tachykinins; Salivation (Takeda, Y. (161) 267)

Airway hyperreactivity; Bradykinin; Cholinergic system (Omini, C. (163) 195)

Gallbladder; Tachykinins; Capsaicin; Neurokinin A; Tachykinin receptors; Thiorphan; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Trachea; Tachykinins; Neurokinin A; Neurokinin B; Tachykinin receptors; (Hamster) (Maggi, C.A. (166) 435)

Histamine; Kinin; Mast cells (peritoneal) (Devillier, P. (168) 53)

Capsaicin; Ruthenium red; Primary afferent neurones; Ileum (guinea-pig) (Chahl, L.A. (169) 241)

Substance P binding sites
Vas deferens (guinea-pig); Capsaicin (8-methyl-N-vanillyl-6-nonenamide) (Mussap, C.J. (168) 337)

Substantia nigra
Basal ganglia; Cocaine; Dopamine; GBR 12909; Neurotensin; Striatum (Hanson, G.R. (160) 23)

Haloperidol; Neurokinin A; Substance P; Tachykinin; Microdialysis (Lindefors, N. (161) 95)

Dopamine; Antipsychotic agents; 5-HT_3 receptor antagonists; (Electrophysiology) (Sorensen, S.M. (163) 115)

Succinate transport
Kidney; Mitochondria; Valproate; Membrane (Rumbach, L. (164) 577)

Sufentanil
Morphine; DADLE ([D-Ala^2,D-Leu^5]enkephalin); DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin; Opioid dependence; Intrathecal infusion (Stevens, C.W. (166) 467)

Sulfasalazine
Sulfasalazine analogues; Leukotrienes; Lipoxygenase; Cyclooxygenase; Thromboxane synthase (Tornhamre, S. (169) 225)

Sulfasalazine analogues
Sulfasalazine; Leukotrienes; Lipoxygenase; Cyclooxygenase; Thromboxane synthase (Tornhamre, S. (169) 225)

Sulfhydryl compounds
Dithiothreitol; Coronary artery; Smooth muscle (vascular); Ca^{2+} ion; (Dog) (Fujioka, H. (166) 13)

Sulfonylureas
DDT_1 MF-2 cells; ATP; G protein; (Patch clamp) (Molleman, A. (169) 167)

K^+ channels; Endothelium; Quinine; Pinacidil (Ramboer, I. (171) 251)

Sulpiride
Apomorphine; Quinpirole; SCH 23390; SK&F 38393; Jaw movements (Koshikawa, N. (163) 227)

Antipsychotic substances; Dopamine; Haloperidol; Desenkephalin-γ-endorphin (DEγE); Brain regions (Van Ree, J.M. (166) 441)

Sumatriptan (GR 43175)
5-HT_{1B} binding sites; 5-HT_{1D} binding sites (Peroutka, S.J. (163) 133)

Supersensitivity
Opioids; Naltrexone; Upregulation; Analgesia; Morphine; (Dose dependence) (Yoburn, B.C. (170) 193)

Supraspinal
p-Octopamine; Analgesia (non-opioid); Spinal; (Mouse) (Raffa, R.B. (169) 317)

Supraspinal analgesia
β-Funaltrexamine; Opioids; Periaqueductal gray; δ Receptors; μ Receptors; (Binding) (Sánchez-Blázquez, P. (159) 9)

N-Ethylmaleimide; Opioids; Opioid receptors; (Agonist efficacy) (Sánchez-Blázquez, P. (166) 193)

Suramin
Smooth muscle; P_2-purinoceptors; α_1-Adrenoceptors (Den Hertog, A. (166) 531)

Swallow
Clozapine; Ketamine; Dyskinesia; Tongue protrusion; Tongue retrusion (Marco, L.A. (164) 171)

Sympathetic activity (renal)
Ventrolateral pressor area; Methiothepin; (±)-Pindolol; (±) 8-OH-DPAT (8-hydroxy-2(di-n-propylamino)tetralin) (Laubie, M. (160) 385)

Sympathetic ganglion
Muscarinic receptors; (Rat) (Newberry, N.R. (163) 237)

Pertussis toxins; GABA receptors; (Rat) (Newberry, N.R. (163) 245)

Muscarinic M_1 receptors; SR 95639A; Turning behaviour (Schumacher, C. (166) 139)

Telenzepine; Muscarinic receptors; EPSP (slow); (Ligand binding) (Galvan, M. (167) 1)

Sympathetic ganglionic transmission
Dopamine receptors; Blood pressure; (Presynaptic receptors) (Dlewati, A. (164) 197)

Sympathetic nervous system
Autoradiography; Kidney; Noradrenaline; Adrenoceptors; Renal nerve (Sripairojthikoon, W. (167) 355)

Epinephrine; Norepinephrine; α_2-Adrenoceptors (Szemeredi, K. (170) 53)

Sympathetic neurotransmission
Benzodiazepines; Atrial responses; Norepinephrine; (Peripheral effects) (Elgoyhen, B. (164) 467)

Sympathetic-parasympathetic interaction
Sinus node pacemaker activity; Atrial contractility; cAMP; Ca^{2+} channels; Atrium (isolated, canine) (Furukawa, Y. (161) 1)

Sympathomimetic activity (intrinsic)
β-Adrenoceptor antagonists; β_1 Selectivity; Noradrenaline; Heart cells (Reithmann, C. (170) 243)

Synaptoneurosomes
Chlormethiazole; t-Butylbicyclophosphorothionate; Cl^- uptake; Benzodiazepines; γ-Aminobutyric acid (GABA) (Moody, E.J. (164) 153)

Synaptosomes
α-Methyldopa; 5-Hydroxytryptamine (5-HT); α-Methyldopamine (Wolf, W.A. (163) 43)

Corticotropin-releasing factor; Dopamine synthesis; Ca^{2+}; Protein kinase C; Striatum; (Rat) (Olianas, M.C. (166) 165)

Synovial cells
Interleukin-1; Bradykinin; Tumour necrosis factor; Prostaglandin E_2 (O'Neill, L.A.J. (166) 131)

Synthetic gene
HIV-1; Protease; Protein dimer; Mutagenesis (Guenet, C. (172) 443)

Tachykinin receptors
Gallbladder; Tachykinins; Capsaicin; Substance P; Neurokinin A; Thiorphan; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Trachea; Tachykinins; Substance P; Neurokinin A; Neurokinin B; (Hamster) (Maggi, C.A. (166) 435)

Tachykinins
Substance P; Salivary secretion; (Dimeric analogue) (Higuchi, Y. (160) 413)

Amphetamine; Neurokinin A; Nucleus accumbens; Caudate-putamen; Microdialysis (Lindefors, N. (160) 417)

Haloperidol; Neurokinin A; Substance P; Substantia nigra; Microdialysis (Lindefors, N. (161) 95)

Substance P; Neurokinin A; γ-PPT-(72-92)-NH_2; Neuropeptide K; Salivation (Takeda, Y. (161) 267)

Stomach; Smooth muscle; Capsaicin (8-methyl-N-vanillyl-6-nonenamide); Calcitonin gene-related peptide (CGRP) (Holzer-Petsche, U. (162) 29)

Gallbladder; Capsaicin; Substance P; Neurokinin A; Tachykinin receptors; Thiorphan; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Trachea; Substance P; Neurokinin A; Neurokinin B; Tachykinin receptors; (Hamster) (Maggi, C.A. (166) 435)

Tail artery (rat)
α-Adrenoceptor subtypes (postsynaptic); Reserpine; Ca^{2+} influx (Abe, K. (171) 59)

Tail flick
BAY k 8644; Dihydropyridine-sensitive Ca^{2+} channels; (Neurotransmitter metabolites, Intracerebroventricular administration) (Bourson, A. (160) 339)

Analgesia; Opioid receptors; Naloxonazine; ICI 154,129; β-Funaltrexamine; Opioid peptides; μ_1 Opioid receptors; μ_2 Opioid receptors (Paul, D. (168) 307)

Tamoxifen
Catecholestrogens; Estrogens; Antiestrogens; Dopamine receptor supersensitivity; Striatum (Ferretti, C. (166) 149)

Tardive dyskinesia
Oral dyskinesia; Haloperidol (intermittent); Neuroleptic sensitization; Amygdala kindling; (Drug holidays, Rat) (Glenthøj, B. (164) 393)

Target size analysis
NMDA receptors; σ Sites (Wong, E.H.F. (172) 493)

Taurine
Blood pressure; Heart rate; Ventilation; Pentobarbitone anaesthesia (Petty, M.A. (162) 359)

TBPS (t-butylbicyclophosphorothionate)
Kindling seizures; FG 7142; GABA (γ-aminobutyric acid); Benzodiazepines; Cl^- channels; (Autoradiography) (Lewin, E. (160) 101)

Chlormethiazole; Cl^- uptake; Synaptoneurosomes; Benzodiazepines; γ-Aminobutyric acid (GABA) (Moody, E.J. (164) 153)

Membrane fluidity; A_2C (2-[2-methoxyethoxy]-ethyl 8-[cis-2-n-octylcyclopropyl]-octanoate); Anesthetics; Temperature; GABA-activated chloride channels (Buck, K.J. (160) 359)

[^{35}S]TBPS binding
[^{3}H]GABA binding; GABA-dependent $^{36}Cl^-$ flux; Zolpidem; Benzodiazepine receptors (type I, type II) (Biggio, G. (161) 173)

$GABA_A$ receptors; Cl^- channels; Isoniazid; (Modulators of GABAergic synapses) (Serra, M. (164) 385)

TCP (N-1[2-thienyl]cyclohexyl)3,4-piperidine
N-Methyl-D-aspartate (NMDA); NMDA-receptor complex; 3-(±)-2-(Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP); Glycine; (Molecular target size, Receptors) (Honoré, T. (172) 239)

[^{3}H]TCP binding
Na^+ channels (voltage-sensitive); $^{22}Na^+$ uptake (synaptosomal); Veratridine; [^{3}H]Batrachotoxin binding; PCP-like drugs; PCP receptors; Anaesthetics (Allaoua, H. (163) 327)

Telenzepine
Muscarinic receptor subtypes; Pirenzepine; Ulcer model (Schudt, C. (165) 87)

Muscarinic receptors; Sympathetic ganglion; EPSP (slow); (Ligand binding) (Galvan, M. (167) 1)

Temperature
Membrane fluidity; A_2C (2-[2-methoxyethoxy]-ethyl 8-[cis-2-n-octylcyclopropyl]-octanoate); Anesthetics; TBPS (t-butylbicyclophosphorothionate); GABA-activated chloride channels (Buck, K.J. (160) 359)

Phencyclidine (PCP); Opiates; Naloxone; Hypothermia; Dependence (Pechnick, R.N. (166) 295)

Testicular capsule
Oxytocin; Ca^{2+} channel blockers; Calmodulin antagonists; (Intracellular calcium antagonists) (Sánchez, M. (168) 169)

Testosterone
Leydig cells; Growth hormone; Insulin-like growth factor I (IGF-I) (Horikawa, R. (166) 87)

Tetrabenazine
Imipramine; α_1-Adrenoceptors; β-Adrenoceptors; 5-HT_2 receptors; Phosphoinositide hydrolysis (Butler, P.D. (160) 93)

Catecholamines; Corpus striatum; Glycoconjugates; Lectins; (Chromatography, Affinity) (Vincent, M.S. (172) 317)

Tetraethylammonium
cAMP; cGMP; Cyclic nucleotides; Trachealis (Chideckel, E.W. (166) 367)

Cromakalim (BRL 34915); Hippocampus; K^+ channels; (Whole cell patch clamp) (Politi, D.M.T. (168) 7)

Δ^1-Tetrahydrocannabinol
Cisplatin; Emesis; Cannabinoid; 7-Hydroxy-Δ^6-tetrahydrocannabinol-dimethylheptyl; Cupric chloride; HU-211; (Pigeon) (Feigenbaum, J.J. (169) 159)

Tetrahydroisoquinoline
Dopamine D-1 receptor antagonists; A-69024; Adenylate cyclase; Dopamine D-1 receptors; Dopamine D-2 receptors; 5-HT_{1C}; DOPA accumulation; Catalepsy; Rotation; Stereotypy; Locomotor activity; Neuroleptics; (Receptor binding) (Kerkman, D.J. (166) 481)

Tetramethylpyrazine
Phenylephrine; Aorta; Endothelium; (High potassium, Rat) (Wu, C.-C. (169) 189)

TFMPP (1-[3-(trifluoromethyl)phenyl]piperazine)
Anxiety; mCPP (1-(3-chlorophenyl)piperazine); 5-HT_{1C} receptors (Kennett, G.A. (164) 445)

5-HT_{1B} receptor subtypes; Ventral tegmental area; Forced swimming test; Desipramine; (Rat) (Cervo, L. (171) 119)

THA (9-amino-1,2,3,4-tetrahydroacridine)
Ion channels; Node of Ranvier (Elinder, F. (164) 599)

THAO (5,6,7,8-tetrahydro-4H-isoxazolo[4,5-c]azepin-3-ol)
Glia; GABA uptake; Seizures; Pentylenetetrazol (PTZ); Isonicotinic acid hydrazide (Gonsalves, S.F. (168) 265)

Theophylline
Positive staircase; Positive inotropism; Ca^{2+}; (Post-rest potentiation) (Zavecz, J.H. (160) 187)

Thermal injury
Corticotropin-releasing factor (CRF); Sauvagine; Urotensin I; CRF-(9-41) antagonist (α-helical); Anti-inflammatory response; Vascular permeability (Wei, E.T. (168) 81)

[Thi^{5,8},D-Phe^7]bradykinin
Paw edema (rat); Mast cell degranulation (Wang, J.-P. (161) 143)

Thioperamide
(R)α-Methylhistamine; Histamine turnover; [^{3}H]Histamine synthesis; N$^\tau$-Methylhistamine (Garbarg, M. (164) 1)

Thioridazine
α_1-Adrenoceptors; α_2-Adrenoceptors; Pithed rat (Cuffi, M.L. (168) 111)

Thiorphan
Antidepressants; Bestatin; Iprindole; Imipramine; Forced swimming test; Motor activity; Opioids (Del Carmen de Felipe, M. (159) 175)

Gallbladder; Tachykinins; Capsaicin; Substance P; Neurokinin A; Tachykinin receptors; Captopril; (Guinea-pig) (Maggi, C.A. (165) 51)

Morphine withdrawal; Naloxone; Enkephalinase inhibitors; Kelatorphan (Maldonado, R. (165) 199)

Enkephalinase; Spinal cord; [Met^5]enkephalin; SCH 34826 (Yaksh, T.L. (167) 367)

Opioid receptors; μ Opioid ligands; δ Opioid ligands; Enkephalins (endogenous); Peptidase inhibitors; RB38A; Enkephalin metabolism; [D-Thr^2,Leu^5]enkephalyl-Thr (DTLET); [D-Ala^2,MePhe^4,Gly-ol^5]enkephalin (DAGO); (Receptor binding in vivo) (Meucci, E. (171) 167)

Thrombin
Bradykinin; Fibroblast; Diacylglycerol; (Homologous desensitization) (Burch, R.M. (168) 39)

Thromboxane A_2
Trachea; Cigarette smoke; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Cortisol; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Bronchus (in vitro, human); Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2 receptors; Thromboxane A_2 antagonists (Armour, C.L. (165) 215)

Platelets; Prostaglandins; (Receptors) (Modesti, P.A. (169) 85)

Thromboxane analogs
Endothelin; Thromboxane antagonists; Kidney (isolated, rat); Glomerular hemodynamics; Tubular function (Ferrario, R.G. (171) 127)

Thromboxane antagonists
Endothelin; Thromboxane analogs; Kidney (isolated, rat); Glomerular hemodynamics; Tubular function (Ferrario, R.G. (171) 127)

Thromboxane A_2/prostaglandin endoperoxide receptor
Platelet aggregation; Coronary thrombosis; Thromboxane A_2/prostaglandin endoperoxide antagonists (Kondo, K. (163) 253)

Thromboxane A_2/prostaglandin endoperoxide receptor antagonists
Thromboxane A_2/prostaglandin endoperoxide receptor; Platelet aggregation; Coronary thrombosis (Kondo, K. (163) 253)

Thromboxane A_2/prostaglandin endoperoxide receptor; Cerebral vasospasm (Kondo, K. (168) 193)

Cerebral vasospasm; Thromboxane A_2/prostaglandin endoperoxide receptor antagonists (Kondo, K. (168) 193)

Thromboxane A_2/prostaglandin H_2 receptors (pig)
Vascular system; Platelets; Coronary artery (contraction); Platelet aggregation; (Ligand binding) (Mihara, S. (160) 313)

Thromboxane A_2 receptor antagonists
Bronchus (in vitro, human); Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2 receptors (Armour, C.L. (165) 215)

S-145; Vascular actions; Platelet actions; (Kinetic binding parameters) (Mihara, S. (171) 179)

Thromboxane A_2 receptors
Phosphoinositide hydrolysis; GTP binding protein; Pertussis toxin (IAP) (Nakahata, N. (162) 407)

Bronchus (in vitro, human); Thromboxane A_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2 antagonists (Armour, C.L. (165) 215)

Thromboxane B_2
Pulmonary parenchymal strips; Smooth muscle (vascular); Leukotriene receptors (Stahl, G.L. (163) 55)

Platelet activating factor (PAF-acether, PAF); Alveolar macrophages; Leukotriene B_4 (LTB_4); BW 137C; BW 755C; 5-Lipoxygenase inhibitors; Indomethacin (Fitzgerald, M.F. (164) 539)

Thromboxane synthase
Sulfasalazine; Sulfasalazine analogues; Leukotrienes; Lipoxygenase; Cyclooxygenase (Tornhamre, S. (169) 225)

Thromboxane synthetase inhibitor
Cerebral ischemia; Cerebral metabolism; Spontaneously hypertensive rat (SHR) (Sadoshima, S. (169) 75)

Thymus gland
Atrial natriuretic peptide (ANP); Pituitary gland; (Receptor, classification, Olfactory bulb) (Agui, T. (162) 301)

Thyroid hormone
(Na^+,K^+)-ATPase; Noradrenaline (metabolic effects); Ouabain binding; 6-Hydroxydopamine (Swann, A.C. (169) 275)

Thyrotropin-releasing hormone (TRH)
Intestinal secretion; Ileum; Submucosal neurons; (Ion transport) (Carey, H.V. (160) 183)

YM-14673; Ataxia; Cytosine arabinoside (Yamamoto, M. (166) 545)

Pituitary; Ca^{2+} mobilization; Diacylglycerol; 1-Oleyl-2-acetyl glycerol (OAG); R59022 (Mollard, P. (172) 71)

Tolerance
GABA (γ-aminobutyric acid); Benzodiazepines; Diazepam (chronic); Chloride influx (J. Marley, R. (159) 217)

U-50,488H; Morphine; κ Opioid receptors; Analgesia; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Midazolam; βCCE (3-carboethoxy-β-carboline hydrochloride); Flumazenil; (Sensitization, Baboon) (Sannerud, C.A. (167) 333)

Morphine; Spinal cord; Opioids; Naloxone; Withdrawal (Bell, J.A. (168) 101)

Microdialysis; Nucleus accumbens; Dopamine; Nicotine; (Rat) (Damsma, G. (168) 363)

Benzodiazepines (chronic); GABA; (Agonist efficacy) (Hernandez, T.D. (170) 145)

Tolerance-dependence
Morphine; Abstinence; 5-HT_2 receptors; Brain regions; Spinal cord (Gulati, A. (167) 185)

Tongue protrusion
Clozapine; Ketamine; Dyskinesia; Tongue retrusion; Swallow (Marco, L.A. (164) 171)

Tongue retrusion
Clozapine; Ketamine; Dyskinesia; Tongue protrusion; Swallow (Marco, L.A. (164) 171)

Torbafylline
Skeletal muscle; Ischaemia; Microcirculation; Peripheral vascular disease; (Performance) (Okyayuz-Baklouti, I. (166) 75)

Trachea
Cigarette smoke; Prostaglandin I_2; Prostaglandin $F_{2\alpha}$; Prostaglandin E_2; Thromboxane A_2; Cortisol; Muscarinic stimulation; Ca^{2+} (Jeremy, J.Y. (160) 107)

Endothelin; Bronchi (main); Airway epithelium; (Guinea-pig) (Maggi, C.A. (160) 179)

Leukotrienes; ICI 198,615; Antigen (Redkar-Brown, D.G. (165) 113)

Endothelin; Heart; Blood vessels; Uterus; Vas deferens; Platelets; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Tachykinins; Substance P; Neurokinin A; Neurokinin B; Tachykinin receptors; (Hamster) (Maggi, C.A. (166) 435)

Pinacidil; K^+ channels; Smooth muscle (vascular) (Mellemkjær, S. (167) 275)

Non-adrenergic, non-cholinergic (NANC); Vasoactive intestinal peptide (VIP); Epithelium; Endopeptidase (neutral) (Rhoden, K.J. (171) 247)

Trachea (guinea-pig)
Endothelin; Airway epithelium; Peptidase inhibitors; Indomethacin; Captopril (Hay, D.W.P. (171) 241)

Trachealis
Vincamine; Vinpocetine; Indomethacin; Ca^{2+}; (Guinea pig) (Machová, J. (162) 387)

Lung parenchyma; Sensitized guinea-pig; Indomethacin; Asthma (experimental); (Non-specific hyperresponsiveness, Guinea-pig) (Cortijo, J. (162) 467)

cAMP; cGMP; Cyclic nucleotides; Tetraethylammonium (Chideckel, E.W. (166) 367)

Transdermal application
Microdialysis; Dopamine release; Stereoisomers; Dopamine receptor agonists; Oral administration (Timmerman, W. (162) 143)

Transmembrane potential
Myocardium (isolated); Contractility; Ca^{2+} action potential; Na^+,K^+-ATPase; Methylmercury; Chlormerodrin; Bromomercurihydroxypropane; p-Chloromercuribenzoic acid (Halbach, S. (167) 255)

Transmitter release
Stannous chloride; Ca^{2+} entry; Ca^{2+} channel; Motor nerve terminal; (Frog) (Hattori, T. (166) 527)

G-proteins; K^+ conductance; Pyramidal cells; cAMP (Fredholm, B.B. (172) 249)

Tranylcypromine
α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Clorgyline; Cocaine; Protriptyline; Clonidine; Yohimbine (Giralt, M.T. (164) 455)

TRH analog (fluorinated)
(Affinity, Receptors) (Vonhof, S. (164) 77)

Tricyclic antidepressants
Stress (acute); [^{3}H]Imipramine binding; Phosphatidylcholine; Phosphatidylserine (Stockert, M. (160) 11)

Trigeminal ganglion
Antiinflammatory drugs; Dura mater; Neurogenic inflammation (Buzzi, M.G. (165) 251)

Tripelennamine
Reward threshold; Brain stimulation reward; Pentazocine; Nalbuphine; Physical dependence (Huston-Lyons, D. (169) 153)

Tryptophan hydroxylase
Adrenalectomy; Corticosterone; 3,4-Methylenedioxymethamphetamine (MDMA); Serotonin (5-HT); (Neurotoxicity) (Johnson, M. (161) 181)

MK-801; Methamphetamine; MDMA neurotoxicity (Johnson, M. (165) 315)

Tubocurarine
Acetylcholine receptors; Acetylcholine release; Ca^{2+} channel blockers; Verapamil (Hong, S.J. (162) 11)

Tubular function
Endothelin; Thromboxane analogs; Thromboxane antagonists; Kidney (isolated, rat); Glomerular hemodynamics (Ferrario, R.G. (171) 127)

Tumour necrosis factor
Interleukin-1; Bradykinin; Synovial cells; Prostaglandin E_2 (O'Neill, L.A.J. (166) 131)

Turning
Dopamine; Dopamine D-1 receptors; Dopamine D-2 receptors; (Receptor supersensitivity) (Morelli, M. (162) 329)

Turning behaviour
Dopamine receptors (presynaptic, postsynaptic); Indolylbutylamines; Acetylcholine; Serotonin; 5-HT_{1A} receptors (Seyfried, C.A. (160) 31)

Muscarinic M_1 receptors; SR 95639A; Sympathetic ganglion (Schumacher, C. (166) 139)

Tyrode solution (Ca^{2+}-free)
ATP; Verapamil; Diltiazem; ^{45}Ca uptake (Bhat, M.B. (164) 163)

Tyrosine
Phenylalanine; Arterial pressure (mean); Heart rate; Phenethylamine; (Rat) (Yourick, D.L. (160) 219)

L-Tyrosine
Blood pressure; Heart rate; Tyrosine metabolism (Ekholm, S. (163) 209)

Blood pressure; Heart rate; Autonomic nervous system; Histamine receptors; Prostaglandin synthesis (Ekholm, S. (168) 145)

Tyrosine hydroxylase
Prolactin; DOPA (2,4-dihydroxyphenylalanine); DOPAC (3,4-dihydroxyphenylacetic acid); Striatum; Nucleus accumbens (Chen, J.-C. (166) 473)

Tyrosine metabolism
L-Tyrosine; Blood pressure; Heart rate (Ekholm, S. (163) 209)

U-46,619
Myocardial ischaemia (simulated); Coronary artery; Adenosine; 5-Hydroxytryptamine; Acetylcholine; Iloprost; (Sheep) (Kwan, Y.W. (168) 31)

U-50,488
Opiate receptors; κ Opioid receptors; U-69,593; (Enantiomers, cis diastereomer of U-50,488) (Rothman, R.B. (167) 345)

U-50,488H
Morphine; κ Opioid receptors; Tolerance; Analgesia; Hypothermia; Hyperthermia; [^{3}H]Ethylketocyclazocine; Brain; Spinal cord (Bhargava, H.N. (162) 257)

Dependence; Morphine; κ-Opioid agonists (Fukagawa, Y. (170) 47)

U-62,066E
κ Opioid receptor agonists; κ Opioid receptor antagonists; MR-2266; [Arg^8]vasopressin; Diuresis; Collecting duct; Water permeability (Imai, K.Y.M. (160) 229)

U-69,593
Opiate receptors; κ Opioid receptors; U-50,488; (Enantiomers, cis diastereomer of U-50,488) (Rothman, R.B. (167) 345)

UK 14,304
Bronchi; Neuropeptide Y; α-Adrenoceptors; Cholinergic contraction; Non-adrenergic, non-cholinergic (NANC) contraction (excitatory); Noradrenaline; Morphine; (Guinea-pig) (Matran, R. (163) 15)

[^{3}H]UK 14,304
α_{2A}-Adrenoceptors; [^{3}H]RX821002; [^{3}H]Yohimbine; [^{3}H]-Idazoxan; HT29 cell-line (Langin, D. (167) 95)

α_2-Adrenoceptors; Adipocytes; Lipolysis; [^{3}H]Yohimbine; [^{3}H]Idazoxan; [^{3}H]RX 821002; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

Ulcer
Gastric mucosa; Vasoconstrictors; Endothelium; Endothelin (Wallace, J.L. (167) 41)

Ulcer model
Muscarinic receptor subtypes; Telenzepine; Pirenzepine (Schudt, C. (165) 87)

Upregulation
Opioids; Naltrexone; Supersensitivity; Analgesia; Morphine; (Dose dependence) (Yoburn, B.C. (170) 193)

Urethra (rabbit)
[^{3}H]Idazoxan; [^{3}H]Rauwolscine; α_2-Adrenoceptors; Amiloride (Yablonsky, F. (164) 167)

Urinary kallikrein excretion
Atrial natriuretic peptide (ANP); Renal function (Lòpez, C. (168) 1)

Urine
Atrial natriuretic factor (ANF); Blood pressure; (Analogs, Receptors) (Song, D.L. (160) 141)

Urine formation
[Arg^8]vasopressin (AVP); Atrial natriuretic peptide (ANP); (Dog) (Hellebrekers, L.J. (164) 55)

Endothelin; Renal function; Renin secretion; (Anesthetized rat) (Matsumura, Y. (166) 577)

Urotensin I
Corticotropin-releasing factor (CRF); Sauvagine; CRF-(9-41) antagonist (α-helical); Anti-inflammatory response; Thermal injury; Vascular permeability (Wei, E.T. (168) 81)

Uterine artery
Vasoactive intestinal peptide (VIP); Vasodilatation; Vasoconstriction (Morris, J.L. (162) 375)

Uterine vasoconstriction
Ca^{2+} (extra-and intra-cellular); Ca^{2+} channels (L-type and T-type); Noradrenaline; Phorbol ester; K^+; Protein kinase C (Fallgren, B. (170) 61)

Uterus
Angiotensin II; Pregnancy; Phospholipase C; (Receptors, Rat) (Varol, F.G. (162) 37)

Endothelin; Heart; Blood vessels; Trachea; Vas deferens; Platelets; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

UV light
Smooth muscle; Lipid peroxidation; Nitrite; Ca^{2+}; cGMP (Nelemans, A. (172) 283)

Vacuous chewing
Dopamine; Dopamine D-1 receptor agonists; Grooming (Murray, A.M. (160) 377)

Vagotomy
Insulin; Glucagon; Somatostatin; Yohimbine; Propranolol; (Secretion) (Ribes, G. (162) 207)

Vagus nerve
5-HT_3 receptors; [^{3}H]GR65630; Area postrema; Brain (human); (Binding) (Kilpatrick, G.J. (159) 157)

Nicotine; Gastric motility; Nicotinic receptors (central) (Nagata, M. (163) 85)

Apomorphine; Dopamine; Dopamine DA2 receptors; Heart rate; Domperidone; SCH 23390 (Montastruc, P. (166) 511)

Capsaicin; Gastric distension; Gastric acid secretion; Histamine; Pentagastrin; (Cholinergic stimulation) (Raybould, H.E. (167) 237)

Valproate
Kidney; Mitochondria; Succinate transport; Membrane (Rumbach, L. (164) 577)

Vascular actions
S-145; Thromboxane A_2 receptor antagonists; Platelet actions; (Kinetic binding parameters) (Mihara, S. (171) 179)

Vascular bed (hindquarters)
Nisoldipine; Adrenergic responses; α_1-Adrenoceptors; α_2-Adrenoceptors (Minkes, R.K. (165) 259)

Vascular effects
5-Hydroxytryptamine (5-HT, serotonin); Ketanserin; 5-HT receptor antagonism; Pulmonary hypertension (Le Roux, M.G.J. (169) 269)

Vascular permeability
Leukocyte accumulation; Prostaglandins; Complement depletion (Hambleton, P.T. (163) 141)

Corticotropin-releasing factor (CRF); Sauvagine; Urotensin I; CRF-(9-41) antagonist (α-helical); Anti-inflammatory response; Thermal injury (Wei, E.T. (168) 81)

Vascular reactivity
Serotonin; Norepinephrine; Platelet adhesion; Eicosapentaenoic acid (Pfister, S.L. (161) 85)

Vascular resistance
Blood flow; Cardiac output; Endothelin; Hemodynamics (Ais, G. (170) 113)

Vascular resistance (regional)
Endothelin; Arterial pressure (Minkes, R.K. (163) 163)

Vascular segments
Ergotamine; Acetylcholine; Endothelium; Endothelium-derived relaxing factor (EDRF) (Demirel, E. (159) 195)

Vascular smooth muscle
Epidermal growth factor receptors; Epidermal growth factor-urogastrone; Vasopressins; Serotonin (Blay, J. (172) 1)

Vascular system
Thromboxane A_2/prostaglandin H_2 receptors (pig); Platelets; Coronary artery (contraction); Platelet aggregation; (Ligand binding) (Mihara, S. (160) 313)

Vascular tissue
Glucocorticoids; Dexamethasone; Vasocortin; Dextran oedema (Carnuccio, R. (166) 535)

Vas deferens
Bradykinin; P_2 purinoceptors; ATP receptors; Bradykinin B_2 receptors; Bradykinin antagonists (Donoso, M.V. (160) 263)

Carbachol; Cromakalim; Glibenclamide; (Rabbit) (Eltze, M. (161) 103)

ATP; Ca^{2+} antagonists; P_2 purinoceptors; (Guinea-pig) (Morishita, H. (164) 507)

Endothelin; Heart; Blood vessels; Uterus; Trachea; Platelets; Chromaffin cells; Neuromuscular junction; Neutrophils (Borges, R. (165) 223)

Noradrenaline contractions; Ryanodine; Nifedipine; Ca^{2+} mobilization; Methoxyverapamil; (Rat) (Vesperinas, G. (165) 309)

Monensin; Ouabain; K^+-free medium; Noradrenaline release; Ca^{2+}-evoked contraction; Na^+/Ca^{2+} exchange transport; (Guinea pig) (Katsuragi, T. (167) 147)

Vas deferens (guinea-pig)
Noradrenaline; Ca^{2+} currents; K^+ currents; Action potential (Mimata, T. (163) 181)

Substance P binding sites; Capsaicin (8-methyl-N-vanillyl-6-nonenamide) (Mussap, C.J. (168) 337)

Vas deferens (rabbit)
Muscarinic receptor subtypes; Muscarinic M_3-selective antagonists; Hexahydro-sila-difenidol analogues; p-Fluorohexahydro-sila-difenidol; Pirenzepine; Methoctramine; Ganglia (rat); (Structure-activity relationships) (Lambrecht, G. (168) 71)

Vas deferens (rat)
Adenosine agonists; Contractions (electrically evoked); Smooth muscle (non-vascular); (Presynaptic) (Major, T.C. (167) 323)

Vasoactive intestinal peptide (VIP)
Leukotriene; Platelet activating factor (PAF-acether, PAF); Lungs; Neuropeptides; Cyclic AMP (Di Marzo, V. (162) 115)

Vasodilatation; Vasoconstriction; Uterine artery (Morris, J.L. (162) 375)

Non-adrenergic, non-cholinergic (NANC); Trachea; Epithelium; Endopeptidase (neutral) (Rhoden, K.J. (171) 247)

Vasoactive intestinal polypeptide (VIP)
Ileum and colon (terminal); Anaesthetics (local); Nicotinic receptors; Non-adrenergic, non-cholinergic (NANC) system; (Electrical stimulation) (Pelckmans, P.A. (170) 235)

Vasoactive peptide
Vasoconstriction; Smooth muscle (vascular); Vasodilatation (Winquist, R.J. (163) 199)

Vasoconstriction
Endothelin; Hemodynamics (regional); Arterial pressure regulation (Han, S.P. (159) 303)

P_2 purinoceptors; Vasodilatation; Reactive blue 2; (In vivo) (Taylor, E.M. (161) 121)

Endothelin; Cerebral artery; Ca^{2+}; (Cat) (Saito, A. (162) 353)

Vasoactive intestinal peptide (VIP); Vasodilatation; Uterine artery (Morris, J.L. (162) 375)

Noradrenaline; Neuropeptide Y; Spleen; Adrenoceptors; (Transmitter release) (Lundberg, J.M. (163) 103)

Smooth muscle (vascular); Vasoactive peptide; Vasodilatation (Winquist, R.J. (163) 199)

Endothelin; Blood flow (regional); Vasodilation; (Rat) (Minkes, R.K. (165) 161)

Endothelin; Coronary circulation; Nifedipine; Langendorff preparation (Fukuda, K. (165) 301)

Endothelin; Positive inotropic effect; (Anesthetized dogs) (Kitayoshi, T. (166) 519)

Aclarubicin; Anthracycline antibiotics (Wakabayashi, I. (167) 177)

Endothelin-1; Artery; Vein; (Dog, Human) (Cocks, T.M. (171) 17)

Vasoconstrictors
Ulcer; Gastric mucosa; Endothelium; Endothelin (Wallace, J.L. (167) 41)

Vasocortin
Glucocorticoids; Dexamethasone; Vascular tissue; Dextran oedema (Carnuccio, R. (166) 535)

Vasodilatation
Smooth muscle (relaxation); Endothelium; cGMP; Nitric oxide; Nitrates (Buga, G.M. (161) 61)

P_2 purinoceptors; Vasoconstriction; Reactive blue 2; (In vivo) (Taylor, E.M. (161) 121)

Vasoactive intestinal peptide (VIP); Vasoconstriction; Uterine artery (Morris, J.L. (162) 375)

Vasoconstriction; Smooth muscle (vascular); Vasoactive peptide (Winquist, R.J. (163) 199)

Endothelin; Blood flow (regional); Vasoconstriction; (Rat) (Minkes, R.K. (165) 161)

Endothelin-1; Nitric oxide; N^G-Monomethyl-L-arginine (Gardiner, S.M. (171) 237)

Vasodilators
Protein phosphorylation; cAMP; cGMP; Platelets; Phosphatidylinositols (Waldmann, R. (159) 317)

Venous tone; Venodilators; Hexamethonium; Ganglionic blocking agents (D'Oyley, H.M. (162) 337)

Vasopressin
ACTH; cAMP; cGMP; Pituitary cells; AtT-20 corticotrophs; Corticotropin-releasing factor (CRF) (Koch, B. (158) 53)

Acetyl-vasopressin; [Cyt^6]vasopressin-(5-9); Passive avoidance behavior; Exploratory behavior; Body temperature (Kovács, G.L. (161) 27)

cAMP; Prostacyclin; Pertussis toxin; Angiotensin II (Vallotton, M.B. (166) 219)

Endothelin; Lymphatic vessels; Arteriole; Venule (Fortes, Z.B. (170) 69)

Neurohypophysis; Interleukin-1β (Christensen, J.D. (171) 233)

[^{3}H]Vasopressin
Vasopressin V_1 receptor antagonists (radioiodinated); Brain (rat); Kidney (rat); (Receptor autoradiography) (Gerstberger, R. (167) 105)

Vasopressin antagonists
Antidiuresis; (Rhesus monkey, Human) (Brooks, D.P. (160) 159)

Vasopressins
Vascular smooth muscle; Epidermal growth factor receptors; Epidermal growth factor-urogastrone; Serotonin (Blay, J. (172) 1)

Vasopressin V_1 receptor antagonists (radioiodinated)
[^{3}H]Vasopressin; Brain (rat); Kidney (rat); (Receptor autoradiography) (Gerstberger, R. (167) 105)

Vasorelaxation
Ethanol; Clonidine; Aorta; Endothelium; Smooth muscle (vascular); (Rat) (Hatake, K. (168) 277)

Des-Arg^9-bradykinin; Bradykinin receptors; Prostaglandins (Nwator, I.A.A. (170) 29)

Vasospasm
Hemolysate; Myogenic tone; Cerebral artery; Ca^{2+} antagonists; Endothelium (Nakayama, K. (169) 33)

Vein
Endothelin-1; BAY k 8644; Methylene blue; Angiotensin converting enzyme (D'Orleans-Juste, P. (165) 289)

Endothelin-1; Artery; Vasoconstriction; (Dog, Human) (Cocks, T.M. (171) 17)

Venodilators
Vasodilators; Venous tone; Hexamethonium; Ganglionic blocking agents (D'Oyley, H.M. (162) 337)

Venous tone
Vasodilators; Venodilators; Hexamethonium; Ganglionic blocking agents (D'Oyley, H.M. (162) 337)

Ventilation
Taurine; Blood pressure; Heart rate; Pentobarbitone anaesthesia (Petty, M.A. (162) 359)

Ventral tegmental area
Clonidine; Dopamine; Idazoxan; Mesolimbic dopamine system; (Firing pattern) (Grenhoff, J. (165) 11)

[^{14}C]2-Deoxyglucose; Antipsychotics; Cholinergic pathways; Desenkephalin-γ-endorphin; Glucose uptake; Local cerebral glucose utilization; Org 5878; (Neuropeptides) (Room, P. (171) 69)

TFMPP (1-(3-trifluoromethylphenyl)piperazine); 5-HT$_{1B}$ receptor subtypes; Forced swimming test; Desipramine; (Rat) (Cervo, L. (171) 119)

Ventricle (bovine, left)
Smooth muscle (bovine, tracheal); Muscarine receptor subtypes; (Allosteric modulation) (Roffel, A.F. (172) 61)

Ventricles
Na^+,K^+-ATPase; [^{3}H]Ouabain binding; Renal hypertension; DOCA/NaCl hypertension (Chen, C.-C. (169) 67)

Ventricular cells
Atrial cells; Slow inward calcium current; β_2-Adrenoceptors; Procaterol; ICI-118551 (Iijima, T. (163) 357)

Ventricular fibrillation threshold
Dantrolene sodium; Antiarrhythmia agents; Cardiac arrhythmia models; Coronary artery ligation; Aconitine; Ouabain (Brooks, R.R. (164) 521)

Ventrolateral pressor area
Sympathetic activity (renal); Methiothepin; (±)-Pindolol; (±) 8-OH-DPAT (8-hydroxy-2(di-n-propylamino)tetralin) (Laubie, M. (160) 385)

Venule
Endothelin; Vasopressin; Lymphatic vessels; Arteriole (Fortes, Z.B. (170) 69)

Verapamil
Ca^{2+} channel blockers; Stress ulcer; Gastric secretion; Nitrendipine; Diltiazem; Ethanol ulcer; Indomethacin; N-Ethylmaleimide (Glavin, G.B. (160) 323)

Sinoatrial conduction; Sinus automaticity; Bepridil; Diltiazem; Disopyramide (Kirchhof, C.J.H.J. (160) 369)

Acetylcholine receptors; Acetylcholine release; Ca^{2+} channel blockers; Tubocurarine (Hong, S.J. (162) 11)

ATP; Diltiazem; ^{45}Ca uptake; Tyrode solution (Ca^{2+}-free) (Bhat, M.B. (164) 163)

Veratridine
Na^+ channels (voltage-sensitive); $^{22}Na^+$ uptake (synaptosomal); [^{3}H]Batrachotoxin binding; [^{3}H]TCP binding; PCP-like drugs; PCP receptors; Anaesthetics (Allaoua, H. (163) 327)

Vincamine
Vinpocetine; Trachealis; Indomethacin; Ca^{2+}; (Guinea pig) (Machová, J. (162) 387)

Vincristine
GM1 ganglioside; Choline acetyltransferase; Choline uptake (high-affinity); Hippocampus (Di Patre, P.L. (162) 43)

Vinpocetine
Vincamine; Trachealis; Indomethacin; Ca^{2+}; (Guinea pig) (Machová, J. (162) 387)

γ-Vinyl GABA
Kindling; Epilepsy; GABA aminotransferase (Löscher, W. (163) 1)

Voltage clamp
Amiloride; Skeletal muscle; Ca^{2+}-dependent K^+ currents; (Frog) (Nasri-Sebdani, M. (171) 97)

Voltammetry (in vivo)
Dopamine; 5-Hydroxytryptamine (5-HT, serotonin); d,l-p-Chloroamphetamine; Amphetamine; (±)-3,4-Methylenedioxymethamphetamine (MDMA) (Gazzara, R.A. (168) 209)

Wakefulness
Sleep; REM (rapid eye movement) sleep; Quinpirole; YM-09151-2; Dopamine D-2 receptors (Monti, J.M. (169) 61)

Water permeability
κ Opioid receptor agonists; U-62,066E; κ Opioid receptor antagonists; MR-2266; [Arg^8]vasopressin; Diuresis; Collecting duct (Imai, K.Y.M. (160) 229)

Wet-dog shakes
5-HT$_2$ receptors; 5-HT uptake inhibitors; MAO inhibition; Spinal cord; (Receptor regulation) (Koshikawa, N. (164) 595)

Wistar-Kyoto rat (WKY)
Purinergic modulation; Spontaneously hypertensive rat (SHR); Portal vein (rat) (Reilly, W.M. (160) 283)

Sprague-Dawley rat (SD); Spontaneously hypertensive rat (SHR); Cholinesterase; Muscarinic receptors; Dopamine receptors (Lim, D.K. (165) 279)

Withdrawal
Morphine; Spinal cord; Tolerance; Opioids; Naloxone (Bell, J.A. (168) 101)

Butorphanol; Naloxone; Morphine dependence (Horan, P. (170) 265)

Withdrawal syndrome
Opiates; Methadone; Naloxone; (Rhesus monkey, Dependence) (Krystal, J.H. (160) 331)

Calcitonin; Morphine; Analgesia; Ca^{2+} (Clementi, G. (163) 175)

Xamoterol
Acebutolol; H142/08; H201/70; β-Adrenoceptor agonists (partial); Atrium (right, isolated); (Rat) (Abrahamsson, T. (164) 121)

Xerostomia
Cis-chlorprothixene; Cytosolic free Ca^{2+}; Cl^- loss; O_2 consumption (Undén, M. (164) 129)

Yawning
Apomorphine; Oxytocin; Oxytocin antagonists; Penile erection; (Rat) (Melis, M.R. (164) 565)

Ca^{2+} channel inhibitors; Penile erection; Apomorphine; Oxytocin; (Rat) (Argiolas, A. (166) 515)

YM-461
PAF antagonists; Airway hyperresponsiveness; (*Ascaris suum*, Late response, Allergic sheep) (Tomioka, K. (170) 209)

YM-09151-2
Sleep; Wakefulness; REM (rapid eye movement) sleep; Quinpirole; Dopamine D-2 receptors (Monti, J.M. (169) 61)

YM-12617
α-Adrenoceptor antagonists; Cell membrane permeability; Creatine kinase; High-energy phosphates; Hypoxia; Reoxygenation (Tanonaka, K. (165) 97)

YM-14673
Thyrotropin releasing hormone (TRH); Ataxia; Cytosine arabinoside (Yamamoto, M. (166) 545)

Yohimbine
Caffeine; Anxiety; (Rat) (Baldwin, H.A. (159) 211)

Insulin; Glucagon; Somatostatin; Propranolol; Vagotomy; (Secretion) (Ribes, G. (162) 207)

α_2-Adrenoceptors (brain); [^{3}H]Clonidine; α-Methyl-p-tyrosine; Reserpine; Clorgyline; Tranylcypromine; Cocaine; Protriptyline; Clonidine (Giralt, M.T. (164) 455)

B-HT 920; Idazoxan; Stereotypy; Dopamine receptor agonists (Meltzer, L.T. (170) 105)

[^{3}H]Yohimbine
α_2-Adrenoceptors; [^{3}H](−)-Adrenaline; HT29 cell-line; [^{3}H]Clonidine; Colon adenocarcinoma (Sénard, J.-M. (162) 225)

α_{2A}-Adrenoceptors; [^{3}H]RX821002; [^{3}H]Idazoxan; [^{3}H]-UK14,304; HT29 cell-line (Langin, D. (167) 95)

α_2-Adrenoceptors; Adipocytes; Lipolysis; [^{3}H]UK 14304; [^{3}H]Idazoxan; [^{3}H]RX 821002; Fat cells; 'Imidazoline-preferring sites'; (Hamster) (Saulnier-Blache, J.-S. (171) 145)

[^{3}H]Zacopride
5-HT_3 receptors; Opiate receptors; [^{3}H]Bremazocine; [^{3}H]Naloxone; Spinal cord; Capsaicin; (Rat) (Hamon, M. (164) 315)

Radiation inactivation; 5-HT_3 receptors; Cerebral cortex (rat); Molecular weight (Gozlan, H. (172) 497)

Zacopride (benzamides)
5-HT receptors; Ileum; (Binding sites, Radioligand assay, Rabbit) (Pinkus, L.M. (168) 355)

Zolpidem
[^{3}H]GABA binding; [^{35}S]TBPS binding; GABA-dependent $^{36}Cl^-$ flux; Benzodiazepine receptors (type I, type II) (Biggio, G. (161) 173)

(continued from page 2 of cover)

Sample references

periodicals:

Carlson, J.H., D.A. Bergstrom and J.R. Walters, 1987, Stimulation of both D-1 and D-2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study, Brain Res. 400, 205.

books:

Howard, C.R., 1986, Arena Viruses (Elsevier, Amsterdam) p. 89.

De Wied, D., 1987, Neuropeptide generation, CNS effects and mode of action, in: Pharmacology, Int. Congr. Series, Vol. 750, eds. M.J. Rand and C. Raper (Excerpta Medica, Amsterdam) p. 173.

5. Illustrations, graphs and tables (for new and explicit instructions see Notice to authors, in Vol. 175, No. 1, p. ix)

(a) Either the original drawings plus two good photographs or three good photographs of the drawings (on glossy paper and unmounted) should be submitted. PHOTOCOPIES MAY NOT BE USED INSTEAD OF ORIGINALS. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.

(b) It is important to allow for reduction to fit a single column, 7.5 cm wide, or at most a double column, maximally 16 cm wide (see example of original and reduced figure in Notice to authors, Vol. 175, No. 1, p. x). When possible, all lettering and key symbols should appear in the legend. Only the following standard characters, for which the printer has type, should be used: ○ ⊕ □ △ ◇ ★ open and solid. The use of Letraset is recommended for letters and numerals; alternatively India ink should be used. All letters and numerals appearing in a particular illustration should be of the same size. Comparable illustrations should carry letters, figures and numerals of the same size when reduced to 7.5 cm width. If the abscissa and the ordinate of a graph require labelling the label to the abscissa should be placed below the related numerals and the label to the ordinate should be placed horizontally and above the ordinate. If this requirement is not complied with, all labels will appear in the legend only.

(c) Graphs, electrocardiograms and oscillograms should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs intensified, and a sharp print obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the original records. Kymograph records on sooted paper should be reversed photographically to ensure records in black on a white background.

(d) Drawings of complicated chemical structures should be prepared in the same way as graphs.

(e) A calibration bar should be drawn on the micrographs instead of giving a magnification rate in the figure legend.

(f) All illustrations should be referred to as figures and numbered in arabic numerals.

(g) Legends to figures should make these comprehensible without reference to the text.

(h) Tables should be numbered separately in Arabic numerals (table 1, 2 etc.).

(i) Colour reproduction of illustrations is available at cost. Detailed information regarding the use of colour may be obtained from the publisher, at the time of submission of the manuscript to the editors.

PROOFS

One set of galley proofs will be sent to the author named on the title page (see 2). Proofs will usually be drawn on lower quality paper. Only printer's errors may be corrected; no changes in, or additions to, the edited manuscript will be allowed. Proofs should be returned within 48 hours preferably by telefax, 31 (20) 5803 454. If this period is exceeded no reminders will be sent, the manuscript will be read by the editorial staff of the publishers only and printed without the author's corrections. Authors of short and rapid communications will not receive galley proofs.

PAGE CHARGES AND REPRINTS

There will be no page charge. Authors of a full length paper will receive, together with the galley proofs, a reprint order form which must be completed and returned to the publisher with the proofs. Authors of short and rapid communications will receive a reprint order form but no proofs: this order form should be mailed to the publisher by return post. Reprints ordered AFTER THE JOURNAL HAS BEEN PRINTED will cost considerably more than those ordered immediately.

SUBSCRIPTION INFORMATION

1990, Volumes 173–189, including Molecular Pharmacology Section (Vols. 188, 189) (173–187, 15 volumes in 45 issues; 188, 189, 2 volumes in 12 issues).
Dfl. 4284.00 (US $ 1965.00) + Dfl. 476.00 (US $ 218.00) postage, packing and handling. Total price Dfl. 4760.00 (US $ 2183.00). The Dutch guilder price is definitive. The US dollar price is subject to exchange rate fluctuations and is only given as a guide. Journals are sent by surface delivery to all countries, except the following countries where SAL air delivery (Surface Airlifted Mail) is ensured: U.S.A., Canada, Japan, Australia, New Zealand, P.R. China, India, Israel, South Africa, Malaysia, Singapore, South Korea, Taiwan, Pakistan, Hong Kong, Brasil, Argentina, Mexico and Thailand. Airmail rates for other countries are available on request.

Subscription orders can only be entered by calendar year (Jan.–Dec.) and should be sent to: Elsevier Science Publishers B.V., Journals Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, Tel. 31 (20) 5803 911, Telex 18582 ESPA NL, or to your usual subscription agent (not for personal subscriptions). Claims for missing issues should be made within three months of publication, otherwise they cannot be honoured free of charge. The publisher reserves the right to issue additional volumes during the course of the year. Such volumes will be invoiced before publication and delivered on receipt of payment. *In the U.S.A. and Canada:* All questions arising after acceptance of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publishers, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam, The Netherlands. For further information and personal subscriptions, contact Elsevier Science Publishers, Journal Information Center, 52 Vanderbilt Avenue, New York, NY 10017. Tel. (212) 370-5520. *Advertising information:* advertising orders and enquiries may be addressed to: Elsevier Science Publishers B.V., Advertising Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands. Tel. 31 (20) 5803 714.

© 1990 Elsevier Science Publishers B.V. (Biomedical Division)

Printed in The Netherlands *Library of Congress Catalog Card Number 68-26539* Published semi-monthly